id	sid	tid	token	lemma	pos
cblr-1794	1	1	destined	destine	VERB
cblr-1794	1	2	for	for	ADP
cblr-1794	1	3	failure	failure	NOUN
cblr-1794	1	4	:	:	PUNCT
cblr-1794	1	5	an	an	DET
cblr-1794	1	6	analysis	analysis	NOUN
cblr-1794	1	7	of	of	ADP
cblr-1794	1	8	the	the	DET
cblr-1794	1	9	biologics	biologic	NOUN
cblr-1794	1	10	price	price	NOUN
cblr-1794	1	11	competition	competition	NOUN
cblr-1794	1	12	and	and	CCONJ
cblr-1794	1	13	innovation	innovation	NOUN
cblr-1794	1	14	act	act	NOUN
cblr-1794	1	15	of	of	ADP
cblr-1794	1	16	2009	2009	NUM
cblr-1794	1	17	destined	destine	VERB
cblr-1794	1	18	for	for	ADP
cblr-1794	1	19	failure	failure	NOUN
cblr-1794	1	20	?	?	PUNCT
cblr-1794	2	1	an	an	DET
cblr-1794	2	2	analysis	analysis	NOUN
cblr-1794	2	3	of	of	ADP
cblr-1794	2	4	the	the	DET
cblr-1794	2	5	biologics	biologic	NOUN
cblr-1794	2	6	price	price	NOUN
cblr-1794	2	7	competition	competition	NOUN
cblr-1794	2	8	and	and	CCONJ
cblr-1794	2	9	innovation	innovation	NOUN
cblr-1794	2	10	act	act	NOUN
cblr-1794	2	11	of	of	ADP
cblr-1794	2	12	2009	2009	NUM
cblr-1794	2	13	sara	sara	PROPN
cblr-1794	2	14	margolis	margolis	PROPN
cblr-1794	2	15	*	*	PROPN
cblr-1794	2	16	in	in	ADP
cblr-1794	2	17	2010	2010	NUM
cblr-1794	2	18	,	,	PUNCT
cblr-1794	2	19	congress	congress	PROPN
cblr-1794	2	20	enacted	enact	VERB
cblr-1794	2	21	the	the	DET
cblr-1794	2	22	biologics	biologic	NOUN
cblr-1794	2	23	price	price	NOUN
cblr-1794	2	24	competition	competition	NOUN
cblr-1794	2	25	and	and	CCONJ
cblr-1794	2	26	innovation	innovation	NOUN
cblr-1794	2	27	act	act	NOUN
cblr-1794	2	28	(	(	PUNCT
cblr-1794	2	29	"	"	PUNCT
cblr-1794	2	30	bpcia	bpcia	NOUN
cblr-1794	2	31	"	"	PUNCT
cblr-1794	2	32	)	)	PUNCT
cblr-1794	2	33	as	as	ADP
cblr-1794	2	34	part	part	NOUN
cblr-1794	2	35	of	of	ADP
cblr-1794	2	36	the	the	DET
cblr-1794	2	37	large	large	ADJ
cblr-1794	2	38	health	health	NOUN
cblr-1794	2	39	care	care	NOUN
cblr-1794	2	40	reform	reform	NOUN
cblr-1794	2	41	bill	bill	NOUN
cblr-1794	2	42	.	.	PUNCT
cblr-1794	3	1	the	the	DET
cblr-1794	3	2	bpcla	bpcla	NOUN
cblr-1794	3	3	creates	create	VERB
cblr-1794	3	4	a	a	DET
cblr-1794	3	5	statutory	statutory	ADJ
cblr-1794	3	6	pathway	pathway	NOUN
cblr-1794	3	7	for	for	ADP
cblr-1794	3	8	fda	fda	PROPN
cblr-1794	3	9	approval	approval	NOUN
cblr-1794	3	10	of	of	ADP
cblr-1794	3	11	"	"	PUNCT
cblr-1794	3	12	biosimilars	biosimilars	ADJ
cblr-1794	3	13	"	"	PUNCT
cblr-1794	3	14	-which	-which	NOUN
cblr-1794	3	15	are	be	AUX
cblr-1794	3	16	generic	generic	ADJ
cblr-1794	3	17	versions	version	NOUN
cblr-1794	3	18	of	of	ADP
cblr-1794	3	19	biologic	biologic	ADJ
cblr-1794	3	20	drugs	drug	NOUN
cblr-1794	3	21	.	.	PUNCT
cblr-1794	4	1	congress	congress	PROPN
cblr-1794	4	2	expects	expect	VERB
cblr-1794	4	3	this	this	DET
cblr-1794	4	4	new	new	ADJ
cblr-1794	4	5	approval	approval	NOUN
cblr-1794	4	6	pathway	pathway	NOUN
cblr-1794	4	7	for	for	ADP
cblr-1794	4	8	biosimilars	biosimilar	NOUN
cblr-1794	4	9	to	to	PART
cblr-1794	4	10	help	help	VERB
cblr-1794	4	11	lower	low	ADJ
cblr-1794	4	12	biologics	biologic	NOUN
cblr-1794	4	13	prices	price	NOUN
cblr-1794	4	14	,	,	PUNCT
cblr-1794	4	15	just	just	ADV
cblr-1794	4	16	as	as	SCONJ
cblr-1794	4	17	generic	generic	ADJ
cblr-1794	4	18	drugs	drug	NOUN
cblr-1794	4	19	have	have	AUX
cblr-1794	4	20	significantly	significantly	ADV
cblr-1794	4	21	lowered	lower	VERB
cblr-1794	4	22	pharmaceutical	pharmaceutical	ADJ
cblr-1794	4	23	prices	price	NOUN
cblr-1794	4	24	.	.	PUNCT
cblr-1794	5	1	this	this	DET
cblr-1794	5	2	note	note	NOUN
cblr-1794	5	3	argues	argue	VERB
cblr-1794	5	4	that	that	SCONJ
cblr-1794	5	5	,	,	PUNCT
cblr-1794	5	6	for	for	ADP
cblr-1794	5	7	three	three	NUM
cblr-1794	5	8	main	main	ADJ
cblr-1794	5	9	reasons	reason	NOUN
cblr-1794	5	10	,	,	PUNCT
cblr-1794	5	11	the	the	DET
cblr-1794	5	12	bpcia	bpcia	NOUN
cblr-1794	5	13	will	will	AUX
cblr-1794	5	14	not	not	PART
cblr-1794	5	15	succeed	succeed	VERB
cblr-1794	5	16	in	in	ADP
cblr-1794	5	17	lowering	lower	VERB
cblr-1794	5	18	drug	drug	NOUN
cblr-1794	5	19	prices	price	NOUN
cblr-1794	5	20	to	to	ADP
cblr-1794	5	21	the	the	DET
cblr-1794	5	22	same	same	ADJ
cblr-1794	5	23	degree	degree	NOUN
cblr-1794	5	24	that	that	SCONJ
cblr-1794	5	25	generic	generic	ADJ
cblr-1794	5	26	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	5	27	have	have	VERB
cblr-1794	5	28	.	.	PUNCT
cblr-1794	6	1	first	first	ADV
cblr-1794	6	2	,	,	PUNCT
cblr-1794	6	3	biosimilars	biosimilar	NOUN
cblr-1794	6	4	are	be	AUX
cblr-1794	6	5	more	more	ADV
cblr-1794	6	6	expensive	expensive	ADJ
cblr-1794	6	7	to	to	PART
cblr-1794	6	8	develop	develop	VERB
cblr-1794	6	9	than	than	ADP
cblr-1794	6	10	generic	generic	ADJ
cblr-1794	6	11	pharmaceutical	pharmaceutical	ADJ
cblr-1794	6	12	drugs	drug	NOUN
cblr-1794	6	13	.	.	PUNCT
cblr-1794	7	1	manufacturers	manufacturer	NOUN
cblr-1794	7	2	will	will	AUX
cblr-1794	7	3	be	be	AUX
cblr-1794	7	4	hesitant	hesitant	ADJ
cblr-1794	7	5	to	to	PART
cblr-1794	7	6	enter	enter	VERB
cblr-1794	7	7	the	the	DET
cblr-1794	7	8	biosimilars	biosimilar	NOUN
cblr-1794	7	9	market	market	NOUN
cblr-1794	7	10	,	,	PUNCT
cblr-1794	7	11	leading	lead	VERB
cblr-1794	7	12	to	to	ADP
cblr-1794	7	13	less	less	ADJ
cblr-1794	7	14	competition	competition	NOUN
cblr-1794	7	15	.	.	PUNCT
cblr-1794	8	1	second	second	ADJ
cblr-1794	8	2	,	,	PUNCT
cblr-1794	8	3	biosimilars	biosimilar	NOUN
cblr-1794	8	4	will	will	AUX
cblr-1794	8	5	struggle	struggle	VERB
cblr-1794	8	6	more	more	ADJ
cblr-1794	8	7	than	than	ADP
cblr-1794	8	8	generics	generic	NOUN
cblr-1794	8	9	to	to	PART
cblr-1794	8	10	capture	capture	VERB
cblr-1794	8	11	market	market	NOUN
cblr-1794	8	12	share	share	NOUN
cblr-1794	8	13	from	from	ADP
cblr-1794	8	14	the	the	DET
cblr-1794	8	15	branded	brand	VERB
cblr-1794	8	16	drug	drug	NOUN
cblr-1794	8	17	.	.	PUNCT
cblr-1794	9	1	third	third	ADJ
cblr-1794	9	2	,	,	PUNCT
cblr-1794	9	3	lengthy	lengthy	ADJ
cblr-1794	9	4	exclusivity	exclusivity	NOUN
cblr-1794	9	5	periods	period	NOUN
cblr-1794	9	6	awarded	award	VERB
cblr-1794	9	7	to	to	ADP
cblr-1794	9	8	the	the	DET
cblr-1794	9	9	branded	brand	VERB
cblr-1794	9	10	biologic	biologic	NOUN
cblr-1794	9	11	and	and	CCONJ
cblr-1794	9	12	the	the	DET
cblr-1794	9	13	first	first	ADJ
cblr-1794	9	14	interchangeable	interchangeable	ADJ
cblr-1794	9	15	biosimilar	biosimilar	NOUN
cblr-1794	9	16	will	will	AUX
cblr-1794	9	17	substantially	substantially	ADV
cblr-1794	9	18	delay	delay	VERB
cblr-1794	9	19	biosimilar	biosimilar	ADJ
cblr-1794	9	20	market	market	NOUN
cblr-1794	9	21	entry	entry	NOUN
cblr-1794	9	22	.	.	PUNCT
cblr-1794	10	1	this	this	DET
cblr-1794	10	2	note	note	NOUN
cblr-1794	10	3	then	then	ADV
cblr-1794	10	4	concludes	conclude	VERB
cblr-1794	10	5	with	with	ADP
cblr-1794	10	6	suggestions	suggestion	NOUN
cblr-1794	10	7	for	for	ADP
cblr-1794	10	8	improving	improve	VERB
cblr-1794	10	9	the	the	DET
cblr-1794	10	10	bpcia	bpcia	NOUN
cblr-1794	10	11	,	,	PUNCT
cblr-1794	10	12	both	both	CCONJ
cblr-1794	10	13	through	through	ADP
cblr-1794	10	14	potential	potential	ADJ
cblr-1794	10	15	amendments	amendment	NOUN
cblr-1794	10	16	and	and	CCONJ
cblr-1794	10	17	regulatory	regulatory	ADJ
cblr-1794	10	18	process	process	NOUN
cblr-1794	10	19	.	.	PUNCT
cblr-1794	11	1	i.	i.	PROPN
cblr-1794	11	2	introduction	introduction	NOUN
cblr-1794	11	3	.................................	.................................	PUNCT
cblr-1794	11	4	210	210	NUM
cblr-1794	11	5	ii	ii	NOUN
cblr-1794	11	6	.	.	PUNCT
cblr-1794	12	1	background	background	NOUN
cblr-1794	12	2	on	on	ADP
cblr-1794	12	3	biologics	biologic	NOUN
cblr-1794	12	4	and	and	CCONJ
cblr-1794	12	5	the	the	DET
cblr-1794	12	6	bpcia	bpcia	NOUN
cblr-1794	12	7	..................	..................	PUNCT
cblr-1794	12	8	213	213	NUM
cblr-1794	12	9	a.	a.	NOUN
cblr-1794	12	10	regulation	regulation	NOUN
cblr-1794	12	11	of	of	ADP
cblr-1794	12	12	biologics	biologic	NOUN
cblr-1794	12	13	..................	..................	PUNCT
cblr-1794	12	14	213	213	NUM
cblr-1794	12	15	b.	b.	NOUN
cblr-1794	12	16	abbreviated	abbreviate	VERB
cblr-1794	12	17	routes	route	NOUN
cblr-1794	12	18	to	to	ADP
cblr-1794	12	19	market	market	NOUN
cblr-1794	12	20	under	under	ADP
cblr-1794	12	21	the	the	DET
cblr-1794	12	22	fdca	fdca	NOUN
cblr-1794	12	23	.	.	PUNCT
cblr-1794	12	24	.......................	.......................	PUNCT
cblr-1794	13	1	........	........	PUNCT
cblr-1794	14	1	215	215	NUM
cblr-1794	14	2	*	*	PUNCT
cblr-1794	14	3	executive	executive	ADJ
cblr-1794	14	4	editor	editor	NOUN
cblr-1794	14	5	.	.	PUNCT
cblr-1794	15	1	j.d	j.d	PROPN
cblr-1794	15	2	.	.	PROPN
cblr-1794	15	3	candidate	candidate	PROPN
cblr-1794	15	4	2013	2013	NUM
cblr-1794	15	5	,	,	PUNCT
cblr-1794	15	6	columbia	columbia	PROPN
cblr-1794	15	7	law	law	PROPN
cblr-1794	15	8	school	school	NOUN
cblr-1794	15	9	;	;	PUNCT
cblr-1794	15	10	b.a	b.a	PROPN
cblr-1794	15	11	.	.	PROPN
cblr-1794	15	12	political	political	ADJ
cblr-1794	15	13	science	science	NOUN
cblr-1794	15	14	2007	2007	NUM
cblr-1794	15	15	,	,	PUNCT
cblr-1794	15	16	middlebury	middlebury	PROPN
cblr-1794	15	17	college	college	PROPN
cblr-1794	15	18	.	.	PUNCT
cblr-1794	16	1	the	the	DET
cblr-1794	16	2	author	author	NOUN
cblr-1794	16	3	would	would	AUX
cblr-1794	16	4	like	like	VERB
cblr-1794	16	5	to	to	PART
cblr-1794	16	6	thank	thank	VERB
cblr-1794	16	7	professor	professor	NOUN
cblr-1794	16	8	abbe	abbe	NOUN
cblr-1794	16	9	gluck	gluck	VERB
cblr-1794	16	10	for	for	ADP
cblr-1794	16	11	her	her	PRON
cblr-1794	16	12	invaluable	invaluable	ADJ
cblr-1794	16	13	assistance	assistance	NOUN
cblr-1794	16	14	and	and	CCONJ
cblr-1794	16	15	insight	insight	NOUN
cblr-1794	16	16	throughout	throughout	ADP
cblr-1794	16	17	the	the	DET
cblr-1794	16	18	writing	writing	NOUN
cblr-1794	16	19	process	process	NOUN
cblr-1794	16	20	.	.	PUNCT
cblr-1794	17	1	additionally	additionally	ADV
cblr-1794	17	2	,	,	PUNCT
cblr-1794	17	3	deepest	deep	ADJ
cblr-1794	17	4	thanks	thank	NOUN
cblr-1794	17	5	go	go	VERB
cblr-1794	17	6	to	to	ADP
cblr-1794	17	7	the	the	DET
cblr-1794	17	8	staff	staff	NOUN
cblr-1794	17	9	of	of	ADP
cblr-1794	17	10	the	the	DET
cblr-1794	17	11	columbia	columbia	PROPN
cblr-1794	17	12	business	business	PROPN
cblr-1794	17	13	law	law	PROPN
cblr-1794	17	14	review	review	NOUN
cblr-1794	17	15	for	for	ADP
cblr-1794	17	16	their	their	PRON
cblr-1794	17	17	feedback	feedback	NOUN
cblr-1794	17	18	and	and	CCONJ
cblr-1794	17	19	editorial	editorial	ADJ
cblr-1794	17	20	assistance	assistance	NOUN
cblr-1794	17	21	with	with	ADP
cblr-1794	17	22	this	this	DET
cblr-1794	17	23	note	note	NOUN
cblr-1794	17	24	.	.	PUNCT
cblr-1794	18	1	c.	c.	NOUN
cblr-1794	18	2	the	the	DET
cblr-1794	18	3	bpcia	bpcia	NOUN
cblr-1794	18	4	...........................	...........................	PUNCT
cblr-1794	19	1	219	219	NUM
cblr-1794	19	2	iii	iii	NOUN
cblr-1794	19	3	.	.	PUNCT
cblr-1794	19	4	will	will	AUX
cblr-1794	19	5	the	the	DET
cblr-1794	19	6	bpcia	bpcia	NOUN
cblr-1794	19	7	prove	prove	VERB
cblr-1794	19	8	as	as	ADV
cblr-1794	19	9	successful	successful	ADJ
cblr-1794	19	10	as	as	ADP
cblr-1794	19	11	hatchwaxman	hatchwaxman	NOUN
cblr-1794	19	12	?	?	PUNCT
cblr-1794	19	13	.	.	PUNCT
cblr-1794	19	14	.	.	PUNCT
cblr-1794	19	15	.	.	PUNCT
cblr-1794	19	16	.	.	PUNCT
cblr-1794	19	17	.	.	PUNCT
cblr-1794	19	18	.	.	PUNCT
cblr-1794	19	19	.	.	PUNCT
cblr-1794	19	20	.	.	PUNCT
cblr-1794	19	21	.	.	PUNCT
cblr-1794	19	22	.	.	PUNCT
cblr-1794	19	23	.	.	PUNCT
cblr-1794	19	24	.	.	PUNCT
cblr-1794	19	25	.	.	PUNCT
cblr-1794	19	26	.	.	PUNCT
cblr-1794	19	27	.	.	PUNCT
cblr-1794	19	28	.	.	PUNCT
cblr-1794	19	29	.	.	PUNCT
cblr-1794	19	30	.	.	PUNCT
cblr-1794	19	31	.	.	PUNCT
cblr-1794	19	32	.	.	PUNCT
cblr-1794	19	33	.	.	PUNCT
cblr-1794	19	34	.	.	PUNCT
cblr-1794	19	35	.	.	PUNCT
cblr-1794	19	36	.	.	PUNCT
cblr-1794	19	37	.	.	PUNCT
cblr-1794	19	38	.	.	PUNCT
cblr-1794	19	39	.	.	PUNCT
cblr-1794	19	40	.	.	PUNCT
cblr-1794	19	41	.	.	PUNCT
cblr-1794	19	42	.	.	PUNCT
cblr-1794	20	1	.	.	PUNCT
cblr-1794	21	1	222	222	NUM
cblr-1794	21	2	a.	a.	NOUN
cblr-1794	21	3	biosimilars	biosimilar	NOUN
cblr-1794	21	4	are	be	AUX
cblr-1794	21	5	more	more	ADV
cblr-1794	21	6	expensive	expensive	ADJ
cblr-1794	21	7	to	to	PART
cblr-1794	21	8	develop	develop	VERB
cblr-1794	21	9	......	......	PUNCT
cblr-1794	21	10	223	223	NUM
cblr-1794	21	11	b.	b.	NOUN
cblr-1794	21	12	interchangeability	interchangeability	NOUN
cblr-1794	21	13	vs.	vs.	ADP
cblr-1794	21	14	bioequivalence	bioequivalence	NOUN
cblr-1794	21	15	................	................	PUNCT
cblr-1794	21	16	226	226	NUM
cblr-1794	21	17	c.	c.	NOUN
cblr-1794	21	18	exclusivity	exclusivity	NOUN
cblr-1794	21	19	periods	period	NOUN
cblr-1794	21	20	........................	........................	PUNCT
cblr-1794	21	21	230	230	NUM
cblr-1794	21	22	1	1	NUM
cblr-1794	21	23	.	.	PUNCT
cblr-1794	21	24	exclusivity	exclusivity	NOUN
cblr-1794	21	25	period	period	NOUN
cblr-1794	21	26	for	for	ADP
cblr-1794	21	27	reference	reference	NOUN
cblr-1794	21	28	biologics	biologic	NOUN
cblr-1794	21	29	....	....	PUNCT
cblr-1794	21	30	231	231	NUM
cblr-1794	21	31	2	2	NUM
cblr-1794	21	32	.	.	PUNCT
cblr-1794	21	33	exclusivity	exclusivity	NOUN
cblr-1794	21	34	period	period	NOUN
cblr-1794	21	35	for	for	ADP
cblr-1794	21	36	the	the	DET
cblr-1794	21	37	first	first	ADJ
cblr-1794	21	38	interchangeable	interchangeable	ADJ
cblr-1794	21	39	biosimilar	biosimilar	NOUN
cblr-1794	21	40	.............	.............	PUNCT
cblr-1794	21	41	234	234	NUM
cblr-1794	21	42	iv	iv	NOUN
cblr-1794	21	43	.	.	PUNCT
cblr-1794	21	44	recommendations	recommendation	NOUN
cblr-1794	21	45	and	and	CCONJ
cblr-1794	21	46	conclusion	conclusion	NOUN
cblr-1794	21	47	........	........	PUNCT
cblr-1794	22	1	........	........	PUNCT
cblr-1794	22	2	236	236	NUM
cblr-1794	22	3	i.	i.	NOUN
cblr-1794	22	4	introduction	introduction	NOUN
cblr-1794	22	5	in	in	ADP
cblr-1794	22	6	2002	2002	NUM
cblr-1794	22	7	,	,	PUNCT
cblr-1794	22	8	after	after	ADP
cblr-1794	22	9	years	year	NOUN
cblr-1794	22	10	of	of	ADP
cblr-1794	22	11	suffering	suffer	VERB
cblr-1794	22	12	from	from	ADP
cblr-1794	22	13	debilitating	debilitate	VERB
cblr-1794	22	14	arthritis	arthritis	NOUN
cblr-1794	22	15	,	,	PUNCT
cblr-1794	22	16	bonnie	bonnie	PROPN
cblr-1794	22	17	cramer	cramer	PROPN
cblr-1794	22	18	began	begin	VERB
cblr-1794	22	19	to	to	PART
cblr-1794	22	20	take	take	VERB
cblr-1794	22	21	a	a	DET
cblr-1794	22	22	new	new	ADJ
cblr-1794	22	23	drug	drug	NOUN
cblr-1794	22	24	called	call	VERB
cblr-1794	22	25	enbrel.1	enbrel.1	PROPN
cblr-1794	22	26	unlike	unlike	ADP
cblr-1794	22	27	a	a	DET
cblr-1794	22	28	traditional	traditional	ADJ
cblr-1794	22	29	pharmaceutical	pharmaceutical	NOUN
cblr-1794	22	30	,	,	PUNCT
cblr-1794	22	31	enbrel	enbrel	PROPN
cblr-1794	22	32	is	be	AUX
cblr-1794	22	33	a	a	DET
cblr-1794	22	34	biologic	biologic	NOUN
cblr-1794	22	35	:	:	PUNCT
cblr-1794	22	36	a	a	DET
cblr-1794	22	37	large	large	ADJ
cblr-1794	22	38	,	,	PUNCT
cblr-1794	22	39	complex	complex	ADJ
cblr-1794	22	40	molecule	molecule	NOUN
cblr-1794	22	41	derived	derive	VERB
cblr-1794	22	42	from	from	ADP
cblr-1794	22	43	cell	cell	NOUN
cblr-1794	22	44	cultures.2	cultures.2	PROPN
cblr-1794	22	45	according	accord	VERB
cblr-1794	22	46	to	to	ADP
cblr-1794	22	47	the	the	DET
cblr-1794	22	48	food	food	NOUN
cblr-1794	22	49	and	and	CCONJ
cblr-1794	22	50	drug	drug	PROPN
cblr-1794	22	51	administration	administration	NOUN
cblr-1794	22	52	(	(	PUNCT
cblr-1794	22	53	"	"	PUNCT
cblr-1794	22	54	fda	fda	PROPN
cblr-1794	22	55	"	"	PUNCT
cblr-1794	22	56	)	)	PUNCT
cblr-1794	22	57	,	,	PUNCT
cblr-1794	22	58	biologics	biologic	NOUN
cblr-1794	22	59	often	often	ADV
cblr-1794	22	60	represent	represent	VERB
cblr-1794	22	61	the	the	DET
cblr-1794	22	62	cutting	cut	VERB
cblr-1794	22	63	edge	edge	NOUN
cblr-1794	22	64	of	of	ADP
cblr-1794	22	65	medical	medical	ADJ
cblr-1794	22	66	science	science	NOUN
cblr-1794	22	67	and	and	CCONJ
cblr-1794	22	68	research.3	research.3	ADJ
cblr-1794	22	69	biologics	biologic	NOUN
cblr-1794	22	70	are	be	AUX
cblr-1794	22	71	"	"	PUNCT
cblr-1794	22	72	may	may	AUX
cblr-1794	22	73	make	make	VERB
cblr-1794	22	74	it	it	PRON
cblr-1794	22	75	possible	possible	ADJ
cblr-1794	22	76	to	to	PART
cblr-1794	22	77	treat	treat	VERB
cblr-1794	22	78	a	a	DET
cblr-1794	22	79	variety	variety	NOUN
cblr-1794	22	80	of	of	ADP
cblr-1794	22	81	medical	medical	ADJ
cblr-1794	22	82	conditions	condition	NOUN
cblr-1794	22	83	,	,	PUNCT
cblr-1794	22	84	including	include	VERB
cblr-1794	22	85	illnesses	illness	NOUN
cblr-1794	22	86	for	for	ADP
cblr-1794	22	87	which	which	PRON
cblr-1794	22	88	no	no	DET
cblr-1794	22	89	other	other	ADJ
cblr-1794	22	90	treatments	treatment	NOUN
cblr-1794	22	91	are	be	AUX
cblr-1794	22	92	available	available	ADJ
cblr-1794	22	93	.	.	PUNCT
cblr-1794	23	1	"	"	PUNCT
cblr-1794	23	2	'	'	PUNCT
cblr-1794	23	3	in	in	ADP
cblr-1794	23	4	recent	recent	ADJ
cblr-1794	23	5	years	year	NOUN
cblr-1794	23	6	,	,	PUNCT
cblr-1794	23	7	biologics	biologic	NOUN
cblr-1794	23	8	have	have	AUX
cblr-1794	23	9	provided	provide	VERB
cblr-1794	23	10	breakthroughs	breakthrough	NOUN
cblr-1794	23	11	in	in	ADP
cblr-1794	23	12	treating	treat	VERB
cblr-1794	23	13	various	various	ADJ
cblr-1794	23	14	cancers	cancer	NOUN
cblr-1794	23	15	,	,	PUNCT
cblr-1794	23	16	multiple	multiple	ADJ
cblr-1794	23	17	sclerosis	sclerosis	NOUN
cblr-1794	23	18	and	and	CCONJ
cblr-1794	23	19	rheumatoid	rheumatoid	VERB
cblr-1794	23	20	arthritis	arthritis	NOUN
cblr-1794	23	21	.	.	PUNCT
cblr-1794	23	22	'	'	PUNCT
cblr-1794	24	1	the	the	DET
cblr-1794	24	2	day	day	NOUN
cblr-1794	24	3	after	after	ADP
cblr-1794	24	4	mrs	mrs	PROPN
cblr-1794	24	5	.	.	PROPN
cblr-1794	24	6	cramer	cramer	PROPN
cblr-1794	24	7	's	's	PART
cblr-1794	24	8	first	first	ADJ
cblr-1794	24	9	injection	injection	NOUN
cblr-1794	24	10	with	with	ADP
cblr-1794	24	11	enbrel	enbrel	PROPN
cblr-1794	24	12	,	,	PUNCT
cblr-1794	24	13	she	she	PRON
cblr-1794	24	14	climbed	climb	VERB
cblr-1794	24	15	out	out	ADP
cblr-1794	24	16	of	of	ADP
cblr-1794	24	17	bed	bed	NOUN
cblr-1794	24	18	without	without	ADP
cblr-1794	24	19	help.6	help.6	PROPN
cblr-1794	24	20	during	during	ADP
cblr-1794	24	21	the	the	DET
cblr-1794	24	22	six	six	NUM
cblr-1794	24	23	years	year	NOUN
cblr-1794	24	24	mrs	mrs	PROPN
cblr-1794	24	25	.	.	PROPN
cblr-1794	24	26	cramer	cramer	PROPN
cblr-1794	24	27	took	take	VERB
cblr-1794	24	28	enbrel	enbrel	PROPN
cblr-1794	24	29	,	,	PUNCT
cblr-1794	24	30	she	she	PRON
cblr-1794	24	31	felt	feel	VERB
cblr-1794	24	32	as	as	SCONJ
cblr-1794	24	33	though	though	SCONJ
cblr-1794	24	34	her	her	PRON
cblr-1794	24	35	arthritis	arthritis	NOUN
cblr-1794	24	36	1	1	NUM
cblr-1794	24	37	barbara	barbara	PROPN
cblr-1794	24	38	barrett	barrett	PROPN
cblr-1794	24	39	,	,	PUNCT
cblr-1794	24	40	health	health	NOUN
cblr-1794	24	41	care	care	NOUN
cblr-1794	24	42	bill	bill	NOUN
cblr-1794	24	43	includes	include	VERB
cblr-1794	24	44	generic	generic	ADJ
cblr-1794	24	45	path	path	NOUN
cblr-1794	24	46	for	for	ADP
cblr-1794	24	47	biologic	biologic	ADJ
cblr-1794	24	48	drugs	drug	NOUN
cblr-1794	24	49	,	,	PUNCT
cblr-1794	24	50	mcclatchy	mcclatchy	PROPN
cblr-1794	24	51	wash	wash	NOUN
cblr-1794	24	52	.	.	PUNCT
cblr-1794	24	53	,	,	PUNCT
cblr-1794	24	54	nov	nov	PROPN
cblr-1794	24	55	.	.	PROPN
cblr-1794	24	56	30	30	NUM
cblr-1794	24	57	,	,	PUNCT
cblr-1794	24	58	2009	2009	NUM
cblr-1794	24	59	,	,	PUNCT
cblr-1794	24	60	http://www.mcclatchydc	http://www.mcclatchydc	NOUN
cblr-1794	24	61	.com/2009/11/29	.com/2009/11/29	PROPN
cblr-1794	24	62	/	/	SYM
cblr-1794	24	63	v	v	PROPN
cblr-1794	24	64	-	-	PUNCT
cblr-1794	24	65	print/79540	print/79540	ADJ
cblr-1794	24	66	/	/	SYM
cblr-1794	24	67	health	health	NOUN
cblr-1794	24	68	-	-	PUNCT
cblr-1794	24	69	care	care	NOUN
cblr-1794	24	70	-	-	PUNCT
cblr-1794	24	71	bill	bill	NOUN
cblr-1794	24	72	-	-	PUNCT
cblr-1794	24	73	includes	include	VERB
cblr-1794	24	74	-	-	PUNCT
cblr-1794	24	75	generic.html	generic.html	PROPN
cblr-1794	24	76	.	.	NOUN
cblr-1794	24	77	2	2	NUM
cblr-1794	24	78	see	see	VERB
cblr-1794	24	79	henry	henry	PROPN
cblr-1794	24	80	g.	g.	PROPN
cblr-1794	24	81	grabowski	grabowski	PROPN
cblr-1794	24	82	,	,	PUNCT
cblr-1794	24	83	data	datum	NOUN
cblr-1794	24	84	exclusivity	exclusivity	NOUN
cblr-1794	24	85	for	for	ADP
cblr-1794	24	86	biologics	biologic	NOUN
cblr-1794	24	87	:	:	PUNCT
cblr-1794	24	88	what	what	PRON
cblr-1794	24	89	is	be	AUX
cblr-1794	24	90	the	the	DET
cblr-1794	24	91	appropriate	appropriate	ADJ
cblr-1794	24	92	period	period	NOUN
cblr-1794	24	93	of	of	ADP
cblr-1794	24	94	protection	protection	NOUN
cblr-1794	24	95	?	?	PUNCT
cblr-1794	24	96	,	,	PUNCT
cblr-1794	24	97	ael	ael	PROPN
cblr-1794	24	98	online	online	PROPN
cblr-1794	24	99	sept	sept	PROPN
cblr-1794	24	100	.	.	PROPN
cblr-1794	24	101	2009	2009	NUM
cblr-1794	24	102	at	at	ADP
cblr-1794	24	103	1	1	NUM
cblr-1794	24	104	,	,	PUNCT
cblr-1794	24	105	http://www.aei.org/files/2009/09/08/10-hpo-grabowski-sep08-g.pdf	http://www.aei.org/files/2009/09/08/10-hpo-grabowski-sep08-g.pdf	PROPN
cblr-1794	24	106	.	.	NOUN
cblr-1794	24	107	3	3	NUM
cblr-1794	24	108	fda	fda	PROPN
cblr-1794	24	109	101	101	NUM
cblr-1794	24	110	:	:	PUNCT
cblr-1794	24	111	regulating	regulate	VERB
cblr-1794	24	112	biological	biological	ADJ
cblr-1794	24	113	products	product	NOUN
cblr-1794	24	114	,	,	PUNCT
cblr-1794	24	115	fda	fda	PROPN
cblr-1794	24	116	,	,	PUNCT
cblr-1794	24	117	http://www.fda.gov/	http://www.fda.gov/	PROPN
cblr-1794	24	118	forconsumers	forconsumer	NOUN
cblr-1794	24	119	/	/	SYM
cblr-1794	24	120	consumerupdates	consumerupdates	PROPN
cblr-1794	24	121	/	/	SYM
cblr-1794	24	122	ucm048341.htm	ucm048341.htm	PROPN
cblr-1794	24	123	(	(	PUNCT
cblr-1794	24	124	last	last	ADJ
cblr-1794	24	125	visited	visit	VERB
cblr-1794	24	126	feb	feb	PROPN
cblr-1794	24	127	.	.	PROPN
cblr-1794	24	128	19	19	NUM
cblr-1794	24	129	,	,	PUNCT
cblr-1794	24	130	2013	2013	NUM
cblr-1794	24	131	)	)	PUNCT
cblr-1794	24	132	.	.	PUNCT
cblr-1794	25	1	4	4	NUM
cblr-1794	26	1	i	i	PRON
cblr-1794	26	2	d.	d.	PROPN
cblr-1794	26	3	5	5	NUM
cblr-1794	26	4	see	see	VERB
cblr-1794	26	5	grabowski	grabowski	PROPN
cblr-1794	26	6	,	,	PUNCT
cblr-1794	26	7	supra	supra	PROPN
cblr-1794	26	8	note	note	NOUN
cblr-1794	26	9	2	2	NUM
cblr-1794	26	10	,	,	PUNCT
cblr-1794	26	11	at	at	ADP
cblr-1794	26	12	1	1	NUM
cblr-1794	26	13	.	.	NOUN
cblr-1794	26	14	6	6	NUM
cblr-1794	26	15	barrett	barrett	PROPN
cblr-1794	26	16	,	,	PUNCT
cblr-1794	26	17	supra	supra	PROPN
cblr-1794	26	18	note	note	NOUN
cblr-1794	26	19	1	1	NUM
cblr-1794	26	20	.	.	PUNCT
cblr-1794	27	1	col	col	PROPN
cblr-1794	27	2	umia	umia	PROPN
cblr-1794	27	3	b	b	PROPN
cblr-1794	27	4	usiness	usiness	PROPN
cblr-1794	27	5	la	la	PROPN
cblr-1794	27	6	w	w	PROPN
cblr-1794	27	7	re	re	PROPN
cblr-1794	27	8	vie	vie	PROPN
cblr-1794	27	9	w	w	PROPN
cblr-1794	28	1	[	[	X
cblr-1794	28	2	vol	vol	NOUN
cblr-1794	28	3	.	.	PUNCT
cblr-1794	29	1	2013210	2013210	NUM
cblr-1794	29	2	had	have	AUX
cblr-1794	29	3	disappeared.7	disappeared.7	VERB
cblr-1794	29	4	however	however	ADV
cblr-1794	29	5	,	,	PUNCT
cblr-1794	29	6	enbrel	enbrel	PROPN
cblr-1794	29	7	costs	cost	VERB
cblr-1794	29	8	approximately	approximately	ADV
cblr-1794	29	9	$	$	SYM
cblr-1794	29	10	48,000	48,000	NUM
cblr-1794	29	11	per	per	ADP
cblr-1794	29	12	year.8	year.8	ADJ
cblr-1794	29	13	other	other	ADJ
cblr-1794	29	14	biologics	biologic	NOUN
cblr-1794	29	15	are	be	AUX
cblr-1794	29	16	just	just	ADV
cblr-1794	29	17	as	as	ADV
cblr-1794	29	18	expensive	expensive	ADJ
cblr-1794	29	19	.	.	PUNCT
cblr-1794	29	20	'	'	PUNCT
cblr-1794	30	1	lawmakers	lawmaker	NOUN
cblr-1794	30	2	and	and	CCONJ
cblr-1794	30	3	doctors	doctor	NOUN
cblr-1794	30	4	alike	alike	ADV
cblr-1794	30	5	have	have	AUX
cblr-1794	30	6	often	often	ADV
cblr-1794	30	7	acknowledged	acknowledge	VERB
cblr-1794	30	8	that	that	SCONJ
cblr-1794	30	9	biologic	biologic	NOUN
cblr-1794	30	10	drugs	drug	NOUN
cblr-1794	30	11	are	be	AUX
cblr-1794	30	12	too	too	ADV
cblr-1794	30	13	expensive	expensive	ADJ
cblr-1794	30	14	for	for	SCONJ
cblr-1794	30	15	many	many	ADJ
cblr-1794	30	16	patients	patient	NOUN
cblr-1794	30	17	to	to	PART
cblr-1794	30	18	afford	afford	VERB
cblr-1794	30	19	.	.	PUNCT
cblr-1794	31	1	10	10	NUM
cblr-1794	31	2	helping	help	VERB
cblr-1794	31	3	drive	drive	VERB
cblr-1794	31	4	these	these	DET
cblr-1794	31	5	astronomical	astronomical	ADJ
cblr-1794	31	6	prices	price	NOUN
cblr-1794	31	7	is	be	AUX
cblr-1794	31	8	the	the	DET
cblr-1794	31	9	fact	fact	NOUN
cblr-1794	31	10	that	that	SCONJ
cblr-1794	31	11	until	until	ADP
cblr-1794	31	12	2010	2010	NUM
cblr-1794	31	13	,	,	PUNCT
cblr-1794	31	14	the	the	DET
cblr-1794	31	15	fda	fda	PROPN
cblr-1794	31	16	was	be	AUX
cblr-1794	31	17	not	not	PART
cblr-1794	31	18	permitted	permit	VERB
cblr-1794	31	19	to	to	PART
cblr-1794	31	20	approve	approve	VERB
cblr-1794	31	21	generic	generic	ADJ
cblr-1794	31	22	versions	version	NOUN
cblr-1794	31	23	of	of	ADP
cblr-1794	31	24	biologics	biologic	NOUN
cblr-1794	31	25	like	like	ADP
cblr-1794	31	26	enbrel	enbrel	PROPN
cblr-1794	31	27	.	.	PUNCT
cblr-1794	32	1	in	in	ADP
cblr-1794	32	2	2010	2010	NUM
cblr-1794	32	3	,	,	PUNCT
cblr-1794	32	4	congress	congress	PROPN
cblr-1794	32	5	enacted	enact	VERB
cblr-1794	32	6	the	the	DET
cblr-1794	32	7	biologics	biologic	NOUN
cblr-1794	32	8	price	price	NOUN
cblr-1794	32	9	competition	competition	NOUN
cblr-1794	32	10	and	and	CCONJ
cblr-1794	32	11	innovation	innovation	NOUN
cblr-1794	32	12	act	act	NOUN
cblr-1794	32	13	(	(	PUNCT
cblr-1794	32	14	"	"	PUNCT
cblr-1794	32	15	bpcia")u	bpcia")u	PROPN
cblr-1794	32	16	as	as	ADP
cblr-1794	32	17	part	part	NOUN
cblr-1794	32	18	of	of	ADP
cblr-1794	32	19	the	the	DET
cblr-1794	32	20	patient	patient	NOUN
cblr-1794	32	21	protection	protection	NOUN
cblr-1794	32	22	and	and	CCONJ
cblr-1794	32	23	affordable	affordable	ADJ
cblr-1794	32	24	care	care	NOUN
cblr-1794	32	25	act	act	NOUN
cblr-1794	32	26	(	(	PUNCT
cblr-1794	32	27	"	"	PUNCT
cblr-1794	32	28	aca	aca	PROPN
cblr-1794	32	29	"	"	PUNCT
cblr-1794	32	30	)	)	PUNCT
cblr-1794	32	31	.	.	PUNCT
cblr-1794	33	1	the	the	DET
cblr-1794	33	2	bpcia	bpcia	NOUN
cblr-1794	33	3	will	will	AUX
cblr-1794	33	4	restructure	restructure	VERB
cblr-1794	33	5	the	the	DET
cblr-1794	33	6	biotechnology	biotechnology	NOUN
cblr-1794	33	7	industry	industry	NOUN
cblr-1794	33	8	by	by	ADP
cblr-1794	33	9	creating	create	VERB
cblr-1794	33	10	a	a	DET
cblr-1794	33	11	statutory	statutory	ADJ
cblr-1794	33	12	pathway	pathway	NOUN
cblr-1794	33	13	for	for	ADP
cblr-1794	33	14	fda	fda	PROPN
cblr-1794	33	15	approval	approval	NOUN
cblr-1794	33	16	of	of	ADP
cblr-1794	33	17	"	"	PUNCT
cblr-1794	33	18	biosimilars	biosimilar	NOUN
cblr-1794	33	19	,	,	PUNCT
cblr-1794	33	20	"	"	PUNCT
cblr-1794	33	21	which	which	PRON
cblr-1794	33	22	are	be	AUX
cblr-1794	33	23	generic	generic	ADJ
cblr-1794	33	24	versions	version	NOUN
cblr-1794	33	25	of	of	ADP
cblr-1794	33	26	biologic	biologic	ADJ
cblr-1794	33	27	drugs	drug	NOUN
cblr-1794	33	28	.	.	PUNCT
cblr-1794	34	1	1	1	NUM
cblr-1794	34	2	2	2	NUM
cblr-1794	34	3	congress	congress	NOUN
cblr-1794	34	4	enacted	enact	VERB
cblr-1794	34	5	the	the	DET
cblr-1794	34	6	bpcia	bpcia	NOUN
cblr-1794	34	7	in	in	ADP
cblr-1794	34	8	an	an	DET
cblr-1794	34	9	attempt	attempt	NOUN
cblr-1794	34	10	to	to	PART
cblr-1794	34	11	tackle	tackle	VERB
cblr-1794	34	12	the	the	DET
cblr-1794	34	13	problem	problem	NOUN
cblr-1794	34	14	of	of	ADP
cblr-1794	34	15	rising	rise	VERB
cblr-1794	34	16	biologics	biologic	NOUN
cblr-1794	34	17	prices	price	NOUN
cblr-1794	34	18	.	.	PUNCT
cblr-1794	35	1	congress	congress	PROPN
cblr-1794	35	2	expects	expect	VERB
cblr-1794	35	3	the	the	DET
cblr-1794	35	4	new	new	ADJ
cblr-1794	35	5	approval	approval	NOUN
cblr-1794	35	6	pathway	pathway	NOUN
cblr-1794	35	7	for	for	ADP
cblr-1794	35	8	biosimilars	biosimilar	NOUN
cblr-1794	35	9	to	to	PART
cblr-1794	35	10	help	help	VERB
cblr-1794	35	11	lower	low	ADJ
cblr-1794	35	12	biologics	biologic	NOUN
cblr-1794	35	13	7	7	NUM
cblr-1794	35	14	barrett	barrett	PROPN
cblr-1794	35	15	,	,	PUNCT
cblr-1794	35	16	supra	supra	PROPN
cblr-1794	35	17	note	note	NOUN
cblr-1794	35	18	1	1	NUM
cblr-1794	35	19	.	.	SYM
cblr-1794	35	20	8	8	NUM
cblr-1794	35	21	judith	judith	PROPN
cblr-1794	35	22	a.	a.	PROPN
cblr-1794	35	23	johnson	johnson	PROPN
cblr-1794	35	24	,	,	PUNCT
cblr-1794	35	25	cong	cong	PROPN
cblr-1794	35	26	.	.	PUNCT
cblr-1794	36	1	research	research	NOUN
cblr-1794	36	2	serv	serv	PROPN
cblr-1794	36	3	.	.	PROPN
cblr-1794	36	4	,	,	PUNCT
cblr-1794	36	5	rl34045	rl34045	PROPN
cblr-1794	36	6	,	,	PUNCT
cblr-1794	36	7	fda	fda	PROPN
cblr-1794	36	8	regulation	regulation	NOUN
cblr-1794	36	9	of	of	ADP
cblr-1794	36	10	follow	follow	NOUN
cblr-1794	36	11	-	-	PUNCT
cblr-1794	36	12	on	on	ADP
cblr-1794	36	13	biologics	biologic	NOUN
cblr-1794	36	14	1	1	NUM
cblr-1794	36	15	(	(	PUNCT
cblr-1794	36	16	2010	2010	NUM
cblr-1794	36	17	)	)	PUNCT
cblr-1794	36	18	,	,	PUNCT
cblr-1794	36	19	available	available	ADJ
cblr-1794	36	20	at	at	ADP
cblr-1794	36	21	http://	http://	PROPN
cblr-1794	36	22	primaryimmune.org/advocacy-center/pdfs/health-carereform/biosimilars	primaryimmune.org/advocacy-center/pdfs/health-carereform/biosimilars	PROPN
cblr-1794	36	23	-congressional	-congressional	ADJ
cblr-1794	36	24	researchservicereport.pdf	researchservicereport.pdf	NOUN
cblr-1794	36	25	.	.	NOUN
cblr-1794	36	26	9	9	NUM
cblr-1794	36	27	the	the	DET
cblr-1794	36	28	congressional	congressional	ADJ
cblr-1794	36	29	research	research	NOUN
cblr-1794	36	30	service	service	NOUN
cblr-1794	36	31	reports	report	VERB
cblr-1794	36	32	that	that	SCONJ
cblr-1794	36	33	"	"	PUNCT
cblr-1794	36	34	the	the	DET
cblr-1794	36	35	cost	cost	NOUN
cblr-1794	36	36	of	of	ADP
cblr-1794	36	37	therapeutic	therapeutic	ADJ
cblr-1794	36	38	biologics	biologic	NOUN
cblr-1794	36	39	is	be	AUX
cblr-1794	36	40	often	often	ADV
cblr-1794	36	41	prohibitively	prohibitively	ADV
cblr-1794	36	42	high	high	ADJ
cblr-1794	36	43	for	for	ADP
cblr-1794	36	44	individual	individual	ADJ
cblr-1794	36	45	patients	patient	NOUN
cblr-1794	36	46	.	.	PUNCT
cblr-1794	36	47	"	"	PUNCT
cblr-1794	37	1	i	i	PRON
cblr-1794	37	2	d.	d.	PROPN
cblr-1794	37	3	treatment	treatment	NOUN
cblr-1794	37	4	for	for	ADP
cblr-1794	37	5	breast	breast	NOUN
cblr-1794	37	6	cancer	cancer	NOUN
cblr-1794	37	7	with	with	ADP
cblr-1794	37	8	herceptin	herceptin	PROPN
cblr-1794	37	9	costs	cost	VERB
cblr-1794	37	10	up	up	ADP
cblr-1794	37	11	to	to	PART
cblr-1794	37	12	$	$	SYM
cblr-1794	37	13	48,000	48,000	NUM
cblr-1794	37	14	annually	annually	ADV
cblr-1794	37	15	,	,	PUNCT
cblr-1794	37	16	treatment	treatment	NOUN
cblr-1794	37	17	for	for	ADP
cblr-1794	37	18	crohn	crohn	NOUN
cblr-1794	37	19	's	's	PART
cblr-1794	37	20	disease	disease	NOUN
cblr-1794	37	21	with	with	ADP
cblr-1794	37	22	humira	humira	PROPN
cblr-1794	37	23	costs	cost	VERB
cblr-1794	37	24	$	$	SYM
cblr-1794	37	25	51,000	51,000	NUM
cblr-1794	37	26	,	,	PUNCT
cblr-1794	37	27	and	and	CCONJ
cblr-1794	37	28	treatment	treatment	NOUN
cblr-1794	37	29	for	for	ADP
cblr-1794	37	30	gaucher	gaucher	PROPN
cblr-1794	37	31	's	's	PART
cblr-1794	37	32	disease	disease	NOUN
cblr-1794	37	33	with	with	ADP
cblr-1794	37	34	cerezyme	cerezyme	NOUN
cblr-1794	37	35	costs	cost	VERB
cblr-1794	37	36	$	$	SYM
cblr-1794	37	37	200,000	200,000	NUM
cblr-1794	37	38	.	.	PUNCT
cblr-1794	38	1	i	i	PRON
cblr-1794	38	2	d.	d.	PROPN
cblr-1794	38	3	biologics	biologics	PROPN
cblr-1794	38	4	cost	cost	NOUN
cblr-1794	38	5	,	,	PUNCT
cblr-1794	38	6	on	on	ADP
cblr-1794	38	7	average	average	ADJ
cblr-1794	38	8	,	,	PUNCT
cblr-1794	38	9	twenty	twenty	NUM
cblr-1794	38	10	-	-	PUNCT
cblr-1794	38	11	two	two	NUM
cblr-1794	38	12	times	time	NOUN
cblr-1794	38	13	as	as	ADV
cblr-1794	38	14	much	much	ADV
cblr-1794	38	15	as	as	ADP
cblr-1794	38	16	traditional	traditional	ADJ
cblr-1794	38	17	pharmaceutical	pharmaceutical	ADJ
cblr-1794	38	18	drugs	drug	NOUN
cblr-1794	38	19	.	.	PUNCT
cblr-1794	39	1	anthony	anthony	PROPN
cblr-1794	39	2	d.	d.	PROPN
cblr-1794	39	3	so	so	PROPN
cblr-1794	39	4	&	&	CCONJ
cblr-1794	39	5	samuel	samuel	PROPN
cblr-1794	39	6	l.	l.	PROPN
cblr-1794	39	7	katz	katz	PROPN
cblr-1794	39	8	,	,	PUNCT
cblr-1794	39	9	op	op	NOUN
cblr-1794	39	10	-	-	PUNCT
cblr-1794	39	11	ed	ed	NOUN
cblr-1794	39	12	,	,	PUNCT
cblr-1794	39	13	biologics	biologic	NOUN
cblr-1794	39	14	boondoggle	boondoggle	NOUN
cblr-1794	39	15	,	,	PUNCT
cblr-1794	39	16	n.y	n.y	PROPN
cblr-1794	39	17	.	.	PROPN
cblr-1794	39	18	times	times	PROPN
cblr-1794	39	19	,	,	PUNCT
cblr-1794	39	20	mar	mar	PROPN
cblr-1794	39	21	.	.	PROPN
cblr-1794	39	22	10	10	NUM
cblr-1794	39	23	,	,	PUNCT
cblr-1794	39	24	2010	2010	NUM
cblr-1794	39	25	,	,	PUNCT
cblr-1794	39	26	at	at	ADP
cblr-1794	39	27	a23	a23	PROPN
cblr-1794	39	28	.	.	PROPN
cblr-1794	40	1	10	10	NUM
cblr-1794	40	2	see	see	VERB
cblr-1794	40	3	letter	letter	NOUN
cblr-1794	40	4	from	from	ADP
cblr-1794	40	5	rep	rep	PROPN
cblr-1794	40	6	.	.	PROPN
cblr-1794	40	7	anna	anna	PROPN
cblr-1794	40	8	eshoo	eshoo	PROPN
cblr-1794	40	9	et	et	PROPN
cblr-1794	40	10	al	al	PROPN
cblr-1794	40	11	.	.	PROPN
cblr-1794	41	1	to	to	ADP
cblr-1794	41	2	president	president	PROPN
cblr-1794	41	3	barack	barack	PROPN
cblr-1794	41	4	obama	obama	PROPN
cblr-1794	41	5	(	(	PUNCT
cblr-1794	41	6	oct	oct	PROPN
cblr-1794	41	7	.	.	PROPN
cblr-1794	41	8	14	14	NUM
cblr-1794	41	9	,	,	PUNCT
cblr-1794	41	10	2011	2011	NUM
cblr-1794	41	11	)	)	PUNCT
cblr-1794	41	12	,	,	PUNCT
cblr-1794	41	13	available	available	ADJ
cblr-1794	41	14	at	at	ADP
cblr-1794	41	15	http://patentdocs.typepad.com/files/houseletter.pdf	http://patentdocs.typepad.com/files/houseletter.pdf	PROPN
cblr-1794	41	16	(	(	PUNCT
cblr-1794	41	17	stating	state	VERB
cblr-1794	41	18	that	that	SCONJ
cblr-1794	41	19	"	"	PUNCT
cblr-1794	41	20	many	many	ADJ
cblr-1794	41	21	of	of	ADP
cblr-1794	41	22	these	these	DET
cblr-1794	41	23	remarkable	remarkable	ADJ
cblr-1794	41	24	drugs	drug	NOUN
cblr-1794	41	25	are	be	AUX
cblr-1794	41	26	out	out	ADP
cblr-1794	41	27	of	of	ADP
cblr-1794	41	28	reach	reach	NOUN
cblr-1794	41	29	for	for	ADP
cblr-1794	41	30	patients	patient	NOUN
cblr-1794	41	31	"	"	PUNCT
cblr-1794	41	32	)	)	PUNCT
cblr-1794	41	33	;	;	PUNCT
cblr-1794	41	34	see	see	VERB
cblr-1794	41	35	also	also	ADV
cblr-1794	41	36	barrett	barrett	PROPN
cblr-1794	41	37	,	,	PUNCT
cblr-1794	41	38	supra	supra	PROPN
cblr-1794	41	39	note	note	NOUN
cblr-1794	41	40	1	1	NUM
cblr-1794	41	41	(	(	PUNCT
cblr-1794	41	42	recounting	recount	VERB
cblr-1794	41	43	that	that	SCONJ
cblr-1794	41	44	doctors	doctor	NOUN
cblr-1794	41	45	and	and	CCONJ
cblr-1794	41	46	patient	patient	ADJ
cblr-1794	41	47	advocates	advocate	NOUN
cblr-1794	41	48	alike	alike	ADV
cblr-1794	41	49	"	"	PUNCT
cblr-1794	41	50	say	say	VERB
cblr-1794	41	51	they	they	PRON
cblr-1794	41	52	've	have	AUX
cblr-1794	41	53	seen	see	VERB
cblr-1794	41	54	heartbreaking	heartbreaking	ADJ
cblr-1794	41	55	stories	story	NOUN
cblr-1794	41	56	about	about	ADP
cblr-1794	41	57	patients	patient	NOUN
cblr-1794	41	58	who	who	PRON
cblr-1794	41	59	ca	can	AUX
cblr-1794	41	60	n't	not	PART
cblr-1794	41	61	afford	afford	VERB
cblr-1794	41	62	the	the	DET
cblr-1794	41	63	pricey	pricey	ADJ
cblr-1794	41	64	medicines	medicine	NOUN
cblr-1794	41	65	"	"	PUNCT
cblr-1794	41	66	)	)	PUNCT
cblr-1794	41	67	.	.	PUNCT
cblr-1794	42	1	11	11	NUM
cblr-1794	42	2	patient	patient	NOUN
cblr-1794	42	3	protection	protection	NOUN
cblr-1794	42	4	and	and	CCONJ
cblr-1794	42	5	affordable	affordable	ADJ
cblr-1794	42	6	care	care	PROPN
cblr-1794	42	7	act	act	PROPN
cblr-1794	42	8	,	,	PUNCT
cblr-1794	42	9	pub	pub	NOUN
cblr-1794	42	10	.	.	PUNCT
cblr-1794	43	1	l.	l.	PROPN
cblr-1794	43	2	no	no	INTJ
cblr-1794	43	3	.	.	NOUN
cblr-1794	44	1	111	111	NUM
cblr-1794	44	2	-	-	SYM
cblr-1794	44	3	148	148	NUM
cblr-1794	44	4	,	,	PUNCT
cblr-1794	44	5	§	§	PROPN
cblr-1794	44	6	§	§	PROPN
cblr-1794	44	7	7001	7001	NUM
cblr-1794	44	8	-	-	SYM
cblr-1794	44	9	03	03	NUM
cblr-1794	44	10	,	,	PUNCT
cblr-1794	44	11	124	124	NUM
cblr-1794	44	12	stat	stat	NOUN
cblr-1794	44	13	.	.	PUNCT
cblr-1794	45	1	119	119	NUM
cblr-1794	45	2	,	,	PUNCT
cblr-1794	45	3	§	§	PROPN
cblr-1794	45	4	§	§	PROPN
cblr-1794	45	5	804	804	NUM
cblr-1794	45	6	-	-	SYM
cblr-1794	45	7	21	21	NUM
cblr-1794	45	8	(	(	PUNCT
cblr-1794	45	9	2010	2010	NUM
cblr-1794	45	10	)	)	PUNCT
cblr-1794	45	11	(	(	PUNCT
cblr-1794	45	12	codified	codify	VERB
cblr-1794	45	13	at	at	ADP
cblr-1794	45	14	42	42	NUM
cblr-1794	45	15	u.s.c	u.s.c	ADJ
cblr-1794	45	16	.	.	PUNCT
cblr-1794	46	1	§	§	PROPN
cblr-1794	46	2	262	262	NUM
cblr-1794	46	3	)	)	PUNCT
cblr-1794	46	4	.	.	PUNCT
cblr-1794	47	1	12	12	NUM
cblr-1794	47	2	richard	richard	PROPN
cblr-1794	47	3	a.	a.	PROPN
cblr-1794	47	4	epstein	epstein	PROPN
cblr-1794	47	5	,	,	PUNCT
cblr-1794	47	6	the	the	DET
cblr-1794	47	7	constitutional	constitutional	ADJ
cblr-1794	47	8	protection	protection	NOUN
cblr-1794	47	9	of	of	ADP
cblr-1794	47	10	trade	trade	NOUN
cblr-1794	47	11	secrets	secret	NOUN
cblr-1794	47	12	and	and	CCONJ
cblr-1794	47	13	patents	patent	NOUN
cblr-1794	47	14	under	under	ADP
cblr-1794	47	15	the	the	DET
cblr-1794	47	16	biologics	biologic	NOUN
cblr-1794	47	17	price	price	NOUN
cblr-1794	47	18	competition	competition	NOUN
cblr-1794	47	19	and	and	CCONJ
cblr-1794	47	20	innovation	innovation	NOUN
cblr-1794	47	21	act	act	NOUN
cblr-1794	47	22	of	of	ADP
cblr-1794	47	23	2009	2009	NUM
cblr-1794	47	24	,	,	PUNCT
cblr-1794	47	25	66	66	NUM
cblr-1794	47	26	food	food	NOUN
cblr-1794	47	27	&	&	CCONJ
cblr-1794	47	28	drug	drug	PROPN
cblr-1794	47	29	l.j	l.j	PROPN
cblr-1794	47	30	.	.	PROPN
cblr-1794	47	31	285	285	NUM
cblr-1794	47	32	,	,	PUNCT
cblr-1794	47	33	286	286	NUM
cblr-1794	47	34	(	(	PUNCT
cblr-1794	47	35	2011	2011	NUM
cblr-1794	47	36	)	)	PUNCT
cblr-1794	47	37	.	.	PUNCT
cblr-1794	48	1	bpcia	bpcia	NOUN
cblr-1794	48	2	:	:	PUNCT
cblr-1794	48	3	destined	destine	VERB
cblr-1794	48	4	for	for	ADP
cblr-1794	48	5	failure	failure	NOUN
cblr-1794	48	6	?	?	PUNCT
cblr-1794	49	1	211no	211no	NOUN
cblr-1794	49	2	.	.	PUNCT
cblr-1794	50	1	1:209]1	1:209]1	NUM
cblr-1794	50	2	prices	price	NOUN
cblr-1794	50	3	,	,	PUNCT
cblr-1794	50	4	just	just	ADV
cblr-1794	50	5	as	as	SCONJ
cblr-1794	50	6	generic	generic	ADJ
cblr-1794	50	7	drugs	drug	NOUN
cblr-1794	50	8	have	have	AUX
cblr-1794	50	9	significantly	significantly	ADV
cblr-1794	50	10	lowered	lower	VERB
cblr-1794	50	11	pharmaceutical	pharmaceutical	ADJ
cblr-1794	50	12	prices	price	NOUN
cblr-1794	50	13	.	.	PUNCT
cblr-1794	51	1	13	13	NUM
cblr-1794	51	2	generic	generic	ADJ
cblr-1794	51	3	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	51	4	have	have	AUX
cblr-1794	51	5	been	be	AUX
cblr-1794	51	6	available	available	ADJ
cblr-1794	51	7	since	since	SCONJ
cblr-1794	51	8	1984	1984	NUM
cblr-1794	51	9	,	,	PUNCT
cblr-1794	51	10	when	when	SCONJ
cblr-1794	51	11	congress	congress	PROPN
cblr-1794	51	12	passed	pass	VERB
cblr-1794	51	13	the	the	DET
cblr-1794	51	14	hatch	hatch	NOUN
cblr-1794	51	15	-	-	PUNCT
cblr-1794	51	16	waxman	waxman	PROPN
cblr-1794	51	17	act	act	PROPN
cblr-1794	51	18	.	.	PUNCT
cblr-1794	52	1	in	in	ADP
cblr-1794	52	2	the	the	DET
cblr-1794	52	3	quarter	quarter	NOUN
cblr-1794	52	4	of	of	ADP
cblr-1794	52	5	a	a	DET
cblr-1794	52	6	century	century	NOUN
cblr-1794	52	7	since	since	SCONJ
cblr-1794	52	8	the	the	DET
cblr-1794	52	9	passage	passage	NOUN
cblr-1794	52	10	of	of	ADP
cblr-1794	52	11	the	the	DET
cblr-1794	52	12	law	law	NOUN
cblr-1794	52	13	,	,	PUNCT
cblr-1794	52	14	hatchwaxman	hatchwaxman	PROPN
cblr-1794	52	15	has	have	AUX
cblr-1794	52	16	had	have	VERB
cblr-1794	52	17	significant	significant	ADJ
cblr-1794	52	18	success	success	NOUN
cblr-1794	52	19	in	in	ADP
cblr-1794	52	20	controlling	control	VERB
cblr-1794	52	21	the	the	DET
cblr-1794	52	22	costs	cost	NOUN
cblr-1794	52	23	of	of	ADP
cblr-1794	52	24	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	52	25	.	.	PUNCT
cblr-1794	53	1	according	accord	VERB
cblr-1794	53	2	to	to	ADP
cblr-1794	53	3	the	the	DET
cblr-1794	53	4	federal	federal	PROPN
cblr-1794	53	5	trade	trade	PROPN
cblr-1794	53	6	commission	commission	PROPN
cblr-1794	53	7	(	(	PUNCT
cblr-1794	53	8	"	"	PUNCT
cblr-1794	53	9	ftc	ftc	X
cblr-1794	53	10	"	"	PUNCT
cblr-1794	53	11	)	)	PUNCT
cblr-1794	53	12	,	,	PUNCT
cblr-1794	53	13	"	"	PUNCT
cblr-1794	53	14	the	the	DET
cblr-1794	53	15	first	first	ADJ
cblr-1794	53	16	generic	generic	ADJ
cblr-1794	53	17	entrant	entrant	NOUN
cblr-1794	53	18	generally	generally	ADV
cblr-1794	53	19	offers	offer	VERB
cblr-1794	53	20	a	a	DET
cblr-1794	53	21	price	price	NOUN
cblr-1794	53	22	that	that	PRON
cblr-1794	53	23	is	be	AUX
cblr-1794	53	24	25	25	NUM
cblr-1794	53	25	percent	percent	NOUN
cblr-1794	53	26	lower	low	ADJ
cblr-1794	53	27	than	than	ADP
cblr-1794	53	28	the	the	DET
cblr-1794	53	29	branded	brand	VERB
cblr-1794	53	30	drug	drug	NOUN
cblr-1794	53	31	's	's	PART
cblr-1794	53	32	price	price	NOUN
cblr-1794	53	33	.	.	PUNCT
cblr-1794	54	1	the	the	DET
cblr-1794	54	2	price	price	NOUN
cblr-1794	54	3	discount	discount	NOUN
cblr-1794	54	4	can	can	AUX
cblr-1794	54	5	rise	rise	VERB
cblr-1794	54	6	to	to	ADP
cblr-1794	54	7	80	80	NUM
cblr-1794	54	8	percent	percent	NOUN
cblr-1794	54	9	with	with	ADP
cblr-1794	54	10	multiple	multiple	ADJ
cblr-1794	54	11	generic	generic	ADJ
cblr-1794	54	12	entrants	entrant	NOUN
cblr-1794	54	13	.	.	PUNCT
cblr-1794	55	1	"1	"1	NOUN
cblr-1794	55	2	4	4	NUM
cblr-1794	55	3	proponents	proponent	NOUN
cblr-1794	55	4	of	of	ADP
cblr-1794	55	5	the	the	DET
cblr-1794	55	6	bpcia	bpcia	NOUN
cblr-1794	55	7	hope	hope	VERB
cblr-1794	55	8	that	that	SCONJ
cblr-1794	55	9	biosimilars	biosimilar	NOUN
cblr-1794	55	10	will	will	AUX
cblr-1794	55	11	spur	spur	VERB
cblr-1794	55	12	an	an	DET
cblr-1794	55	13	analogous	analogous	ADJ
cblr-1794	55	14	price	price	NOUN
cblr-1794	55	15	discount	discount	NOUN
cblr-1794	55	16	.	.	PUNCT
cblr-1794	56	1	however	however	ADV
cblr-1794	56	2	,	,	PUNCT
cblr-1794	56	3	biologics	biologic	NOUN
cblr-1794	56	4	and	and	CCONJ
cblr-1794	56	5	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	56	6	differ	differ	VERB
cblr-1794	56	7	in	in	ADP
cblr-1794	56	8	many	many	ADJ
cblr-1794	56	9	important	important	ADJ
cblr-1794	56	10	ways	way	NOUN
cblr-1794	56	11	.	.	PUNCT
cblr-1794	57	1	this	this	DET
cblr-1794	57	2	note	note	NOUN
cblr-1794	57	3	will	will	AUX
cblr-1794	57	4	argue	argue	VERB
cblr-1794	57	5	that	that	SCONJ
cblr-1794	57	6	the	the	DET
cblr-1794	57	7	bpcia	bpcia	NOUN
cblr-1794	57	8	,	,	PUNCT
cblr-1794	57	9	as	as	SCONJ
cblr-1794	57	10	written	write	VERB
cblr-1794	57	11	,	,	PUNCT
cblr-1794	57	12	will	will	AUX
cblr-1794	57	13	not	not	PART
cblr-1794	57	14	be	be	AUX
cblr-1794	57	15	as	as	ADV
cblr-1794	57	16	successful	successful	ADJ
cblr-1794	57	17	in	in	ADP
cblr-1794	57	18	reducing	reduce	VERB
cblr-1794	57	19	drug	drug	NOUN
cblr-1794	57	20	prices	price	NOUN
cblr-1794	57	21	as	as	ADP
cblr-1794	57	22	hatch	hatch	NOUN
cblr-1794	57	23	-	-	PUNCT
cblr-1794	57	24	waxman	waxman	NOUN
cblr-1794	57	25	.	.	PUNCT
cblr-1794	58	1	part	part	PROPN
cblr-1794	58	2	ii	ii	PROPN
cblr-1794	58	3	will	will	AUX
cblr-1794	58	4	provide	provide	VERB
cblr-1794	58	5	a	a	DET
cblr-1794	58	6	brief	brief	ADJ
cblr-1794	58	7	background	background	NOUN
cblr-1794	58	8	on	on	ADP
cblr-1794	58	9	both	both	DET
cblr-1794	58	10	biologics	biologic	NOUN
cblr-1794	58	11	and	and	CCONJ
cblr-1794	58	12	the	the	DET
cblr-1794	58	13	bpcia	bpcia	NOUN
cblr-1794	58	14	.	.	PUNCT
cblr-1794	59	1	biologics	biologic	NOUN
cblr-1794	59	2	and	and	CCONJ
cblr-1794	59	3	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	59	4	are	be	AUX
cblr-1794	59	5	regulated	regulate	VERB
cblr-1794	59	6	under	under	ADP
cblr-1794	59	7	different	different	ADJ
cblr-1794	59	8	federal	federal	ADJ
cblr-1794	59	9	statutes	statute	NOUN
cblr-1794	59	10	,	,	PUNCT
cblr-1794	59	11	and	and	CCONJ
cblr-1794	59	12	the	the	DET
cblr-1794	59	13	hatch	hatch	NOUN
cblr-1794	59	14	-	-	PUNCT
cblr-1794	59	15	waxman	waxman	PROPN
cblr-1794	59	16	act	act	NOUN
cblr-1794	59	17	only	only	ADV
cblr-1794	59	18	amended	amend	VERB
cblr-1794	59	19	the	the	DET
cblr-1794	59	20	statute	statute	NOUN
cblr-1794	59	21	regulating	regulate	VERB
cblr-1794	59	22	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	59	23	.	.	PUNCT
cblr-1794	60	1	biosimilars	biosimilar	NOUN
cblr-1794	60	2	,	,	PUNCT
cblr-1794	60	3	therefore	therefore	ADV
cblr-1794	60	4	,	,	PUNCT
cblr-1794	60	5	could	could	AUX
cblr-1794	60	6	not	not	PART
cblr-1794	60	7	be	be	AUX
cblr-1794	60	8	approved	approve	VERB
cblr-1794	60	9	under	under	ADP
cblr-1794	60	10	federal	federal	ADJ
cblr-1794	60	11	law	law	NOUN
cblr-1794	60	12	until	until	SCONJ
cblr-1794	60	13	the	the	DET
cblr-1794	60	14	bpcia	bpcia	NOUN
cblr-1794	60	15	was	be	AUX
cblr-1794	60	16	passed	pass	VERB
cblr-1794	60	17	.	.	PUNCT
cblr-1794	61	1	part	part	NOUN
cblr-1794	61	2	iii	iii	PROPN
cblr-1794	61	3	will	will	AUX
cblr-1794	61	4	argue	argue	VERB
cblr-1794	61	5	that	that	SCONJ
cblr-1794	61	6	the	the	DET
cblr-1794	61	7	bpcia	bpcia	NOUN
cblr-1794	61	8	will	will	AUX
cblr-1794	61	9	not	not	PART
cblr-1794	61	10	be	be	AUX
cblr-1794	61	11	as	as	ADV
cblr-1794	61	12	successful	successful	ADJ
cblr-1794	61	13	in	in	ADP
cblr-1794	61	14	bringing	bring	VERB
cblr-1794	61	15	down	down	ADP
cblr-1794	61	16	drug	drug	NOUN
cblr-1794	61	17	prices	price	NOUN
cblr-1794	61	18	as	as	ADP
cblr-1794	61	19	hatch	hatch	NOUN
cblr-1794	61	20	-	-	PUNCT
cblr-1794	61	21	waxman	waxman	NOUN
cblr-1794	61	22	.	.	PUNCT
cblr-1794	62	1	biosimilars	biosimilar	NOUN
cblr-1794	62	2	are	be	AUX
cblr-1794	62	3	more	more	ADV
cblr-1794	62	4	expensive	expensive	ADJ
cblr-1794	62	5	to	to	PART
cblr-1794	62	6	develop	develop	VERB
cblr-1794	62	7	than	than	ADP
cblr-1794	62	8	generic	generic	ADJ
cblr-1794	62	9	pharmaceutical	pharmaceutical	ADJ
cblr-1794	62	10	drugs	drug	NOUN
cblr-1794	62	11	,	,	PUNCT
cblr-1794	62	12	which	which	PRON
cblr-1794	62	13	will	will	AUX
cblr-1794	62	14	lead	lead	VERB
cblr-1794	62	15	to	to	ADP
cblr-1794	62	16	less	less	ADJ
cblr-1794	62	17	competition	competition	NOUN
cblr-1794	62	18	in	in	ADP
cblr-1794	62	19	the	the	DET
cblr-1794	62	20	market	market	NOUN
cblr-1794	62	21	because	because	SCONJ
cblr-1794	62	22	fewer	few	ADJ
cblr-1794	62	23	biosimilars	biosimilar	NOUN
cblr-1794	62	24	will	will	AUX
cblr-1794	62	25	be	be	AUX
cblr-1794	62	26	produced	produce	VERB
cblr-1794	62	27	.	.	PUNCT
cblr-1794	63	1	additionally	additionally	ADV
cblr-1794	63	2	,	,	PUNCT
cblr-1794	63	3	biosimilars	biosimilar	NOUN
cblr-1794	63	4	will	will	AUX
cblr-1794	63	5	struggle	struggle	VERB
cblr-1794	63	6	more	more	ADJ
cblr-1794	63	7	than	than	ADP
cblr-1794	63	8	generics	generic	NOUN
cblr-1794	63	9	to	to	PART
cblr-1794	63	10	capture	capture	VERB
cblr-1794	63	11	market	market	NOUN
cblr-1794	63	12	share	share	NOUN
cblr-1794	63	13	from	from	ADP
cblr-1794	63	14	the	the	DET
cblr-1794	63	15	branded	brand	VERB
cblr-1794	63	16	drug	drug	NOUN
cblr-1794	63	17	.	.	PUNCT
cblr-1794	64	1	finally	finally	ADV
cblr-1794	64	2	,	,	PUNCT
cblr-1794	64	3	lengthy	lengthy	ADJ
cblr-1794	64	4	exclusivity	exclusivity	NOUN
cblr-1794	64	5	periods	period	NOUN
cblr-1794	64	6	awarded	award	VERB
cblr-1794	64	7	to	to	ADP
cblr-1794	64	8	the	the	DET
cblr-1794	64	9	branded	brand	VERB
cblr-1794	64	10	drug	drug	NOUN
cblr-1794	64	11	and	and	CCONJ
cblr-1794	64	12	the	the	DET
cblr-1794	64	13	first	first	ADJ
cblr-1794	64	14	interchangeable	interchangeable	ADJ
cblr-1794	64	15	biosimilar	biosimilar	NOUN
cblr-1794	64	16	will	will	AUX
cblr-1794	64	17	ensure	ensure	VERB
cblr-1794	64	18	that	that	DET
cblr-1794	64	19	biologic	biologic	NOUN
cblr-1794	64	20	13	13	NUM
cblr-1794	64	21	letter	letter	NOUN
cblr-1794	64	22	from	from	ADP
cblr-1794	64	23	rep	rep	PROPN
cblr-1794	64	24	.	.	PROPN
cblr-1794	64	25	anna	anna	PROPN
cblr-1794	64	26	eshoo	eshoo	PROPN
cblr-1794	64	27	et	et	PROPN
cblr-1794	64	28	al	al	PROPN
cblr-1794	64	29	.	.	PROPN
cblr-1794	65	1	to	to	PART
cblr-1794	65	2	barack	barack	VERB
cblr-1794	65	3	obama	obama	PROPN
cblr-1794	65	4	,	,	PUNCT
cblr-1794	65	5	supra	supra	PROPN
cblr-1794	65	6	note	note	NOUN
cblr-1794	65	7	9	9	NUM
cblr-1794	65	8	,	,	PUNCT
cblr-1794	65	9	at	at	ADP
cblr-1794	65	10	1	1	NUM
cblr-1794	65	11	(	(	PUNCT
cblr-1794	65	12	"	"	PUNCT
cblr-1794	65	13	following	follow	VERB
cblr-1794	65	14	in	in	ADP
cblr-1794	65	15	the	the	DET
cblr-1794	65	16	footsteps	footstep	NOUN
cblr-1794	65	17	of	of	ADP
cblr-1794	65	18	the	the	DET
cblr-1794	65	19	earlier	early	ADJ
cblr-1794	65	20	hatch	hatch	NOUN
cblr-1794	65	21	-	-	PUNCT
cblr-1794	65	22	waxman	waxman	PROPN
cblr-1794	65	23	act	act	PROPN
cblr-1794	65	24	,	,	PUNCT
cblr-1794	65	25	which	which	PRON
cblr-1794	65	26	ushered	usher	VERB
cblr-1794	65	27	in	in	ADP
cblr-1794	65	28	a	a	DET
cblr-1794	65	29	new	new	ADJ
cblr-1794	65	30	era	era	NOUN
cblr-1794	65	31	of	of	ADP
cblr-1794	65	32	competition	competition	NOUN
cblr-1794	65	33	and	and	CCONJ
cblr-1794	65	34	affordable	affordable	ADJ
cblr-1794	65	35	drugs	drug	NOUN
cblr-1794	65	36	,	,	PUNCT
cblr-1794	65	37	the	the	DET
cblr-1794	65	38	[	[	X
cblr-1794	65	39	bpcia	bpcia	NOUN
cblr-1794	65	40	]	]	PUNCT
cblr-1794	65	41	would	would	AUX
cblr-1794	65	42	for	for	ADP
cblr-1794	65	43	the	the	DET
cblr-1794	65	44	very	very	ADV
cblr-1794	65	45	first	first	ADJ
cblr-1794	65	46	time	time	NOUN
cblr-1794	65	47	allow	allow	VERB
cblr-1794	65	48	patients	patient	NOUN
cblr-1794	65	49	access	access	VERB
cblr-1794	65	50	to	to	ADP
cblr-1794	65	51	generic	generic	ADJ
cblr-1794	65	52	,	,	PUNCT
cblr-1794	65	53	cheaper	cheap	ADJ
cblr-1794	65	54	versions	version	NOUN
cblr-1794	65	55	of	of	ADP
cblr-1794	65	56	biologic	biologic	ADJ
cblr-1794	65	57	drugs	drug	NOUN
cblr-1794	65	58	.	.	PUNCT
cblr-1794	65	59	"	"	PUNCT
cblr-1794	65	60	)	)	PUNCT
cblr-1794	65	61	.	.	PUNCT
cblr-1794	66	1	14	14	NUM
cblr-1794	66	2	ftc	ftc	PROPN
cblr-1794	66	3	,	,	PUNCT
cblr-1794	66	4	emerging	emerge	VERB
cblr-1794	66	5	health	health	NOUN
cblr-1794	66	6	care	care	NOUN
cblr-1794	66	7	issues	issue	NOUN
cblr-1794	66	8	:	:	PUNCT
cblr-1794	66	9	follow	follow	VERB
cblr-1794	66	10	-	-	PUNCT
cblr-1794	66	11	on	on	ADP
cblr-1794	66	12	biologic	biologic	NOUN
cblr-1794	66	13	drug	drug	NOUN
cblr-1794	66	14	competition	competition	NOUN
cblr-1794	66	15	12	12	NUM
cblr-1794	66	16	(	(	PUNCT
cblr-1794	66	17	2009	2009	NUM
cblr-1794	66	18	)	)	PUNCT
cblr-1794	67	1	[	[	X
cblr-1794	67	2	hereinafter	hereinafter	NOUN
cblr-1794	67	3	ftc	ftc	PROPN
cblr-1794	67	4	report	report	PROPN
cblr-1794	67	5	]	]	PUNCT
cblr-1794	67	6	,	,	PUNCT
cblr-1794	67	7	available	available	ADJ
cblr-1794	67	8	at	at	ADP
cblr-1794	67	9	www.ftc.gov/os/2009/06/po83901biologicsreport.pdf	www.ftc.gov/os/2009/06/po83901biologicsreport.pdf	NOUN
cblr-1794	67	10	.	.	PUNCT
cblr-1794	68	1	212	212	NUM
cblr-1794	68	2	col	col	PROPN
cblr-1794	68	3	umia	umia	PROPN
cblr-1794	68	4	b	b	PROPN
cblr-1794	68	5	usiness	usiness	PROPN
cblr-1794	68	6	la	la	PROPN
cblr-1794	68	7	w	w	PROPN
cblr-1794	68	8	re	re	PROPN
cblr-1794	68	9	vie	vie	PROPN
cblr-1794	68	10	w	w	PROPN
cblr-1794	69	1	[	[	X
cblr-1794	69	2	vol	vol	NOUN
cblr-1794	69	3	.	.	PUNCT
cblr-1794	70	1	2013	2013	NUM
cblr-1794	70	2	prices	price	NOUN
cblr-1794	70	3	will	will	AUX
cblr-1794	70	4	not	not	PART
cblr-1794	70	5	drop	drop	VERB
cblr-1794	70	6	as	as	ADV
cblr-1794	70	7	quickly	quickly	ADV
cblr-1794	70	8	as	as	ADP
cblr-1794	70	9	pharmaceutical	pharmaceutical	ADJ
cblr-1794	70	10	prices	price	NOUN
cblr-1794	70	11	under	under	ADP
cblr-1794	70	12	hatch	hatch	NOUN
cblr-1794	70	13	-	-	PUNCT
cblr-1794	70	14	waxman	waxman	NOUN
cblr-1794	70	15	.	.	PUNCT
cblr-1794	71	1	part	part	NOUN
cblr-1794	71	2	iv	iv	PRON
cblr-1794	71	3	will	will	AUX
cblr-1794	71	4	recommend	recommend	VERB
cblr-1794	71	5	that	that	SCONJ
cblr-1794	71	6	congress	congress	PROPN
cblr-1794	71	7	and	and	CCONJ
cblr-1794	71	8	the	the	DET
cblr-1794	71	9	fda	fda	PROPN
cblr-1794	71	10	act	act	NOUN
cblr-1794	71	11	to	to	PART
cblr-1794	71	12	improve	improve	VERB
cblr-1794	71	13	the	the	DET
cblr-1794	71	14	bpcia	bpcia	NOUN
cblr-1794	71	15	.	.	PUNCT
cblr-1794	72	1	first	first	ADV
cblr-1794	72	2	,	,	PUNCT
cblr-1794	72	3	congress	congress	PROPN
cblr-1794	72	4	can	can	AUX
cblr-1794	72	5	create	create	VERB
cblr-1794	72	6	a	a	DET
cblr-1794	72	7	tax	tax	NOUN
cblr-1794	72	8	structure	structure	NOUN
cblr-1794	72	9	that	that	PRON
cblr-1794	72	10	incentivizes	incentivize	VERB
cblr-1794	72	11	the	the	DET
cblr-1794	72	12	manufacture	manufacture	NOUN
cblr-1794	72	13	of	of	ADP
cblr-1794	72	14	biosimilars	biosimilar	NOUN
cblr-1794	72	15	.	.	PUNCT
cblr-1794	73	1	having	have	VERB
cblr-1794	73	2	more	more	ADJ
cblr-1794	73	3	biosimilars	biosimilar	NOUN
cblr-1794	73	4	on	on	ADP
cblr-1794	73	5	the	the	DET
cblr-1794	73	6	market	market	NOUN
cblr-1794	73	7	will	will	AUX
cblr-1794	73	8	lead	lead	VERB
cblr-1794	73	9	to	to	ADP
cblr-1794	73	10	lower	low	ADJ
cblr-1794	73	11	prices	price	NOUN
cblr-1794	73	12	.	.	PUNCT
cblr-1794	74	1	second	second	ADV
cblr-1794	74	2	,	,	PUNCT
cblr-1794	74	3	the	the	DET
cblr-1794	74	4	fda	fda	PROPN
cblr-1794	74	5	can	can	AUX
cblr-1794	74	6	issue	issue	VERB
cblr-1794	74	7	guidance	guidance	NOUN
cblr-1794	74	8	documents	document	NOUN
cblr-1794	74	9	to	to	PART
cblr-1794	74	10	ensure	ensure	VERB
cblr-1794	74	11	that	that	SCONJ
cblr-1794	74	12	biosimilar	biosimilar	PROPN
cblr-1794	74	13	manufacturers	manufacturer	NOUN
cblr-1794	74	14	understand	understand	VERB
cblr-1794	74	15	the	the	DET
cblr-1794	74	16	regulatory	regulatory	ADJ
cblr-1794	74	17	approval	approval	NOUN
cblr-1794	74	18	process	process	NOUN
cblr-1794	74	19	.	.	PUNCT
cblr-1794	75	1	regulatory	regulatory	ADJ
cblr-1794	75	2	predictability	predictability	NOUN
cblr-1794	75	3	and	and	CCONJ
cblr-1794	75	4	transparency	transparency	NOUN
cblr-1794	75	5	will	will	AUX
cblr-1794	75	6	help	help	VERB
cblr-1794	75	7	entice	entice	VERB
cblr-1794	75	8	more	more	ADJ
cblr-1794	75	9	firms	firm	NOUN
cblr-1794	75	10	into	into	ADP
cblr-1794	75	11	the	the	DET
cblr-1794	75	12	biosimilars	biosimilar	NOUN
cblr-1794	75	13	arena	arena	NOUN
cblr-1794	75	14	.	.	PUNCT
cblr-1794	76	1	third	third	ADJ
cblr-1794	76	2	,	,	PUNCT
cblr-1794	76	3	congress	congress	PROPN
cblr-1794	76	4	can	can	AUX
cblr-1794	76	5	reduce	reduce	VERB
cblr-1794	76	6	the	the	DET
cblr-1794	76	7	exclusivity	exclusivity	NOUN
cblr-1794	76	8	period	period	NOUN
cblr-1794	76	9	for	for	ADP
cblr-1794	76	10	branded	brand	VERB
cblr-1794	76	11	drugs	drug	NOUN
cblr-1794	76	12	from	from	ADP
cblr-1794	76	13	twelve	twelve	NUM
cblr-1794	76	14	to	to	ADP
cblr-1794	76	15	seven	seven	NUM
cblr-1794	76	16	years	year	NOUN
cblr-1794	76	17	.	.	PUNCT
cblr-1794	77	1	biosimilars	biosimilar	NOUN
cblr-1794	77	2	will	will	AUX
cblr-1794	77	3	be	be	AUX
cblr-1794	77	4	able	able	ADJ
cblr-1794	77	5	to	to	PART
cblr-1794	77	6	enter	enter	VERB
cblr-1794	77	7	the	the	DET
cblr-1794	77	8	market	market	NOUN
cblr-1794	77	9	more	more	ADV
cblr-1794	77	10	quickly	quickly	ADV
cblr-1794	77	11	,	,	PUNCT
cblr-1794	77	12	and	and	CCONJ
cblr-1794	77	13	prices	price	NOUN
cblr-1794	77	14	will	will	AUX
cblr-1794	77	15	fall	fall	VERB
cblr-1794	77	16	as	as	ADP
cblr-1794	77	17	a	a	DET
cblr-1794	77	18	result	result	NOUN
cblr-1794	77	19	.	.	PUNCT
cblr-1794	78	1	ii	ii	PROPN
cblr-1794	78	2	.	.	PUNCT
cblr-1794	79	1	background	background	NOUN
cblr-1794	79	2	on	on	ADP
cblr-1794	79	3	biologics	biologic	NOUN
cblr-1794	79	4	and	and	CCONJ
cblr-1794	79	5	the	the	DET
cblr-1794	79	6	bpcia	bpcia	NOUN
cblr-1794	79	7	a.	a.	NOUN
cblr-1794	79	8	regulation	regulation	NOUN
cblr-1794	79	9	of	of	ADP
cblr-1794	79	10	biologics	biologic	NOUN
cblr-1794	79	11	biologics	biologic	NOUN
cblr-1794	79	12	are	be	AUX
cblr-1794	79	13	"	"	PUNCT
cblr-1794	79	14	medical	medical	ADJ
cblr-1794	79	15	products	product	NOUN
cblr-1794	79	16	derived	derive	VERB
cblr-1794	79	17	from	from	ADP
cblr-1794	79	18	living	live	VERB
cblr-1794	79	19	sources	source	NOUN
cblr-1794	79	20	(	(	PUNCT
cblr-1794	79	21	animals	animal	NOUN
cblr-1794	79	22	,	,	PUNCT
cblr-1794	79	23	humans	human	NOUN
cblr-1794	79	24	,	,	PUNCT
cblr-1794	79	25	and	and	CCONJ
cblr-1794	79	26	microorganisms	microorganism	NOUN
cblr-1794	79	27	)	)	PUNCT
cblr-1794	79	28	and	and	CCONJ
cblr-1794	79	29	include	include	VERB
cblr-1794	79	30	viruses	virus	NOUN
cblr-1794	79	31	,	,	PUNCT
cblr-1794	79	32	therapeutic	therapeutic	ADJ
cblr-1794	79	33	serums	serum	NOUN
cblr-1794	79	34	,	,	PUNCT
cblr-1794	79	35	toxins	toxin	NOUN
cblr-1794	79	36	and	and	CCONJ
cblr-1794	79	37	antitoxins	antitoxin	NOUN
cblr-1794	79	38	,	,	PUNCT
cblr-1794	79	39	vaccines	vaccine	NOUN
cblr-1794	79	40	,	,	PUNCT
cblr-1794	79	41	blood	blood	NOUN
cblr-1794	79	42	and	and	CCONJ
cblr-1794	79	43	blood	blood	NOUN
cblr-1794	79	44	products	product	NOUN
cblr-1794	79	45	,	,	PUNCT
cblr-1794	79	46	and	and	CCONJ
cblr-1794	79	47	cells	cell	NOUN
cblr-1794	79	48	,	,	PUNCT
cblr-1794	79	49	tissues	tissue	NOUN
cblr-1794	79	50	and	and	CCONJ
cblr-1794	79	51	gene	gene	NOUN
cblr-1794	79	52	therapy	therapy	NOUN
cblr-1794	79	53	products	product	NOUN
cblr-1794	79	54	.	.	PUNCT
cblr-1794	80	1	"'6	"'6	PUNCT
cblr-1794	80	2	biologics	biologic	NOUN
cblr-1794	80	3	differ	differ	VERB
cblr-1794	80	4	from	from	ADP
cblr-1794	80	5	traditional	traditional	ADJ
cblr-1794	80	6	pharmaceutical	pharmaceutical	ADJ
cblr-1794	80	7	drugs	drug	NOUN
cblr-1794	80	8	in	in	ADP
cblr-1794	80	9	a	a	DET
cblr-1794	80	10	number	number	NOUN
cblr-1794	80	11	of	of	ADP
cblr-1794	80	12	ways	way	NOUN
cblr-1794	80	13	.	.	PUNCT
cblr-1794	81	1	first	first	ADV
cblr-1794	81	2	,	,	PUNCT
cblr-1794	81	3	biologics	biologic	NOUN
cblr-1794	81	4	originate	originate	VERB
cblr-1794	81	5	from	from	ADP
cblr-1794	81	6	living	live	VERB
cblr-1794	81	7	sources	source	NOUN
cblr-1794	81	8	,	,	PUNCT
cblr-1794	81	9	while	while	SCONJ
cblr-1794	81	10	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	81	11	originate	originate	VERB
cblr-1794	81	12	from	from	ADP
cblr-1794	81	13	chemically	chemically	ADV
cblr-1794	81	14	synthesized	synthesize	VERB
cblr-1794	81	15	sources.16	sources.16	PROPN
cblr-1794	81	16	second	second	NOUN
cblr-1794	81	17	,	,	PUNCT
cblr-1794	81	18	biologics	biologic	NOUN
cblr-1794	81	19	are	be	AUX
cblr-1794	81	20	more	more	ADV
cblr-1794	81	21	complex	complex	ADJ
cblr-1794	81	22	macromolecular	macromolecular	ADJ
cblr-1794	81	23	entities	entity	NOUN
cblr-1794	81	24	,	,	PUNCT
cblr-1794	81	25	consisting	consist	VERB
cblr-1794	81	26	of	of	ADP
cblr-1794	81	27	proteins	protein	NOUN
cblr-1794	81	28	15	15	NUM
cblr-1794	81	29	see	see	VERB
cblr-1794	81	30	jordan	jordan	PROPN
cblr-1794	81	31	paradise	paradise	PROPN
cblr-1794	81	32	,	,	PUNCT
cblr-1794	81	33	follow	follow	VERB
cblr-1794	81	34	-	-	PUNCT
cblr-1794	81	35	on	on	ADP
cblr-1794	81	36	biologics	biologic	NOUN
cblr-1794	81	37	:	:	PUNCT
cblr-1794	81	38	implementation	implementation	NOUN
cblr-1794	81	39	challenges	challenge	NOUN
cblr-1794	81	40	and	and	CCONJ
cblr-1794	81	41	opportunities	opportunity	NOUN
cblr-1794	81	42	,	,	PUNCT
cblr-1794	81	43	41	41	NUM
cblr-1794	81	44	seton	seton	PROPN
cblr-1794	81	45	hall	hall	PROPN
cblr-1794	81	46	l.	l.	PROPN
cblr-1794	81	47	rev	rev	PROPN
cblr-1794	81	48	.	.	PROPN
cblr-1794	81	49	501	501	NUM
cblr-1794	81	50	,	,	PUNCT
cblr-1794	81	51	502	502	NUM
cblr-1794	81	52	(	(	PUNCT
cblr-1794	81	53	2011	2011	NUM
cblr-1794	81	54	)	)	PUNCT
cblr-1794	81	55	.	.	PUNCT
cblr-1794	82	1	under	under	ADP
cblr-1794	82	2	federal	federal	ADJ
cblr-1794	82	3	law	law	NOUN
cblr-1794	82	4	,	,	PUNCT
cblr-1794	82	5	a	a	DET
cblr-1794	82	6	biologic	biologic	NOUN
cblr-1794	82	7	is	be	AUX
cblr-1794	82	8	defined	define	VERB
cblr-1794	82	9	as	as	ADP
cblr-1794	82	10	"	"	PUNCT
cblr-1794	82	11	a	a	DET
cblr-1794	82	12	virus	virus	NOUN
cblr-1794	82	13	,	,	PUNCT
cblr-1794	82	14	therapeutic	therapeutic	ADJ
cblr-1794	82	15	serum	serum	NOUN
cblr-1794	82	16	,	,	PUNCT
cblr-1794	82	17	toxin	toxin	NOUN
cblr-1794	82	18	,	,	PUNCT
cblr-1794	82	19	antitoxin	antitoxin	NOUN
cblr-1794	82	20	,	,	PUNCT
cblr-1794	82	21	vaccine	vaccine	NOUN
cblr-1794	82	22	,	,	PUNCT
cblr-1794	82	23	blood	blood	NOUN
cblr-1794	82	24	,	,	PUNCT
cblr-1794	82	25	blood	blood	NOUN
cblr-1794	82	26	component	component	NOUN
cblr-1794	82	27	or	or	CCONJ
cblr-1794	82	28	derivative	derivative	ADJ
cblr-1794	82	29	,	,	PUNCT
cblr-1794	82	30	allergenic	allergenic	ADJ
cblr-1794	82	31	product	product	NOUN
cblr-1794	82	32	,	,	PUNCT
cblr-1794	82	33	protein	protein	NOUN
cblr-1794	82	34	(	(	PUNCT
cblr-1794	82	35	except	except	SCONJ
cblr-1794	82	36	any	any	DET
cblr-1794	82	37	chemically	chemically	ADV
cblr-1794	82	38	synthesized	synthesize	VERB
cblr-1794	82	39	polypeptide	polypeptide	ADJ
cblr-1794	82	40	)	)	PUNCT
cblr-1794	82	41	or	or	CCONJ
cblr-1794	82	42	analogous	analogous	ADJ
cblr-1794	82	43	product	product	NOUN
cblr-1794	82	44	,	,	PUNCT
cblr-1794	82	45	or	or	CCONJ
cblr-1794	82	46	arsphenamine	arsphenamine	VERB
cblr-1794	82	47	or	or	CCONJ
cblr-1794	82	48	derivative	derivative	NOUN
cblr-1794	82	49	of	of	ADP
cblr-1794	82	50	arsphenamine	arsphenamine	NOUN
cblr-1794	82	51	(	(	PUNCT
cblr-1794	82	52	or	or	CCONJ
cblr-1794	82	53	any	any	DET
cblr-1794	82	54	other	other	ADJ
cblr-1794	82	55	trivalent	trivalent	NOUN
cblr-1794	82	56	organic	organic	ADJ
cblr-1794	82	57	arsenic	arsenic	ADJ
cblr-1794	82	58	compound	compound	NOUN
cblr-1794	82	59	)	)	PUNCT
cblr-1794	82	60	,	,	PUNCT
cblr-1794	82	61	applicable	applicable	ADJ
cblr-1794	82	62	to	to	ADP
cblr-1794	82	63	the	the	DET
cblr-1794	82	64	prevention	prevention	NOUN
cblr-1794	82	65	,	,	PUNCT
cblr-1794	82	66	treatment	treatment	NOUN
cblr-1794	82	67	,	,	PUNCT
cblr-1794	82	68	or	or	CCONJ
cblr-1794	82	69	cure	cure	NOUN
cblr-1794	82	70	of	of	ADP
cblr-1794	82	71	a	a	DET
cblr-1794	82	72	disease	disease	NOUN
cblr-1794	82	73	or	or	CCONJ
cblr-1794	82	74	condition	condition	NOUN
cblr-1794	82	75	of	of	ADP
cblr-1794	82	76	human	human	ADJ
cblr-1794	82	77	beings	being	NOUN
cblr-1794	82	78	.	.	PUNCT
cblr-1794	82	79	"	"	PUNCT
cblr-1794	83	1	42	42	NUM
cblr-1794	83	2	u.s.c.a	u.s.c.a	PROPN
cblr-1794	83	3	.	.	PUNCT
cblr-1794	83	4	§	§	PROPN
cblr-1794	83	5	262(i	262(i	PROPN
cblr-1794	83	6	)	)	PUNCT
cblr-1794	83	7	(	(	PUNCT
cblr-1794	83	8	west	west	NOUN
cblr-1794	83	9	2012	2012	NUM
cblr-1794	83	10	)	)	PUNCT
cblr-1794	83	11	.	.	PUNCT
cblr-1794	84	1	16	16	NUM
cblr-1794	84	2	paradise	paradise	PROPN
cblr-1794	84	3	,	,	PUNCT
cblr-1794	84	4	supra	supra	PROPN
cblr-1794	84	5	note	note	PROPN
cblr-1794	84	6	15	15	NUM
cblr-1794	84	7	,	,	PUNCT
cblr-1794	84	8	at	at	ADP
cblr-1794	84	9	503	503	NUM
cblr-1794	84	10	.	.	PUNCT
cblr-1794	85	1	bpcia	bpcia	NOUN
cblr-1794	85	2	:	:	PUNCT
cblr-1794	85	3	destined	destine	VERB
cblr-1794	85	4	for	for	ADP
cblr-1794	85	5	failure	failure	NOUN
cblr-1794	85	6	?	?	PUNCT
cblr-1794	86	1	213no	213no	PROPN
cblr-1794	86	2	.	.	PUNCT
cblr-1794	87	1	1:209]1	1:209]1	NUM
cblr-1794	87	2	whose	whose	DET
cblr-1794	87	3	structure	structure	NOUN
cblr-1794	87	4	is	be	AUX
cblr-1794	87	5	determined	determine	VERB
cblr-1794	87	6	by	by	ADP
cblr-1794	87	7	four	four	NUM
cblr-1794	87	8	organizational	organizational	ADJ
cblr-1794	87	9	levels	level	NOUN
cblr-1794	87	10	:	:	PUNCT
cblr-1794	87	11	the	the	DET
cblr-1794	87	12	sequence	sequence	NOUN
cblr-1794	87	13	of	of	ADP
cblr-1794	87	14	amino	amino	ADJ
cblr-1794	87	15	acids	acid	NOUN
cblr-1794	87	16	in	in	ADP
cblr-1794	87	17	the	the	DET
cblr-1794	87	18	protein	protein	NOUN
cblr-1794	87	19	chain	chain	NOUN
cblr-1794	87	20	,	,	PUNCT
cblr-1794	87	21	the	the	DET
cblr-1794	87	22	spatial	spatial	ADJ
cblr-1794	87	23	configuration	configuration	NOUN
cblr-1794	87	24	of	of	ADP
cblr-1794	87	25	the	the	DET
cblr-1794	87	26	amino	amino	NOUN
cblr-1794	87	27	acids	acid	NOUN
cblr-1794	87	28	within	within	ADP
cblr-1794	87	29	the	the	DET
cblr-1794	87	30	chain	chain	NOUN
cblr-1794	87	31	,	,	PUNCT
cblr-1794	87	32	any	any	DET
cblr-1794	87	33	three	three	NUM
cblr-1794	87	34	dimensional	dimensional	ADJ
cblr-1794	87	35	folding	folding	NOUN
cblr-1794	87	36	that	that	PRON
cblr-1794	87	37	occurs	occur	VERB
cblr-1794	87	38	,	,	PUNCT
cblr-1794	87	39	and	and	CCONJ
cblr-1794	87	40	the	the	DET
cblr-1794	87	41	interactions	interaction	NOUN
cblr-1794	87	42	between	between	ADP
cblr-1794	87	43	different	different	ADJ
cblr-1794	87	44	chains	chain	NOUN
cblr-1794	87	45	.	.	PUNCT
cblr-1794	87	46	"	"	PUNCT
cblr-1794	88	1	third	third	ADV
cblr-1794	88	2	,	,	PUNCT
cblr-1794	88	3	biologics	biologic	NOUN
cblr-1794	88	4	are	be	AUX
cblr-1794	88	5	typically	typically	ADV
cblr-1794	88	6	manufactured	manufacture	VERB
cblr-1794	88	7	using	use	VERB
cblr-1794	88	8	more	more	ADV
cblr-1794	88	9	sophisticated	sophisticated	ADJ
cblr-1794	88	10	techniques	technique	NOUN
cblr-1794	88	11	,	,	PUNCT
cblr-1794	88	12	and	and	CCONJ
cblr-1794	88	13	due	due	ADP
cblr-1794	88	14	to	to	ADP
cblr-1794	88	15	the	the	DET
cblr-1794	88	16	complexity	complexity	NOUN
cblr-1794	88	17	of	of	ADP
cblr-1794	88	18	protein	protein	NOUN
cblr-1794	88	19	structure	structure	NOUN
cblr-1794	88	20	-	-	PUNCT
cblr-1794	88	21	the	the	DET
cblr-1794	88	22	final	final	ADJ
cblr-1794	88	23	biologic	biologic	NOUN
cblr-1794	88	24	product	product	NOUN
cblr-1794	88	25	is	be	AUX
cblr-1794	88	26	extremely	extremely	ADV
cblr-1794	88	27	susceptible	susceptible	ADJ
cblr-1794	88	28	to	to	ADP
cblr-1794	88	29	even	even	ADV
cblr-1794	88	30	the	the	DET
cblr-1794	88	31	slightest	slight	ADJ
cblr-1794	88	32	changes	change	NOUN
cblr-1794	88	33	in	in	ADP
cblr-1794	88	34	the	the	DET
cblr-1794	88	35	manufacturing	manufacturing	NOUN
cblr-1794	88	36	process	process	NOUN
cblr-1794	88	37	.	.	PUNCT
cblr-1794	88	38	"	"	PUNCT
cblr-1794	89	1	due	due	ADP
cblr-1794	89	2	to	to	ADP
cblr-1794	89	3	a	a	DET
cblr-1794	89	4	complicated	complicated	ADJ
cblr-1794	89	5	legislative	legislative	ADJ
cblr-1794	89	6	history	history	NOUN
cblr-1794	89	7	,	,	PUNCT
cblr-1794	89	8	biologics	biologic	NOUN
cblr-1794	89	9	and	and	CCONJ
cblr-1794	89	10	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	89	11	are	be	AUX
cblr-1794	89	12	regulated	regulate	VERB
cblr-1794	89	13	under	under	ADP
cblr-1794	89	14	different	different	ADJ
cblr-1794	89	15	federal	federal	ADJ
cblr-1794	89	16	statutes	statute	NOUN
cblr-1794	89	17	.	.	PUNCT
cblr-1794	90	1	in	in	ADP
cblr-1794	90	2	1938	1938	NUM
cblr-1794	90	3	,	,	PUNCT
cblr-1794	90	4	congress	congress	PROPN
cblr-1794	90	5	passed	pass	VERB
cblr-1794	90	6	the	the	DET
cblr-1794	90	7	federal	federal	ADJ
cblr-1794	90	8	food	food	NOUN
cblr-1794	90	9	,	,	PUNCT
cblr-1794	90	10	drug	drug	NOUN
cblr-1794	90	11	and	and	CCONJ
cblr-1794	90	12	cosmetic	cosmetic	ADJ
cblr-1794	90	13	act	act	NOUN
cblr-1794	90	14	(	(	PUNCT
cblr-1794	90	15	"	"	PUNCT
cblr-1794	90	16	fdca")1	fdca")1	ADV
cblr-1794	90	17	to	to	PART
cblr-1794	90	18	strengthen	strengthen	VERB
cblr-1794	90	19	federal	federal	ADJ
cblr-1794	90	20	oversight	oversight	NOUN
cblr-1794	90	21	of	of	ADP
cblr-1794	90	22	drugs.20	drugs.20	NOUN
cblr-1794	90	23	the	the	DET
cblr-1794	90	24	fdca	fdca	NOUN
cblr-1794	90	25	's	's	PART
cblr-1794	90	26	definition	definition	NOUN
cblr-1794	90	27	of	of	ADP
cblr-1794	90	28	drug	drug	NOUN
cblr-1794	90	29	was	be	AUX
cblr-1794	90	30	broad	broad	ADJ
cblr-1794	90	31	enough	enough	ADV
cblr-1794	90	32	to	to	PART
cblr-1794	90	33	capture	capture	VERB
cblr-1794	90	34	both	both	DET
cblr-1794	90	35	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	90	36	and	and	CCONJ
cblr-1794	90	37	biologics.2	biologics.2	ADJ
cblr-1794	90	38	1	1	NUM
cblr-1794	90	39	under	under	ADP
cblr-1794	90	40	the	the	DET
cblr-1794	90	41	fdca	fdca	NOUN
cblr-1794	90	42	,	,	PUNCT
cblr-1794	90	43	a	a	DET
cblr-1794	90	44	new	new	ADJ
cblr-1794	90	45	drug22	drug22	NOUN
cblr-1794	90	46	must	must	AUX
cblr-1794	90	47	be	be	AUX
cblr-1794	90	48	tested	test	VERB
cblr-1794	90	49	for	for	ADP
cblr-1794	90	50	safety	safety	NOUN
cblr-1794	90	51	in	in	ADP
cblr-1794	90	52	humans	human	NOUN
cblr-1794	90	53	before	before	SCONJ
cblr-1794	90	54	the	the	DET
cblr-1794	90	55	drug	drug	NOUN
cblr-1794	90	56	is	be	AUX
cblr-1794	90	57	released	release	VERB
cblr-1794	90	58	to	to	ADP
cblr-1794	90	59	the	the	DET
cblr-1794	90	60	market.2	market.2	PROPN
cblr-1794	90	61	3	3	NUM
cblr-1794	90	62	the	the	DET
cblr-1794	90	63	sponsor	sponsor	NOUN
cblr-1794	90	64	of	of	ADP
cblr-1794	90	65	the	the	DET
cblr-1794	90	66	drug	drug	NOUN
cblr-1794	90	67	must	must	AUX
cblr-1794	90	68	submit	submit	VERB
cblr-1794	90	69	a	a	DET
cblr-1794	90	70	new	new	ADJ
cblr-1794	90	71	drug	drug	NOUN
cblr-1794	90	72	application	application	NOUN
cblr-1794	90	73	(	(	PUNCT
cblr-1794	90	74	"	"	PUNCT
cblr-1794	90	75	nda	nda	PROPN
cblr-1794	90	76	"	"	PUNCT
cblr-1794	90	77	)	)	PUNCT
cblr-1794	90	78	,	,	PUNCT
cblr-1794	90	79	17	17	NUM
cblr-1794	90	80	see	see	VERB
cblr-1794	90	81	generally	generally	ADV
cblr-1794	90	82	johnson	johnson	PROPN
cblr-1794	90	83	,	,	PUNCT
cblr-1794	90	84	supra	supra	PROPN
cblr-1794	90	85	note	note	PROPN
cblr-1794	90	86	8	8	NUM
cblr-1794	90	87	,	,	PUNCT
cblr-1794	90	88	at	at	ADP
cblr-1794	90	89	10	10	NUM
cblr-1794	90	90	(	(	PUNCT
cblr-1794	90	91	"	"	PUNCT
cblr-1794	90	92	a	a	DET
cblr-1794	90	93	protein	protein	NOUN
cblr-1794	90	94	is	be	AUX
cblr-1794	90	95	a	a	DET
cblr-1794	90	96	large	large	ADJ
cblr-1794	90	97	organic	organic	ADJ
cblr-1794	90	98	molecule	molecule	NOUN
cblr-1794	90	99	composed	compose	VERB
cblr-1794	90	100	of	of	ADP
cblr-1794	90	101	a	a	DET
cblr-1794	90	102	long	long	ADJ
cblr-1794	90	103	chain	chain	NOUN
cblr-1794	90	104	of	of	ADP
cblr-1794	90	105	component	component	NOUN
cblr-1794	90	106	parts	part	NOUN
cblr-1794	90	107	,	,	PUNCT
cblr-1794	90	108	called	call	VERB
cblr-1794	90	109	amino	amino	NOUN
cblr-1794	90	110	acids	acid	NOUN
cblr-1794	90	111	,	,	PUNCT
cblr-1794	90	112	which	which	PRON
cblr-1794	90	113	are	be	AUX
cblr-1794	90	114	linked	link	VERB
cblr-1794	90	115	by	by	ADP
cblr-1794	90	116	chemical	chemical	ADJ
cblr-1794	90	117	bonds	bond	NOUN
cblr-1794	90	118	.	.	PUNCT
cblr-1794	91	1	this	this	DET
cblr-1794	91	2	amino	amino	NOUN
cblr-1794	91	3	acid	acid	NOUN
cblr-1794	91	4	chain	chain	NOUN
cblr-1794	91	5	folds	fold	NOUN
cblr-1794	91	6	into	into	ADP
cblr-1794	91	7	a	a	DET
cblr-1794	91	8	complex	complex	ADJ
cblr-1794	91	9	three	three	NUM
cblr-1794	91	10	-	-	PUNCT
cblr-1794	91	11	dimensional	dimensional	ADJ
cblr-1794	91	12	structure	structure	NOUN
cblr-1794	91	13	"	"	PUNCT
cblr-1794	91	14	)	)	PUNCT
cblr-1794	91	15	.	.	PUNCT
cblr-1794	92	1	18	18	NUM
cblr-1794	92	2	paradise	paradise	PROPN
cblr-1794	92	3	,	,	PUNCT
cblr-1794	92	4	supra	supra	PROPN
cblr-1794	92	5	note	note	PROPN
cblr-1794	92	6	15	15	NUM
cblr-1794	92	7	,	,	PUNCT
cblr-1794	92	8	at	at	ADP
cblr-1794	92	9	503	503	NUM
cblr-1794	92	10	.	.	PUNCT
cblr-1794	92	11	19	19	NUM
cblr-1794	92	12	food	food	NOUN
cblr-1794	92	13	,	,	PUNCT
cblr-1794	92	14	drug	drug	NOUN
cblr-1794	92	15	and	and	CCONJ
cblr-1794	92	16	cosmetic	cosmetic	ADJ
cblr-1794	92	17	act	act	NOUN
cblr-1794	92	18	(	(	PUNCT
cblr-1794	92	19	"	"	PUNCT
cblr-1794	92	20	fdca	fdca	ADJ
cblr-1794	92	21	"	"	PUNCT
cblr-1794	92	22	)	)	PUNCT
cblr-1794	92	23	,	,	PUNCT
cblr-1794	92	24	pub	pub	NOUN
cblr-1794	92	25	.	.	PUNCT
cblr-1794	93	1	l.	l.	PROPN
cblr-1794	93	2	no	no	INTJ
cblr-1794	93	3	.	.	PROPN
cblr-1794	94	1	75	75	NUM
cblr-1794	94	2	-	-	SYM
cblr-1794	94	3	717	717	NUM
cblr-1794	94	4	,	,	PUNCT
cblr-1794	94	5	52	52	NUM
cblr-1794	94	6	stat	stat	NOUN
cblr-1794	94	7	.	.	PUNCT
cblr-1794	95	1	1040	1040	NUM
cblr-1794	95	2	(	(	PUNCT
cblr-1794	95	3	1938	1938	NUM
cblr-1794	95	4	)	)	PUNCT
cblr-1794	95	5	(	(	PUNCT
cblr-1794	95	6	codified	codify	VERB
cblr-1794	95	7	as	as	SCONJ
cblr-1794	95	8	amended	amend	VERB
cblr-1794	95	9	in	in	ADP
cblr-1794	95	10	scattered	scatter	VERB
cblr-1794	95	11	sections	section	NOUN
cblr-1794	95	12	of	of	ADP
cblr-1794	95	13	21	21	NUM
cblr-1794	95	14	u.s.c	u.s.c	ADJ
cblr-1794	95	15	.	.	PUNCT
cblr-1794	95	16	)	)	PUNCT
cblr-1794	95	17	.	.	PUNCT
cblr-1794	96	1	20	20	NUM
cblr-1794	96	2	krista	krista	PROPN
cblr-1794	96	3	h.	h.	PROPN
cblr-1794	96	4	carver	carver	PROPN
cblr-1794	96	5	,	,	PUNCT
cblr-1794	96	6	jeffrey	jeffrey	PROPN
cblr-1794	96	7	elikan	elikan	PROPN
cblr-1794	96	8	&	&	CCONJ
cblr-1794	96	9	erika	erika	PROPN
cblr-1794	96	10	lietzan	lietzan	PROPN
cblr-1794	96	11	,	,	PUNCT
cblr-1794	96	12	an	an	DET
cblr-1794	96	13	unofficial	unofficial	ADJ
cblr-1794	96	14	legislative	legislative	ADJ
cblr-1794	96	15	history	history	NOUN
cblr-1794	96	16	of	of	ADP
cblr-1794	96	17	the	the	DET
cblr-1794	96	18	biologics	biologic	NOUN
cblr-1794	96	19	price	price	NOUN
cblr-1794	96	20	competition	competition	NOUN
cblr-1794	96	21	and	and	CCONJ
cblr-1794	96	22	innovation	innovation	NOUN
cblr-1794	96	23	act	act	NOUN
cblr-1794	96	24	of	of	ADP
cblr-1794	96	25	2009	2009	NUM
cblr-1794	96	26	,	,	PUNCT
cblr-1794	96	27	65	65	NUM
cblr-1794	96	28	food	food	NOUN
cblr-1794	96	29	&	&	CCONJ
cblr-1794	96	30	drug	drug	PROPN
cblr-1794	96	31	l.j	l.j	PROPN
cblr-1794	96	32	.	.	PROPN
cblr-1794	96	33	671	671	NUM
cblr-1794	96	34	,	,	PUNCT
cblr-1794	96	35	673	673	NUM
cblr-1794	96	36	(	(	PUNCT
cblr-1794	96	37	2010	2010	NUM
cblr-1794	96	38	)	)	PUNCT
cblr-1794	96	39	.	.	PUNCT
cblr-1794	97	1	21	21	NUM
cblr-1794	98	1	i	i	PRON
cblr-1794	98	2	d.	d.	PROPN
cblr-1794	98	3	22	22	NUM
cblr-1794	98	4	the	the	DET
cblr-1794	98	5	fdca	fdca	NOUN
cblr-1794	98	6	defined	define	VERB
cblr-1794	98	7	"	"	PUNCT
cblr-1794	98	8	new	new	ADJ
cblr-1794	98	9	drug	drug	NOUN
cblr-1794	98	10	"	"	PUNCT
cblr-1794	98	11	as	as	ADP
cblr-1794	98	12	[	[	X
cblr-1794	98	13	any	any	DET
cblr-1794	98	14	drug	drug	NOUN
cblr-1794	98	15	(	(	PUNCT
cblr-1794	98	16	except	except	SCONJ
cblr-1794	98	17	a	a	DET
cblr-1794	98	18	new	new	ADJ
cblr-1794	98	19	animal	animal	NOUN
cblr-1794	98	20	drug	drug	NOUN
cblr-1794	98	21	or	or	CCONJ
cblr-1794	98	22	an	an	DET
cblr-1794	98	23	animal	animal	NOUN
cblr-1794	98	24	feed	feed	NOUN
cblr-1794	98	25	bearing	bearing	NOUN
cblr-1794	98	26	or	or	CCONJ
cblr-1794	98	27	containing	contain	VERB
cblr-1794	98	28	a	a	DET
cblr-1794	98	29	new	new	ADJ
cblr-1794	98	30	animal	animal	NOUN
cblr-1794	98	31	drug	drug	NOUN
cblr-1794	98	32	)	)	PUNCT
cblr-1794	98	33	the	the	DET
cblr-1794	98	34	composition	composition	NOUN
cblr-1794	98	35	of	of	ADP
cblr-1794	98	36	which	which	PRON
cblr-1794	98	37	is	be	AUX
cblr-1794	98	38	such	such	ADJ
cblr-1794	98	39	that	that	SCONJ
cblr-1794	98	40	such	such	ADJ
cblr-1794	98	41	drug	drug	NOUN
cblr-1794	98	42	is	be	AUX
cblr-1794	98	43	not	not	PART
cblr-1794	98	44	generally	generally	ADV
cblr-1794	98	45	recognized	recognize	VERB
cblr-1794	98	46	,	,	PUNCT
cblr-1794	98	47	among	among	ADP
cblr-1794	98	48	experts	expert	NOUN
cblr-1794	98	49	qualified	qualify	VERB
cblr-1794	98	50	by	by	ADP
cblr-1794	98	51	scientific	scientific	ADJ
cblr-1794	98	52	training	training	NOUN
cblr-1794	98	53	and	and	CCONJ
cblr-1794	98	54	experience	experience	NOUN
cblr-1794	98	55	to	to	PART
cblr-1794	98	56	evaluate	evaluate	VERB
cblr-1794	98	57	the	the	DET
cblr-1794	98	58	safety	safety	NOUN
cblr-1794	98	59	and	and	CCONJ
cblr-1794	98	60	effectiveness	effectiveness	NOUN
cblr-1794	98	61	of	of	ADP
cblr-1794	98	62	drugs	drug	NOUN
cblr-1794	98	63	,	,	PUNCT
cblr-1794	98	64	as	as	ADV
cblr-1794	98	65	safe	safe	ADJ
cblr-1794	98	66	and	and	CCONJ
cblr-1794	98	67	effective	effective	ADJ
cblr-1794	98	68	for	for	ADP
cblr-1794	98	69	use	use	NOUN
cblr-1794	98	70	under	under	ADP
cblr-1794	98	71	the	the	DET
cblr-1794	98	72	condition	condition	NOUN
cblr-1794	98	73	prescribed	prescribe	VERB
cblr-1794	98	74	,	,	PUNCT
cblr-1794	98	75	recommended	recommend	VERB
cblr-1794	98	76	,	,	PUNCT
cblr-1794	98	77	or	or	CCONJ
cblr-1794	98	78	suggested	suggest	VERB
cblr-1794	98	79	in	in	ADP
cblr-1794	98	80	the	the	DET
cblr-1794	98	81	labeling	labeling	NOUN
cblr-1794	98	82	thereof	thereof	ADV
cblr-1794	98	83	....	....	PUNCT
cblr-1794	99	1	food	food	NOUN
cblr-1794	99	2	,	,	PUNCT
cblr-1794	99	3	drug	drug	NOUN
cblr-1794	99	4	,	,	PUNCT
cblr-1794	99	5	and	and	CCONJ
cblr-1794	99	6	cosmetic	cosmetic	ADJ
cblr-1794	99	7	act	act	NOUN
cblr-1794	99	8	,	,	PUNCT
cblr-1794	99	9	§	§	PROPN
cblr-1794	99	10	201(p	201(p	PROPN
cblr-1794	99	11	)	)	PUNCT
cblr-1794	99	12	,	,	PUNCT
cblr-1794	99	13	21	21	NUM
cblr-1794	99	14	u.s.c.a	u.s.c.a	PROPN
cblr-1794	99	15	.	.	PUNCT
cblr-1794	100	1	§	§	PROPN
cblr-1794	100	2	321	321	NUM
cblr-1794	100	3	(	(	PUNCT
cblr-1794	100	4	west	west	NOUN
cblr-1794	100	5	2012	2012	NUM
cblr-1794	100	6	)	)	PUNCT
cblr-1794	100	7	.	.	PUNCT
cblr-1794	101	1	23	23	NUM
cblr-1794	101	2	carver	carver	NOUN
cblr-1794	101	3	et	et	PROPN
cblr-1794	101	4	al	al	PROPN
cblr-1794	101	5	.	.	PROPN
cblr-1794	101	6	,	,	PUNCT
cblr-1794	101	7	supra	supra	PROPN
cblr-1794	101	8	note	note	PROPN
cblr-1794	101	9	20	20	NUM
cblr-1794	101	10	,	,	PUNCT
cblr-1794	101	11	at	at	ADP
cblr-1794	101	12	673	673	NUM
cblr-1794	101	13	.	.	PUNCT
cblr-1794	102	1	214	214	NUM
cblr-1794	102	2	col	col	PROPN
cblr-1794	102	3	umia	umia	PROPN
cblr-1794	102	4	b	b	PROPN
cblr-1794	102	5	usiness	usiness	PROPN
cblr-1794	102	6	la	la	PROPN
cblr-1794	102	7	wre	wre	PROPN
cblr-1794	102	8	vie	vie	PROPN
cblr-1794	102	9	w	w	PROPN
cblr-1794	103	1	[	[	X
cblr-1794	103	2	vol	vol	NOUN
cblr-1794	103	3	.	.	PUNCT
cblr-1794	103	4	2013	2013	NUM
cblr-1794	103	5	which	which	PRON
cblr-1794	103	6	is	be	AUX
cblr-1794	103	7	reviewed	review	VERB
cblr-1794	103	8	for	for	ADP
cblr-1794	103	9	approval	approval	NOUN
cblr-1794	103	10	by	by	ADP
cblr-1794	103	11	the	the	DET
cblr-1794	103	12	center	center	NOUN
cblr-1794	103	13	for	for	ADP
cblr-1794	103	14	drug	drug	NOUN
cblr-1794	103	15	evaluation	evaluation	NOUN
cblr-1794	103	16	and	and	CCONJ
cblr-1794	103	17	research	research	NOUN
cblr-1794	103	18	(	(	PUNCT
cblr-1794	103	19	"	"	PUNCT
cblr-1794	103	20	cder").24	cder").24	PROPN
cblr-1794	103	21	however	however	ADV
cblr-1794	103	22	,	,	PUNCT
cblr-1794	103	23	six	six	NUM
cblr-1794	103	24	years	year	NOUN
cblr-1794	103	25	after	after	ADP
cblr-1794	103	26	passing	pass	VERB
cblr-1794	103	27	the	the	DET
cblr-1794	103	28	fdca	fdca	NOUN
cblr-1794	103	29	,	,	PUNCT
cblr-1794	103	30	congress	congress	PROPN
cblr-1794	103	31	passed	pass	VERB
cblr-1794	103	32	the	the	DET
cblr-1794	103	33	public	public	ADJ
cblr-1794	103	34	health	health	PROPN
cblr-1794	103	35	service	service	PROPN
cblr-1794	103	36	act	act	NOUN
cblr-1794	103	37	(	(	PUNCT
cblr-1794	103	38	"	"	PUNCT
cblr-1794	103	39	psha").25	psha").25	VERB
cblr-1794	103	40	the	the	DET
cblr-1794	103	41	phsa	phsa	NOUN
cblr-1794	103	42	specified	specify	VERB
cblr-1794	103	43	that	that	SCONJ
cblr-1794	103	44	biologic	biologic	NOUN
cblr-1794	103	45	drugs	drug	NOUN
cblr-1794	103	46	would	would	AUX
cblr-1794	103	47	from	from	ADP
cblr-1794	103	48	then	then	ADV
cblr-1794	103	49	on	on	ADV
cblr-1794	103	50	be	be	AUX
cblr-1794	103	51	approved	approve	VERB
cblr-1794	103	52	under	under	ADP
cblr-1794	103	53	section	section	NOUN
cblr-1794	103	54	351	351	NUM
cblr-1794	103	55	of	of	ADP
cblr-1794	103	56	the	the	DET
cblr-1794	103	57	phsa	phsa	NOUN
cblr-1794	103	58	while	while	SCONJ
cblr-1794	103	59	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	103	60	continued	continue	VERB
cblr-1794	103	61	to	to	PART
cblr-1794	103	62	be	be	AUX
cblr-1794	103	63	approved	approve	VERB
cblr-1794	103	64	under	under	ADP
cblr-1794	103	65	the	the	DET
cblr-1794	103	66	fdca.2	fdca.2	PROPN
cblr-1794	103	67	6	6	NUM
cblr-1794	103	68	in	in	ADP
cblr-1794	103	69	1997	1997	NUM
cblr-1794	103	70	,	,	PUNCT
cblr-1794	103	71	congress	congress	PROPN
cblr-1794	103	72	passed	pass	VERB
cblr-1794	103	73	the	the	DET
cblr-1794	103	74	food	food	NOUN
cblr-1794	103	75	and	and	CCONJ
cblr-1794	103	76	drug	drug	PROPN
cblr-1794	103	77	administration	administration	PROPN
cblr-1794	103	78	modernization	modernization	PROPN
cblr-1794	103	79	act	act	PROPN
cblr-1794	103	80	(	(	PUNCT
cblr-1794	103	81	"	"	PUNCT
cblr-1794	103	82	fdama	fdama	NOUN
cblr-1794	103	83	"	"	PUNCT
cblr-1794	103	84	)	)	PUNCT
cblr-1794	103	85	,	,	PUNCT
cblr-1794	103	86	which	which	PRON
cblr-1794	103	87	amended	amend	VERB
cblr-1794	103	88	the	the	DET
cblr-1794	103	89	phsa	phsa	NOUN
cblr-1794	103	90	to	to	PART
cblr-1794	103	91	require	require	VERB
cblr-1794	103	92	sponsors	sponsor	NOUN
cblr-1794	103	93	to	to	PART
cblr-1794	103	94	submit	submit	VERB
cblr-1794	103	95	a	a	DET
cblr-1794	103	96	biologics	biologic	NOUN
cblr-1794	103	97	license	license	NOUN
cblr-1794	103	98	application	application	NOUN
cblr-1794	103	99	(	(	PUNCT
cblr-1794	103	100	"	"	PUNCT
cblr-1794	103	101	bla	bla	NOUN
cblr-1794	103	102	"	"	PUNCT
cblr-1794	103	103	)	)	PUNCT
cblr-1794	103	104	when	when	SCONJ
cblr-1794	103	105	seeking	seek	VERB
cblr-1794	103	106	fda	fda	PROPN
cblr-1794	103	107	approval	approval	NOUN
cblr-1794	103	108	of	of	ADP
cblr-1794	103	109	a	a	DET
cblr-1794	103	110	biologic.2	biologic.2	PROPN
cblr-1794	103	111	7	7	NUM
cblr-1794	103	112	blas	bla	NOUN
cblr-1794	103	113	are	be	AUX
cblr-1794	103	114	reviewed	review	VERB
cblr-1794	103	115	either	either	CCONJ
cblr-1794	103	116	by	by	ADP
cblr-1794	103	117	the	the	DET
cblr-1794	103	118	center	center	NOUN
cblr-1794	103	119	for	for	ADP
cblr-1794	103	120	biologics	biologic	NOUN
cblr-1794	103	121	evaluation	evaluation	NOUN
cblr-1794	103	122	and	and	CCONJ
cblr-1794	103	123	research	research	NOUN
cblr-1794	103	124	(	(	PUNCT
cblr-1794	103	125	"	"	PUNCT
cblr-1794	103	126	cber	cber	NOUN
cblr-1794	103	127	"	"	PUNCT
cblr-1794	103	128	)	)	PUNCT
cblr-1794	103	129	or	or	CCONJ
cblr-1794	103	130	by	by	ADP
cblr-1794	103	131	cder	cder	NOUN
cblr-1794	103	132	,	,	PUNCT
cblr-1794	103	133	depending	depend	VERB
cblr-1794	103	134	on	on	ADP
cblr-1794	103	135	the	the	DET
cblr-1794	103	136	product	product	NOUN
cblr-1794	103	137	type.28	type.28	NOUN
cblr-1794	103	138	the	the	DET
cblr-1794	103	139	bla	bla	NOUN
cblr-1794	103	140	approval	approval	NOUN
cblr-1794	103	141	process	process	NOUN
cblr-1794	103	142	for	for	ADP
cblr-1794	103	143	biologics	biologic	NOUN
cblr-1794	103	144	closely	closely	ADV
cblr-1794	103	145	parallels	parallel	VERB
cblr-1794	103	146	the	the	DET
cblr-1794	103	147	nda	nda	PROPN
cblr-1794	103	148	approval	approval	NOUN
cblr-1794	103	149	process	process	NOUN
cblr-1794	103	150	for	for	ADP
cblr-1794	103	151	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	103	152	;	;	PUNCT
cblr-1794	103	153	however	however	ADV
cblr-1794	103	154	,	,	PUNCT
cblr-1794	103	155	these	these	DET
cblr-1794	103	156	processes	process	NOUN
cblr-1794	103	157	remain	remain	VERB
cblr-1794	103	158	under	under	ADP
cblr-1794	103	159	separate	separate	ADJ
cblr-1794	103	160	statutory	statutory	ADJ
cblr-1794	103	161	authority.2	authority.2	PROPN
cblr-1794	103	162	9	9	NUM
cblr-1794	103	163	b.	b.	NOUN
cblr-1794	103	164	abbreviated	abbreviate	VERB
cblr-1794	103	165	routes	route	NOUN
cblr-1794	103	166	to	to	ADP
cblr-1794	103	167	market	market	NOUN
cblr-1794	103	168	under	under	ADP
cblr-1794	103	169	the	the	DET
cblr-1794	103	170	fdca	fdca	NOUN
cblr-1794	103	171	before	before	SCONJ
cblr-1794	103	172	the	the	DET
cblr-1794	103	173	bpcia	bpcia	NOUN
cblr-1794	103	174	was	be	AUX
cblr-1794	103	175	passed	pass	VERB
cblr-1794	103	176	,	,	PUNCT
cblr-1794	103	177	this	this	DET
cblr-1794	103	178	bifurcated	bifurcate	VERB
cblr-1794	103	179	statutory	statutory	ADJ
cblr-1794	103	180	authority	authority	NOUN
cblr-1794	103	181	led	lead	VERB
cblr-1794	103	182	to	to	ADP
cblr-1794	103	183	the	the	DET
cblr-1794	103	184	existence	existence	NOUN
cblr-1794	103	185	of	of	ADP
cblr-1794	103	186	an	an	DET
cblr-1794	103	187	abbreviated	abbreviate	VERB
cblr-1794	103	188	route	route	NOUN
cblr-1794	103	189	to	to	ADP
cblr-1794	103	190	market	market	NOUN
cblr-1794	103	191	for	for	ADP
cblr-1794	103	192	generic	generic	ADJ
cblr-1794	103	193	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	103	194	without	without	ADP
cblr-1794	103	195	a	a	DET
cblr-1794	103	196	similar	similar	ADJ
cblr-1794	103	197	pathway	pathway	NOUN
cblr-1794	103	198	for	for	ADP
cblr-1794	103	199	biosimilars	biosimilar	NOUN
cblr-1794	103	200	.	.	PUNCT
cblr-1794	104	1	the	the	DET
cblr-1794	104	2	drug	drug	NOUN
cblr-1794	104	3	price	price	NOUN
cblr-1794	104	4	competition	competition	NOUN
cblr-1794	104	5	and	and	CCONJ
cblr-1794	104	6	patent	patent	NOUN
cblr-1794	104	7	term	term	NOUN
cblr-1794	104	8	restoration	restoration	NOUN
cblr-1794	104	9	act,3	act,3	NOUN
cblr-1794	104	10	0	0	PUNCT
cblr-1794	104	11	often	often	ADV
cblr-1794	104	12	referred	refer	VERB
cblr-1794	104	13	to	to	ADP
cblr-1794	104	14	as	as	SCONJ
cblr-1794	104	15	the	the	DET
cblr-1794	104	16	hatch	hatch	NOUN
cblr-1794	104	17	-	-	PUNCT
cblr-1794	104	18	waxman	waxman	PROPN
cblr-1794	104	19	act	act	PROPN
cblr-1794	104	20	,	,	PUNCT
cblr-1794	104	21	created	create	VERB
cblr-1794	104	22	abbreviated	abbreviate	VERB
cblr-1794	104	23	routes	route	NOUN
cblr-1794	104	24	to	to	ADP
cblr-1794	104	25	market	market	NOUN
cblr-1794	104	26	for	for	ADP
cblr-1794	104	27	generic	generic	ADJ
cblr-1794	104	28	versions	version	NOUN
cblr-1794	104	29	of	of	ADP
cblr-1794	104	30	drugs	drug	NOUN
cblr-1794	104	31	under	under	ADP
cblr-1794	104	32	the	the	DET
cblr-1794	104	33	fdca	fdca	NOUN
cblr-1794	104	34	but	but	CCONJ
cblr-1794	104	35	not	not	PART
cblr-1794	104	36	under	under	ADP
cblr-1794	104	37	24	24	NUM
cblr-1794	104	38	see	see	NOUN
cblr-1794	104	39	paradise	paradise	PROPN
cblr-1794	104	40	,	,	PUNCT
cblr-1794	104	41	supra	supra	PROPN
cblr-1794	104	42	note	note	PROPN
cblr-1794	104	43	15	15	NUM
cblr-1794	104	44	,	,	PUNCT
cblr-1794	104	45	at	at	ADP
cblr-1794	104	46	503	503	NUM
cblr-1794	104	47	(	(	PUNCT
cblr-1794	104	48	citing	cite	VERB
cblr-1794	104	49	new	new	ADJ
cblr-1794	104	50	drug	drug	NOUN
cblr-1794	104	51	application	application	NOUN
cblr-1794	104	52	(	(	PUNCT
cblr-1794	104	53	"	"	PUNCT
cblr-1794	104	54	nda	nda	PROPN
cblr-1794	104	55	"	"	PUNCT
cblr-1794	104	56	)	)	PUNCT
cblr-1794	104	57	,	,	PUNCT
cblr-1794	104	58	fda	fda	PROPN
cblr-1794	104	59	,	,	PUNCT
cblr-1794	104	60	http://www.fda.gov/drugs/developmentapprovalprocess/	http://www.fda.gov/drugs/developmentapprovalprocess/	PROPN
cblr-1794	104	61	howdrugsaredevelopedandapproved	howdrugsaredevelopedandapprove	VERB
cblr-1794	104	62	/	/	SYM
cblr-1794	104	63	approvalapplications	approvalapplication	NOUN
cblr-1794	104	64	/	/	SYM
cblr-1794	104	65	newdrugappl	newdrugappl	ADJ
cblr-1794	104	66	icationndaldefault.htm	icationndaldefault.htm	NOUN
cblr-1794	104	67	(	(	PUNCT
cblr-1794	104	68	last	last	ADJ
cblr-1794	104	69	visited	visit	VERB
cblr-1794	104	70	mar	mar	PROPN
cblr-1794	104	71	.	.	PROPN
cblr-1794	104	72	19	19	NUM
cblr-1794	104	73	,	,	PUNCT
cblr-1794	104	74	2013	2013	NUM
cblr-1794	104	75	)	)	PUNCT
cblr-1794	104	76	)	)	PUNCT
cblr-1794	104	77	.	.	PUNCT
cblr-1794	105	1	25	25	NUM
cblr-1794	105	2	public	public	ADJ
cblr-1794	105	3	health	health	PROPN
cblr-1794	105	4	service	service	PROPN
cblr-1794	105	5	act	act	PROPN
cblr-1794	105	6	,	,	PUNCT
cblr-1794	105	7	pub	pub	NOUN
cblr-1794	105	8	.	.	PUNCT
cblr-1794	106	1	l.	l.	PROPN
cblr-1794	106	2	no	no	INTJ
cblr-1794	106	3	.	.	PROPN
cblr-1794	107	1	78	78	NUM
cblr-1794	107	2	-	-	SYM
cblr-1794	107	3	410	410	NUM
cblr-1794	107	4	,	,	PUNCT
cblr-1794	107	5	58	58	NUM
cblr-1794	107	6	stat	stat	NOUN
cblr-1794	107	7	.	.	PUNCT
cblr-1794	108	1	682	682	NUM
cblr-1794	108	2	(	(	PUNCT
cblr-1794	108	3	1944	1944	NUM
cblr-1794	108	4	)	)	PUNCT
cblr-1794	108	5	(	(	PUNCT
cblr-1794	108	6	codified	codify	VERB
cblr-1794	108	7	as	as	SCONJ
cblr-1794	108	8	amended	amend	VERB
cblr-1794	108	9	in	in	ADP
cblr-1794	108	10	scattered	scatter	VERB
cblr-1794	108	11	sections	section	NOUN
cblr-1794	108	12	of	of	ADP
cblr-1794	108	13	42	42	NUM
cblr-1794	108	14	u.s.c	u.s.c	ADJ
cblr-1794	108	15	.	.	PUNCT
cblr-1794	108	16	)	)	PUNCT
cblr-1794	108	17	.	.	PUNCT
cblr-1794	109	1	26	26	NUM
cblr-1794	109	2	see	see	VERB
cblr-1794	109	3	johnson	johnson	PROPN
cblr-1794	109	4	,	,	PUNCT
cblr-1794	109	5	supra	supra	PROPN
cblr-1794	109	6	note	note	PROPN
cblr-1794	109	7	8	8	NUM
cblr-1794	109	8	,	,	PUNCT
cblr-1794	109	9	at	at	ADP
cblr-1794	109	10	6	6	NUM
cblr-1794	109	11	.	.	SYM
cblr-1794	109	12	27	27	NUM
cblr-1794	110	1	i	i	PROPN
cblr-1794	110	2	d.	d.	PROPN
cblr-1794	110	3	28	28	NUM
cblr-1794	110	4	paradise	paradise	PROPN
cblr-1794	110	5	,	,	PUNCT
cblr-1794	110	6	supra	supra	PROPN
cblr-1794	110	7	note	note	PROPN
cblr-1794	110	8	15	15	NUM
cblr-1794	110	9	,	,	PUNCT
cblr-1794	110	10	at	at	ADP
cblr-1794	110	11	503	503	NUM
cblr-1794	110	12	.	.	NOUN
cblr-1794	110	13	29	29	NUM
cblr-1794	111	1	i	i	PRON
cblr-1794	111	2	d.	d.	NOUN
cblr-1794	111	3	at	at	ADP
cblr-1794	111	4	504	504	NUM
cblr-1794	111	5	.	.	PUNCT
cblr-1794	111	6	30	30	NUM
cblr-1794	111	7	drug	drug	NOUN
cblr-1794	111	8	price	price	NOUN
cblr-1794	111	9	competition	competition	NOUN
cblr-1794	111	10	and	and	CCONJ
cblr-1794	111	11	patent	patent	NOUN
cblr-1794	111	12	term	term	NOUN
cblr-1794	111	13	restoration	restoration	NOUN
cblr-1794	111	14	act	act	NOUN
cblr-1794	111	15	,	,	PUNCT
cblr-1794	111	16	pub	pub	NOUN
cblr-1794	111	17	.	.	PUNCT
cblr-1794	112	1	l.	l.	PROPN
cblr-1794	112	2	no	no	INTJ
cblr-1794	112	3	.	.	PROPN
cblr-1794	113	1	98	98	NUM
cblr-1794	113	2	-	-	SYM
cblr-1794	113	3	417	417	NUM
cblr-1794	113	4	,	,	PUNCT
cblr-1794	113	5	98	98	NUM
cblr-1794	113	6	stat	stat	NOUN
cblr-1794	113	7	.	.	PUNCT
cblr-1794	114	1	1585	1585	NUM
cblr-1794	114	2	(	(	PUNCT
cblr-1794	114	3	1984	1984	NUM
cblr-1794	114	4	)	)	PUNCT
cblr-1794	114	5	(	(	PUNCT
cblr-1794	114	6	codified	codify	VERB
cblr-1794	114	7	as	as	SCONJ
cblr-1794	114	8	amended	amend	VERB
cblr-1794	114	9	in	in	ADP
cblr-1794	114	10	scattered	scatter	VERB
cblr-1794	114	11	sections	section	NOUN
cblr-1794	114	12	of	of	ADP
cblr-1794	114	13	15	15	NUM
cblr-1794	114	14	,	,	PUNCT
cblr-1794	114	15	21	21	NUM
cblr-1794	114	16	,	,	PUNCT
cblr-1794	114	17	35	35	NUM
cblr-1794	114	18	,	,	PUNCT
cblr-1794	114	19	and	and	CCONJ
cblr-1794	114	20	42	42	NUM
cblr-1794	114	21	u.s.c	u.s.c	ADJ
cblr-1794	114	22	.	.	PUNCT
cblr-1794	114	23	)	)	PUNCT
cblr-1794	114	24	.	.	PUNCT
cblr-1794	115	1	215no	215no	NOUN
cblr-1794	115	2	.	.	PUNCT
cblr-1794	116	1	i:209]1	i:209]1	PROPN
cblr-1794	116	2	bpcia	bpcia	PROPN
cblr-1794	116	3	:	:	PUNCT
cblr-1794	116	4	destined	destine	VERB
cblr-1794	116	5	for	for	ADP
cblr-1794	116	6	failure	failure	NOUN
cblr-1794	116	7	?	?	PUNCT
cblr-1794	117	1	the	the	DET
cblr-1794	117	2	phsa.31	phsa.31	NOUN
cblr-1794	117	3	the	the	DET
cblr-1794	117	4	hatch	hatch	NOUN
cblr-1794	117	5	-	-	PUNCT
cblr-1794	117	6	waxman	waxman	PROPN
cblr-1794	117	7	act	act	PROPN
cblr-1794	117	8	established	establish	VERB
cblr-1794	117	9	two	two	NUM
cblr-1794	117	10	new	new	ADJ
cblr-1794	117	11	sections	section	NOUN
cblr-1794	117	12	of	of	ADP
cblr-1794	117	13	the	the	DET
cblr-1794	117	14	fdca	fdca	NOUN
cblr-1794	117	15	under	under	ADP
cblr-1794	117	16	which	which	PRON
cblr-1794	117	17	generic	generic	ADJ
cblr-1794	117	18	versions	version	NOUN
cblr-1794	117	19	of	of	ADP
cblr-1794	117	20	brandname	brandname	ADJ
cblr-1794	117	21	pharmaceutical	pharmaceutical	ADJ
cblr-1794	117	22	drugs	drug	NOUN
cblr-1794	117	23	could	could	AUX
cblr-1794	117	24	be	be	AUX
cblr-1794	117	25	approved	approve	VERB
cblr-1794	117	26	.	.	PUNCT
cblr-1794	118	1	32	32	NUM
cblr-1794	118	2	the	the	DET
cblr-1794	118	3	first	first	ADJ
cblr-1794	118	4	pathway	pathway	NOUN
cblr-1794	118	5	is	be	AUX
cblr-1794	118	6	through	through	ADP
cblr-1794	118	7	an	an	DET
cblr-1794	118	8	abbreviated	abbreviate	VERB
cblr-1794	118	9	new	new	ADJ
cblr-1794	118	10	drug	drug	NOUN
cblr-1794	118	11	application	application	NOUN
cblr-1794	118	12	(	(	PUNCT
cblr-1794	118	13	"	"	PUNCT
cblr-1794	118	14	anda	anda	PROPN
cblr-1794	118	15	"	"	PUNCT
cblr-1794	118	16	)	)	PUNCT
cblr-1794	118	17	,	,	PUNCT
cblr-1794	118	18	established	establish	VERB
cblr-1794	118	19	in	in	ADP
cblr-1794	118	20	fdca	fdca	ADJ
cblr-1794	118	21	section	section	NOUN
cblr-1794	118	22	505(j	505(j	PROPN
cblr-1794	118	23	)	)	PUNCT
cblr-1794	118	24	.	.	PUNCT
cblr-1794	119	1	33	33	NUM
cblr-1794	119	2	under	under	ADP
cblr-1794	119	3	the	the	DET
cblr-1794	119	4	anda	anda	PROPN
cblr-1794	119	5	pathway	pathway	NOUN
cblr-1794	119	6	,	,	PUNCT
cblr-1794	119	7	the	the	DET
cblr-1794	119	8	generic	generic	ADJ
cblr-1794	119	9	drug	drug	NOUN
cblr-1794	119	10	sponsor	sponsor	NOUN
cblr-1794	119	11	must	must	AUX
cblr-1794	119	12	prove	prove	VERB
cblr-1794	119	13	bioequivalence	bioequivalence	NOUN
cblr-1794	119	14	with	with	ADP
cblr-1794	119	15	the	the	DET
cblr-1794	119	16	brand	brand	NOUN
cblr-1794	119	17	-	-	PUNCT
cblr-1794	119	18	name	name	NOUN
cblr-1794	119	19	reference	reference	NOUN
cblr-1794	119	20	drug	drug	NOUN
cblr-1794	119	21	through	through	ADP
cblr-1794	119	22	comparison	comparison	NOUN
cblr-1794	119	23	studies	study	NOUN
cblr-1794	119	24	.	.	PUNCT
cblr-1794	120	1	34	34	NUM
cblr-1794	120	2	to	to	PART
cblr-1794	120	3	prove	prove	VERB
cblr-1794	120	4	bioequivalence	bioequivalence	NOUN
cblr-1794	120	5	,	,	PUNCT
cblr-1794	120	6	comparison	comparison	NOUN
cblr-1794	120	7	studies	study	NOUN
cblr-1794	120	8	must	must	AUX
cblr-1794	120	9	show	show	VERB
cblr-1794	120	10	that	that	SCONJ
cblr-1794	120	11	"	"	PUNCT
cblr-1794	120	12	the	the	DET
cblr-1794	120	13	product	product	NOUN
cblr-1794	120	14	has	have	VERB
cblr-1794	120	15	the	the	DET
cblr-1794	120	16	same	same	ADJ
cblr-1794	120	17	active	active	ADJ
cblr-1794	120	18	ingredient(s	ingredient(s	PROPN
cblr-1794	120	19	)	)	PUNCT
cblr-1794	120	20	as	as	ADP
cblr-1794	120	21	the	the	DET
cblr-1794	120	22	reference	reference	NOUN
cblr-1794	120	23	product	product	NOUN
cblr-1794	120	24	and	and	CCONJ
cblr-1794	120	25	the	the	DET
cblr-1794	120	26	same	same	ADJ
cblr-1794	120	27	route	route	NOUN
cblr-1794	120	28	of	of	ADP
cblr-1794	120	29	administration	administration	NOUN
cblr-1794	120	30	,	,	PUNCT
cblr-1794	120	31	dosage	dosage	NOUN
cblr-1794	120	32	form	form	NOUN
cblr-1794	120	33	,	,	PUNCT
cblr-1794	120	34	and	and	CCONJ
cblr-1794	120	35	strength	strength	NOUN
cblr-1794	120	36	.	.	PUNCT
cblr-1794	121	1	"35	"35	PUNCT
cblr-1794	122	1	the	the	DET
cblr-1794	122	2	fda	fda	PROPN
cblr-1794	122	3	is	be	AUX
cblr-1794	122	4	not	not	PART
cblr-1794	122	5	permitted	permit	VERB
cblr-1794	122	6	to	to	PART
cblr-1794	122	7	request	request	VERB
cblr-1794	122	8	preclinical	preclinical	ADJ
cblr-1794	122	9	or	or	CCONJ
cblr-1794	122	10	clinical	clinical	ADJ
cblr-1794	122	11	data	datum	NOUN
cblr-1794	122	12	to	to	PART
cblr-1794	122	13	support	support	VERB
cblr-1794	122	14	the	the	DET
cblr-1794	122	15	generic	generic	ADJ
cblr-1794	122	16	drug	drug	NOUN
cblr-1794	122	17	's	's	PART
cblr-1794	122	18	approval.3	approval.3	NOUN
cblr-1794	122	19	1	1	NUM
cblr-1794	122	20	proving	prove	VERB
cblr-1794	122	21	bioequivalence	bioequivalence	NOUN
cblr-1794	122	22	permits	permit	VERB
cblr-1794	122	23	the	the	DET
cblr-1794	122	24	generic	generic	ADJ
cblr-1794	122	25	drug	drug	NOUN
cblr-1794	122	26	sponsor	sponsor	NOUN
cblr-1794	122	27	to	to	PART
cblr-1794	122	28	rely	rely	VERB
cblr-1794	122	29	on	on	ADP
cblr-1794	122	30	the	the	DET
cblr-1794	122	31	fda	fda	PROPN
cblr-1794	122	32	's	's	PART
cblr-1794	122	33	previous	previous	ADJ
cblr-1794	122	34	findings	finding	NOUN
cblr-1794	122	35	of	of	ADP
cblr-1794	122	36	safety	safety	NOUN
cblr-1794	122	37	and	and	CCONJ
cblr-1794	122	38	efficacy	efficacy	NOUN
cblr-1794	122	39	of	of	ADP
cblr-1794	122	40	the	the	DET
cblr-1794	122	41	reference	reference	NOUN
cblr-1794	122	42	product	product	NOUN
cblr-1794	122	43	in	in	ADP
cblr-1794	122	44	the	the	DET
cblr-1794	122	45	anda.37	anda.37	NOUN
cblr-1794	122	46	therefore	therefore	ADV
cblr-1794	122	47	,	,	PUNCT
cblr-1794	122	48	the	the	DET
cblr-1794	122	49	sponsor	sponsor	NOUN
cblr-1794	122	50	of	of	ADP
cblr-1794	122	51	the	the	DET
cblr-1794	122	52	generic	generic	ADJ
cblr-1794	122	53	drug	drug	NOUN
cblr-1794	122	54	does	do	AUX
cblr-1794	122	55	not	not	PART
cblr-1794	122	56	have	have	VERB
cblr-1794	122	57	to	to	PART
cblr-1794	122	58	engage	engage	VERB
cblr-1794	122	59	in	in	ADP
cblr-1794	122	60	the	the	DET
cblr-1794	122	61	lengthy	lengthy	ADJ
cblr-1794	122	62	and	and	CCONJ
cblr-1794	122	63	expensive	expensive	ADJ
cblr-1794	122	64	clinical	clinical	ADJ
cblr-1794	122	65	trial	trial	NOUN
cblr-1794	122	66	process	process	NOUN
cblr-1794	122	67	.	.	PUNCT
cblr-1794	123	1	it	it	PRON
cblr-1794	123	2	is	be	AUX
cblr-1794	123	3	typically	typically	ADV
cblr-1794	123	4	not	not	PART
cblr-1794	123	5	difficult	difficult	ADJ
cblr-1794	123	6	to	to	PART
cblr-1794	123	7	show	show	VERB
cblr-1794	123	8	bioequivalence	bioequivalence	NOUN
cblr-1794	123	9	because	because	SCONJ
cblr-1794	123	10	the	the	DET
cblr-1794	123	11	structure	structure	NOUN
cblr-1794	123	12	of	of	ADP
cblr-1794	123	13	traditional	traditional	ADJ
cblr-1794	123	14	pharmaceutical	pharmaceutical	ADJ
cblr-1794	123	15	drugs	drug	NOUN
cblr-1794	123	16	can	can	AUX
cblr-1794	123	17	be	be	AUX
cblr-1794	123	18	verified	verify	VERB
cblr-1794	123	19	analytically	analytically	ADV
cblr-1794	123	20	and	and	CCONJ
cblr-1794	123	21	copied	copy	VERB
cblr-1794	123	22	by	by	ADP
cblr-1794	123	23	the	the	DET
cblr-1794	123	24	generic	generic	ADJ
cblr-1794	123	25	manufacturer	manufacturer	NOUN
cblr-1794	123	26	.	.	PUNCT
cblr-1794	123	27	"	"	PUNCT
cblr-1794	124	1	most	most	ADJ
cblr-1794	124	2	of	of	ADP
cblr-1794	124	3	the	the	DET
cblr-1794	124	4	generics	generic	NOUN
cblr-1794	124	5	that	that	PRON
cblr-1794	124	6	are	be	AUX
cblr-1794	124	7	31	31	NUM
cblr-1794	124	8	johnson	johnson	PROPN
cblr-1794	124	9	,	,	PUNCT
cblr-1794	124	10	supra	supra	PROPN
cblr-1794	124	11	note	note	PROPN
cblr-1794	124	12	8	8	NUM
cblr-1794	124	13	,	,	PUNCT
cblr-1794	124	14	at	at	ADP
cblr-1794	124	15	7	7	NUM
cblr-1794	124	16	.	.	SYM
cblr-1794	124	17	32	32	NUM
cblr-1794	125	1	i	i	PRON
cblr-1794	125	2	d.	d.	NOUN
cblr-1794	125	3	33	33	NUM
cblr-1794	125	4	21	21	NUM
cblr-1794	125	5	u.s.c	u.s.c	NOUN
cblr-1794	125	6	.	.	PUNCT
cblr-1794	126	1	§	§	PROPN
cblr-1794	126	2	355(j	355(j	PROPN
cblr-1794	126	3	)	)	PUNCT
cblr-1794	126	4	(	(	PUNCT
cblr-1794	126	5	2011	2011	NUM
cblr-1794	126	6	)	)	PUNCT
cblr-1794	126	7	.	.	PUNCT
cblr-1794	127	1	34	34	NUM
cblr-1794	127	2	paradise	paradise	PROPN
cblr-1794	127	3	,	,	PUNCT
cblr-1794	127	4	supra	supra	PROPN
cblr-1794	127	5	note	note	PROPN
cblr-1794	127	6	15	15	NUM
cblr-1794	127	7	,	,	PUNCT
cblr-1794	127	8	at	at	ADP
cblr-1794	127	9	504	504	NUM
cblr-1794	127	10	.	.	PUNCT
cblr-1794	128	1	see	see	VERB
cblr-1794	128	2	also	also	ADV
cblr-1794	128	3	ftc	ftc	PROPN
cblr-1794	128	4	report	report	PROPN
cblr-1794	128	5	,	,	PUNCT
cblr-1794	128	6	supra	supra	PROPN
cblr-1794	128	7	note	note	PROPN
cblr-1794	128	8	14	14	NUM
cblr-1794	128	9	,	,	PUNCT
cblr-1794	128	10	at	at	ADP
cblr-1794	128	11	7	7	NUM
cblr-1794	128	12	n.15	n.15	PART
cblr-1794	128	13	(	(	PUNCT
cblr-1794	128	14	"	"	PUNCT
cblr-1794	128	15	bioequivalence	bioequivalence	NOUN
cblr-1794	128	16	means	mean	VERB
cblr-1794	128	17	that	that	SCONJ
cblr-1794	128	18	the	the	DET
cblr-1794	128	19	rate	rate	NOUN
cblr-1794	128	20	and	and	CCONJ
cblr-1794	128	21	extent	extent	NOUN
cblr-1794	128	22	of	of	ADP
cblr-1794	128	23	the	the	DET
cblr-1794	128	24	absorption	absorption	NOUN
cblr-1794	128	25	of	of	ADP
cblr-1794	128	26	the	the	DET
cblr-1794	128	27	generic	generic	ADJ
cblr-1794	128	28	drug	drug	NOUN
cblr-1794	128	29	is	be	AUX
cblr-1794	128	30	not	not	PART
cblr-1794	128	31	significantly	significantly	ADV
cblr-1794	128	32	different	different	ADJ
cblr-1794	128	33	from	from	ADP
cblr-1794	128	34	the	the	DET
cblr-1794	128	35	rate	rate	NOUN
cblr-1794	128	36	and	and	CCONJ
cblr-1794	128	37	extent	extent	NOUN
cblr-1794	128	38	of	of	ADP
cblr-1794	128	39	absorption	absorption	NOUN
cblr-1794	128	40	of	of	ADP
cblr-1794	128	41	the	the	DET
cblr-1794	128	42	reference	reference	NOUN
cblr-1794	128	43	listed	list	VERB
cblr-1794	128	44	drug	drug	NOUN
cblr-1794	128	45	when	when	SCONJ
cblr-1794	128	46	administered	administer	VERB
cblr-1794	128	47	at	at	ADP
cblr-1794	128	48	the	the	DET
cblr-1794	128	49	same	same	ADJ
cblr-1794	128	50	dosage	dosage	NOUN
cblr-1794	128	51	.	.	PUNCT
cblr-1794	129	1	"	"	PUNCT
cblr-1794	129	2	)	)	PUNCT
cblr-1794	129	3	.	.	PUNCT
cblr-1794	130	1	35	35	NUM
cblr-1794	130	2	carver	carver	NOUN
cblr-1794	130	3	,	,	PUNCT
cblr-1794	130	4	supra	supra	PROPN
cblr-1794	130	5	note	note	NOUN
cblr-1794	130	6	20	20	NUM
cblr-1794	130	7	,	,	PUNCT
cblr-1794	130	8	at	at	ADP
cblr-1794	130	9	677	677	NUM
cblr-1794	130	10	(	(	PUNCT
cblr-1794	130	11	citing	cite	VERB
cblr-1794	130	12	21	21	NUM
cblr-1794	130	13	u.s.c	u.s.c	ADJ
cblr-1794	130	14	.	.	PUNCT
cblr-1794	131	1	§	§	PROPN
cblr-1794	131	2	505(j)(2)(a)(ii)-(iii	505(j)(2)(a)(ii)-(iii	NUM
cblr-1794	131	3	)	)	PUNCT
cblr-1794	131	4	(	(	PUNCT
cblr-1794	131	5	2011	2011	NUM
cblr-1794	131	6	)	)	PUNCT
cblr-1794	131	7	)	)	PUNCT
cblr-1794	131	8	.	.	PUNCT
cblr-1794	132	1	36	36	NUM
cblr-1794	132	2	21	21	NUM
cblr-1794	132	3	u.s.c	u.s.c	NOUN
cblr-1794	132	4	.	.	PUNCT
cblr-1794	133	1	§	§	PROPN
cblr-1794	133	2	505(j)(2)(a	505(j)(2)(a	NUM
cblr-1794	133	3	)	)	PUNCT
cblr-1794	133	4	(	(	PUNCT
cblr-1794	133	5	2011	2011	NUM
cblr-1794	133	6	)	)	PUNCT
cblr-1794	133	7	.	.	PUNCT
cblr-1794	134	1	37	37	NUM
cblr-1794	134	2	johnson	johnson	PROPN
cblr-1794	134	3	,	,	PUNCT
cblr-1794	134	4	supra	supra	PROPN
cblr-1794	134	5	note	note	PROPN
cblr-1794	134	6	8	8	NUM
cblr-1794	134	7	,	,	PUNCT
cblr-1794	134	8	at	at	ADP
cblr-1794	134	9	7	7	NUM
cblr-1794	134	10	.	.	NOUN
cblr-1794	134	11	38	38	NUM
cblr-1794	134	12	see	see	VERB
cblr-1794	134	13	generally	generally	ADV
cblr-1794	134	14	janet	janet	PROPN
cblr-1794	134	15	woodcock	woodcock	PROPN
cblr-1794	134	16	et	et	PROPN
cblr-1794	134	17	al	al	PROPN
cblr-1794	134	18	.	.	PROPN
cblr-1794	134	19	,	,	PUNCT
cblr-1794	134	20	the	the	DET
cblr-1794	134	21	fda	fda	PROPN
cblr-1794	134	22	's	's	PART
cblr-1794	134	23	assessment	assessment	NOUN
cblr-1794	134	24	of	of	ADP
cblr-1794	134	25	follow	follow	VERB
cblr-1794	134	26	-	-	PUNCT
cblr-1794	134	27	on	on	ADP
cblr-1794	134	28	protein	protein	NOUN
cblr-1794	134	29	products	product	NOUN
cblr-1794	134	30	:	:	PUNCT
cblr-1794	134	31	a	a	DET
cblr-1794	134	32	historical	historical	ADJ
cblr-1794	134	33	perspective	perspective	NOUN
cblr-1794	134	34	,	,	PUNCT
cblr-1794	134	35	6	6	NUM
cblr-1794	134	36	nature	nature	NOUN
cblr-1794	134	37	revs	revs	VERB
cblr-1794	134	38	.	.	PUNCT
cblr-1794	135	1	drug	drug	NOUN
cblr-1794	135	2	discovery	discovery	PROPN
cblr-1794	135	3	437	437	NUM
cblr-1794	135	4	,	,	PUNCT
cblr-1794	135	5	437	437	NUM
cblr-1794	135	6	(	(	PUNCT
cblr-1794	135	7	2007	2007	NUM
cblr-1794	135	8	)	)	PUNCT
cblr-1794	135	9	(	(	PUNCT
cblr-1794	135	10	"	"	PUNCT
cblr-1794	135	11	non	non	ADJ
cblr-1794	135	12	-	-	ADJ
cblr-1794	135	13	protein	protein	ADJ
cblr-1794	135	14	,	,	PUNCT
cblr-1794	135	15	small	small	ADJ
cblr-1794	135	16	-	-	PUNCT
cblr-1794	135	17	molecule	molecule	NOUN
cblr-1794	135	18	drugs	drug	NOUN
cblr-1794	135	19	are	be	AUX
cblr-1794	135	20	typically	typically	ADV
cblr-1794	135	21	organic	organic	ADJ
cblr-1794	135	22	molecules	molecule	NOUN
cblr-1794	135	23	of	of	ADP
cblr-1794	135	24	low	low	ADJ
cblr-1794	135	25	molecular	molecular	ADJ
cblr-1794	135	26	mass	mass	NOUN
cblr-1794	135	27	and	and	CCONJ
cblr-1794	135	28	known	known	ADJ
cblr-1794	135	29	structure	structure	NOUN
cblr-1794	135	30	.	.	PUNCT
cblr-1794	136	1	because	because	SCONJ
cblr-1794	136	2	the	the	DET
cblr-1794	136	3	molecular	molecular	ADJ
cblr-1794	136	4	structure	structure	NOUN
cblr-1794	136	5	of	of	ADP
cblr-1794	136	6	such	such	DET
cblr-1794	136	7	a	a	DET
cblr-1794	136	8	drug	drug	NOUN
cblr-1794	136	9	can	can	AUX
cblr-1794	136	10	usually	usually	ADV
cblr-1794	136	11	be	be	AUX
cblr-1794	136	12	verified	verify	VERB
cblr-1794	136	13	analytically	analytically	ADV
cblr-1794	136	14	,	,	PUNCT
cblr-1794	136	15	it	it	PRON
cblr-1794	136	16	is	be	AUX
cblr-1794	136	17	fairly	fairly	ADV
cblr-1794	136	18	easy	easy	ADJ
cblr-1794	136	19	for	for	SCONJ
cblr-1794	136	20	a	a	DET
cblr-1794	136	21	generic	generic	ADJ
cblr-1794	136	22	-	-	PUNCT
cblr-1794	136	23	drug	drug	NOUN
cblr-1794	136	24	manufacturer	manufacturer	NOUN
cblr-1794	136	25	to	to	PART
cblr-1794	136	26	produce	produce	VERB
cblr-1794	136	27	a	a	DET
cblr-1794	136	28	duplicate	duplicate	ADJ
cblr-1794	136	29	product	product	NOUN
cblr-1794	136	30	containing	contain	VERB
cblr-1794	136	31	an	an	DET
cblr-1794	136	32	active	active	ADJ
cblr-1794	136	33	ingredient	ingredient	NOUN
cblr-1794	136	34	that	that	PRON
cblr-1794	136	35	is	be	AUX
cblr-1794	136	36	the	the	DET
cblr-1794	136	37	same	same	ADJ
cblr-1794	136	38	as	as	ADP
cblr-1794	136	39	the	the	DET
cblr-1794	136	40	active	active	ADJ
cblr-1794	136	41	ingredient	ingredient	NOUN
cblr-1794	136	42	in	in	ADP
cblr-1794	136	43	an	an	DET
cblr-1794	136	44	innovator	innovator	NOUN
cblr-1794	136	45	's	's	PART
cblr-1794	136	46	approved	approve	VERB
cblr-1794	136	47	drug	drug	NOUN
cblr-1794	136	48	product	product	NOUN
cblr-1794	136	49	.	.	PUNCT
cblr-1794	137	1	"	"	PUNCT
cblr-1794	137	2	)	)	PUNCT
cblr-1794	137	3	.	.	PUNCT
cblr-1794	138	1	216	216	NUM
cblr-1794	138	2	col	col	PROPN
cblr-1794	138	3	umbia	umbia	PROPN
cblr-1794	138	4	b	b	PROPN
cblr-1794	138	5	usiness	usiness	PROPN
cblr-1794	138	6	la	la	PROPN
cblr-1794	138	7	w	w	PROPN
cblr-1794	138	8	re	re	PROPN
cblr-1794	138	9	vie	vie	PROPN
cblr-1794	138	10	w	w	PROPN
cblr-1794	139	1	[	[	X
cblr-1794	139	2	vol	vol	NOUN
cblr-1794	139	3	.	.	PUNCT
cblr-1794	139	4	2013	2013	NUM
cblr-1794	139	5	found	find	VERB
cblr-1794	139	6	on	on	ADP
cblr-1794	139	7	the	the	DET
cblr-1794	139	8	shelves	shelf	NOUN
cblr-1794	139	9	of	of	ADP
cblr-1794	139	10	pharmacies	pharmacy	NOUN
cblr-1794	139	11	have	have	AUX
cblr-1794	139	12	been	be	AUX
cblr-1794	139	13	approved	approve	VERB
cblr-1794	139	14	under	under	ADP
cblr-1794	139	15	section	section	NOUN
cblr-1794	139	16	505(j	505(j	PROPN
cblr-1794	139	17	)	)	PUNCT
cblr-1794	139	18	.	.	PUNCT
cblr-1794	140	1	39	39	NUM
cblr-1794	140	2	the	the	DET
cblr-1794	140	3	second	second	ADJ
cblr-1794	140	4	pathway	pathway	NOUN
cblr-1794	140	5	,	,	PUNCT
cblr-1794	140	6	section	section	NOUN
cblr-1794	140	7	505(b)(2	505(b)(2	NUM
cblr-1794	140	8	)	)	PUNCT
cblr-1794	140	9	,	,	PUNCT
cblr-1794	140	10	40	40	NUM
cblr-1794	140	11	allows	allow	VERB
cblr-1794	140	12	for	for	ADP
cblr-1794	140	13	the	the	DET
cblr-1794	140	14	approval	approval	NOUN
cblr-1794	140	15	of	of	ADP
cblr-1794	140	16	"	"	PUNCT
cblr-1794	140	17	a	a	DET
cblr-1794	140	18	drug	drug	NOUN
cblr-1794	140	19	that	that	PRON
cblr-1794	140	20	has	have	VERB
cblr-1794	140	21	a	a	DET
cblr-1794	140	22	significant	significant	ADJ
cblr-1794	140	23	difference	difference	NOUN
cblr-1794	140	24	from	from	ADP
cblr-1794	140	25	an	an	DET
cblr-1794	140	26	innovator	innovator	NOUN
cblr-1794	140	27	drug	drug	NOUN
cblr-1794	140	28	,	,	PUNCT
cblr-1794	140	29	but	but	CCONJ
cblr-1794	140	30	is	be	AUX
cblr-1794	140	31	still	still	ADV
cblr-1794	140	32	sufficiently	sufficiently	ADV
cblr-1794	140	33	similar	similar	ADJ
cblr-1794	140	34	to	to	ADP
cblr-1794	140	35	[	[	PUNCT
cblr-1794	140	36	the	the	DET
cblr-1794	140	37	innovator	innovator	NOUN
cblr-1794	140	38	]	]	PUNCT
cblr-1794	140	39	drug	drug	NOUN
cblr-1794	140	40	.	.	PUNCT
cblr-1794	141	1	"41	"41	PUNCT
cblr-1794	142	1	a	a	DET
cblr-1794	142	2	sponsor	sponsor	NOUN
cblr-1794	142	3	files	file	NOUN
cblr-1794	142	4	under	under	ADP
cblr-1794	142	5	505(b)(2	505(b)(2	NUM
cblr-1794	142	6	)	)	PUNCT
cblr-1794	142	7	when	when	SCONJ
cblr-1794	142	8	the	the	DET
cblr-1794	142	9	new	new	ADJ
cblr-1794	142	10	drug	drug	NOUN
cblr-1794	142	11	application	application	NOUN
cblr-1794	142	12	"	"	PUNCT
cblr-1794	142	13	contains	contain	VERB
cblr-1794	142	14	full	full	ADJ
cblr-1794	142	15	reports	report	NOUN
cblr-1794	142	16	of	of	ADP
cblr-1794	142	17	investigations	investigation	NOUN
cblr-1794	142	18	of	of	ADP
cblr-1794	142	19	safety	safety	NOUN
cblr-1794	142	20	and	and	CCONJ
cblr-1794	142	21	effectiveness	effectiveness	NOUN
cblr-1794	142	22	but	but	CCONJ
cblr-1794	142	23	where	where	SCONJ
cblr-1794	142	24	at	at	ADV
cblr-1794	142	25	least	least	ADJ
cblr-1794	142	26	some	some	PRON
cblr-1794	142	27	of	of	ADP
cblr-1794	142	28	the	the	DET
cblr-1794	142	29	information	information	NOUN
cblr-1794	142	30	required	require	VERB
cblr-1794	142	31	for	for	ADP
cblr-1794	142	32	approval	approval	NOUN
cblr-1794	142	33	comes	come	VERB
cblr-1794	142	34	from	from	ADP
cblr-1794	142	35	studies	study	NOUN
cblr-1794	142	36	not	not	PART
cblr-1794	142	37	conducted	conduct	VERB
cblr-1794	142	38	by	by	ADP
cblr-1794	142	39	or	or	CCONJ
cblr-1794	142	40	for	for	ADP
cblr-1794	142	41	the	the	DET
cblr-1794	142	42	applicant	applicant	NOUN
cblr-1794	142	43	and	and	CCONJ
cblr-1794	142	44	for	for	ADP
cblr-1794	142	45	which	which	PRON
cblr-1794	142	46	the	the	DET
cblr-1794	142	47	applicant	applicant	NOUN
cblr-1794	142	48	has	have	AUX
cblr-1794	142	49	not	not	PART
cblr-1794	142	50	obtained	obtain	VERB
cblr-1794	142	51	a	a	DET
cblr-1794	142	52	right	right	NOUN
cblr-1794	142	53	of	of	ADP
cblr-1794	142	54	reference	reference	NOUN
cblr-1794	142	55	.	.	PUNCT
cblr-1794	143	1	"42	"42	NOUN
cblr-1794	144	1	a	a	DET
cblr-1794	144	2	505(b)(2	505(b)(2	NUM
cblr-1794	144	3	)	)	PUNCT
cblr-1794	144	4	application	application	NOUN
cblr-1794	144	5	is	be	AUX
cblr-1794	144	6	permitted	permit	VERB
cblr-1794	144	7	to	to	PART
cblr-1794	144	8	rely	rely	VERB
cblr-1794	144	9	upon	upon	SCONJ
cblr-1794	144	10	published	publish	VERB
cblr-1794	144	11	literature	literature	NOUN
cblr-1794	144	12	and	and	CCONJ
cblr-1794	144	13	the	the	DET
cblr-1794	144	14	fda	fda	PROPN
cblr-1794	144	15	's	's	PART
cblr-1794	144	16	previous	previous	ADJ
cblr-1794	144	17	findings	finding	NOUN
cblr-1794	144	18	of	of	ADP
cblr-1794	144	19	safety	safety	NOUN
cblr-1794	144	20	and	and	CCONJ
cblr-1794	144	21	effectiveness	effectiveness	NOUN
cblr-1794	144	22	for	for	ADP
cblr-1794	144	23	an	an	DET
cblr-1794	144	24	approved	approve	VERB
cblr-1794	144	25	drug.4	drug.4	PROPN
cblr-1794	144	26	3	3	NUM
cblr-1794	144	27	however	however	ADV
cblr-1794	144	28	,	,	PUNCT
cblr-1794	144	29	the	the	DET
cblr-1794	144	30	fda	fda	PROPN
cblr-1794	144	31	may	may	AUX
cblr-1794	144	32	also	also	ADV
cblr-1794	144	33	require	require	VERB
cblr-1794	144	34	the	the	DET
cblr-1794	144	35	sponsor	sponsor	NOUN
cblr-1794	144	36	to	to	PART
cblr-1794	144	37	provide	provide	VERB
cblr-1794	144	38	additional	additional	ADJ
cblr-1794	144	39	non	non	ADJ
cblr-1794	144	40	-	-	ADJ
cblr-1794	144	41	clinical	clinical	ADJ
cblr-1794	144	42	and	and	CCONJ
cblr-1794	144	43	clinical	clinical	ADJ
cblr-1794	144	44	data	datum	NOUN
cblr-1794	144	45	.	.	PUNCT
cblr-1794	145	1	4	4	NUM
cblr-1794	145	2	the	the	DET
cblr-1794	145	3	505(b)(2	505(b)(2	NUM
cblr-1794	145	4	)	)	PUNCT
cblr-1794	145	5	application	application	NOUN
cblr-1794	145	6	pathway	pathway	NOUN
cblr-1794	145	7	may	may	AUX
cblr-1794	145	8	have	have	AUX
cblr-1794	145	9	acted	act	VERB
cblr-1794	145	10	as	as	ADP
cblr-1794	145	11	a	a	DET
cblr-1794	145	12	framework	framework	NOUN
cblr-1794	145	13	for	for	ADP
cblr-1794	145	14	the	the	DET
cblr-1794	145	15	bpcia	bpcia	NOUN
cblr-1794	145	16	.	.	PUNCT
cblr-1794	146	1	due	due	ADP
cblr-1794	146	2	to	to	ADP
cblr-1794	146	3	a	a	DET
cblr-1794	146	4	regulatory	regulatory	ADJ
cblr-1794	146	5	irregularity	irregularity	NOUN
cblr-1794	146	6	,	,	PUNCT
cblr-1794	146	7	a	a	DET
cblr-1794	146	8	small	small	ADJ
cblr-1794	146	9	set	set	NOUN
cblr-1794	146	10	of	of	ADP
cblr-1794	146	11	biologic	biologic	NOUN
cblr-1794	146	12	products	product	NOUN
cblr-1794	146	13	(	(	PUNCT
cblr-1794	146	14	mostly	mostly	ADV
cblr-1794	146	15	hormones	hormone	NOUN
cblr-1794	146	16	)	)	PUNCT
cblr-1794	146	17	are	be	AUX
cblr-1794	146	18	regulated	regulate	VERB
cblr-1794	146	19	as	as	ADP
cblr-1794	146	20	drugs	drug	NOUN
cblr-1794	146	21	under	under	ADP
cblr-1794	146	22	the	the	DET
cblr-1794	146	23	fdca	fdca	NOUN
cblr-1794	146	24	rather	rather	ADV
cblr-1794	146	25	than	than	ADP
cblr-1794	146	26	as	as	ADP
cblr-1794	146	27	biologics	biologic	NOUN
cblr-1794	146	28	under	under	ADP
cblr-1794	146	29	the	the	DET
cblr-1794	146	30	phsa.45	phsa.45	NOUN
cblr-1794	146	31	in	in	ADP
cblr-1794	146	32	2003	2003	NUM
cblr-1794	146	33	,	,	PUNCT
cblr-1794	146	34	the	the	DET
cblr-1794	146	35	biologic	biologic	NOUN
cblr-1794	146	36	manufacturer	manufacturer	NOUN
cblr-1794	146	37	sandoz	sandoz	PROPN
cblr-1794	146	38	filed	file	VERB
cblr-1794	146	39	a	a	DET
cblr-1794	146	40	505(b)(2	505(b)(2	NUM
cblr-1794	146	41	)	)	PUNCT
cblr-1794	146	42	application	application	NOUN
cblr-1794	146	43	for	for	ADP
cblr-1794	146	44	omnitrope	omnitrope	NOUN
cblr-1794	146	45	,	,	PUNCT
cblr-1794	146	46	a	a	DET
cblr-1794	146	47	biologic	biologic	ADJ
cblr-1794	146	48	human	human	ADJ
cblr-1794	146	49	growth	growth	NOUN
cblr-1794	146	50	hormone	hormone	NOUN
cblr-1794	146	51	,	,	PUNCT
cblr-1794	146	52	citing	cite	VERB
cblr-1794	146	53	the	the	DET
cblr-1794	146	54	previously	previously	ADV
cblr-1794	146	55	approved	approve	VERB
cblr-1794	146	56	genotropin	genotropin	NOUN
cblr-1794	146	57	as	as	ADP
cblr-1794	146	58	the	the	DET
cblr-1794	146	59	reference	reference	NOUN
cblr-1794	146	60	product.46	product.46	PROPN
cblr-1794	146	61	when	when	SCONJ
cblr-1794	146	62	the	the	DET
cblr-1794	146	63	fda	fda	PROPN
cblr-1794	146	64	did	do	AUX
cblr-1794	146	65	not	not	PART
cblr-1794	146	66	act	act	VERB
cblr-1794	146	67	on	on	ADP
cblr-1794	146	68	the	the	DET
cblr-1794	146	69	application	application	NOUN
cblr-1794	146	70	for	for	ADP
cblr-1794	146	71	two	two	NUM
cblr-1794	146	72	years	year	NOUN
cblr-1794	146	73	,	,	PUNCT
cblr-1794	146	74	sandoz	sandoz	PROPN
cblr-1794	146	75	filed	file	VERB
cblr-1794	146	76	suit	suit	NOUN
cblr-1794	146	77	in	in	ADP
cblr-1794	146	78	federal	federal	ADJ
cblr-1794	146	79	court	court	NOUN
cblr-1794	146	80	,	,	PUNCT
cblr-1794	146	81	claiming	claim	VERB
cblr-1794	146	82	that	that	SCONJ
cblr-1794	146	83	the	the	DET
cblr-1794	146	84	fda	fda	PROPN
cblr-1794	146	85	had	have	AUX
cblr-1794	146	86	violated	violate	VERB
cblr-1794	146	87	its	its	PRON
cblr-1794	146	88	39	39	NUM
cblr-1794	146	89	see	see	NOUN
cblr-1794	146	90	generally	generally	ADV
cblr-1794	146	91	johnson	johnson	PROPN
cblr-1794	146	92	,	,	PUNCT
cblr-1794	146	93	supra	supra	PROPN
cblr-1794	146	94	note	note	PROPN
cblr-1794	146	95	8	8	NUM
cblr-1794	146	96	,	,	PUNCT
cblr-1794	146	97	at	at	ADP
cblr-1794	146	98	7	7	NUM
cblr-1794	146	99	(	(	PUNCT
cblr-1794	146	100	stating	state	VERB
cblr-1794	146	101	that	that	SCONJ
cblr-1794	146	102	the	the	DET
cblr-1794	146	103	505(j	505(j	PROPN
cblr-1794	146	104	)	)	PUNCT
cblr-1794	146	105	pathway	pathway	NOUN
cblr-1794	146	106	is	be	AUX
cblr-1794	146	107	used	use	VERB
cblr-1794	146	108	for	for	ADP
cblr-1794	146	109	the	the	DET
cblr-1794	146	110	approval	approval	NOUN
cblr-1794	146	111	of	of	ADP
cblr-1794	146	112	most	most	ADJ
cblr-1794	146	113	generic	generic	ADJ
cblr-1794	146	114	pharmaceutical	pharmaceutical	ADJ
cblr-1794	146	115	drugs	drug	NOUN
cblr-1794	146	116	)	)	PUNCT
cblr-1794	146	117	.	.	PUNCT
cblr-1794	147	1	40	40	NUM
cblr-1794	147	2	21	21	NUM
cblr-1794	147	3	u.s.c	u.s.c	NOUN
cblr-1794	147	4	.	.	PUNCT
cblr-1794	148	1	§	§	PROPN
cblr-1794	148	2	355(b)(2	355(b)(2	NUM
cblr-1794	148	3	)	)	PUNCT
cblr-1794	148	4	(	(	PUNCT
cblr-1794	148	5	2011	2011	NUM
cblr-1794	148	6	)	)	PUNCT
cblr-1794	148	7	.	.	PUNCT
cblr-1794	149	1	41	41	NUM
cblr-1794	149	2	johnson	johnson	PROPN
cblr-1794	149	3	,	,	PUNCT
cblr-1794	149	4	supra	supra	PROPN
cblr-1794	149	5	note	note	PROPN
cblr-1794	149	6	8	8	NUM
cblr-1794	149	7	,	,	PUNCT
cblr-1794	149	8	at	at	ADP
cblr-1794	149	9	7	7	NUM
cblr-1794	149	10	.	.	X
cblr-1794	149	11	42	42	NUM
cblr-1794	149	12	ctr	ctr	PROPN
cblr-1794	149	13	.	.	PUNCT
cblr-1794	150	1	for	for	ADP
cblr-1794	150	2	drug	drug	NOUN
cblr-1794	150	3	evaluation	evaluation	NOUN
cblr-1794	150	4	and	and	CCONJ
cblr-1794	150	5	research	research	NOUN
cblr-1794	150	6	,	,	PUNCT
cblr-1794	150	7	fda	fda	PROPN
cblr-1794	150	8	,	,	PUNCT
cblr-1794	150	9	guidance	guidance	NOUN
cblr-1794	150	10	for	for	ADP
cblr-1794	150	11	industry	industry	NOUN
cblr-1794	150	12	:	:	PUNCT
cblr-1794	150	13	applications	application	NOUN
cblr-1794	150	14	covered	cover	VERB
cblr-1794	150	15	by	by	ADP
cblr-1794	150	16	section	section	NOUN
cblr-1794	150	17	505(b)(2	505(b)(2	NUM
cblr-1794	150	18	)	)	PUNCT
cblr-1794	150	19	,	,	PUNCT
cblr-1794	150	20	at	at	ADP
cblr-1794	150	21	1	1	NUM
cblr-1794	150	22	(	(	PUNCT
cblr-1794	150	23	1999	1999	NUM
cblr-1794	150	24	)	)	PUNCT
cblr-1794	150	25	,	,	PUNCT
cblr-1794	150	26	available	available	ADJ
cblr-1794	150	27	at	at	ADP
cblr-1794	150	28	http://www.fda.gov/downloads/drugs/guidancecompliance	http://www.fda.gov/downloads/drugs/guidancecompliance	NOUN
cblr-1794	150	29	regulatoryinformationl	regulatoryinformationl	NOUN
cblr-1794	150	30	/	/	SYM
cblr-1794	150	31	guidances	guidance	NOUN
cblr-1794	150	32	/	/	SYM
cblr-1794	150	33	ucm079345.pdf	ucm079345.pdf	NOUN
cblr-1794	150	34	(	(	PUNCT
cblr-1794	150	35	quoting	quote	VERB
cblr-1794	150	36	21	21	NUM
cblr-1794	150	37	u.s.c	u.s.c	ADJ
cblr-1794	150	38	.	.	PUNCT
cblr-1794	151	1	§	§	PROPN
cblr-1794	151	2	505(b)(2	505(b)(2	NUM
cblr-1794	151	3	)	)	PUNCT
cblr-1794	151	4	)	)	PUNCT
cblr-1794	151	5	.	.	PUNCT
cblr-1794	152	1	43	43	NUM
cblr-1794	153	1	i	i	PRON
cblr-1794	153	2	d.	d.	VERB
cblr-1794	153	3	at	at	ADP
cblr-1794	153	4	2	2	NUM
cblr-1794	153	5	.	.	NUM
cblr-1794	153	6	44	44	NUM
cblr-1794	153	7	johnson	johnson	PROPN
cblr-1794	153	8	,	,	PUNCT
cblr-1794	153	9	supra	supra	PROPN
cblr-1794	153	10	note	note	PROPN
cblr-1794	153	11	8	8	NUM
cblr-1794	153	12	,	,	PUNCT
cblr-1794	153	13	at	at	ADP
cblr-1794	153	14	7	7	NUM
cblr-1794	153	15	.	.	NUM
cblr-1794	153	16	45	45	NUM
cblr-1794	154	1	i	i	PROPN
cblr-1794	154	2	d.	d.	PROPN
cblr-1794	154	3	46	46	NUM
cblr-1794	154	4	sandoz	sandoz	PROPN
cblr-1794	154	5	,	,	PUNCT
cblr-1794	154	6	inc	inc	PROPN
cblr-1794	154	7	.	.	PROPN
cblr-1794	155	1	v.	v.	PROPN
cblr-1794	155	2	leavitt	leavitt	PROPN
cblr-1794	155	3	,	,	PUNCT
cblr-1794	155	4	427	427	NUM
cblr-1794	155	5	f.	f.	NOUN
cblr-1794	155	6	supp	supp	PROPN
cblr-1794	155	7	.	.	PUNCT
cblr-1794	156	1	2d	2d	PROPN
cblr-1794	156	2	29	29	NUM
cblr-1794	156	3	,	,	PUNCT
cblr-1794	156	4	32	32	NUM
cblr-1794	156	5	(	(	PUNCT
cblr-1794	156	6	d.d.c	d.d.c	PROPN
cblr-1794	156	7	.	.	PROPN
cblr-1794	156	8	2006	2006	NUM
cblr-1794	156	9	)	)	PUNCT
cblr-1794	156	10	.	.	PUNCT
cblr-1794	157	1	no	no	INTJ
cblr-1794	157	2	.	.	PUNCT
cblr-1794	158	1	1:209	1:209	NUM
cblr-1794	158	2	]	]	X
cblr-1794	158	3	bpcia	bpcia	NOUN
cblr-1794	158	4	:	:	PUNCT
cblr-1794	158	5	destined	destine	VERB
cblr-1794	158	6	for	for	ADP
cblr-1794	158	7	failure	failure	NOUN
cblr-1794	158	8	?	?	PUNCT
cblr-1794	159	1	217	217	NUM
cblr-1794	159	2	statutory	statutory	ADJ
cblr-1794	159	3	obligation	obligation	NOUN
cblr-1794	159	4	to	to	PART
cblr-1794	159	5	act	act	VERB
cblr-1794	159	6	on	on	ADP
cblr-1794	159	7	applications	application	NOUN
cblr-1794	159	8	within	within	ADP
cblr-1794	159	9	180	180	NUM
cblr-1794	159	10	days.4	days.4	NOUN
cblr-1794	159	11	7	7	NUM
cblr-1794	159	12	the	the	DET
cblr-1794	159	13	court	court	NOUN
cblr-1794	159	14	ruled	rule	VERB
cblr-1794	159	15	that	that	SCONJ
cblr-1794	159	16	the	the	DET
cblr-1794	159	17	fda	fda	PROPN
cblr-1794	159	18	must	must	AUX
cblr-1794	159	19	consider	consider	VERB
cblr-1794	159	20	sandoz	sandoz	PROPN
cblr-1794	159	21	's	's	PART
cblr-1794	159	22	505(b)(2	505(b)(2	NUM
cblr-1794	159	23	)	)	PUNCT
cblr-1794	159	24	application,4	application,4	NOUN
cblr-1794	159	25	8	8	NUM
cblr-1794	159	26	and	and	CCONJ
cblr-1794	159	27	in	in	ADP
cblr-1794	159	28	2006	2006	NUM
cblr-1794	159	29	,	,	PUNCT
cblr-1794	159	30	the	the	DET
cblr-1794	159	31	fda	fda	PROPN
cblr-1794	159	32	approved	approve	VERB
cblr-1794	159	33	the	the	DET
cblr-1794	159	34	505(b)(2	505(b)(2	NUM
cblr-1794	159	35	)	)	PUNCT
cblr-1794	159	36	application	application	NOUN
cblr-1794	159	37	for	for	ADP
cblr-1794	159	38	omnitrope.4	omnitrope.4	PROPN
cblr-1794	159	39	9	9	NUM
cblr-1794	159	40	however	however	ADV
cblr-1794	159	41	,	,	PUNCT
cblr-1794	159	42	in	in	ADP
cblr-1794	159	43	its	its	PRON
cblr-1794	159	44	decision	decision	NOUN
cblr-1794	159	45	letter	letter	NOUN
cblr-1794	159	46	,	,	PUNCT
cblr-1794	159	47	the	the	DET
cblr-1794	159	48	fda	fda	PROPN
cblr-1794	159	49	emphasized	emphasize	VERB
cblr-1794	159	50	that	that	SCONJ
cblr-1794	159	51	the	the	DET
cblr-1794	159	52	omnitrope	omnitrope	NOUN
cblr-1794	159	53	review	review	NOUN
cblr-1794	159	54	process	process	NOUN
cblr-1794	159	55	was	be	AUX
cblr-1794	159	56	simplified	simplify	VERB
cblr-1794	159	57	because	because	SCONJ
cblr-1794	159	58	human	human	ADJ
cblr-1794	159	59	growth	growth	NOUN
cblr-1794	159	60	hormones	hormone	NOUN
cblr-1794	159	61	can	can	AUX
cblr-1794	159	62	be	be	AUX
cblr-1794	159	63	more	more	ADV
cblr-1794	159	64	easily	easily	ADV
cblr-1794	159	65	compared	compare	VERB
cblr-1794	159	66	to	to	ADP
cblr-1794	159	67	one	one	NUM
cblr-1794	159	68	another	another	DET
cblr-1794	159	69	than	than	ADP
cblr-1794	159	70	most	most	ADJ
cblr-1794	159	71	biologics.5	biologics.5	ADJ
cblr-1794	159	72	o	o	NOUN
cblr-1794	159	73	although	although	SCONJ
cblr-1794	159	74	the	the	DET
cblr-1794	159	75	fda	fda	PROPN
cblr-1794	159	76	drafted	draft	VERB
cblr-1794	159	77	the	the	DET
cblr-1794	159	78	decision	decision	NOUN
cblr-1794	159	79	letter	letter	NOUN
cblr-1794	159	80	narrowly	narrowly	ADV
cblr-1794	159	81	,	,	PUNCT
cblr-1794	159	82	"	"	PUNCT
cblr-1794	159	83	limiting	limit	VERB
cblr-1794	159	84	its	its	PRON
cblr-1794	159	85	scientific	scientific	ADJ
cblr-1794	159	86	and	and	CCONJ
cblr-1794	159	87	legal	legal	ADJ
cblr-1794	159	88	conclusions	conclusion	NOUN
cblr-1794	159	89	to	to	ADP
cblr-1794	159	90	the	the	DET
cblr-1794	159	91	product	product	NOUN
cblr-1794	159	92	and	and	CCONJ
cblr-1794	159	93	application	application	NOUN
cblr-1794	159	94	before	before	ADP
cblr-1794	159	95	it	it	PRON
cblr-1794	159	96	,	,	PUNCT
cblr-1794	159	97	many	many	ADJ
cblr-1794	159	98	believed	believe	VERB
cblr-1794	159	99	that	that	SCONJ
cblr-1794	159	100	[	[	X
cblr-1794	159	101	this	this	DET
cblr-1794	159	102	decision	decision	NOUN
cblr-1794	159	103	]	]	PUNCT
cblr-1794	159	104	signaled	signal	VERB
cblr-1794	159	105	to	to	ADP
cblr-1794	159	106	congress	congress	PROPN
cblr-1794	159	107	that	that	SCONJ
cblr-1794	159	108	the	the	DET
cblr-1794	159	109	agency	agency	NOUN
cblr-1794	159	110	was	be	AUX
cblr-1794	159	111	prepared	prepared	ADJ
cblr-1794	159	112	to	to	PART
cblr-1794	159	113	begin	begin	VERB
cblr-1794	159	114	approvals	approval	NOUN
cblr-1794	159	115	of	of	ADP
cblr-1794	159	116	biosimilars	biosimilar	NOUN
cblr-1794	159	117	.	.	PUNCT
cblr-1794	160	1	"	"	PUNCT
cblr-1794	160	2	'	'	PUNCT
cblr-1794	160	3	47	47	NUM
cblr-1794	160	4	johnson	johnson	PROPN
cblr-1794	160	5	,	,	PUNCT
cblr-1794	160	6	supra	supra	PROPN
cblr-1794	160	7	note	note	PROPN
cblr-1794	160	8	8	8	NUM
cblr-1794	160	9	,	,	PUNCT
cblr-1794	160	10	at	at	ADP
cblr-1794	160	11	3	3	NUM
cblr-1794	160	12	.	.	PUNCT
cblr-1794	160	13	48	48	NUM
cblr-1794	160	14	sandoz	sandoz	NOUN
cblr-1794	160	15	,	,	PUNCT
cblr-1794	160	16	427	427	NUM
cblr-1794	160	17	f.	f.	NOUN
cblr-1794	160	18	supp	supp	PROPN
cblr-1794	160	19	.	.	PUNCT
cblr-1794	160	20	2d	2d	PROPN
cblr-1794	160	21	at	at	ADP
cblr-1794	160	22	33	33	NUM
cblr-1794	160	23	.	.	PROPN
cblr-1794	160	24	49	49	NUM
cblr-1794	160	25	covington	covington	PROPN
cblr-1794	160	26	&	&	CCONJ
cblr-1794	160	27	burling	burling	PROPN
cblr-1794	160	28	,	,	PUNCT
cblr-1794	160	29	fda	fda	PROPN
cblr-1794	160	30	approval	approval	NOUN
cblr-1794	160	31	of	of	ADP
cblr-1794	160	32	sandoz	sandoz	PROPN
cblr-1794	160	33	's	's	PART
cblr-1794	160	34	505(b)(2	505(b)(2	NUM
cblr-1794	160	35	)	)	PUNCT
cblr-1794	160	36	application	application	NOUN
cblr-1794	160	37	for	for	ADP
cblr-1794	160	38	a	a	DET
cblr-1794	160	39	follow	follow	NOUN
cblr-1794	160	40	-	-	PUNCT
cblr-1794	160	41	on	on	ADP
cblr-1794	160	42	recombinant	recombinant	ADJ
cblr-1794	160	43	human	human	ADJ
cblr-1794	160	44	growth	growth	NOUN
cblr-1794	160	45	hormone	hormone	NOUN
cblr-1794	160	46	product	product	NOUN
cblr-1794	160	47	2	2	NUM
cblr-1794	160	48	(	(	PUNCT
cblr-1794	160	49	2006	2006	NUM
cblr-1794	160	50	)	)	PUNCT
cblr-1794	160	51	,	,	PUNCT
cblr-1794	160	52	available	available	ADJ
cblr-1794	160	53	at	at	ADP
cblr-1794	160	54	http://www.cov.com/files/publication/	http://www.cov.com/files/publication/	PROPN
cblr-1794	160	55	8405cdb8	8405cdb8	NUM
cblr-1794	160	56	-	-	PUNCT
cblr-1794	160	57	b5ca-4050	b5ca-4050	NOUN
cblr-1794	160	58	-	-	PUNCT
cblr-1794	160	59	a2a784ea54b23aaclpresentation	a2a784ea54b23aaclpresentation	NOUN
cblr-1794	160	60	/	/	SYM
cblr-1794	160	61	publication	publication	NOUN
cblr-1794	160	62	attachment/356e78e0	attachment/356e78e0	PROPN
cblr-1794	160	63	-	-	PUNCT
cblr-1794	160	64	o6fc-45e3	o6fc-45e3	PROPN
cblr-1794	160	65	-	-	PUNCT
cblr-1794	160	66	bob8	bob8	NOUN
cblr-1794	160	67	-	-	PUNCT
cblr-1794	160	68	9385b2b205b0	9385b2b205b0	NUM
cblr-1794	160	69	/	/	SYM
cblr-1794	160	70	oid20985.pdf	oid20985.pdf	NOUN
cblr-1794	160	71	.	.	PUNCT
cblr-1794	161	1	50	50	NUM
cblr-1794	161	2	see	see	VERB
cblr-1794	161	3	letter	letter	NOUN
cblr-1794	161	4	from	from	ADP
cblr-1794	161	5	fda	fda	PROPN
cblr-1794	161	6	to	to	ADP
cblr-1794	161	7	kathleen	kathleen	PROPN
cblr-1794	161	8	m.	m.	PROPN
cblr-1794	161	9	sanzo	sanzo	PROPN
cblr-1794	161	10	,	,	PUNCT
cblr-1794	161	11	stephan	stephan	PROPN
cblr-1794	161	12	e.	e.	PROPN
cblr-1794	161	13	lawton	lawton	PROPN
cblr-1794	161	14	&	&	CCONJ
cblr-1794	161	15	stephen	stephen	PROPN
cblr-1794	161	16	g.	g.	PROPN
cblr-1794	161	17	juelsgaard	juelsgaard	PROPN
cblr-1794	161	18	7	7	NUM
cblr-1794	161	19	(	(	PUNCT
cblr-1794	161	20	may	may	PROPN
cblr-1794	161	21	30	30	NUM
cblr-1794	161	22	,	,	PUNCT
cblr-1794	161	23	2006	2006	NUM
cblr-1794	161	24	)	)	PUNCT
cblr-1794	162	1	[	[	X
cblr-1794	162	2	hereinafter	hereinafter	NOUN
cblr-1794	162	3	fda	fda	PROPN
cblr-1794	162	4	decision	decision	NOUN
cblr-1794	162	5	letter	letter	NOUN
cblr-1794	162	6	]	]	PUNCT
cblr-1794	162	7	,	,	PUNCT
cblr-1794	162	8	available	available	ADJ
cblr-1794	162	9	at	at	ADP
cblr-1794	162	10	http://www.fda.gov/ohrms/dockets/dockets/04p0231/	http://www.fda.gov/ohrms/dockets/dockets/04p0231/	NOUN
cblr-1794	162	11	04p-0231-pdn0001.pdf	04p-0231-pdn0001.pdf	ADJ
cblr-1794	162	12	.	.	PUNCT
cblr-1794	163	1	the	the	DET
cblr-1794	163	2	fda	fda	PROPN
cblr-1794	163	3	decision	decision	NOUN
cblr-1794	163	4	letter	letter	NOUN
cblr-1794	163	5	lists	list	VERB
cblr-1794	163	6	four	four	NUM
cblr-1794	163	7	characteristics	characteristic	NOUN
cblr-1794	163	8	of	of	ADP
cblr-1794	163	9	human	human	ADJ
cblr-1794	163	10	growth	growth	NOUN
cblr-1794	163	11	hormone	hormone	NOUN
cblr-1794	163	12	(	(	PUNCT
cblr-1794	163	13	"	"	PUNCT
cblr-1794	163	14	hgh	hgh	PROPN
cblr-1794	163	15	"	"	PUNCT
cblr-1794	163	16	)	)	PUNCT
cblr-1794	163	17	that	that	PRON
cblr-1794	163	18	facilitate	facilitate	VERB
cblr-1794	163	19	comparisons	comparison	NOUN
cblr-1794	163	20	:	:	PUNCT
cblr-1794	163	21	1	1	X
cblr-1794	163	22	)	)	PUNCT
cblr-1794	163	23	hgh	hgh	PROPN
cblr-1794	163	24	is	be	AUX
cblr-1794	163	25	a	a	DET
cblr-1794	163	26	single	single	ADJ
cblr-1794	163	27	-	-	PUNCT
cblr-1794	163	28	chain	chain	NOUN
cblr-1794	163	29	,	,	PUNCT
cblr-1794	163	30	191	191	NUM
cblr-1794	163	31	amino	amino	NOUN
cblr-1794	163	32	acid	acid	NOUN
cblr-1794	163	33	,	,	PUNCT
cblr-1794	163	34	non	non	ADJ
cblr-1794	163	35	-	-	ADJ
cblr-1794	163	36	glycosylated	glycosylated	ADJ
cblr-1794	163	37	protein	protein	NOUN
cblr-1794	163	38	with	with	ADP
cblr-1794	163	39	two	two	NUM
cblr-1794	163	40	intramolecular	intramolecular	ADJ
cblr-1794	163	41	disulfide	disulfide	NOUN
cblr-1794	163	42	bonds	bond	NOUN
cblr-1794	163	43	.	.	PUNCT
cblr-1794	164	1	2	2	X
cblr-1794	164	2	)	)	PUNCT
cblr-1794	164	3	hgh	hgh	PROPN
cblr-1794	164	4	is	be	AUX
cblr-1794	164	5	readily	readily	ADV
cblr-1794	164	6	purified	purify	VERB
cblr-1794	164	7	for	for	ADP
cblr-1794	164	8	structural	structural	ADJ
cblr-1794	164	9	assessments	assessment	NOUN
cblr-1794	164	10	.	.	PUNCT
cblr-1794	165	1	the	the	DET
cblr-1794	165	2	primary	primary	ADJ
cblr-1794	165	3	structure	structure	NOUN
cblr-1794	165	4	of	of	ADP
cblr-1794	165	5	hgh	hgh	PROPN
cblr-1794	165	6	is	be	AUX
cblr-1794	165	7	known	know	VERB
cblr-1794	165	8	,	,	PUNCT
cblr-1794	165	9	and	and	CCONJ
cblr-1794	165	10	physicochemical	physicochemical	ADJ
cblr-1794	165	11	tests	test	NOUN
cblr-1794	165	12	exist	exist	VERB
cblr-1794	165	13	for	for	ADP
cblr-1794	165	14	the	the	DET
cblr-1794	165	15	determination	determination	NOUN
cblr-1794	165	16	of	of	ADP
cblr-1794	165	17	an	an	DET
cblr-1794	165	18	hgh	hgh	NOUN
cblr-1794	165	19	product	product	NOUN
cblr-1794	165	20	's	's	PART
cblr-1794	165	21	secondary	secondary	ADJ
cblr-1794	165	22	and	and	CCONJ
cblr-1794	165	23	tertiary	tertiary	ADJ
cblr-1794	165	24	structures	structure	NOUN
cblr-1794	165	25	....	....	PUNCT
cblr-1794	166	1	3	3	X
cblr-1794	166	2	)	)	PUNCT
cblr-1794	166	3	clinically	clinically	ADV
cblr-1794	166	4	relevant	relevant	ADJ
cblr-1794	166	5	bioassays	bioassay	NOUN
cblr-1794	166	6	and	and	CCONJ
cblr-1794	166	7	qualified	qualified	ADJ
cblr-1794	166	8	biomarkers	biomarker	NOUN
cblr-1794	166	9	are	be	AUX
cblr-1794	166	10	available	available	ADJ
cblr-1794	166	11	for	for	ADP
cblr-1794	166	12	hgh	hgh	PROPN
cblr-1794	166	13	.	.	PUNCT
cblr-1794	167	1	the	the	DET
cblr-1794	167	2	mechanism	mechanism	NOUN
cblr-1794	167	3	of	of	ADP
cblr-1794	167	4	drug	drug	NOUN
cblr-1794	167	5	action	action	NOUN
cblr-1794	167	6	is	be	AUX
cblr-1794	167	7	known	know	VERB
cblr-1794	167	8	and	and	CCONJ
cblr-1794	167	9	the	the	DET
cblr-1794	167	10	human	human	ADJ
cblr-1794	167	11	toxicity	toxicity	NOUN
cblr-1794	167	12	profile	profile	NOUN
cblr-1794	167	13	is	be	AUX
cblr-1794	167	14	well	well	ADV
cblr-1794	167	15	understood	understand	VERB
cblr-1794	167	16	....	....	PUNCT
cblr-1794	168	1	4	4	X
cblr-1794	168	2	)	)	PUNCT
cblr-1794	168	3	hgh	hgh	PROPN
cblr-1794	168	4	has	have	VERB
cblr-1794	168	5	a	a	DET
cblr-1794	168	6	long	long	ADJ
cblr-1794	168	7	history	history	NOUN
cblr-1794	168	8	of	of	ADP
cblr-1794	168	9	clinical	clinical	ADJ
cblr-1794	168	10	use	use	NOUN
cblr-1794	168	11	as	as	ADP
cblr-1794	168	12	replacement	replacement	NOUN
cblr-1794	168	13	therapy	therapy	NOUN
cblr-1794	168	14	for	for	ADP
cblr-1794	168	15	endogenous	endogenous	ADJ
cblr-1794	168	16	ghd	ghd	NOUN
cblr-1794	168	17	and	and	CCONJ
cblr-1794	168	18	its	its	PRON
cblr-1794	168	19	safety	safety	NOUN
cblr-1794	168	20	and	and	CCONJ
cblr-1794	168	21	efficacy	efficacy	NOUN
cblr-1794	168	22	profile	profile	NOUN
cblr-1794	168	23	is	be	AUX
cblr-1794	168	24	thoroughly	thoroughly	ADV
cblr-1794	168	25	described	describe	VERB
cblr-1794	168	26	in	in	ADP
cblr-1794	168	27	the	the	DET
cblr-1794	168	28	literature	literature	NOUN
cblr-1794	168	29	and	and	CCONJ
cblr-1794	168	30	well	well	ADV
cblr-1794	168	31	understood	understand	VERB
cblr-1794	168	32	.	.	PUNCT
cblr-1794	169	1	i	i	PRON
cblr-1794	169	2	d.	d.	PROPN
cblr-1794	169	3	51	51	NUM
cblr-1794	169	4	carver	carver	PROPN
cblr-1794	169	5	et	et	PROPN
cblr-1794	169	6	al	al	PROPN
cblr-1794	169	7	.	.	PROPN
cblr-1794	169	8	,	,	PUNCT
cblr-1794	169	9	supra	supra	PROPN
cblr-1794	169	10	note	note	PROPN
cblr-1794	169	11	20	20	NUM
cblr-1794	169	12	,	,	PUNCT
cblr-1794	169	13	at	at	ADP
cblr-1794	169	14	706	706	NUM
cblr-1794	169	15	.	.	NOUN
cblr-1794	169	16	218	218	NUM
cblr-1794	169	17	col	col	PROPN
cblr-1794	169	18	umbia	umbia	PROPN
cblr-1794	169	19	b	b	PROPN
cblr-1794	169	20	usiness	usiness	PROPN
cblr-1794	169	21	la	la	PROPN
cblr-1794	169	22	wre	wre	PROPN
cblr-1794	169	23	vie	vie	PROPN
cblr-1794	169	24	w	w	PROPN
cblr-1794	170	1	[	[	X
cblr-1794	170	2	vol	vol	NOUN
cblr-1794	170	3	.	.	PUNCT
cblr-1794	170	4	2013	2013	NUM
cblr-1794	170	5	bpcia	bpcia	NOUN
cblr-1794	170	6	:	:	PUNCT
cblr-1794	170	7	destined	destine	VERB
cblr-1794	170	8	for	for	ADP
cblr-1794	170	9	failure	failure	NOUN
cblr-1794	170	10	?	?	PUNCT
cblr-1794	171	1	c.	c.	NOUN
cblr-1794	172	1	the	the	DET
cblr-1794	172	2	bpcia	bpcia	NOUN
cblr-1794	172	3	in	in	ADP
cblr-1794	172	4	2006	2006	NUM
cblr-1794	172	5	,	,	PUNCT
cblr-1794	172	6	representative	representative	ADJ
cblr-1794	172	7	henry	henry	PROPN
cblr-1794	172	8	waxman	waxman	PROPN
cblr-1794	172	9	introduced	introduce	VERB
cblr-1794	172	10	the	the	DET
cblr-1794	172	11	first	first	ADJ
cblr-1794	172	12	biosimilars	biosimilar	NOUN
cblr-1794	172	13	bill	bill	NOUN
cblr-1794	172	14	in	in	ADP
cblr-1794	172	15	the	the	DET
cblr-1794	172	16	house	house	NOUN
cblr-1794	172	17	of	of	ADP
cblr-1794	172	18	representatives.5	representatives.5	PROPN
cblr-1794	172	19	2	2	NUM
cblr-1794	172	20	senator	senator	NOUN
cblr-1794	172	21	charles	charles	PROPN
cblr-1794	172	22	schumer	schumer	PROPN
cblr-1794	172	23	introduced	introduce	VERB
cblr-1794	172	24	a	a	DET
cblr-1794	172	25	similar	similar	ADJ
cblr-1794	172	26	bill	bill	NOUN
cblr-1794	172	27	in	in	ADP
cblr-1794	172	28	the	the	DET
cblr-1794	172	29	senate.5	senate.5	ADJ
cblr-1794	172	30	3	3	NUM
cblr-1794	172	31	these	these	DET
cblr-1794	172	32	bills	bill	NOUN
cblr-1794	172	33	"	"	PUNCT
cblr-1794	172	34	would	would	AUX
cblr-1794	172	35	have	have	AUX
cblr-1794	172	36	permitted	permit	VERB
cblr-1794	172	37	a	a	DET
cblr-1794	172	38	case	case	NOUN
cblr-1794	172	39	-	-	PUNCT
cblr-1794	172	40	by	by	ADP
cblr-1794	172	41	-	-	PUNCT
cblr-1794	172	42	case	case	NOUN
cblr-1794	172	43	approach	approach	NOUN
cblr-1794	172	44	with	with	ADP
cblr-1794	172	45	respect	respect	NOUN
cblr-1794	172	46	to	to	ADP
cblr-1794	172	47	clinical	clinical	ADJ
cblr-1794	172	48	and	and	CCONJ
cblr-1794	172	49	other	other	ADJ
cblr-1794	172	50	data	datum	NOUN
cblr-1794	172	51	supporting	support	VERB
cblr-1794	172	52	licensure	licensure	NOUN
cblr-1794	172	53	of	of	ADP
cblr-1794	172	54	the	the	DET
cblr-1794	172	55	biosimilar	biosimilar	NOUN
cblr-1794	172	56	.	.	PUNCT
cblr-1794	173	1	"5	"5	X
cblr-1794	174	1	4	4	NUM
cblr-1794	174	2	such	such	DET
cblr-1794	174	3	an	an	DET
cblr-1794	174	4	approach	approach	NOUN
cblr-1794	174	5	contrasts	contrast	VERB
cblr-1794	174	6	sharply	sharply	ADV
cblr-1794	174	7	with	with	ADP
cblr-1794	174	8	the	the	DET
cblr-1794	174	9	anda	anda	PROPN
cblr-1794	174	10	process	process	NOUN
cblr-1794	174	11	,	,	PUNCT
cblr-1794	174	12	which	which	PRON
cblr-1794	174	13	specifies	specify	VERB
cblr-1794	174	14	the	the	DET
cblr-1794	174	15	data	datum	NOUN
cblr-1794	174	16	and	and	CCONJ
cblr-1794	174	17	information	information	NOUN
cblr-1794	174	18	that	that	PRON
cblr-1794	174	19	the	the	DET
cblr-1794	174	20	fda	fda	PROPN
cblr-1794	174	21	is	be	AUX
cblr-1794	174	22	permitted	permit	VERB
cblr-1794	174	23	to	to	PART
cblr-1794	174	24	request	request	VERB
cblr-1794	174	25	in	in	ADP
cblr-1794	174	26	evaluating	evaluate	VERB
cblr-1794	174	27	an	an	DET
cblr-1794	174	28	anda	anda	NOUN
cblr-1794	174	29	.	.	PUNCT
cblr-1794	175	1	5	5	NUM
cblr-1794	175	2	the	the	DET
cblr-1794	175	3	bills	bill	NOUN
cblr-1794	175	4	also	also	ADV
cblr-1794	175	5	did	do	AUX
cblr-1794	175	6	not	not	PART
cblr-1794	175	7	provide	provide	VERB
cblr-1794	175	8	a	a	DET
cblr-1794	175	9	data	data	NOUN
cblr-1794	175	10	exclusivity	exclusivity	NOUN
cblr-1794	175	11	period	period	NOUN
cblr-1794	175	12	for	for	ADP
cblr-1794	175	13	brand	brand	NOUN
cblr-1794	175	14	-	-	PUNCT
cblr-1794	175	15	name	name	NOUN
cblr-1794	175	16	products	product	NOUN
cblr-1794	175	17	.	.	PUNCT
cblr-1794	176	1	6	6	NUM
cblr-1794	176	2	biosimilars	biosimilar	NOUN
cblr-1794	176	3	bills	bill	NOUN
cblr-1794	176	4	were	be	AUX
cblr-1794	176	5	introduced	introduce	VERB
cblr-1794	176	6	in	in	ADP
cblr-1794	176	7	every	every	DET
cblr-1794	176	8	congressional	congressional	ADJ
cblr-1794	176	9	session	session	NOUN
cblr-1794	176	10	after	after	ADP
cblr-1794	176	11	2006	2006	NUM
cblr-1794	176	12	,	,	PUNCT
cblr-1794	176	13	but	but	CCONJ
cblr-1794	176	14	no	no	DET
cblr-1794	176	15	such	such	ADJ
cblr-1794	176	16	bill	bill	NOUN
cblr-1794	176	17	passed	pass	VERB
cblr-1794	176	18	in	in	ADP
cblr-1794	176	19	either	either	CCONJ
cblr-1794	176	20	the	the	DET
cblr-1794	176	21	house	house	NOUN
cblr-1794	176	22	or	or	CCONJ
cblr-1794	176	23	the	the	DET
cblr-1794	176	24	senate	senate	PROPN
cblr-1794	176	25	until	until	SCONJ
cblr-1794	176	26	the	the	DET
cblr-1794	176	27	bpcia	bpcia	NOUN
cblr-1794	176	28	was	be	AUX
cblr-1794	176	29	included	include	VERB
cblr-1794	176	30	in	in	ADP
cblr-1794	176	31	the	the	DET
cblr-1794	176	32	recent	recent	ADJ
cblr-1794	176	33	health	health	NOUN
cblr-1794	176	34	care	care	NOUN
cblr-1794	176	35	reform	reform	PROPN
cblr-1794	176	36	legislation.5	legislation.5	PROPN
cblr-1794	176	37	'	'	PUNCT
cblr-1794	176	38	the	the	DET
cblr-1794	176	39	bpcia	bpcia	NOUN
cblr-1794	176	40	"	"	PUNCT
cblr-1794	176	41	amends	amend	VERB
cblr-1794	176	42	certain	certain	ADJ
cblr-1794	176	43	existing	exist	VERB
cblr-1794	176	44	provisions	provision	NOUN
cblr-1794	176	45	of	of	ADP
cblr-1794	176	46	section	section	NOUN
cblr-1794	176	47	351	351	NUM
cblr-1794	177	1	[	[	X
cblr-1794	177	2	of	of	ADP
cblr-1794	177	3	the	the	DET
cblr-1794	177	4	phsa	phsa	NOUN
cblr-1794	177	5	]	]	PUNCT
cblr-1794	177	6	and	and	CCONJ
cblr-1794	177	7	adds	add	VERB
cblr-1794	177	8	.	.	PUNCT
cblr-1794	178	1	..	..	PUNCT
cblr-1794	179	1	new	new	ADJ
cblr-1794	179	2	subsections	subsection	NOUN
cblr-1794	179	3	at	at	ADP
cblr-1794	179	4	the	the	DET
cblr-1794	179	5	end	end	NOUN
cblr-1794	179	6	of	of	ADP
cblr-1794	179	7	section	section	NOUN
cblr-1794	179	8	351	351	NUM
cblr-1794	179	9	:	:	PUNCT
cblr-1794	179	10	new	new	ADJ
cblr-1794	179	11	subsection	subsection	NOUN
cblr-1794	179	12	(	(	PUNCT
cblr-1794	179	13	k	k	NOUN
cblr-1794	179	14	)	)	PUNCT
cblr-1794	179	15	sets	set	VERB
cblr-1794	179	16	forth	forth	ADP
cblr-1794	179	17	the	the	DET
cblr-1794	179	18	regulatory	regulatory	ADJ
cblr-1794	179	19	pathway	pathway	NOUN
cblr-1794	179	20	for	for	ADP
cblr-1794	179	21	the	the	DET
cblr-1794	179	22	approval	approval	NOUN
cblr-1794	179	23	of	of	ADP
cblr-1794	179	24	[	[	X
cblr-1794	179	25	biosimilar	biosimilar	X
cblr-1794	179	26	]	]	X
cblr-1794	179	27	products	product	NOUN
cblr-1794	179	28	;	;	PUNCT
cblr-1794	179	29	new	new	ADJ
cblr-1794	179	30	subsection	subsection	NOUN
cblr-1794	179	31	(	(	PUNCT
cblr-1794	179	32	1	1	X
cblr-1794	179	33	)	)	PUNCT
cblr-1794	179	34	sets	set	VERB
cblr-1794	179	35	forth	forth	ADP
cblr-1794	179	36	the	the	DET
cblr-1794	179	37	rules	rule	NOUN
cblr-1794	179	38	for	for	ADP
cblr-1794	179	39	identifying	identify	VERB
cblr-1794	179	40	and	and	CCONJ
cblr-1794	179	41	resolving	resolve	VERB
cblr-1794	179	42	patent	patent	NOUN
cblr-1794	179	43	disputes	dispute	NOUN
cblr-1794	179	44	.	.	PUNCT
cblr-1794	180	1	"5	"5	NOUN
cblr-1794	181	1	52	52	NUM
cblr-1794	181	2	see	see	NOUN
cblr-1794	181	3	h.r	h.r	PROPN
cblr-1794	181	4	.	.	PROPN
cblr-1794	181	5	6257	6257	NUM
cblr-1794	181	6	,	,	PUNCT
cblr-1794	181	7	109th	109th	ADJ
cblr-1794	181	8	cong	cong	NOUN
cblr-1794	181	9	.	.	PUNCT
cblr-1794	182	1	(	(	PUNCT
cblr-1794	182	2	2006	2006	NUM
cblr-1794	182	3	)	)	PUNCT
cblr-1794	182	4	.	.	PUNCT
cblr-1794	183	1	53	53	NUM
cblr-1794	183	2	see	see	VERB
cblr-1794	183	3	s.	s.	PROPN
cblr-1794	183	4	4016	4016	NUM
cblr-1794	183	5	,	,	PUNCT
cblr-1794	183	6	109th	109th	ADJ
cblr-1794	183	7	cong	cong	NOUN
cblr-1794	183	8	.	.	PUNCT
cblr-1794	184	1	(	(	PUNCT
cblr-1794	184	2	2006	2006	NUM
cblr-1794	184	3	)	)	PUNCT
cblr-1794	184	4	.	.	PUNCT
cblr-1794	185	1	54	54	NUM
cblr-1794	185	2	carver	carver	NOUN
cblr-1794	185	3	et	et	PROPN
cblr-1794	185	4	al	al	PROPN
cblr-1794	185	5	.	.	PROPN
cblr-1794	185	6	,	,	PUNCT
cblr-1794	185	7	supra	supra	PROPN
cblr-1794	185	8	note	note	PROPN
cblr-1794	185	9	20	20	NUM
cblr-1794	185	10	,	,	PUNCT
cblr-1794	185	11	at	at	ADP
cblr-1794	185	12	716	716	NUM
cblr-1794	185	13	.	.	PUNCT
cblr-1794	186	1	55	55	NUM
cblr-1794	187	1	i	i	PRON
cblr-1794	187	2	d.	d.	PROPN
cblr-1794	187	3	56	56	NUM
cblr-1794	188	1	i	i	PRON
cblr-1794	188	2	d.	d.	PROPN
cblr-1794	188	3	at	at	ADP
cblr-1794	188	4	717	717	NUM
cblr-1794	188	5	.	.	PUNCT
cblr-1794	188	6	57	57	NUM
cblr-1794	189	1	i	i	PRON
cblr-1794	189	2	d.	d.	NOUN
cblr-1794	189	3	at	at	ADP
cblr-1794	189	4	716	716	NUM
cblr-1794	189	5	-	-	SYM
cblr-1794	189	6	806	806	NUM
cblr-1794	189	7	(	(	PUNCT
cblr-1794	189	8	describing	describe	VERB
cblr-1794	189	9	-	-	PUNCT
cblr-1794	189	10	before	before	ADP
cblr-1794	189	11	the	the	DET
cblr-1794	189	12	passage	passage	NOUN
cblr-1794	189	13	of	of	ADP
cblr-1794	189	14	the	the	DET
cblr-1794	189	15	bpcia	bpcia	NOUN
cblr-1794	189	16	-	-	PUNCT
cblr-1794	189	17	the	the	DET
cblr-1794	189	18	introduction	introduction	NOUN
cblr-1794	189	19	of	of	ADP
cblr-1794	189	20	biosimilar	biosimilar	ADJ
cblr-1794	189	21	bills	bill	NOUN
cblr-1794	189	22	in	in	ADP
cblr-1794	189	23	every	every	DET
cblr-1794	189	24	session	session	NOUN
cblr-1794	189	25	of	of	ADP
cblr-1794	189	26	congress	congress	PROPN
cblr-1794	189	27	beginning	begin	VERB
cblr-1794	189	28	in	in	ADP
cblr-1794	189	29	2006	2006	NUM
cblr-1794	189	30	)	)	PUNCT
cblr-1794	189	31	.	.	PUNCT
cblr-1794	190	1	see	see	VERB
cblr-1794	190	2	also	also	ADV
cblr-1794	190	3	martha	martha	PROPN
cblr-1794	190	4	m.	m.	PROPN
cblr-1794	190	5	rumore	rumore	PROPN
cblr-1794	190	6	,	,	PUNCT
cblr-1794	190	7	the	the	DET
cblr-1794	190	8	hatch	hatch	NOUN
cblr-1794	190	9	-	-	PUNCT
cblr-1794	190	10	waxman	waxman	NOUN
cblr-1794	190	11	act-25	act-25	ADP
cblr-1794	190	12	years	year	NOUN
cblr-1794	190	13	later	later	ADV
cblr-1794	190	14	:	:	PUNCT
cblr-1794	190	15	keeping	keep	VERB
cblr-1794	190	16	the	the	DET
cblr-1794	190	17	pharmaceutical	pharmaceutical	NOUN
cblr-1794	190	18	scales	scale	NOUN
cblr-1794	190	19	balanced	balance	VERB
cblr-1794	190	20	,	,	PUNCT
cblr-1794	190	21	pharmacy	pharmacy	NOUN
cblr-1794	190	22	times	time	NOUN
cblr-1794	190	23	,	,	PUNCT
cblr-1794	190	24	aug	aug	PROPN
cblr-1794	190	25	.	.	PROPN
cblr-1794	190	26	15	15	NUM
cblr-1794	190	27	,	,	PUNCT
cblr-1794	190	28	2009	2009	NUM
cblr-1794	190	29	,	,	PUNCT
cblr-1794	190	30	available	available	ADJ
cblr-1794	190	31	at	at	ADP
cblr-1794	190	32	http://www.pharmacytimes.com/publications/	http://www.pharmacytimes.com/publications/	PROPN
cblr-1794	190	33	supplement/2009	supplement/2009	PROPN
cblr-1794	190	34	/	/	SYM
cblr-1794	190	35	genericsupplemento8o9	genericsupplemento8o9	ADJ
cblr-1794	190	36	/	/	SYM
cblr-1794	190	37	generic	generic	ADJ
cblr-1794	190	38	-	-	PUNCT
cblr-1794	190	39	hatchwaxman-0809	hatchwaxman-0809	NOUN
cblr-1794	190	40	(	(	PUNCT
cblr-1794	190	41	stating	state	VERB
cblr-1794	190	42	that	that	SCONJ
cblr-1794	190	43	congress	congress	PROPN
cblr-1794	190	44	failed	fail	VERB
cblr-1794	190	45	to	to	PART
cblr-1794	190	46	pass	pass	VERB
cblr-1794	190	47	biosimilars	biosimilars	ADJ
cblr-1794	190	48	initiatives	initiative	NOUN
cblr-1794	190	49	because	because	SCONJ
cblr-1794	190	50	an	an	DET
cblr-1794	190	51	agreement	agreement	NOUN
cblr-1794	190	52	could	could	AUX
cblr-1794	190	53	not	not	PART
cblr-1794	190	54	be	be	AUX
cblr-1794	190	55	reached	reach	VERB
cblr-1794	190	56	on	on	ADP
cblr-1794	190	57	the	the	DET
cblr-1794	190	58	data	data	NOUN
cblr-1794	190	59	exclusivity	exclusivity	NOUN
cblr-1794	190	60	period	period	NOUN
cblr-1794	190	61	innovative	innovative	ADJ
cblr-1794	190	62	biologics	biologic	NOUN
cblr-1794	190	63	would	would	AUX
cblr-1794	190	64	enjoy	enjoy	VERB
cblr-1794	190	65	)	)	PUNCT
cblr-1794	190	66	.	.	PUNCT
cblr-1794	191	1	58	58	NUM
cblr-1794	191	2	michael	michael	PROPN
cblr-1794	191	3	p.	p.	PROPN
cblr-1794	191	4	dougherty	dougherty	PROPN
cblr-1794	191	5	,	,	PUNCT
cblr-1794	191	6	the	the	DET
cblr-1794	191	7	new	new	ADJ
cblr-1794	191	8	follow	follow	VERB
cblr-1794	191	9	-	-	PUNCT
cblr-1794	191	10	on	on	ADP
cblr-1794	191	11	-	-	PUNCT
cblr-1794	191	12	biologics	biologic	NOUN
cblr-1794	191	13	law	law	NOUN
cblr-1794	191	14	:	:	PUNCT
cblr-1794	191	15	a	a	DET
cblr-1794	191	16	section	section	NOUN
cblr-1794	191	17	by	by	ADP
cblr-1794	191	18	section	section	NOUN
cblr-1794	191	19	analysis	analysis	NOUN
cblr-1794	191	20	of	of	ADP
cblr-1794	191	21	the	the	DET
cblr-1794	191	22	patent	patent	NOUN
cblr-1794	191	23	litigation	litigation	NOUN
cblr-1794	191	24	provisions	provision	NOUN
cblr-1794	191	25	in	in	ADP
cblr-1794	191	26	the	the	DET
cblr-1794	191	27	biologics	biologic	NOUN
cblr-1794	191	28	price	price	NOUN
cblr-1794	191	29	competition	competition	NOUN
cblr-1794	191	30	and	and	CCONJ
cblr-1794	191	31	innovation	innovation	NOUN
cblr-1794	191	32	act	act	NOUN
cblr-1794	191	33	of	of	ADP
cblr-1794	191	34	2009	2009	NUM
cblr-1794	191	35	,	,	PUNCT
cblr-1794	191	36	65	65	NUM
cblr-1794	191	37	food	food	NOUN
cblr-1794	191	38	&	&	CCONJ
cblr-1794	191	39	drug	drug	PROPN
cblr-1794	191	40	l.j	l.j	PROPN
cblr-1794	191	41	.	.	PROPN
cblr-1794	191	42	231	231	NUM
cblr-1794	191	43	,	,	PUNCT
cblr-1794	191	44	231	231	NUM
cblr-1794	191	45	-	-	SYM
cblr-1794	191	46	32	32	NUM
cblr-1794	191	47	(	(	PUNCT
cblr-1794	191	48	2010	2010	NUM
cblr-1794	191	49	)	)	PUNCT
cblr-1794	191	50	.	.	PUNCT
cblr-1794	192	1	no	no	INTJ
cblr-1794	192	2	.	.	PUNCT
cblr-1794	193	1	i1:209	i1:209	NOUN
cblr-1794	193	2	]	]	PUNCT
cblr-1794	193	3	219	219	NUM
cblr-1794	193	4	subsection	subsection	NOUN
cblr-1794	193	5	(	(	PUNCT
cblr-1794	193	6	k	k	NOUN
cblr-1794	193	7	)	)	PUNCT
cblr-1794	193	8	creates	create	VERB
cblr-1794	193	9	approval	approval	NOUN
cblr-1794	193	10	pathways	pathway	NOUN
cblr-1794	193	11	for	for	ADP
cblr-1794	193	12	submission	submission	NOUN
cblr-1794	193	13	of	of	ADP
cblr-1794	193	14	a	a	DET
cblr-1794	193	15	bla	bla	NOUN
cblr-1794	193	16	that	that	PRON
cblr-1794	193	17	is	be	AUX
cblr-1794	193	18	either	either	CCONJ
cblr-1794	193	19	"	"	PUNCT
cblr-1794	193	20	biosimilar	biosimilar	NOUN
cblr-1794	193	21	"	"	PUNCT
cblr-1794	193	22	to	to	ADP
cblr-1794	193	23	or	or	CCONJ
cblr-1794	193	24	"	"	PUNCT
cblr-1794	193	25	interchangeable	interchangeable	ADJ
cblr-1794	193	26	"	"	PUNCT
cblr-1794	193	27	with	with	ADP
cblr-1794	193	28	the	the	DET
cblr-1794	193	29	reference	reference	NOUN
cblr-1794	193	30	product	product	NOUN
cblr-1794	193	31	.	.	PUNCT
cblr-1794	193	32	"	"	PUNCT
cblr-1794	194	1	in	in	ADP
cblr-1794	194	2	order	order	NOUN
cblr-1794	194	3	to	to	PART
cblr-1794	194	4	support	support	VERB
cblr-1794	194	5	a	a	DET
cblr-1794	194	6	determination	determination	NOUN
cblr-1794	194	7	of	of	ADP
cblr-1794	194	8	biosimilarity	biosimilarity	NOUN
cblr-1794	194	9	,	,	PUNCT
cblr-1794	194	10	sponsors	sponsor	NOUN
cblr-1794	194	11	of	of	ADP
cblr-1794	194	12	biosimilars	biosimilar	NOUN
cblr-1794	194	13	must	must	AUX
cblr-1794	194	14	meet	meet	VERB
cblr-1794	194	15	five	five	NUM
cblr-1794	194	16	requirements	requirement	NOUN
cblr-1794	194	17	.	.	PUNCT
cblr-1794	195	1	first	first	ADV
cblr-1794	195	2	,	,	PUNCT
cblr-1794	195	3	the	the	DET
cblr-1794	195	4	sponsor	sponsor	NOUN
cblr-1794	195	5	must	must	AUX
cblr-1794	195	6	show	show	VERB
cblr-1794	195	7	that	that	SCONJ
cblr-1794	195	8	the	the	DET
cblr-1794	195	9	product	product	NOUN
cblr-1794	195	10	is	be	AUX
cblr-1794	195	11	biosimilar	biosimilar	ADJ
cblr-1794	195	12	to	to	ADP
cblr-1794	195	13	the	the	DET
cblr-1794	195	14	reference	reference	NOUN
cblr-1794	195	15	product.6	product.6	PROPN
cblr-1794	195	16	0	0	NUM
cblr-1794	195	17	a	a	DET
cblr-1794	195	18	product	product	NOUN
cblr-1794	195	19	is	be	AUX
cblr-1794	195	20	biosimilar	biosimilar	ADJ
cblr-1794	195	21	if	if	SCONJ
cblr-1794	195	22	it	it	PRON
cblr-1794	195	23	is	be	AUX
cblr-1794	195	24	highly	highly	ADV
cblr-1794	195	25	similar	similar	ADJ
cblr-1794	195	26	to	to	ADP
cblr-1794	195	27	the	the	DET
cblr-1794	195	28	reference	reference	NOUN
cblr-1794	195	29	product	product	NOUN
cblr-1794	195	30	,	,	PUNCT
cblr-1794	195	31	notwithstanding	notwithstanding	ADP
cblr-1794	195	32	minor	minor	ADJ
cblr-1794	195	33	differences	difference	NOUN
cblr-1794	195	34	in	in	ADP
cblr-1794	195	35	clinically	clinically	ADV
cblr-1794	195	36	inactive	inactive	ADJ
cblr-1794	195	37	components.6	components.6	PROPN
cblr-1794	195	38	1	1	NUM
cblr-1794	195	39	the	the	DET
cblr-1794	195	40	sponsor	sponsor	NOUN
cblr-1794	195	41	must	must	AUX
cblr-1794	195	42	provide	provide	VERB
cblr-1794	195	43	data	datum	NOUN
cblr-1794	195	44	from	from	ADP
cblr-1794	195	45	analytical	analytical	ADJ
cblr-1794	195	46	studies	study	NOUN
cblr-1794	195	47	,	,	PUNCT
cblr-1794	195	48	animal	animal	NOUN
cblr-1794	195	49	studies	study	NOUN
cblr-1794	195	50	(	(	PUNCT
cblr-1794	195	51	including	include	VERB
cblr-1794	195	52	the	the	DET
cblr-1794	195	53	assessment	assessment	NOUN
cblr-1794	195	54	of	of	ADP
cblr-1794	195	55	toxicology	toxicology	NOUN
cblr-1794	195	56	)	)	PUNCT
cblr-1794	195	57	,	,	PUNCT
cblr-1794	195	58	and	and	CCONJ
cblr-1794	195	59	clinical	clinical	ADJ
cblr-1794	195	60	studies	study	NOUN
cblr-1794	195	61	that	that	PRON
cblr-1794	195	62	demonstrate	demonstrate	VERB
cblr-1794	195	63	safety	safety	NOUN
cblr-1794	195	64	,	,	PUNCT
cblr-1794	195	65	purity	purity	NOUN
cblr-1794	195	66	,	,	PUNCT
cblr-1794	195	67	and	and	CCONJ
cblr-1794	195	68	potency.62	potency.62	VERB
cblr-1794	195	69	second	second	ADJ
cblr-1794	195	70	,	,	PUNCT
cblr-1794	195	71	the	the	DET
cblr-1794	195	72	sponsor	sponsor	NOUN
cblr-1794	195	73	must	must	AUX
cblr-1794	195	74	show	show	VERB
cblr-1794	195	75	that	that	SCONJ
cblr-1794	195	76	the	the	DET
cblr-1794	195	77	biosimilar	biosimilar	NOUN
cblr-1794	195	78	and	and	CCONJ
cblr-1794	195	79	reference	reference	NOUN
cblr-1794	195	80	product	product	NOUN
cblr-1794	195	81	utilize	utilize	VERB
cblr-1794	195	82	the	the	DET
cblr-1794	195	83	same	same	ADJ
cblr-1794	195	84	mechanism	mechanism	NOUN
cblr-1794	195	85	of	of	ADP
cblr-1794	195	86	action	action	NOUN
cblr-1794	195	87	for	for	ADP
cblr-1794	195	88	the	the	DET
cblr-1794	195	89	condition	condition	NOUN
cblr-1794	195	90	or	or	CCONJ
cblr-1794	195	91	conditions	condition	NOUN
cblr-1794	195	92	of	of	ADP
cblr-1794	195	93	use	use	NOUN
cblr-1794	195	94	prescribed	prescribe	VERB
cblr-1794	195	95	in	in	ADP
cblr-1794	195	96	the	the	DET
cblr-1794	195	97	proposed	propose	VERB
cblr-1794	195	98	labeling	labeling	NOUN
cblr-1794	195	99	,	,	PUNCT
cblr-1794	195	100	but	but	CCONJ
cblr-1794	195	101	only	only	ADV
cblr-1794	195	102	to	to	ADP
cblr-1794	195	103	the	the	DET
cblr-1794	195	104	extent	extent	NOUN
cblr-1794	195	105	that	that	SCONJ
cblr-1794	195	106	the	the	DET
cblr-1794	195	107	mechanism	mechanism	NOUN
cblr-1794	195	108	of	of	ADP
cblr-1794	195	109	action	action	NOUN
cblr-1794	195	110	is	be	AUX
cblr-1794	195	111	known.63	known.63	PROPN
cblr-1794	195	112	third	third	ADJ
cblr-1794	195	113	,	,	PUNCT
cblr-1794	195	114	the	the	DET
cblr-1794	195	115	sponsor	sponsor	NOUN
cblr-1794	195	116	must	must	AUX
cblr-1794	195	117	demonstrate	demonstrate	VERB
cblr-1794	195	118	that	that	SCONJ
cblr-1794	195	119	reference	reference	NOUN
cblr-1794	195	120	product	product	NOUN
cblr-1794	195	121	has	have	AUX
cblr-1794	195	122	been	be	AUX
cblr-1794	195	123	approved	approve	VERB
cblr-1794	195	124	for	for	ADP
cblr-1794	195	125	the	the	DET
cblr-1794	195	126	condition	condition	NOUN
cblr-1794	195	127	or	or	CCONJ
cblr-1794	195	128	conditions	condition	NOUN
cblr-1794	195	129	of	of	ADP
cblr-1794	195	130	use	use	NOUN
cblr-1794	195	131	prescribed	prescribe	VERB
cblr-1794	195	132	in	in	ADP
cblr-1794	195	133	the	the	DET
cblr-1794	195	134	proposed	propose	VERB
cblr-1794	195	135	labeling	labeling	NOUN
cblr-1794	195	136	.	.	PUNCT
cblr-1794	196	1	64	64	NUM
cblr-1794	196	2	fourth	fourth	ADJ
cblr-1794	196	3	,	,	PUNCT
cblr-1794	196	4	the	the	DET
cblr-1794	196	5	sponsor	sponsor	NOUN
cblr-1794	196	6	must	must	AUX
cblr-1794	196	7	provide	provide	VERB
cblr-1794	196	8	evidence	evidence	NOUN
cblr-1794	196	9	that	that	SCONJ
cblr-1794	196	10	the	the	DET
cblr-1794	196	11	biosimilar	biosimilar	NOUN
cblr-1794	196	12	and	and	CCONJ
cblr-1794	196	13	reference	reference	NOUN
cblr-1794	196	14	product	product	NOUN
cblr-1794	196	15	possess	possess	VERB
cblr-1794	196	16	the	the	DET
cblr-1794	196	17	same	same	ADJ
cblr-1794	196	18	route	route	NOUN
cblr-1794	196	19	of	of	ADP
cblr-1794	196	20	administration	administration	NOUN
cblr-1794	196	21	,	,	PUNCT
cblr-1794	196	22	dosage	dosage	NOUN
cblr-1794	196	23	form	form	NOUN
cblr-1794	196	24	,	,	PUNCT
cblr-1794	196	25	and	and	CCONJ
cblr-1794	196	26	strength.6	strength.6	PROPN
cblr-1794	196	27	'	'	PUNCT
cblr-1794	196	28	finally	finally	ADV
cblr-1794	196	29	,	,	PUNCT
cblr-1794	196	30	the	the	DET
cblr-1794	196	31	sponsor	sponsor	NOUN
cblr-1794	196	32	must	must	AUX
cblr-1794	196	33	show	show	VERB
cblr-1794	196	34	that	that	SCONJ
cblr-1794	196	35	the	the	DET
cblr-1794	196	36	facility	facility	NOUN
cblr-1794	196	37	in	in	ADP
cblr-1794	196	38	which	which	PRON
cblr-1794	196	39	the	the	DET
cblr-1794	196	40	biosimilar	biosimilar	NOUN
cblr-1794	196	41	is	be	AUX
cblr-1794	196	42	manufactured	manufacture	VERB
cblr-1794	196	43	,	,	PUNCT
cblr-1794	196	44	processed	process	VERB
cblr-1794	196	45	,	,	PUNCT
cblr-1794	196	46	packed	pack	VERB
cblr-1794	196	47	,	,	PUNCT
cblr-1794	196	48	or	or	CCONJ
cblr-1794	196	49	held	hold	VERB
cblr-1794	196	50	meets	meet	VERB
cblr-1794	196	51	standards	standard	NOUN
cblr-1794	196	52	designed	design	VERB
cblr-1794	196	53	to	to	PART
cblr-1794	196	54	assure	assure	VERB
cblr-1794	196	55	that	that	SCONJ
cblr-1794	196	56	the	the	DET
cblr-1794	196	57	biosimilar	biosimilar	NOUN
cblr-1794	196	58	continues	continue	VERB
cblr-1794	196	59	to	to	PART
cblr-1794	196	60	be	be	AUX
cblr-1794	196	61	safe	safe	ADJ
cblr-1794	196	62	,	,	PUNCT
cblr-1794	196	63	pure	pure	ADJ
cblr-1794	196	64	,	,	PUNCT
cblr-1794	196	65	and	and	CCONJ
cblr-1794	196	66	potent	potent	ADJ
cblr-1794	196	67	.	.	PUNCT
cblr-1794	197	1	however	however	ADV
cblr-1794	197	2	,	,	PUNCT
cblr-1794	197	3	the	the	DET
cblr-1794	197	4	bill	bill	NOUN
cblr-1794	197	5	gives	give	VERB
cblr-1794	197	6	the	the	DET
cblr-1794	197	7	fda	fda	PROPN
cblr-1794	197	8	broad	broad	PROPN
cblr-1794	197	9	authority	authority	PROPN
cblr-1794	197	10	to	to	PART
cblr-1794	197	11	deem	deem	VERB
cblr-1794	197	12	any	any	PRON
cblr-1794	197	13	of	of	ADP
cblr-1794	197	14	the	the	DET
cblr-1794	197	15	above	above	ADJ
cblr-1794	197	16	five	five	NUM
cblr-1794	197	17	requirements	requirement	NOUN
cblr-1794	197	18	unnecessary	unnecessary	ADJ
cblr-1794	197	19	for	for	ADP
cblr-1794	197	20	a	a	DET
cblr-1794	197	21	particular	particular	ADJ
cblr-1794	197	22	biosimilar	biosimilar	NOUN
cblr-1794	197	23	application	application	NOUN
cblr-1794	197	24	.	.	PUNCT
cblr-1794	198	1	59	59	NUM
cblr-1794	198	2	biosimilarity	biosimilarity	NOUN
cblr-1794	198	3	requirements	requirement	NOUN
cblr-1794	198	4	are	be	AUX
cblr-1794	198	5	laid	lay	VERB
cblr-1794	198	6	out	out	ADP
cblr-1794	198	7	under	under	ADP
cblr-1794	198	8	42	42	NUM
cblr-1794	198	9	u.s.c	u.s.c	ADJ
cblr-1794	198	10	.	.	PUNCT
cblr-1794	199	1	§	§	PROPN
cblr-1794	199	2	262(k)(2)(a)(i	262(k)(2)(a)(i	NUM
cblr-1794	199	3	)	)	PUNCT
cblr-1794	199	4	(	(	PUNCT
cblr-1794	199	5	2011	2011	NUM
cblr-1794	199	6	)	)	PUNCT
cblr-1794	199	7	,	,	PUNCT
cblr-1794	199	8	while	while	SCONJ
cblr-1794	199	9	interchangeability	interchangeability	NOUN
cblr-1794	199	10	requirements	requirement	NOUN
cblr-1794	199	11	are	be	AUX
cblr-1794	199	12	laid	lay	VERB
cblr-1794	199	13	out	out	ADP
cblr-1794	199	14	under	under	ADP
cblr-1794	199	15	§	§	PROPN
cblr-1794	199	16	262(k)(4	262(k)(4	PROPN
cblr-1794	199	17	)	)	PUNCT
cblr-1794	199	18	.	.	PUNCT
cblr-1794	200	1	60	60	NUM
cblr-1794	200	2	42	42	NUM
cblr-1794	200	3	u.s.c.a	u.s.c.a	PROPN
cblr-1794	200	4	.	.	PUNCT
cblr-1794	200	5	§	§	PROPN
cblr-1794	200	6	262(k)(2)(a)(i)(i	262(k)(2)(a)(i)(i	NUM
cblr-1794	200	7	)	)	PUNCT
cblr-1794	200	8	(	(	PUNCT
cblr-1794	200	9	west	west	NOUN
cblr-1794	200	10	2012	2012	NUM
cblr-1794	200	11	)	)	PUNCT
cblr-1794	200	12	.	.	PUNCT
cblr-1794	201	1	61	61	NUM
cblr-1794	202	1	i	i	PRON
cblr-1794	202	2	d.	d.	PROPN
cblr-1794	202	3	62	62	NUM
cblr-1794	203	1	i	i	PRON
cblr-1794	203	2	d.	d.	PROPN
cblr-1794	203	3	63	63	NUM
cblr-1794	203	4	see	see	VERB
cblr-1794	203	5	i	i	PRON
cblr-1794	203	6	d.	d.	PROPN
cblr-1794	203	7	§	§	PROPN
cblr-1794	203	8	262(k)(2)(a)(i)(ii	262(k)(2)(a)(i)(ii	NUM
cblr-1794	203	9	)	)	PUNCT
cblr-1794	203	10	.	.	PUNCT
cblr-1794	204	1	64	64	NUM
cblr-1794	204	2	see	see	VERB
cblr-1794	204	3	i	i	PRON
cblr-1794	204	4	d.	d.	PROPN
cblr-1794	204	5	§	§	PROPN
cblr-1794	204	6	262(k)(2)(a)(i)(iii	262(k)(2)(a)(i)(iii	NUM
cblr-1794	204	7	)	)	PUNCT
cblr-1794	204	8	.	.	PUNCT
cblr-1794	205	1	65	65	NUM
cblr-1794	205	2	see	see	VERB
cblr-1794	205	3	i	i	PRON
cblr-1794	205	4	d.	d.	PROPN
cblr-1794	205	5	§	§	PROPN
cblr-1794	205	6	262(k)(2)(a)(i)(iv	262(k)(2)(a)(i)(iv	NUM
cblr-1794	205	7	)	)	PUNCT
cblr-1794	205	8	.	.	PUNCT
cblr-1794	206	1	66	66	NUM
cblr-1794	206	2	42	42	NUM
cblr-1794	206	3	u.s.c.a	u.s.c.a	PROPN
cblr-1794	206	4	.	.	PUNCT
cblr-1794	206	5	§	§	PROPN
cblr-1794	206	6	262(k)(2)(a)(i)(v	262(k)(2)(a)(i)(v	NUM
cblr-1794	206	7	)	)	PUNCT
cblr-1794	206	8	(	(	PUNCT
cblr-1794	206	9	west	west	NOUN
cblr-1794	206	10	2012	2012	NUM
cblr-1794	206	11	)	)	PUNCT
cblr-1794	206	12	.	.	PUNCT
cblr-1794	207	1	67	67	NUM
cblr-1794	207	2	see	see	VERB
cblr-1794	207	3	i	i	PRON
cblr-1794	207	4	d.	d.	PROPN
cblr-1794	207	5	§	§	PROPN
cblr-1794	207	6	262(k)(2)(a)(ii	262(k)(2)(a)(ii	PROPN
cblr-1794	207	7	)	)	PUNCT
cblr-1794	207	8	.	.	PUNCT
cblr-1794	208	1	220	220	NUM
cblr-1794	208	2	col	col	PROPN
cblr-1794	208	3	umia	umia	PROPN
cblr-1794	208	4	b	b	PROPN
cblr-1794	208	5	usiness	usiness	PROPN
cblr-1794	208	6	la	la	PROPN
cblr-1794	208	7	wre	wre	PROPN
cblr-1794	208	8	vie	vie	PROPN
cblr-1794	208	9	w	w	PROPN
cblr-1794	209	1	[	[	X
cblr-1794	209	2	vol	vol	NOUN
cblr-1794	209	3	.	.	PUNCT
cblr-1794	209	4	2013	2013	NUM
cblr-1794	209	5	bpcl4	bpcl4	NOUN
cblr-1794	209	6	:	:	PUNCT
cblr-1794	209	7	destined	destine	VERB
cblr-1794	209	8	for	for	ADP
cblr-1794	209	9	failure	failure	NOUN
cblr-1794	209	10	?	?	PUNCT
cblr-1794	210	1	a	a	DET
cblr-1794	210	2	showing	showing	NOUN
cblr-1794	210	3	of	of	ADP
cblr-1794	210	4	interchangeability	interchangeability	NOUN
cblr-1794	210	5	requires	require	VERB
cblr-1794	210	6	the	the	DET
cblr-1794	210	7	sponsor	sponsor	NOUN
cblr-1794	210	8	to	to	PART
cblr-1794	210	9	clear	clear	VERB
cblr-1794	210	10	a	a	DET
cblr-1794	210	11	higher	high	ADJ
cblr-1794	210	12	hurdle	hurdle	NOUN
cblr-1794	210	13	.	.	PUNCT
cblr-1794	211	1	first	first	ADV
cblr-1794	211	2	,	,	PUNCT
cblr-1794	211	3	the	the	DET
cblr-1794	211	4	sponsor	sponsor	NOUN
cblr-1794	211	5	must	must	AUX
cblr-1794	211	6	show	show	VERB
cblr-1794	211	7	biosimilarity.68	biosimilarity.68	PROPN
cblr-1794	211	8	second	second	ADJ
cblr-1794	211	9	,	,	PUNCT
cblr-1794	211	10	the	the	DET
cblr-1794	211	11	sponsor	sponsor	NOUN
cblr-1794	211	12	must	must	AUX
cblr-1794	211	13	show	show	VERB
cblr-1794	211	14	that	that	SCONJ
cblr-1794	211	15	the	the	DET
cblr-1794	211	16	biosimilar	biosimilar	NOUN
cblr-1794	211	17	can	can	AUX
cblr-1794	211	18	be	be	AUX
cblr-1794	211	19	expected	expect	VERB
cblr-1794	211	20	to	to	PART
cblr-1794	211	21	produce	produce	VERB
cblr-1794	211	22	the	the	DET
cblr-1794	211	23	same	same	ADJ
cblr-1794	211	24	clinical	clinical	ADJ
cblr-1794	211	25	result	result	NOUN
cblr-1794	211	26	as	as	ADP
cblr-1794	211	27	the	the	DET
cblr-1794	211	28	reference	reference	NOUN
cblr-1794	211	29	product	product	NOUN
cblr-1794	211	30	in	in	ADP
cblr-1794	211	31	any	any	DET
cblr-1794	211	32	given	give	VERB
cblr-1794	211	33	patient.69	patient.69	NOUN
cblr-1794	211	34	third	third	NOUN
cblr-1794	211	35	,	,	PUNCT
cblr-1794	211	36	the	the	DET
cblr-1794	211	37	sponsor	sponsor	NOUN
cblr-1794	211	38	must	must	AUX
cblr-1794	211	39	show	show	VERB
cblr-1794	211	40	that	that	SCONJ
cblr-1794	211	41	for	for	ADP
cblr-1794	211	42	a	a	DET
cblr-1794	211	43	biologic	biologic	NOUN
cblr-1794	211	44	administered	administer	VERB
cblr-1794	211	45	more	more	ADJ
cblr-1794	211	46	than	than	ADP
cblr-1794	211	47	once	once	ADV
cblr-1794	211	48	to	to	ADP
cblr-1794	211	49	a	a	DET
cblr-1794	211	50	patient	patient	NOUN
cblr-1794	211	51	,	,	PUNCT
cblr-1794	211	52	the	the	DET
cblr-1794	211	53	"	"	PUNCT
cblr-1794	211	54	risk	risk	NOUN
cblr-1794	211	55	in	in	ADP
cblr-1794	211	56	terms	term	NOUN
cblr-1794	211	57	of	of	ADP
cblr-1794	211	58	safety	safety	NOUN
cblr-1794	211	59	or	or	CCONJ
cblr-1794	211	60	diminished	diminish	VERB
cblr-1794	211	61	efficacy	efficacy	NOUN
cblr-1794	211	62	of	of	ADP
cblr-1794	211	63	alternating	alternate	VERB
cblr-1794	211	64	or	or	CCONJ
cblr-1794	211	65	switching	switch	VERB
cblr-1794	211	66	between	between	ADP
cblr-1794	211	67	use	use	NOUN
cblr-1794	211	68	of	of	ADP
cblr-1794	211	69	the	the	DET
cblr-1794	211	70	[	[	X
cblr-1794	211	71	biosimilar	biosimilar	NOUN
cblr-1794	211	72	]	]	X
cblr-1794	211	73	and	and	CCONJ
cblr-1794	211	74	the	the	DET
cblr-1794	211	75	reference	reference	NOUN
cblr-1794	211	76	product	product	NOUN
cblr-1794	211	77	is	be	AUX
cblr-1794	211	78	not	not	PART
cblr-1794	211	79	greater	great	ADJ
cblr-1794	211	80	than	than	ADP
cblr-1794	211	81	the	the	DET
cblr-1794	211	82	risk	risk	NOUN
cblr-1794	211	83	of	of	ADP
cblr-1794	211	84	using	use	VERB
cblr-1794	211	85	the	the	DET
cblr-1794	211	86	reference	reference	NOUN
cblr-1794	211	87	product	product	NOUN
cblr-1794	211	88	without	without	ADP
cblr-1794	211	89	such	such	ADJ
cblr-1794	211	90	alteration	alteration	NOUN
cblr-1794	211	91	or	or	CCONJ
cblr-1794	211	92	switch	switch	NOUN
cblr-1794	211	93	.	.	PUNCT
cblr-1794	212	1	"7	"7	ADJ
cblr-1794	212	2	o	o	NOUN
cblr-1794	212	3	subsection	subsection	NOUN
cblr-1794	212	4	(	(	PUNCT
cblr-1794	212	5	k	k	NOUN
cblr-1794	212	6	)	)	PUNCT
cblr-1794	212	7	also	also	ADV
cblr-1794	212	8	describes	describe	VERB
cblr-1794	212	9	exclusivity	exclusivity	NOUN
cblr-1794	212	10	provisions	provision	NOUN
cblr-1794	212	11	for	for	ADP
cblr-1794	212	12	both	both	CCONJ
cblr-1794	212	13	the	the	DET
cblr-1794	212	14	reference	reference	NOUN
cblr-1794	212	15	product	product	NOUN
cblr-1794	212	16	and	and	CCONJ
cblr-1794	212	17	the	the	DET
cblr-1794	212	18	first	first	ADJ
cblr-1794	212	19	biosimilar	biosimilar	NOUN
cblr-1794	212	20	to	to	PART
cblr-1794	212	21	reach	reach	VERB
cblr-1794	212	22	the	the	DET
cblr-1794	212	23	market	market	NOUN
cblr-1794	212	24	.	.	PUNCT
cblr-1794	212	25	"	"	PUNCT
cblr-1794	213	1	the	the	DET
cblr-1794	213	2	bpcia	bpcia	NOUN
cblr-1794	213	3	grants	grant	VERB
cblr-1794	213	4	twelve	twelve	NUM
cblr-1794	213	5	years	year	NOUN
cblr-1794	213	6	of	of	ADP
cblr-1794	213	7	exclusivity	exclusivity	NOUN
cblr-1794	213	8	to	to	PART
cblr-1794	213	9	reference	reference	NOUN
cblr-1794	213	10	products	product	NOUN
cblr-1794	213	11	;	;	PUNCT
cblr-1794	213	12	no	no	DET
cblr-1794	213	13	biosimilar	biosimilar	NOUN
cblr-1794	213	14	may	may	AUX
cblr-1794	213	15	be	be	AUX
cblr-1794	213	16	approved	approve	VERB
cblr-1794	213	17	until	until	ADP
cblr-1794	213	18	twelve	twelve	NUM
cblr-1794	213	19	years	year	NOUN
cblr-1794	213	20	after	after	SCONJ
cblr-1794	213	21	the	the	DET
cblr-1794	213	22	reference	reference	NOUN
cblr-1794	213	23	product	product	NOUN
cblr-1794	213	24	was	be	AUX
cblr-1794	213	25	first	first	ADJ
cblr-1794	213	26	licensed.72	licensed.72	PROPN
cblr-1794	213	27	however	however	ADV
cblr-1794	213	28	,	,	PUNCT
cblr-1794	213	29	scholars	scholar	NOUN
cblr-1794	213	30	have	have	AUX
cblr-1794	213	31	noted	note	VERB
cblr-1794	213	32	that	that	SCONJ
cblr-1794	213	33	the	the	DET
cblr-1794	213	34	bpcia	bpcia	NOUN
cblr-1794	213	35	does	do	AUX
cblr-1794	213	36	not	not	PART
cblr-1794	213	37	specify	specify	VERB
cblr-1794	213	38	the	the	DET
cblr-1794	213	39	type	type	NOUN
cblr-1794	213	40	of	of	ADP
cblr-1794	213	41	exclusivity	exclusivity	NOUN
cblr-1794	213	42	it	it	PRON
cblr-1794	213	43	provides.7	provides.7	VERB
cblr-1794	213	44	'	'	PUNCT
cblr-1794	213	45	the	the	DET
cblr-1794	213	46	fda	fda	PROPN
cblr-1794	213	47	has	have	AUX
cblr-1794	213	48	tentatively	tentatively	ADV
cblr-1794	213	49	"	"	PUNCT
cblr-1794	213	50	interpreted	interpret	VERB
cblr-1794	213	51	the	the	DET
cblr-1794	213	52	language	language	NOUN
cblr-1794	213	53	of	of	ADP
cblr-1794	213	54	the	the	DET
cblr-1794	213	55	bpcia	bpcia	NOUN
cblr-1794	213	56	to	to	PART
cblr-1794	213	57	provide	provide	VERB
cblr-1794	213	58	twelve	twelve	NUM
cblr-1794	213	59	years	year	NOUN
cblr-1794	213	60	of	of	ADP
cblr-1794	213	61	market	market	NOUN
cblr-1794	213	62	exclusivity	exclusivity	NOUN
cblr-1794	213	63	,	,	PUNCT
cblr-1794	213	64	while	while	SCONJ
cblr-1794	213	65	some	some	DET
cblr-1794	213	66	members	member	NOUN
cblr-1794	213	67	of	of	ADP
cblr-1794	213	68	congress	congress	PROPN
cblr-1794	213	69	and	and	CCONJ
cblr-1794	213	70	industry	industry	NOUN
cblr-1794	213	71	argue	argue	VERB
cblr-1794	213	72	that	that	SCONJ
cblr-1794	213	73	it	it	PRON
cblr-1794	213	74	provides	provide	VERB
cblr-1794	213	75	either	either	DET
cblr-1794	213	76	twelve	twelve	NUM
cblr-1794	213	77	years	year	NOUN
cblr-1794	213	78	of	of	ADP
cblr-1794	213	79	data	datum	NOUN
cblr-1794	213	80	exclusivity	exclusivity	NOUN
cblr-1794	213	81	or	or	CCONJ
cblr-1794	213	82	four	four	NUM
cblr-1794	213	83	years	year	NOUN
cblr-1794	213	84	of	of	ADP
cblr-1794	213	85	data	datum	NOUN
cblr-1794	213	86	exclusivity	exclusivity	NOUN
cblr-1794	213	87	followed	follow	VERB
cblr-1794	213	88	by	by	ADP
cblr-1794	213	89	eight	eight	NUM
cblr-1794	213	90	years	year	NOUN
cblr-1794	213	91	of	of	ADP
cblr-1794	213	92	market	market	NOUN
cblr-1794	213	93	exclusivity	exclusivity	NOUN
cblr-1794	213	94	.	.	PUNCT
cblr-1794	214	1	"7	"7	NOUN
cblr-1794	214	2	4	4	NUM
cblr-1794	214	3	the	the	DET
cblr-1794	214	4	difference	difference	NOUN
cblr-1794	214	5	is	be	AUX
cblr-1794	214	6	significant	significant	ADJ
cblr-1794	214	7	;	;	PUNCT
cblr-1794	214	8	if	if	SCONJ
cblr-1794	214	9	biosimilar	biosimilar	PROPN
cblr-1794	214	10	manufacturers	manufacturer	NOUN
cblr-1794	214	11	are	be	AUX
cblr-1794	214	12	forced	force	VERB
cblr-1794	214	13	to	to	PART
cblr-1794	214	14	wait	wait	VERB
cblr-1794	214	15	twelve	twelve	NUM
cblr-1794	214	16	years	year	NOUN
cblr-1794	214	17	to	to	PART
cblr-1794	214	18	get	get	VERB
cblr-1794	214	19	access	access	NOUN
cblr-1794	214	20	to	to	ADP
cblr-1794	214	21	the	the	DET
cblr-1794	214	22	reference	reference	NOUN
cblr-1794	214	23	product	product	NOUN
cblr-1794	214	24	's	's	PART
cblr-1794	214	25	data	datum	NOUN
cblr-1794	214	26	,	,	PUNCT
cblr-1794	214	27	the	the	DET
cblr-1794	214	28	reference	reference	NOUN
cblr-1794	214	29	product	product	NOUN
cblr-1794	214	30	will	will	AUX
cblr-1794	214	31	likely	likely	ADV
cblr-1794	214	32	be	be	AUX
cblr-1794	214	33	alone	alone	ADJ
cblr-1794	214	34	on	on	ADP
cblr-1794	214	35	the	the	DET
cblr-1794	214	36	market	market	NOUN
cblr-1794	214	37	for	for	ADP
cblr-1794	214	38	far	far	ADV
cblr-1794	214	39	longer	long	ADJ
cblr-1794	214	40	than	than	ADP
cblr-1794	214	41	twelve	twelve	NUM
cblr-1794	214	42	years.7	years.7	NOUN
cblr-1794	214	43	'	'	PUNCT
cblr-1794	214	44	the	the	DET
cblr-1794	214	45	bpcia	bpcia	NOUN
cblr-1794	214	46	68	68	NUM
cblr-1794	214	47	42	42	NUM
cblr-1794	214	48	u.s.c.a	u.s.c.a	PROPN
cblr-1794	214	49	.	.	PUNCT
cblr-1794	215	1	§	§	PROPN
cblr-1794	215	2	262(k)(4)(a)(i	262(k)(4)(a)(i	NUM
cblr-1794	215	3	)	)	PUNCT
cblr-1794	215	4	(	(	PUNCT
cblr-1794	215	5	west	west	NOUN
cblr-1794	215	6	2012	2012	NUM
cblr-1794	215	7	)	)	PUNCT
cblr-1794	215	8	.	.	PUNCT
cblr-1794	216	1	69	69	NUM
cblr-1794	216	2	see	see	VERB
cblr-1794	216	3	i	i	PROPN
cblr-1794	216	4	d.	d.	PROPN
cblr-1794	216	5	§	§	PROPN
cblr-1794	216	6	262(k)(4)(a)(ii	262(k)(4)(a)(ii	NUM
cblr-1794	216	7	)	)	PUNCT
cblr-1794	216	8	.	.	PUNCT
cblr-1794	217	1	70	70	NUM
cblr-1794	217	2	see	see	VERB
cblr-1794	217	3	i	i	PRON
cblr-1794	217	4	d.	d.	PROPN
cblr-1794	217	5	§	§	PROPN
cblr-1794	217	6	262(k)(4)(b	262(k)(4)(b	PROPN
cblr-1794	217	7	)	)	PUNCT
cblr-1794	217	8	.	.	PUNCT
cblr-1794	218	1	71	71	NUM
cblr-1794	218	2	see	see	VERB
cblr-1794	218	3	i	i	PRON
cblr-1794	218	4	d.	d.	PROPN
cblr-1794	218	5	§	§	PROPN
cblr-1794	218	6	262(k)(7	262(k)(7	PROPN
cblr-1794	218	7	)	)	PUNCT
cblr-1794	218	8	.	.	PUNCT
cblr-1794	219	1	72	72	NUM
cblr-1794	219	2	see	see	VERB
cblr-1794	219	3	i	i	PROPN
cblr-1794	219	4	d.	d.	PROPN
cblr-1794	219	5	§	§	PROPN
cblr-1794	219	6	262(k)(7)(a	262(k)(7)(a	PROPN
cblr-1794	219	7	)	)	PUNCT
cblr-1794	219	8	.	.	PUNCT
cblr-1794	220	1	73	73	NUM
cblr-1794	220	2	paradise	paradise	PROPN
cblr-1794	220	3	,	,	PUNCT
cblr-1794	220	4	supra	supra	PROPN
cblr-1794	220	5	note	note	PROPN
cblr-1794	220	6	15	15	NUM
cblr-1794	220	7	,	,	PUNCT
cblr-1794	220	8	at	at	ADP
cblr-1794	220	9	507	507	NUM
cblr-1794	220	10	.	.	PUNCT
cblr-1794	220	11	74	74	NUM
cblr-1794	221	1	i	i	PRON
cblr-1794	221	2	d.	d.	PROPN
cblr-1794	221	3	75	75	NUM
cblr-1794	221	4	see	see	VERB
cblr-1794	221	5	generally	generally	ADV
cblr-1794	221	6	alicia	alicia	PROPN
cblr-1794	221	7	mundy	mundy	NOUN
cblr-1794	221	8	,	,	PUNCT
cblr-1794	221	9	firms	firm	NOUN
cblr-1794	221	10	push	push	VERB
cblr-1794	221	11	for	for	ADP
cblr-1794	221	12	biotech	biotech	ADJ
cblr-1794	221	13	generics	generic	NOUN
cblr-1794	221	14	,	,	PUNCT
cblr-1794	221	15	wall	wall	PROPN
cblr-1794	221	16	st	st	PROPN
cblr-1794	221	17	.	.	PROPN
cblr-1794	221	18	j.	j.	PROPN
cblr-1794	221	19	,	,	PUNCT
cblr-1794	221	20	jan	jan	PROPN
cblr-1794	221	21	.	.	PROPN
cblr-1794	221	22	26	26	NUM
cblr-1794	221	23	,	,	PUNCT
cblr-1794	221	24	2011	2011	NUM
cblr-1794	221	25	,	,	PUNCT
cblr-1794	221	26	at	at	ADP
cblr-1794	221	27	b1	b1	NOUN
cblr-1794	221	28	(	(	PUNCT
cblr-1794	221	29	"	"	PUNCT
cblr-1794	221	30	the	the	DET
cblr-1794	221	31	question	question	NOUN
cblr-1794	221	32	[	[	X
cblr-1794	221	33	surrounding	surround	VERB
cblr-1794	221	34	exclusivity	exclusivity	NOUN
cblr-1794	221	35	]	]	PUNCT
cblr-1794	221	36	is	be	AUX
cblr-1794	221	37	whether	whether	SCONJ
cblr-1794	221	38	makers	maker	NOUN
cblr-1794	221	39	of	of	ADP
cblr-1794	221	40	generics	generic	NOUN
cblr-1794	221	41	have	have	VERB
cblr-1794	221	42	to	to	PART
cblr-1794	221	43	wait	wait	VERB
cblr-1794	221	44	the	the	DET
cblr-1794	221	45	whole	whole	ADJ
cblr-1794	221	46	period	period	NOUN
cblr-1794	221	47	before	before	ADP
cblr-1794	221	48	even	even	ADV
cblr-1794	221	49	beginning	begin	VERB
cblr-1794	221	50	to	to	PART
cblr-1794	221	51	seek	seek	VERB
cblr-1794	221	52	approval	approval	NOUN
cblr-1794	221	53	-	-	PUNCT
cblr-1794	221	54	or	or	CCONJ
cblr-1794	221	55	can	can	AUX
cblr-1794	221	56	get	get	VERB
cblr-1794	221	57	a	a	DET
cblr-1794	221	58	head	head	NOUN
cblr-1794	221	59	start	start	VERB
cblr-1794	221	60	with	with	ADP
cblr-1794	221	61	regulators	regulator	NOUN
cblr-1794	221	62	so	so	SCONJ
cblr-1794	221	63	their	their	PRON
cblr-1794	221	64	copies	copy	NOUN
cblr-1794	221	65	can	can	AUX
cblr-1794	221	66	hit	hit	VERB
cblr-1794	221	67	the	the	DET
cblr-1794	221	68	shelves	shelf	NOUN
cblr-1794	221	69	as	as	ADV
cblr-1794	221	70	soon	soon	ADV
cblr-1794	221	71	as	as	SCONJ
cblr-1794	221	72	the	the	DET
cblr-1794	221	73	12	12	NUM
cblr-1794	221	74	years	year	NOUN
cblr-1794	221	75	are	be	AUX
cblr-1794	221	76	up	up	ADV
cblr-1794	221	77	.	.	PUNCT
cblr-1794	221	78	"	"	PUNCT
cblr-1794	221	79	)	)	PUNCT
cblr-1794	221	80	.	.	PUNCT
cblr-1794	222	1	no	no	INTJ
cblr-1794	222	2	.	.	PUNCT
cblr-1794	223	1	1:209	1:209	NUM
cblr-1794	223	2	]	]	PUNCT
cblr-1794	223	3	221	221	NUM
cblr-1794	223	4	also	also	ADV
cblr-1794	223	5	provides	provide	VERB
cblr-1794	223	6	a	a	DET
cblr-1794	223	7	shorter	short	ADJ
cblr-1794	223	8	period	period	NOUN
cblr-1794	223	9	of	of	ADP
cblr-1794	223	10	market	market	NOUN
cblr-1794	223	11	exclusivity	exclusivity	NOUN
cblr-1794	223	12	for	for	ADP
cblr-1794	223	13	the	the	DET
cblr-1794	223	14	first	first	ADJ
cblr-1794	223	15	interchangeable	interchangeable	ADJ
cblr-1794	223	16	biosimilar	biosimilar	NOUN
cblr-1794	223	17	approved	approve	VERB
cblr-1794	223	18	for	for	ADP
cblr-1794	223	19	each	each	DET
cblr-1794	223	20	reference	reference	NOUN
cblr-1794	223	21	drug	drug	NOUN
cblr-1794	223	22	.	.	PUNCT
cblr-1794	223	23	"	"	PUNCT
cblr-1794	224	1	subsection	subsection	NOUN
cblr-1794	224	2	(	(	PUNCT
cblr-1794	224	3	1	1	X
cblr-1794	224	4	)	)	PUNCT
cblr-1794	224	5	establishes	establish	VERB
cblr-1794	224	6	the	the	DET
cblr-1794	224	7	rules	rule	NOUN
cblr-1794	224	8	related	relate	VERB
cblr-1794	224	9	to	to	ADP
cblr-1794	224	10	the	the	DET
cblr-1794	224	11	exchange	exchange	NOUN
cblr-1794	224	12	of	of	ADP
cblr-1794	224	13	patented	patented	ADJ
cblr-1794	224	14	information	information	NOUN
cblr-1794	224	15	between	between	ADP
cblr-1794	224	16	the	the	DET
cblr-1794	224	17	sponsor	sponsor	NOUN
cblr-1794	224	18	of	of	ADP
cblr-1794	224	19	the	the	DET
cblr-1794	224	20	biosimilar	biosimilar	NOUN
cblr-1794	224	21	and	and	CCONJ
cblr-1794	224	22	the	the	DET
cblr-1794	224	23	sponsor	sponsor	NOUN
cblr-1794	224	24	of	of	ADP
cblr-1794	224	25	the	the	DET
cblr-1794	224	26	reference	reference	NOUN
cblr-1794	224	27	product	product	NOUN
cblr-1794	224	28	.	.	PUNCT
cblr-1794	225	1	the	the	DET
cblr-1794	225	2	full	full	ADJ
cblr-1794	225	3	patent	patent	NOUN
cblr-1794	225	4	provisions	provision	NOUN
cblr-1794	225	5	are	be	AUX
cblr-1794	225	6	outside	outside	ADP
cblr-1794	225	7	the	the	DET
cblr-1794	225	8	scope	scope	NOUN
cblr-1794	225	9	of	of	ADP
cblr-1794	225	10	this	this	DET
cblr-1794	225	11	note	note	NOUN
cblr-1794	225	12	;	;	PUNCT
cblr-1794	225	13	however	however	ADV
cblr-1794	225	14	,	,	PUNCT
cblr-1794	225	15	it	it	PRON
cblr-1794	225	16	is	be	AUX
cblr-1794	225	17	important	important	ADJ
cblr-1794	225	18	to	to	PART
cblr-1794	225	19	note	note	VERB
cblr-1794	225	20	significant	significant	ADJ
cblr-1794	225	21	areas	area	NOUN
cblr-1794	225	22	of	of	ADP
cblr-1794	225	23	departure	departure	NOUN
cblr-1794	225	24	from	from	ADP
cblr-1794	225	25	the	the	DET
cblr-1794	225	26	hatch	hatch	PROPN
cblr-1794	225	27	-	-	PUNCT
cblr-1794	225	28	waxman	waxman	PROPN
cblr-1794	225	29	act	act	PROPN
cblr-1794	225	30	.	.	PUNCT
cblr-1794	226	1	first	first	ADV
cblr-1794	226	2	,	,	PUNCT
cblr-1794	226	3	the	the	DET
cblr-1794	226	4	scope	scope	NOUN
cblr-1794	226	5	of	of	ADP
cblr-1794	226	6	patents	patent	NOUN
cblr-1794	226	7	the	the	DET
cblr-1794	226	8	sponsor	sponsor	NOUN
cblr-1794	226	9	must	must	AUX
cblr-1794	226	10	identify	identify	VERB
cblr-1794	226	11	under	under	ADP
cblr-1794	226	12	the	the	DET
cblr-1794	226	13	bpcia	bpcia	NOUN
cblr-1794	226	14	is	be	AUX
cblr-1794	226	15	broader	broad	ADJ
cblr-1794	226	16	than	than	ADP
cblr-1794	226	17	under	under	ADP
cblr-1794	226	18	hatch	hatch	NOUN
cblr-1794	226	19	-	-	PUNCT
cblr-1794	226	20	waxman.7	waxman.7	PROPN
cblr-1794	226	21	'	'	PUNCT
cblr-1794	226	22	the	the	DET
cblr-1794	226	23	bpcia	bpcia	NOUN
cblr-1794	226	24	patent	patent	NOUN
cblr-1794	226	25	provisions	provision	NOUN
cblr-1794	226	26	include	include	VERB
cblr-1794	226	27	not	not	PART
cblr-1794	226	28	only	only	ADV
cblr-1794	226	29	patents	patent	NOUN
cblr-1794	226	30	that	that	PRON
cblr-1794	226	31	relate	relate	VERB
cblr-1794	226	32	to	to	ADP
cblr-1794	226	33	the	the	DET
cblr-1794	226	34	biosimilar	biosimilar	NOUN
cblr-1794	226	35	and	and	CCONJ
cblr-1794	226	36	methods	method	NOUN
cblr-1794	226	37	of	of	ADP
cblr-1794	226	38	use	use	NOUN
cblr-1794	226	39	,	,	PUNCT
cblr-1794	226	40	but	but	CCONJ
cblr-1794	226	41	also	also	ADV
cblr-1794	226	42	"	"	PUNCT
cblr-1794	226	43	patents	patent	NOUN
cblr-1794	226	44	relevant	relevant	ADJ
cblr-1794	226	45	to	to	ADP
cblr-1794	226	46	the	the	DET
cblr-1794	226	47	product	product	NOUN
cblr-1794	226	48	's	's	PART
cblr-1794	226	49	manufacturing	manufacturing	NOUN
cblr-1794	226	50	process	process	NOUN
cblr-1794	226	51	.	.	PUNCT
cblr-1794	227	1	"79	"79	PROPN
cblr-1794	228	1	second	second	ADJ
cblr-1794	228	2	,	,	PUNCT
cblr-1794	228	3	under	under	ADP
cblr-1794	228	4	the	the	DET
cblr-1794	228	5	hatch	hatch	NOUN
cblr-1794	228	6	-	-	PUNCT
cblr-1794	228	7	waxman	waxman	PROPN
cblr-1794	228	8	act	act	PROPN
cblr-1794	228	9	,	,	PUNCT
cblr-1794	228	10	the	the	DET
cblr-1794	228	11	approval	approval	NOUN
cblr-1794	228	12	of	of	ADP
cblr-1794	228	13	a	a	DET
cblr-1794	228	14	generic	generic	NOUN
cblr-1794	228	15	is	be	AUX
cblr-1794	228	16	automatically	automatically	ADV
cblr-1794	228	17	stayed	stay	VERB
cblr-1794	228	18	upon	upon	SCONJ
cblr-1794	228	19	the	the	DET
cblr-1794	228	20	filing	filing	NOUN
cblr-1794	228	21	of	of	ADP
cblr-1794	228	22	a	a	DET
cblr-1794	228	23	patent	patent	NOUN
cblr-1794	228	24	infringement	infringement	NOUN
cblr-1794	228	25	suit	suit	NOUN
cblr-1794	228	26	.	.	PUNCT
cblr-1794	228	27	"	"	PUNCT
cblr-1794	229	1	under	under	ADP
cblr-1794	229	2	the	the	DET
cblr-1794	229	3	bpcia	bpcia	NOUN
cblr-1794	229	4	,	,	PUNCT
cblr-1794	229	5	however	however	ADV
cblr-1794	229	6	,	,	PUNCT
cblr-1794	229	7	the	the	DET
cblr-1794	229	8	patentee	patentee	NOUN
cblr-1794	229	9	must	must	AUX
cblr-1794	229	10	obtain	obtain	VERB
cblr-1794	229	11	a	a	DET
cblr-1794	229	12	final	final	ADJ
cblr-1794	229	13	judgment	judgment	NOUN
cblr-1794	229	14	of	of	ADP
cblr-1794	229	15	infringement	infringement	NOUN
cblr-1794	229	16	before	before	SCONJ
cblr-1794	229	17	approval	approval	NOUN
cblr-1794	229	18	is	be	AUX
cblr-1794	229	19	stayed	stay	VERB
cblr-1794	229	20	,	,	PUNCT
cblr-1794	229	21	requiring	require	VERB
cblr-1794	229	22	that	that	SCONJ
cblr-1794	229	23	no	no	DET
cblr-1794	229	24	appeal	appeal	NOUN
cblr-1794	229	25	other	other	ADJ
cblr-1794	229	26	than	than	ADP
cblr-1794	229	27	a	a	DET
cblr-1794	229	28	petition	petition	NOUN
cblr-1794	229	29	for	for	ADP
cblr-1794	229	30	certiorari	certiorari	NOUN
cblr-1794	229	31	is	be	AUX
cblr-1794	229	32	available	available	ADJ
cblr-1794	229	33	.	.	PUNCT
cblr-1794	229	34	"	"	PUNCT
cblr-1794	230	1	further	far	ADV
cblr-1794	230	2	,	,	PUNCT
cblr-1794	230	3	even	even	ADV
cblr-1794	230	4	a	a	DET
cblr-1794	230	5	final	final	ADJ
cblr-1794	230	6	judgment	judgment	NOUN
cblr-1794	230	7	does	do	AUX
cblr-1794	230	8	not	not	PART
cblr-1794	230	9	result	result	VERB
cblr-1794	230	10	in	in	ADP
cblr-1794	230	11	an	an	DET
cblr-1794	230	12	automatic	automatic	ADJ
cblr-1794	230	13	stay	stay	NOUN
cblr-1794	230	14	of	of	ADP
cblr-1794	230	15	approval	approval	NOUN
cblr-1794	230	16	,	,	PUNCT
cblr-1794	230	17	but	but	CCONJ
cblr-1794	230	18	instead	instead	ADV
cblr-1794	230	19	,	,	PUNCT
cblr-1794	230	20	an	an	DET
cblr-1794	230	21	injunction	injunction	NOUN
cblr-1794	230	22	against	against	ADP
cblr-1794	230	23	infringement	infringement	NOUN
cblr-1794	230	24	of	of	ADP
cblr-1794	230	25	the	the	DET
cblr-1794	230	26	patent.8	patent.8	PROPN
cblr-1794	230	27	2	2	NUM
cblr-1794	230	28	iii	iii	NOUN
cblr-1794	230	29	.	.	PROPN
cblr-1794	230	30	will	will	AUX
cblr-1794	230	31	the	the	DET
cblr-1794	230	32	bpcia	bpcia	NOUN
cblr-1794	230	33	prove	prove	VERB
cblr-1794	230	34	as	as	ADV
cblr-1794	230	35	successful	successful	ADJ
cblr-1794	230	36	as	as	ADP
cblr-1794	230	37	hatch	hatch	NOUN
cblr-1794	230	38	-	-	PUNCT
cblr-1794	230	39	waxman	waxman	NOUN
cblr-1794	230	40	?	?	PUNCT
cblr-1794	231	1	the	the	DET
cblr-1794	231	2	hatch	hatch	PROPN
cblr-1794	231	3	-	-	PUNCT
cblr-1794	231	4	waxman	waxman	PROPN
cblr-1794	231	5	act	act	NOUN
cblr-1794	231	6	has	have	AUX
cblr-1794	231	7	had	have	VERB
cblr-1794	231	8	significant	significant	ADJ
cblr-1794	231	9	success	success	NOUN
cblr-1794	231	10	in	in	ADP
cblr-1794	231	11	lowering	lower	VERB
cblr-1794	231	12	the	the	DET
cblr-1794	231	13	prices	price	NOUN
cblr-1794	231	14	of	of	ADP
cblr-1794	231	15	pharmaceutical	pharmaceutical	ADJ
cblr-1794	231	16	drugs	drug	NOUN
cblr-1794	231	17	.	.	PUNCT
cblr-1794	232	1	as	as	SCONJ
cblr-1794	232	2	previously	previously	ADV
cblr-1794	232	3	noted	note	VERB
cblr-1794	232	4	,	,	PUNCT
cblr-1794	232	5	"	"	PUNCT
cblr-1794	232	6	the	the	DET
cblr-1794	232	7	first	first	ADJ
cblr-1794	232	8	generic	generic	ADJ
cblr-1794	232	9	entrant	entrant	NOUN
cblr-1794	232	10	generally	generally	ADV
cblr-1794	232	11	offers	offer	VERB
cblr-1794	232	12	a	a	DET
cblr-1794	232	13	price	price	NOUN
cblr-1794	232	14	that	that	PRON
cblr-1794	232	15	is	be	AUX
cblr-1794	232	16	25	25	NUM
cblr-1794	232	17	percent	percent	NOUN
cblr-1794	232	18	lower	low	ADJ
cblr-1794	232	19	than	than	ADP
cblr-1794	232	20	the	the	DET
cblr-1794	232	21	branded	brand	VERB
cblr-1794	232	22	drug	drug	NOUN
cblr-1794	232	23	's	's	PART
cblr-1794	232	24	price	price	NOUN
cblr-1794	232	25	.	.	PUNCT
cblr-1794	233	1	the	the	DET
cblr-1794	233	2	price	price	NOUN
cblr-1794	233	3	discount	discount	NOUN
cblr-1794	233	4	can	can	AUX
cblr-1794	233	5	rise	rise	VERB
cblr-1794	233	6	to	to	ADP
cblr-1794	233	7	80	80	NUM
cblr-1794	233	8	percent	percent	NOUN
cblr-1794	233	9	with	with	ADP
cblr-1794	233	10	multiple	multiple	ADJ
cblr-1794	233	11	generic	generic	ADJ
cblr-1794	233	12	76	76	NUM
cblr-1794	233	13	public	public	ADJ
cblr-1794	233	14	health	health	NOUN
cblr-1794	233	15	service	service	PROPN
cblr-1794	233	16	act	act	NOUN
cblr-1794	233	17	§	§	PROPN
cblr-1794	233	18	351(k)(6	351(k)(6	NUM
cblr-1794	233	19	)	)	PUNCT
cblr-1794	233	20	,	,	PUNCT
cblr-1794	233	21	42	42	NUM
cblr-1794	233	22	u.s.c.a	u.s.c.a	PROPN
cblr-1794	233	23	.	.	PUNCT
cblr-1794	234	1	§	§	PROPN
cblr-1794	234	2	262(k)(6	262(k)(6	NUM
cblr-1794	234	3	)	)	PUNCT
cblr-1794	234	4	(	(	PUNCT
cblr-1794	234	5	west	west	NOUN
cblr-1794	234	6	2012	2012	NUM
cblr-1794	234	7	)	)	PUNCT
cblr-1794	234	8	.	.	PUNCT
cblr-1794	235	1	77	77	NUM
cblr-1794	235	2	see	see	VERB
cblr-1794	235	3	i	i	PROPN
cblr-1794	235	4	d.	d.	PROPN
cblr-1794	235	5	§	§	PROPN
cblr-1794	235	6	351(1	351(1	NUM
cblr-1794	235	7	)	)	PUNCT
cblr-1794	235	8	,	,	PUNCT
cblr-1794	235	9	42	42	NUM
cblr-1794	235	10	u.s.c.a	u.s.c.a	PROPN
cblr-1794	235	11	§	§	PROPN
cblr-1794	235	12	262(1	262(1	NUM
cblr-1794	235	13	)	)	PUNCT
cblr-1794	235	14	(	(	PUNCT
cblr-1794	235	15	west	west	NOUN
cblr-1794	235	16	2012	2012	NUM
cblr-1794	235	17	)	)	PUNCT
cblr-1794	235	18	.	.	PUNCT
cblr-1794	236	1	78	78	NUM
cblr-1794	236	2	dougherty	dougherty	NOUN
cblr-1794	236	3	,	,	PUNCT
cblr-1794	236	4	supra	supra	PROPN
cblr-1794	236	5	note	note	PROPN
cblr-1794	236	6	58	58	NUM
cblr-1794	236	7	,	,	PUNCT
cblr-1794	236	8	at	at	ADP
cblr-1794	236	9	234	234	NUM
cblr-1794	236	10	.	.	PUNCT
cblr-1794	237	1	79	79	NUM
cblr-1794	238	1	i	i	PRON
cblr-1794	238	2	d.	d.	PROPN
cblr-1794	238	3	80	80	NUM
cblr-1794	238	4	see	see	VERB
cblr-1794	239	1	i	i	PRON
cblr-1794	239	2	d.	d.	PROPN
cblr-1794	239	3	81	81	NUM
cblr-1794	240	1	i	i	PROPN
cblr-1794	240	2	d.	d.	PROPN
cblr-1794	240	3	82	82	NUM
cblr-1794	241	1	i	i	PROPN
cblr-1794	241	2	d.	d.	PROPN
cblr-1794	241	3	col	col	PROPN
cblr-1794	241	4	umia	umia	PROPN
cblr-1794	241	5	b	b	PROPN
cblr-1794	241	6	usiness	usiness	PROPN
cblr-1794	241	7	la	la	PROPN
cblr-1794	241	8	w	w	PROPN
cblr-1794	241	9	re	re	PROPN
cblr-1794	241	10	vie	vie	PROPN
cblr-1794	241	11	w	w	PROPN
cblr-1794	242	1	[	[	X
cblr-1794	242	2	vol	vol	NOUN
cblr-1794	242	3	.	.	NOUN
cblr-1794	242	4	2013222	2013222	NUM
cblr-1794	242	5	entrants	entrant	NOUN
cblr-1794	242	6	.	.	PUNCT
cblr-1794	243	1	"	"	PUNCT
cblr-1794	243	2	"	"	PUNCT
cblr-1794	243	3	more	more	ADJ
cblr-1794	243	4	than	than	ADP
cblr-1794	243	5	seventy	seventy	NUM
cblr-1794	243	6	percent	percent	NOUN
cblr-1794	243	7	of	of	ADP
cblr-1794	243	8	pharmaceutical	pharmaceutical	ADJ
cblr-1794	243	9	prescriptions	prescription	NOUN
cblr-1794	243	10	are	be	AUX
cblr-1794	243	11	written	write	VERB
cblr-1794	243	12	for	for	ADP
cblr-1794	243	13	generic	generic	ADJ
cblr-1794	243	14	drugs	drug	NOUN
cblr-1794	243	15	,	,	PUNCT
cblr-1794	243	16	creating	create	VERB
cblr-1794	243	17	substantial	substantial	ADJ
cblr-1794	243	18	cost	cost	NOUN
cblr-1794	243	19	savings	saving	NOUN
cblr-1794	243	20	for	for	ADP
cblr-1794	243	21	consumers	consumer	NOUN
cblr-1794	243	22	and	and	CCONJ
cblr-1794	243	23	insurers	insurer	NOUN
cblr-1794	243	24	.	.	PUNCT
cblr-1794	243	25	"	"	PUNCT
cblr-1794	244	1	however	however	ADV
cblr-1794	244	2	,	,	PUNCT
cblr-1794	244	3	as	as	SCONJ
cblr-1794	244	4	currently	currently	ADV
cblr-1794	244	5	written	write	VERB
cblr-1794	244	6	,	,	PUNCT
cblr-1794	244	7	the	the	DET
cblr-1794	244	8	bpcia	bpcia	NOUN
cblr-1794	244	9	is	be	AUX
cblr-1794	244	10	unlikely	unlikely	ADJ
cblr-1794	244	11	to	to	PART
cblr-1794	244	12	have	have	VERB
cblr-1794	244	13	as	as	ADV
cblr-1794	244	14	much	much	ADJ
cblr-1794	244	15	success	success	NOUN
cblr-1794	244	16	in	in	ADP
cblr-1794	244	17	lowering	lower	VERB
cblr-1794	244	18	drug	drug	NOUN
cblr-1794	244	19	prices	price	NOUN
cblr-1794	244	20	as	as	ADP
cblr-1794	244	21	the	the	DET
cblr-1794	244	22	hatchwaxman	hatchwaxman	PROPN
cblr-1794	244	23	act	act	PROPN
cblr-1794	244	24	.	.	PUNCT
cblr-1794	245	1	three	three	NUM
cblr-1794	245	2	main	main	ADJ
cblr-1794	245	3	factors	factor	NOUN
cblr-1794	245	4	suggest	suggest	VERB
cblr-1794	245	5	that	that	SCONJ
cblr-1794	245	6	the	the	DET
cblr-1794	245	7	bpcia	bpcia	NOUN
cblr-1794	245	8	will	will	AUX
cblr-1794	245	9	not	not	PART
cblr-1794	245	10	be	be	AUX
cblr-1794	245	11	as	as	ADV
cblr-1794	245	12	successful	successful	ADJ
cblr-1794	245	13	in	in	ADP
cblr-1794	245	14	bringing	bring	VERB
cblr-1794	245	15	down	down	ADP
cblr-1794	245	16	prices	price	NOUN
cblr-1794	245	17	as	as	ADP
cblr-1794	245	18	hatch	hatch	NOUN
cblr-1794	245	19	-	-	PUNCT
cblr-1794	245	20	waxman	waxman	NOUN
cblr-1794	245	21	.	.	PUNCT
cblr-1794	246	1	first	first	ADV
cblr-1794	246	2	,	,	PUNCT
cblr-1794	246	3	biosimilars	biosimilar	NOUN
cblr-1794	246	4	are	be	AUX
cblr-1794	246	5	more	more	ADV
cblr-1794	246	6	expensive	expensive	ADJ
cblr-1794	246	7	to	to	PART
cblr-1794	246	8	develop	develop	VERB
cblr-1794	246	9	than	than	ADP
cblr-1794	246	10	generic	generic	ADJ
cblr-1794	246	11	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	246	12	,	,	PUNCT
cblr-1794	246	13	which	which	PRON
cblr-1794	246	14	will	will	AUX
cblr-1794	246	15	lead	lead	VERB
cblr-1794	246	16	to	to	ADP
cblr-1794	246	17	fewer	few	ADJ
cblr-1794	246	18	entrants	entrant	NOUN
cblr-1794	246	19	into	into	ADP
cblr-1794	246	20	the	the	DET
cblr-1794	246	21	biosimilar	biosimilar	ADJ
cblr-1794	246	22	market	market	NOUN
cblr-1794	246	23	and	and	CCONJ
cblr-1794	246	24	thus	thus	ADV
cblr-1794	246	25	less	less	ADJ
cblr-1794	246	26	competition	competition	NOUN
cblr-1794	246	27	.	.	PUNCT
cblr-1794	247	1	less	less	ADJ
cblr-1794	247	2	competition	competition	NOUN
cblr-1794	247	3	will	will	AUX
cblr-1794	247	4	lead	lead	VERB
cblr-1794	247	5	to	to	ADP
cblr-1794	247	6	stagnant	stagnant	ADJ
cblr-1794	247	7	prices	price	NOUN
cblr-1794	247	8	.	.	PUNCT
cblr-1794	248	1	second	second	ADV
cblr-1794	248	2	,	,	PUNCT
cblr-1794	248	3	biosimilars	biosimilar	NOUN
cblr-1794	248	4	will	will	AUX
cblr-1794	248	5	not	not	PART
cblr-1794	248	6	capture	capture	VERB
cblr-1794	248	7	market	market	NOUN
cblr-1794	248	8	share	share	NOUN
cblr-1794	248	9	from	from	ADP
cblr-1794	248	10	the	the	DET
cblr-1794	248	11	branded	brand	VERB
cblr-1794	248	12	drug	drug	NOUN
cblr-1794	248	13	as	as	ADV
cblr-1794	248	14	quickly	quickly	ADV
cblr-1794	248	15	as	as	SCONJ
cblr-1794	248	16	generic	generic	ADJ
cblr-1794	248	17	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	248	18	do	do	VERB
cblr-1794	248	19	.	.	PUNCT
cblr-1794	249	1	third	third	ADJ
cblr-1794	249	2	,	,	PUNCT
cblr-1794	249	3	lengthy	lengthy	ADJ
cblr-1794	249	4	exclusivity	exclusivity	NOUN
cblr-1794	249	5	periods	period	NOUN
cblr-1794	249	6	awarded	award	VERB
cblr-1794	249	7	to	to	ADP
cblr-1794	249	8	both	both	DET
cblr-1794	249	9	the	the	DET
cblr-1794	249	10	innovative	innovative	ADJ
cblr-1794	249	11	biologic	biologic	NOUN
cblr-1794	249	12	and	and	CCONJ
cblr-1794	249	13	the	the	DET
cblr-1794	249	14	first	first	ADJ
cblr-1794	249	15	interchangeable	interchangeable	ADJ
cblr-1794	249	16	biosimilar	biosimilar	NOUN
cblr-1794	249	17	will	will	AUX
cblr-1794	249	18	marginalize	marginalize	VERB
cblr-1794	249	19	the	the	DET
cblr-1794	249	20	bpcia	bpcia	NOUN
cblr-1794	249	21	's	's	PART
cblr-1794	249	22	ability	ability	NOUN
cblr-1794	249	23	to	to	PART
cblr-1794	249	24	quickly	quickly	ADV
cblr-1794	249	25	reduce	reduce	VERB
cblr-1794	249	26	costs	cost	NOUN
cblr-1794	249	27	.	.	PUNCT
cblr-1794	250	1	a.	a.	NOUN
cblr-1794	250	2	biosimilars	biosimilars	PROPN
cblr-1794	250	3	are	be	AUX
cblr-1794	250	4	more	more	ADV
cblr-1794	250	5	expensive	expensive	ADJ
cblr-1794	250	6	to	to	PART
cblr-1794	250	7	develop	develop	VERB
cblr-1794	250	8	the	the	DET
cblr-1794	250	9	cost	cost	NOUN
cblr-1794	250	10	of	of	ADP
cblr-1794	250	11	developing	develop	VERB
cblr-1794	250	12	a	a	DET
cblr-1794	250	13	biologic	biologic	NOUN
cblr-1794	250	14	is	be	AUX
cblr-1794	250	15	roughly	roughly	ADV
cblr-1794	250	16	equal	equal	ADJ
cblr-1794	250	17	to	to	ADP
cblr-1794	250	18	the	the	DET
cblr-1794	250	19	cost	cost	NOUN
cblr-1794	250	20	of	of	ADP
cblr-1794	250	21	developing	develop	VERB
cblr-1794	250	22	a	a	DET
cblr-1794	250	23	pharmaceutical	pharmaceutical	NOUN
cblr-1794	250	24	.	.	PUNCT
cblr-1794	250	25	"	"	PUNCT
cblr-1794	251	1	however	however	ADV
cblr-1794	251	2	,	,	PUNCT
cblr-1794	251	3	this	this	DET
cblr-1794	251	4	equivalence	equivalence	NOUN
cblr-1794	251	5	in	in	ADP
cblr-1794	251	6	cost	cost	NOUN
cblr-1794	251	7	does	do	AUX
cblr-1794	251	8	not	not	PART
cblr-1794	251	9	extend	extend	VERB
cblr-1794	251	10	to	to	ADP
cblr-1794	251	11	biosimilars	biosimilar	NOUN
cblr-1794	251	12	and	and	CCONJ
cblr-1794	251	13	generics	generic	NOUN
cblr-1794	251	14	.	.	PUNCT
cblr-1794	252	1	experts	expert	NOUN
cblr-1794	252	2	have	have	AUX
cblr-1794	252	3	estimated	estimate	VERB
cblr-1794	252	4	that	that	SCONJ
cblr-1794	252	5	biosimilars	biosimilar	NOUN
cblr-1794	252	6	will	will	AUX
cblr-1794	252	7	take	take	VERB
cblr-1794	252	8	eight	eight	NUM
cblr-1794	252	9	to	to	PART
cblr-1794	252	10	ten	ten	NUM
cblr-1794	252	11	years	year	NOUN
cblr-1794	252	12	to	to	PART
cblr-1794	252	13	develop	develop	VERB
cblr-1794	252	14	,	,	PUNCT
cblr-1794	252	15	and	and	CCONJ
cblr-1794	252	16	will	will	AUX
cblr-1794	252	17	cost	cost	VERB
cblr-1794	252	18	between	between	ADP
cblr-1794	252	19	$	$	SYM
cblr-1794	252	20	100	100	NUM
cblr-1794	252	21	and	and	CCONJ
cblr-1794	252	22	$	$	SYM
cblr-1794	252	23	200	200	NUM
cblr-1794	252	24	million	million	NUM
cblr-1794	252	25	.	.	PUNCT
cblr-1794	252	26	"	"	PUNCT
cblr-1794	253	1	in	in	ADP
cblr-1794	253	2	contrast	contrast	NOUN
cblr-1794	253	3	,	,	PUNCT
cblr-1794	253	4	the	the	DET
cblr-1794	253	5	cost	cost	NOUN
cblr-1794	253	6	to	to	PART
cblr-1794	253	7	develop	develop	VERB
cblr-1794	253	8	a	a	DET
cblr-1794	253	9	generic	generic	ADJ
cblr-1794	253	10	pharmaceutical	pharmaceutical	NOUN
cblr-1794	253	11	typically	typically	ADV
cblr-1794	253	12	ranges	range	VERB
cblr-1794	253	13	from	from	ADP
cblr-1794	253	14	$	$	SYM
cblr-1794	253	15	1	1	NUM
cblr-1794	253	16	to	to	PART
cblr-1794	253	17	$	$	SYM
cblr-1794	253	18	5	5	NUM
cblr-1794	253	19	million	million	NUM
cblr-1794	253	20	,	,	PUNCT
cblr-1794	253	21	a	a	DET
cblr-1794	253	22	difference	difference	NOUN
cblr-1794	253	23	of	of	ADP
cblr-1794	253	24	two	two	NUM
cblr-1794	253	25	orders	order	NOUN
cblr-1794	253	26	of	of	ADP
cblr-1794	253	27	magnitude	magnitude	NOUN
cblr-1794	253	28	.	.	PUNCT
cblr-1794	253	29	"	"	PUNCT
cblr-1794	254	1	this	this	DET
cblr-1794	254	2	difference	difference	NOUN
cblr-1794	254	3	in	in	ADP
cblr-1794	254	4	manufacturing	manufacturing	NOUN
cblr-1794	254	5	cost	cost	NOUN
cblr-1794	254	6	stems	stem	VERB
cblr-1794	254	7	from	from	ADP
cblr-1794	254	8	two	two	NUM
cblr-1794	254	9	major	major	ADJ
cblr-1794	254	10	factors	factor	NOUN
cblr-1794	254	11	.	.	PUNCT
cblr-1794	255	1	first	first	ADV
cblr-1794	255	2	,	,	PUNCT
cblr-1794	255	3	83	83	NUM
cblr-1794	255	4	ftc	ftc	PROPN
cblr-1794	255	5	report	report	NOUN
cblr-1794	255	6	,	,	PUNCT
cblr-1794	255	7	supra	supra	PROPN
cblr-1794	255	8	note	note	PROPN
cblr-1794	255	9	14	14	NUM
cblr-1794	255	10	,	,	PUNCT
cblr-1794	255	11	at	at	ADP
cblr-1794	255	12	12	12	NUM
cblr-1794	255	13	.	.	PUNCT
cblr-1794	256	1	84	84	NUM
cblr-1794	256	2	rumore	rumore	NOUN
cblr-1794	256	3	,	,	PUNCT
cblr-1794	256	4	supra	supra	PROPN
cblr-1794	256	5	note	note	PROPN
cblr-1794	256	6	57	57	NUM
cblr-1794	256	7	.	.	SYM
cblr-1794	256	8	85	85	NUM
cblr-1794	256	9	henry	henry	PROPN
cblr-1794	256	10	g.	g.	PROPN
cblr-1794	256	11	grabowski	grabowski	PROPN
cblr-1794	256	12	,	,	PUNCT
cblr-1794	256	13	genia	genia	PROPN
cblr-1794	256	14	long	long	PROPN
cblr-1794	256	15	&	&	CCONJ
cblr-1794	256	16	richard	richard	PROPN
cblr-1794	256	17	mortimer	mortimer	PROPN
cblr-1794	256	18	,	,	PUNCT
cblr-1794	256	19	implementation	implementation	NOUN
cblr-1794	256	20	of	of	ADP
cblr-1794	256	21	the	the	DET
cblr-1794	256	22	biosimilar	biosimilar	ADJ
cblr-1794	256	23	pathway	pathway	NOUN
cblr-1794	256	24	:	:	PUNCT
cblr-1794	256	25	economic	economic	ADJ
cblr-1794	256	26	and	and	CCONJ
cblr-1794	256	27	policy	policy	NOUN
cblr-1794	256	28	issues	issue	NOUN
cblr-1794	256	29	,	,	PUNCT
cblr-1794	256	30	41	41	NUM
cblr-1794	256	31	seton	seton	PROPN
cblr-1794	256	32	hall	hall	PROPN
cblr-1794	256	33	l.	l.	PROPN
cblr-1794	256	34	rev	rev	PROPN
cblr-1794	256	35	.	.	PROPN
cblr-1794	256	36	511	511	NUM
cblr-1794	256	37	,	,	PUNCT
cblr-1794	256	38	550	550	NUM
cblr-1794	256	39	(	(	PUNCT
cblr-1794	256	40	2011	2011	NUM
cblr-1794	256	41	)	)	PUNCT
cblr-1794	256	42	.	.	PUNCT
cblr-1794	257	1	86	86	NUM
cblr-1794	257	2	ftc	ftc	PROPN
cblr-1794	257	3	report	report	PROPN
cblr-1794	257	4	,	,	PUNCT
cblr-1794	257	5	supra	supra	PROPN
cblr-1794	257	6	note	note	PROPN
cblr-1794	257	7	14	14	NUM
cblr-1794	257	8	,	,	PUNCT
cblr-1794	257	9	at	at	ADP
cblr-1794	257	10	14	14	NUM
cblr-1794	257	11	.	.	PUNCT
cblr-1794	257	12	87	87	NUM
cblr-1794	258	1	the	the	DET
cblr-1794	258	2	european	european	PROPN
cblr-1794	258	3	biosimilars	biosimilars	PROPN
cblr-1794	258	4	market	market	NOUN
cblr-1794	258	5	:	:	PUNCT
cblr-1794	258	6	trends	trend	NOUN
cblr-1794	258	7	and	and	CCONJ
cblr-1794	258	8	key	key	ADJ
cblr-1794	258	9	success	success	NOUN
cblr-1794	258	10	factors	factor	NOUN
cblr-1794	258	11	,	,	PUNCT
cblr-1794	258	12	scicasts	scicast	NOUN
cblr-1794	258	13	(	(	PUNCT
cblr-1794	258	14	oct	oct	PROPN
cblr-1794	258	15	.	.	PROPN
cblr-1794	258	16	27	27	NUM
cblr-1794	258	17	,	,	PUNCT
cblr-1794	258	18	2008	2008	NUM
cblr-1794	258	19	)	)	PUNCT
cblr-1794	258	20	,	,	PUNCT
cblr-1794	258	21	http://scicasts.com/specialreports/20-biopharm	http://scicasts.com/specialreports/20-biopharm	PROPN
cblr-1794	258	22	aceuticals/2152	aceuticals/2152	PROPN
cblr-1794	258	23	-	-	PUNCT
cblr-1794	258	24	the	the	DET
cblr-1794	258	25	-	-	PUNCT
cblr-1794	258	26	european	european	ADJ
cblr-1794	258	27	-	-	PUNCT
cblr-1794	258	28	biosimilars	biosimilars	ADJ
cblr-1794	258	29	-	-	PUNCT
cblr-1794	258	30	market	market	NOUN
cblr-1794	258	31	-	-	PUNCT
cblr-1794	258	32	trends	trend	NOUN
cblr-1794	258	33	-	-	PUNCT
cblr-1794	258	34	and	and	CCONJ
cblr-1794	258	35	-	-	PUNCT
cblr-1794	258	36	key	key	ADJ
cblr-1794	258	37	-	-	PUNCT
cblr-1794	258	38	successfactors	successfactor	NOUN
cblr-1794	258	39	.	.	PUNCT
cblr-1794	259	1	88	88	NUM
cblr-1794	259	2	ftc	ftc	PROPN
cblr-1794	259	3	report	report	NOUN
cblr-1794	259	4	,	,	PUNCT
cblr-1794	259	5	supra	supra	PROPN
cblr-1794	259	6	note	note	PROPN
cblr-1794	259	7	14	14	NUM
cblr-1794	259	8	,	,	PUNCT
cblr-1794	259	9	at	at	ADP
cblr-1794	259	10	14	14	NUM
cblr-1794	259	11	.	.	PUNCT
cblr-1794	260	1	no	no	INTJ
cblr-1794	260	2	.	.	PUNCT
cblr-1794	261	1	i:209]1	i:209]1	PROPN
cblr-1794	261	2	bpcia	bpcia	PROPN
cblr-1794	261	3	:	:	PUNCT
cblr-1794	261	4	destined	destine	VERB
cblr-1794	261	5	for	for	ADP
cblr-1794	261	6	failure	failure	NOUN
cblr-1794	261	7	?	?	PUNCT
cblr-1794	262	1	223	223	NUM
cblr-1794	262	2	biosimilar	biosimilar	ADJ
cblr-1794	262	3	sponsors	sponsor	NOUN
cblr-1794	262	4	will	will	AUX
cblr-1794	262	5	incur	incur	VERB
cblr-1794	262	6	increased	increase	VERB
cblr-1794	262	7	costs	cost	NOUN
cblr-1794	262	8	due	due	ADP
cblr-1794	262	9	to	to	ADP
cblr-1794	262	10	the	the	DET
cblr-1794	262	11	complexity	complexity	NOUN
cblr-1794	262	12	of	of	ADP
cblr-1794	262	13	manufacturing	manufacture	VERB
cblr-1794	262	14	a	a	DET
cblr-1794	262	15	large	large	ADJ
cblr-1794	262	16	-	-	PUNCT
cblr-1794	262	17	molecule	molecule	NOUN
cblr-1794	262	18	protein	protein	NOUN
cblr-1794	262	19	.	.	PUNCT
cblr-1794	263	1	89	89	NUM
cblr-1794	263	2	even	even	ADV
cblr-1794	263	3	the	the	DET
cblr-1794	263	4	slightest	slight	ADJ
cblr-1794	263	5	differences	difference	NOUN
cblr-1794	263	6	in	in	ADP
cblr-1794	263	7	temperature	temperature	NOUN
cblr-1794	263	8	,	,	PUNCT
cblr-1794	263	9	media	medium	NOUN
cblr-1794	263	10	,	,	PUNCT
cblr-1794	263	11	and	and	CCONJ
cblr-1794	263	12	storage	storage	NOUN
cblr-1794	263	13	conditions	condition	NOUN
cblr-1794	263	14	in	in	ADP
cblr-1794	263	15	the	the	DET
cblr-1794	263	16	manufacturing	manufacturing	NOUN
cblr-1794	263	17	process	process	NOUN
cblr-1794	263	18	will	will	AUX
cblr-1794	263	19	have	have	VERB
cblr-1794	263	20	a	a	DET
cblr-1794	263	21	significant	significant	ADJ
cblr-1794	263	22	impact	impact	NOUN
cblr-1794	263	23	on	on	ADP
cblr-1794	263	24	the	the	DET
cblr-1794	263	25	final	final	ADJ
cblr-1794	263	26	biological	biological	ADJ
cblr-1794	263	27	product	product	NOUN
cblr-1794	263	28	.	.	PUNCT
cblr-1794	263	29	"	"	PUNCT
cblr-1794	264	1	experts	expert	NOUN
cblr-1794	264	2	have	have	AUX
cblr-1794	264	3	posited	posit	VERB
cblr-1794	264	4	that	that	SCONJ
cblr-1794	264	5	manufacturing	manufacturing	NOUN
cblr-1794	264	6	costs	cost	NOUN
cblr-1794	264	7	for	for	ADP
cblr-1794	264	8	biosimilars	biosimilar	NOUN
cblr-1794	264	9	will	will	AUX
cblr-1794	264	10	be	be	AUX
cblr-1794	264	11	higher	high	ADJ
cblr-1794	264	12	than	than	ADP
cblr-1794	264	13	manufacturing	manufacture	VERB
cblr-1794	264	14	costs	cost	NOUN
cblr-1794	264	15	for	for	ADP
cblr-1794	264	16	the	the	DET
cblr-1794	264	17	reference	reference	NOUN
cblr-1794	264	18	product	product	NOUN
cblr-1794	264	19	because	because	SCONJ
cblr-1794	264	20	the	the	DET
cblr-1794	264	21	biosimilar	biosimilar	ADJ
cblr-1794	264	22	manufacturer	manufacturer	NOUN
cblr-1794	264	23	must	must	AUX
cblr-1794	264	24	"	"	PUNCT
cblr-1794	264	25	modifyf	modifyf	VERB
cblr-1794	264	26	[	[	PUNCT
cblr-1794	264	27	[	[	X
cblr-1794	264	28	its	its	PRON
cblr-1794	264	29	]	]	PUNCT
cblr-1794	264	30	production	production	NOUN
cblr-1794	264	31	process	process	NOUN
cblr-1794	264	32	to	to	PART
cblr-1794	264	33	achieve	achieve	VERB
cblr-1794	264	34	a	a	DET
cblr-1794	264	35	very	very	ADV
cblr-1794	264	36	specific	specific	ADJ
cblr-1794	264	37	profile	profile	NOUN
cblr-1794	264	38	that	that	PRON
cblr-1794	264	39	closely	closely	ADV
cblr-1794	264	40	approximates	approximate	VERB
cblr-1794	264	41	the	the	DET
cblr-1794	264	42	reference	reference	NOUN
cblr-1794	264	43	product	product	NOUN
cblr-1794	264	44	.	.	PUNCT
cblr-1794	265	1	"91	"91	VERB
cblr-1794	266	1	second	second	ADJ
cblr-1794	266	2	,	,	PUNCT
cblr-1794	266	3	biosimilar	biosimilar	ADJ
cblr-1794	266	4	sponsors	sponsor	NOUN
cblr-1794	266	5	will	will	AUX
cblr-1794	266	6	likely	likely	ADV
cblr-1794	266	7	face	face	VERB
cblr-1794	266	8	increased	increase	VERB
cblr-1794	266	9	data	datum	NOUN
cblr-1794	266	10	requirements	requirement	NOUN
cblr-1794	266	11	imposed	impose	VERB
cblr-1794	266	12	by	by	ADP
cblr-1794	266	13	the	the	DET
cblr-1794	266	14	fda	fda	PROPN
cblr-1794	266	15	.	.	PUNCT
cblr-1794	267	1	under	under	ADP
cblr-1794	267	2	hatch	hatch	NOUN
cblr-1794	267	3	-	-	PUNCT
cblr-1794	267	4	waxman	waxman	NOUN
cblr-1794	267	5	,	,	PUNCT
cblr-1794	267	6	the	the	DET
cblr-1794	267	7	fda	fda	PROPN
cblr-1794	267	8	is	be	AUX
cblr-1794	267	9	not	not	PART
cblr-1794	267	10	permitted	permit	VERB
cblr-1794	267	11	to	to	PART
cblr-1794	267	12	request	request	VERB
cblr-1794	267	13	additional	additional	ADJ
cblr-1794	267	14	preclinical	preclinical	ADJ
cblr-1794	267	15	or	or	CCONJ
cblr-1794	267	16	clinical	clinical	ADJ
cblr-1794	267	17	data	datum	NOUN
cblr-1794	267	18	from	from	ADP
cblr-1794	267	19	anda	anda	PROPN
cblr-1794	267	20	applicants	applicant	NOUN
cblr-1794	267	21	to	to	PART
cblr-1794	267	22	support	support	VERB
cblr-1794	267	23	a	a	DET
cblr-1794	267	24	finding	finding	NOUN
cblr-1794	267	25	of	of	ADP
cblr-1794	267	26	bioequivalence	bioequivalence	NOUN
cblr-1794	267	27	.	.	PUNCT
cblr-1794	268	1	92	92	NUM
cblr-1794	268	2	however	however	ADV
cblr-1794	268	3	,	,	PUNCT
cblr-1794	268	4	under	under	ADP
cblr-1794	268	5	the	the	DET
cblr-1794	268	6	bpcia	bpcia	NOUN
cblr-1794	268	7	,	,	PUNCT
cblr-1794	268	8	for	for	ADP
cblr-1794	268	9	any	any	DET
cblr-1794	268	10	given	give	VERB
cblr-1794	268	11	biosimilar	biosimilar	ADJ
cblr-1794	268	12	application	application	NOUN
cblr-1794	268	13	,	,	PUNCT
cblr-1794	268	14	the	the	DET
cblr-1794	268	15	fda	fda	PROPN
cblr-1794	268	16	determines	determine	VERB
cblr-1794	268	17	on	on	ADP
cblr-1794	268	18	a	a	DET
cblr-1794	268	19	case	case	NOUN
cblr-1794	268	20	-	-	PUNCT
cblr-1794	268	21	by	by	ADP
cblr-1794	268	22	-	-	PUNCT
cblr-1794	268	23	case	case	NOUN
cblr-1794	268	24	basis	basis	NOUN
cblr-1794	268	25	the	the	DET
cblr-1794	268	26	information	information	NOUN
cblr-1794	268	27	the	the	DET
cblr-1794	268	28	sponsor	sponsor	NOUN
cblr-1794	268	29	must	must	AUX
cblr-1794	268	30	submit	submit	VERB
cblr-1794	268	31	to	to	PART
cblr-1794	268	32	support	support	VERB
cblr-1794	268	33	a	a	DET
cblr-1794	268	34	finding	finding	NOUN
cblr-1794	268	35	of	of	ADP
cblr-1794	268	36	biosimilarity	biosimilarity	NOUN
cblr-1794	268	37	.	.	PUNCT
cblr-1794	269	1	at	at	ADP
cblr-1794	269	2	one	one	NUM
cblr-1794	269	3	end	end	NOUN
cblr-1794	269	4	of	of	ADP
cblr-1794	269	5	the	the	DET
cblr-1794	269	6	spectrum	spectrum	NOUN
cblr-1794	269	7	,	,	PUNCT
cblr-1794	269	8	the	the	DET
cblr-1794	269	9	fda	fda	PROPN
cblr-1794	269	10	could	could	AUX
cblr-1794	269	11	simply	simply	ADV
cblr-1794	269	12	require	require	VERB
cblr-1794	269	13	a	a	DET
cblr-1794	269	14	bioequivalence	bioequivalence	NOUN
cblr-1794	269	15	study	study	NOUN
cblr-1794	269	16	.	.	PUNCT
cblr-1794	270	1	however	however	ADV
cblr-1794	270	2	,	,	PUNCT
cblr-1794	270	3	at	at	ADP
cblr-1794	270	4	the	the	DET
cblr-1794	270	5	other	other	ADJ
cblr-1794	270	6	end	end	NOUN
cblr-1794	270	7	of	of	ADP
cblr-1794	270	8	the	the	DET
cblr-1794	270	9	spectrum	spectrum	NOUN
cblr-1794	270	10	,	,	PUNCT
cblr-1794	270	11	the	the	DET
cblr-1794	270	12	fda	fda	PROPN
cblr-1794	270	13	could	could	AUX
cblr-1794	270	14	require	require	VERB
cblr-1794	270	15	a	a	DET
cblr-1794	270	16	full	full	ADJ
cblr-1794	270	17	program	program	NOUN
cblr-1794	270	18	of	of	ADP
cblr-1794	270	19	clinical	clinical	ADJ
cblr-1794	270	20	studies	study	NOUN
cblr-1794	270	21	,	,	PUNCT
cblr-1794	270	22	similar	similar	ADJ
cblr-1794	270	23	to	to	ADP
cblr-1794	270	24	what	what	PRON
cblr-1794	270	25	is	be	AUX
cblr-1794	270	26	required	require	VERB
cblr-1794	270	27	for	for	ADP
cblr-1794	270	28	a	a	DET
cblr-1794	270	29	bla.9	bla.9	NOUN
cblr-1794	270	30	"	"	PUNCT
cblr-1794	270	31	the	the	DET
cblr-1794	270	32	european	european	PROPN
cblr-1794	270	33	union	union	PROPN
cblr-1794	270	34	(	(	PUNCT
cblr-1794	270	35	"	"	PUNCT
cblr-1794	270	36	eu	eu	PROPN
cblr-1794	270	37	'	'	PUNCT
cblr-1794	270	38	)	)	PUNCT
cblr-1794	270	39	regulatory	regulatory	ADJ
cblr-1794	270	40	agency	agency	NOUN
cblr-1794	270	41	charged	charge	VERB
cblr-1794	270	42	with	with	ADP
cblr-1794	270	43	overseeing	oversee	VERB
cblr-1794	270	44	the	the	DET
cblr-1794	270	45	approval	approval	NOUN
cblr-1794	270	46	of	of	ADP
cblr-1794	270	47	biosimilars	biosimilar	NOUN
cblr-1794	270	48	in	in	ADP
cblr-1794	270	49	europe	europe	PROPN
cblr-1794	270	50	has	have	AUX
cblr-1794	270	51	required	require	VERB
cblr-1794	270	52	at	at	ADP
cblr-1794	270	53	least	least	ADV
cblr-1794	270	54	one	one	NUM
cblr-1794	270	55	phase	phase	NOUN
cblr-1794	270	56	ii	ii	NOUN
cblr-1794	270	57	or	or	CCONJ
cblr-1794	270	58	phase	phase	VERB
cblr-1794	270	59	iii	iii	NUM
cblr-1794	270	60	clinical	clinical	ADJ
cblr-1794	270	61	trial	trial	NOUN
cblr-1794	270	62	per	per	ADP
cblr-1794	270	63	biosimilar	biosimilar	NOUN
cblr-1794	270	64	to	to	PART
cblr-1794	270	65	show	show	VERB
cblr-1794	270	66	similar	similar	ADJ
cblr-1794	270	67	safety	safety	NOUN
cblr-1794	270	68	and	and	CCONJ
cblr-1794	270	69	89	89	NUM
cblr-1794	270	70	see	see	VERB
cblr-1794	270	71	supra	supra	PROPN
cblr-1794	270	72	notes	note	VERB
cblr-1794	270	73	16	16	NUM
cblr-1794	270	74	-	-	SYM
cblr-1794	270	75	18	18	NUM
cblr-1794	270	76	and	and	CCONJ
cblr-1794	270	77	accompanying	accompany	VERB
cblr-1794	270	78	text	text	NOUN
cblr-1794	270	79	.	.	PUNCT
cblr-1794	271	1	90	90	NUM
cblr-1794	271	2	see	see	VERB
cblr-1794	271	3	generally	generally	ADV
cblr-1794	271	4	jordan	jordan	PROPN
cblr-1794	271	5	paradise	paradise	PROPN
cblr-1794	271	6	,	,	PUNCT
cblr-1794	271	7	the	the	DET
cblr-1794	271	8	devil	devil	NOUN
cblr-1794	271	9	is	be	AUX
cblr-1794	271	10	in	in	ADP
cblr-1794	271	11	the	the	DET
cblr-1794	271	12	details	detail	NOUN
cblr-1794	271	13	:	:	PUNCT
cblr-1794	271	14	healthcare	healthcare	NOUN
cblr-1794	271	15	reform	reform	NOUN
cblr-1794	271	16	,	,	PUNCT
cblr-1794	271	17	biosimilars	biosimilar	NOUN
cblr-1794	271	18	,	,	PUNCT
cblr-1794	271	19	and	and	CCONJ
cblr-1794	271	20	implementation	implementation	NOUN
cblr-1794	271	21	challenges	challenge	NOUN
cblr-1794	271	22	for	for	ADP
cblr-1794	271	23	the	the	DET
cblr-1794	271	24	food	food	NOUN
cblr-1794	271	25	and	and	CCONJ
cblr-1794	271	26	drug	drug	NOUN
cblr-1794	271	27	administration	administration	NOUN
cblr-1794	271	28	,	,	PUNCT
cblr-1794	271	29	51	51	NUM
cblr-1794	271	30	jurimetrics	jurimetric	NOUN
cblr-1794	271	31	j.	j.	PROPN
cblr-1794	271	32	279	279	NUM
cblr-1794	271	33	,	,	PUNCT
cblr-1794	271	34	281	281	NUM
cblr-1794	271	35	(	(	PUNCT
cblr-1794	271	36	2011	2011	NUM
cblr-1794	271	37	)	)	PUNCT
cblr-1794	271	38	(	(	PUNCT
cblr-1794	271	39	"	"	PUNCT
cblr-1794	271	40	biologics	biologic	NOUN
cblr-1794	271	41	are	be	AUX
cblr-1794	271	42	complex	complex	ADJ
cblr-1794	271	43	macromolecular	macromolecular	ADJ
cblr-1794	271	44	entities	entity	NOUN
cblr-1794	271	45	that	that	PRON
cblr-1794	271	46	are	be	AUX
cblr-1794	271	47	more	more	ADV
cblr-1794	271	48	susceptible	susceptible	ADJ
cblr-1794	271	49	to	to	ADP
cblr-1794	271	50	variations	variation	NOUN
cblr-1794	271	51	in	in	ADP
cblr-1794	271	52	biological	biological	ADJ
cblr-1794	271	53	activity	activity	NOUN
cblr-1794	271	54	of	of	ADP
cblr-1794	271	55	the	the	DET
cblr-1794	271	56	final	final	ADJ
cblr-1794	271	57	product	product	NOUN
cblr-1794	271	58	given	give	VERB
cblr-1794	271	59	manufacturing	manufacturing	NOUN
cblr-1794	271	60	procedures	procedure	NOUN
cblr-1794	271	61	;	;	PUNCT
cblr-1794	271	62	temperature	temperature	NOUN
cblr-1794	271	63	,	,	PUNCT
cblr-1794	271	64	media	medium	NOUN
cblr-1794	271	65	,	,	PUNCT
cblr-1794	271	66	and	and	CCONJ
cblr-1794	271	67	storage	storage	NOUN
cblr-1794	271	68	conditions	condition	NOUN
cblr-1794	271	69	;	;	PUNCT
cblr-1794	271	70	and	and	CCONJ
cblr-1794	271	71	interaction	interaction	NOUN
cblr-1794	271	72	of	of	ADP
cblr-1794	271	73	the	the	DET
cblr-1794	271	74	final	final	ADJ
cblr-1794	271	75	product	product	NOUN
cblr-1794	271	76	with	with	ADP
cblr-1794	271	77	the	the	DET
cblr-1794	271	78	human	human	ADJ
cblr-1794	271	79	body	body	NOUN
cblr-1794	271	80	.	.	PUNCT
cblr-1794	272	1	"	"	PUNCT
cblr-1794	272	2	)	)	PUNCT
cblr-1794	272	3	.	.	PUNCT
cblr-1794	273	1	91	91	NUM
cblr-1794	274	1	grabowski	grabowski	PROPN
cblr-1794	274	2	et	et	PROPN
cblr-1794	274	3	al	al	PROPN
cblr-1794	274	4	.	.	PROPN
cblr-1794	274	5	,	,	PUNCT
cblr-1794	274	6	supra	supra	PROPN
cblr-1794	274	7	note	note	PROPN
cblr-1794	274	8	85	85	NUM
cblr-1794	274	9	,	,	PUNCT
cblr-1794	274	10	at	at	ADP
cblr-1794	274	11	522	522	NUM
cblr-1794	274	12	(	(	PUNCT
cblr-1794	274	13	citing	cite	VERB
cblr-1794	274	14	interview	interview	NOUN
cblr-1794	274	15	with	with	ADP
cblr-1794	274	16	mark	mark	PROPN
cblr-1794	274	17	mccamish	mccamish	PROPN
cblr-1794	274	18	,	,	PUNCT
cblr-1794	274	19	global	global	ADJ
cblr-1794	274	20	head	head	NOUN
cblr-1794	274	21	of	of	ADP
cblr-1794	274	22	biopharmaceutical	biopharmaceutical	PROPN
cblr-1794	274	23	dev	dev	PROPN
cblr-1794	274	24	.	.	PROPN
cblr-1794	274	25	,	,	PUNCT
cblr-1794	274	26	sandoz	sandoz	PROPN
cblr-1794	274	27	int'l	int'l	PROPN
cblr-1794	274	28	,	,	PUNCT
cblr-1794	274	29	available	available	ADJ
cblr-1794	274	30	at	at	ADP
cblr-1794	274	31	http://www.iirusa.com/upload/wysiwyg/2010-p-div/pl586/	http://www.iirusa.com/upload/wysiwyg/2010-p-div/pl586/	ADJ
cblr-1794	274	32	podcast	podcast	NOUN
cblr-1794	274	33	/	/	SYM
cblr-1794	274	34	podcastscriptmarkmccamish.pdf	podcastscriptmarkmccamish.pdf	X
cblr-1794	274	35	)	)	PUNCT
cblr-1794	274	36	.	.	PUNCT
cblr-1794	275	1	92	92	NUM
cblr-1794	275	2	food	food	NOUN
cblr-1794	275	3	,	,	PUNCT
cblr-1794	275	4	drug	drug	NOUN
cblr-1794	275	5	,	,	PUNCT
cblr-1794	275	6	and	and	CCONJ
cblr-1794	275	7	cosmetic	cosmetic	ADJ
cblr-1794	275	8	act	act	NOUN
cblr-1794	275	9	§	§	PROPN
cblr-1794	275	10	505()(2)(a	505()(2)(a	NUM
cblr-1794	275	11	)	)	PUNCT
cblr-1794	275	12	,	,	PUNCT
cblr-1794	275	13	21	21	NUM
cblr-1794	275	14	u.s.c	u.s.c	ADJ
cblr-1794	275	15	.	.	PUNCT
cblr-1794	276	1	§	§	PROPN
cblr-1794	276	2	355()(2)(a	355()(2)(a	NUM
cblr-1794	276	3	)	)	PUNCT
cblr-1794	276	4	(	(	PUNCT
cblr-1794	276	5	2012	2012	NUM
cblr-1794	276	6	)	)	PUNCT
cblr-1794	276	7	.	.	PUNCT
cblr-1794	277	1	93	93	NUM
cblr-1794	277	2	see	see	VERB
cblr-1794	277	3	grabowski	grabowski	PROPN
cblr-1794	277	4	et	et	PROPN
cblr-1794	277	5	al	al	PROPN
cblr-1794	277	6	.	.	PROPN
cblr-1794	277	7	,	,	PUNCT
cblr-1794	277	8	supra	supra	PROPN
cblr-1794	277	9	note	note	PROPN
cblr-1794	277	10	85	85	NUM
cblr-1794	277	11	,	,	PUNCT
cblr-1794	277	12	at	at	ADP
cblr-1794	277	13	518	518	NUM
cblr-1794	277	14	-	-	SYM
cblr-1794	277	15	19	19	NUM
cblr-1794	277	16	.	.	NOUN
cblr-1794	277	17	224	224	NUM
cblr-1794	277	18	col	col	PROPN
cblr-1794	277	19	umbia	umbia	PROPN
cblr-1794	277	20	b	b	PROPN
cblr-1794	278	1	usiness	usiness	PROPN
cblr-1794	278	2	la	la	PROPN
cblr-1794	278	3	w	w	PROPN
cblr-1794	278	4	re	re	PROPN
cblr-1794	278	5	vie	vie	PROPN
cblr-1794	278	6	w	w	PROPN
cblr-1794	279	1	[	[	X
cblr-1794	279	2	vol	vol	NOUN
cblr-1794	279	3	2013	2013	NUM
cblr-1794	279	4	efficacy	efficacy	NOUN
cblr-1794	279	5	to	to	ADP
cblr-1794	279	6	the	the	DET
cblr-1794	279	7	reference	reference	NOUN
cblr-1794	279	8	drug.94	drug.94	NOUN
cblr-1794	279	9	in	in	ADP
cblr-1794	279	10	the	the	DET
cblr-1794	279	11	united	united	PROPN
cblr-1794	279	12	states	states	PROPN
cblr-1794	279	13	,	,	PUNCT
cblr-1794	279	14	a	a	DET
cblr-1794	279	15	reference	reference	NOUN
cblr-1794	279	16	product	product	NOUN
cblr-1794	279	17	manufacturer	manufacturer	NOUN
cblr-1794	279	18	submitting	submit	VERB
cblr-1794	279	19	a	a	DET
cblr-1794	279	20	bla	bla	NOUN
cblr-1794	279	21	is	be	AUX
cblr-1794	279	22	typically	typically	ADV
cblr-1794	279	23	required	require	VERB
cblr-1794	279	24	to	to	PART
cblr-1794	279	25	produce	produce	VERB
cblr-1794	279	26	data	datum	NOUN
cblr-1794	279	27	from	from	ADP
cblr-1794	279	28	at	at	ADV
cblr-1794	279	29	least	least	ADV
cblr-1794	279	30	two	two	NUM
cblr-1794	279	31	phase	phase	NOUN
cblr-1794	279	32	iii	iii	NUM
cblr-1794	279	33	clinical	clinical	ADJ
cblr-1794	279	34	trials.95	trials.95	NOUN
cblr-1794	279	35	if	if	SCONJ
cblr-1794	279	36	the	the	DET
cblr-1794	279	37	fda	fda	PROPN
cblr-1794	279	38	follows	follow	VERB
cblr-1794	279	39	the	the	DET
cblr-1794	279	40	eu	eu	PROPN
cblr-1794	279	41	and	and	CCONJ
cblr-1794	279	42	requires	require	VERB
cblr-1794	279	43	at	at	ADV
cblr-1794	279	44	least	least	ADV
cblr-1794	279	45	one	one	NUM
cblr-1794	279	46	large	large	ADJ
cblr-1794	279	47	scale	scale	NOUN
cblr-1794	279	48	clinical	clinical	ADJ
cblr-1794	279	49	trial	trial	NOUN
cblr-1794	279	50	,	,	PUNCT
cblr-1794	279	51	the	the	DET
cblr-1794	279	52	clinical	clinical	ADJ
cblr-1794	279	53	cost	cost	NOUN
cblr-1794	279	54	to	to	ADP
cblr-1794	279	55	manufacturers	manufacturer	NOUN
cblr-1794	279	56	producing	produce	VERB
cblr-1794	279	57	a	a	DET
cblr-1794	279	58	biosimilar	biosimilar	NOUN
cblr-1794	279	59	may	may	AUX
cblr-1794	279	60	total	total	VERB
cblr-1794	279	61	almost	almost	ADV
cblr-1794	279	62	half	half	DET
cblr-1794	279	63	the	the	DET
cblr-1794	279	64	clinical	clinical	ADJ
cblr-1794	279	65	cost	cost	NOUN
cblr-1794	279	66	of	of	ADP
cblr-1794	279	67	producing	produce	VERB
cblr-1794	279	68	an	an	DET
cblr-1794	279	69	innovative	innovative	ADJ
cblr-1794	279	70	biologic	biologic	NOUN
cblr-1794	279	71	.	.	PUNCT
cblr-1794	280	1	in	in	ADP
cblr-1794	280	2	addition	addition	NOUN
cblr-1794	280	3	to	to	ADP
cblr-1794	280	4	the	the	DET
cblr-1794	280	5	$	$	SYM
cblr-1794	280	6	100	100	NUM
cblr-1794	280	7	-	-	PUNCT
cblr-1794	280	8	200	200	NUM
cblr-1794	280	9	million	million	NUM
cblr-1794	280	10	investment	investment	NOUN
cblr-1794	280	11	per	per	ADP
cblr-1794	280	12	biosimilar	biosimilar	NOUN
cblr-1794	280	13	,	,	PUNCT
cblr-1794	280	14	biosimilar	biosimilar	ADJ
cblr-1794	280	15	manufacturers	manufacturer	NOUN
cblr-1794	280	16	will	will	AUX
cblr-1794	280	17	have	have	VERB
cblr-1794	280	18	to	to	PART
cblr-1794	280	19	build	build	VERB
cblr-1794	280	20	and	and	CCONJ
cblr-1794	280	21	equip	equip	VERB
cblr-1794	280	22	their	their	PRON
cblr-1794	280	23	own	own	ADJ
cblr-1794	280	24	manufacturing	manufacturing	NOUN
cblr-1794	280	25	facilities	facility	NOUN
cblr-1794	280	26	in	in	ADP
cblr-1794	280	27	order	order	NOUN
cblr-1794	280	28	for	for	SCONJ
cblr-1794	280	29	the	the	DET
cblr-1794	280	30	fda	fda	PROPN
cblr-1794	280	31	to	to	PART
cblr-1794	280	32	consider	consider	VERB
cblr-1794	280	33	a	a	DET
cblr-1794	280	34	product	product	NOUN
cblr-1794	280	35	biosimilar	biosimilar	NOUN
cblr-1794	280	36	.	.	PUNCT
cblr-1794	280	37	"	"	PUNCT
cblr-1794	281	1	according	accord	VERB
cblr-1794	281	2	to	to	ADP
cblr-1794	281	3	the	the	DET
cblr-1794	281	4	ftc	ftc	PROPN
cblr-1794	281	5	,	,	PUNCT
cblr-1794	281	6	this	this	PRON
cblr-1794	281	7	is	be	AUX
cblr-1794	281	8	likely	likely	ADJ
cblr-1794	281	9	to	to	PART
cblr-1794	281	10	cost	cost	VERB
cblr-1794	281	11	a	a	DET
cblr-1794	281	12	manufacturer	manufacturer	NOUN
cblr-1794	281	13	between	between	ADP
cblr-1794	281	14	$	$	SYM
cblr-1794	281	15	250	250	NUM
cblr-1794	281	16	million	million	NUM
cblr-1794	281	17	and	and	CCONJ
cblr-1794	281	18	$	$	SYM
cblr-1794	281	19	1	1	NUM
cblr-1794	281	20	billion.9	billion.9	PROPN
cblr-1794	281	21	7	7	NUM
cblr-1794	281	22	this	this	DET
cblr-1794	281	23	cost	cost	NOUN
cblr-1794	281	24	alone	alone	ADV
cblr-1794	281	25	will	will	AUX
cblr-1794	281	26	likely	likely	ADV
cblr-1794	281	27	persuade	persuade	VERB
cblr-1794	281	28	some	some	DET
cblr-1794	281	29	would	would	AUX
cblr-1794	281	30	-	-	PUNCT
cblr-1794	281	31	be	be	AUX
cblr-1794	281	32	biologics	biologic	NOUN
cblr-1794	281	33	manufacturers	manufacturer	NOUN
cblr-1794	281	34	that	that	SCONJ
cblr-1794	281	35	the	the	DET
cblr-1794	281	36	cost	cost	NOUN
cblr-1794	281	37	of	of	ADP
cblr-1794	281	38	entrance	entrance	NOUN
cblr-1794	281	39	into	into	ADP
cblr-1794	281	40	the	the	DET
cblr-1794	281	41	biosimilars	biosimilar	NOUN
cblr-1794	281	42	market	market	NOUN
cblr-1794	281	43	is	be	AUX
cblr-1794	281	44	too	too	ADV
cblr-1794	281	45	high	high	ADJ
cblr-1794	281	46	.	.	PUNCT
cblr-1794	281	47	"	"	PUNCT
cblr-1794	282	1	finally	finally	ADV
cblr-1794	282	2	,	,	PUNCT
cblr-1794	282	3	biosimilar	biosimilar	ADJ
cblr-1794	282	4	manufacturers	manufacturer	NOUN
cblr-1794	282	5	will	will	AUX
cblr-1794	282	6	likely	likely	ADV
cblr-1794	282	7	need	need	VERB
cblr-1794	282	8	to	to	PART
cblr-1794	282	9	engage	engage	VERB
cblr-1794	282	10	in	in	ADP
cblr-1794	282	11	post	post	ADJ
cblr-1794	282	12	-	-	ADJ
cblr-1794	282	13	approval	approval	ADJ
cblr-1794	282	14	surveillance	surveillance	NOUN
cblr-1794	282	15	of	of	ADP
cblr-1794	282	16	the	the	DET
cblr-1794	282	17	biosimilar	biosimilar	NOUN
cblr-1794	282	18	to	to	PART
cblr-1794	282	19	ensure	ensure	VERB
cblr-1794	282	20	that	that	SCONJ
cblr-1794	282	21	initial	initial	ADJ
cblr-1794	282	22	dissimilarities	dissimilarity	NOUN
cblr-1794	282	23	between	between	ADP
cblr-1794	282	24	the	the	DET
cblr-1794	282	25	biosimilar	biosimilar	NOUN
cblr-1794	282	26	and	and	CCONJ
cblr-1794	282	27	the	the	DET
cblr-1794	282	28	reference	reference	NOUN
cblr-1794	282	29	product	product	NOUN
cblr-1794	282	30	do	do	AUX
cblr-1794	282	31	not	not	PART
cblr-1794	282	32	increase	increase	VERB
cblr-1794	282	33	over	over	ADP
cblr-1794	282	34	time.99	time.99	NOUN
cblr-1794	282	35	postapproval	postapproval	PROPN
cblr-1794	282	36	drift	drift	NOUN
cblr-1794	282	37	occurs	occur	VERB
cblr-1794	282	38	when	when	SCONJ
cblr-1794	282	39	slight	slight	ADJ
cblr-1794	282	40	changes	change	NOUN
cblr-1794	282	41	in	in	ADP
cblr-1794	282	42	the	the	DET
cblr-1794	282	43	manufacturing	manufacturing	NOUN
cblr-1794	282	44	process	process	NOUN
cblr-1794	282	45	cause	cause	VERB
cblr-1794	282	46	changes	change	NOUN
cblr-1794	282	47	in	in	ADP
cblr-1794	282	48	the	the	DET
cblr-1794	282	49	biologic	biologic	NOUN
cblr-1794	282	50	.	.	PUNCT
cblr-1794	283	1	drift	drift	NOUN
cblr-1794	283	2	"	"	PUNCT
cblr-1794	283	3	will	will	AUX
cblr-1794	283	4	result	result	VERB
cblr-1794	283	5	in	in	ADP
cblr-1794	283	6	both	both	CCONJ
cblr-1794	283	7	the	the	DET
cblr-1794	283	8	reference	reference	NOUN
cblr-1794	283	9	product	product	NOUN
cblr-1794	283	10	and	and	CCONJ
cblr-1794	283	11	the	the	DET
cblr-1794	283	12	biosimilar	biosimilar	NOUN
cblr-1794	283	13	changing	change	VERB
cblr-1794	283	14	separately	separately	ADV
cblr-1794	283	15	over	over	ADP
cblr-1794	283	16	time	time	NOUN
cblr-1794	283	17	following	follow	VERB
cblr-1794	283	18	biosimilar	biosimilar	PROPN
cblr-1794	283	19	94	94	NUM
cblr-1794	283	20	see	see	VERB
cblr-1794	283	21	grabowski	grabowski	PROPN
cblr-1794	283	22	et	et	PROPN
cblr-1794	283	23	al	al	PROPN
cblr-1794	283	24	.	.	PROPN
cblr-1794	283	25	,	,	PUNCT
cblr-1794	283	26	supra	supra	PROPN
cblr-1794	283	27	note	note	PROPN
cblr-1794	283	28	85	85	NUM
cblr-1794	283	29	,	,	PUNCT
cblr-1794	283	30	at	at	ADP
cblr-1794	283	31	521	521	NUM
cblr-1794	283	32	.	.	NOUN
cblr-1794	283	33	95	95	NUM
cblr-1794	283	34	lisa	lisa	PROPN
cblr-1794	283	35	m.	m.	NOUN
cblr-1794	283	36	schwartz	schwartz	PROPN
cblr-1794	283	37	&	&	CCONJ
cblr-1794	283	38	steven	steven	PROPN
cblr-1794	283	39	woloshin	woloshin	PROPN
cblr-1794	283	40	,	,	PUNCT
cblr-1794	283	41	lost	lose	VERB
cblr-1794	283	42	in	in	ADP
cblr-1794	283	43	translation	translation	NOUN
cblr-1794	283	44	-	-	PUNCT
cblr-1794	283	45	fda	fda	PROPN
cblr-1794	283	46	drug	drug	NOUN
cblr-1794	283	47	information	information	NOUN
cblr-1794	283	48	that	that	PRON
cblr-1794	283	49	never	never	ADV
cblr-1794	283	50	reaches	reach	VERB
cblr-1794	283	51	clinicians	clinician	NOUN
cblr-1794	283	52	,	,	PUNCT
cblr-1794	283	53	361	361	NUM
cblr-1794	283	54	new	new	ADJ
cblr-1794	283	55	eng	eng	PROPN
cblr-1794	283	56	.	.	PUNCT
cblr-1794	284	1	j.	j.	PROPN
cblr-1794	284	2	med	med	PROPN
cblr-1794	284	3	.	.	PROPN
cblr-1794	285	1	1717	1717	NUM
cblr-1794	285	2	,	,	PUNCT
cblr-1794	285	3	1717	1717	NUM
cblr-1794	285	4	(	(	PUNCT
cblr-1794	285	5	2009	2009	NUM
cblr-1794	285	6	)	)	PUNCT
cblr-1794	285	7	.	.	PUNCT
cblr-1794	286	1	96	96	NUM
cblr-1794	286	2	public	public	ADJ
cblr-1794	286	3	health	health	NOUN
cblr-1794	286	4	service	service	PROPN
cblr-1794	286	5	act	act	NOUN
cblr-1794	286	6	§	§	PROPN
cblr-1794	286	7	351(k)(2)(a)(i)(v	351(k)(2)(a)(i)(v	NUM
cblr-1794	286	8	)	)	PUNCT
cblr-1794	286	9	,	,	PUNCT
cblr-1794	286	10	42	42	NUM
cblr-1794	286	11	u.s.c	u.s.c	ADJ
cblr-1794	286	12	.	.	PUNCT
cblr-1794	287	1	§	§	PROPN
cblr-1794	287	2	262(k)(2)(a)(i)(v	262(k)(2)(a)(i)(v	NUM
cblr-1794	287	3	)	)	PUNCT
cblr-1794	287	4	(	(	PUNCT
cblr-1794	287	5	2011	2011	NUM
cblr-1794	287	6	)	)	PUNCT
cblr-1794	287	7	.	.	PUNCT
cblr-1794	288	1	97	97	NUM
cblr-1794	288	2	ftc	ftc	PROPN
cblr-1794	288	3	report	report	NOUN
cblr-1794	288	4	,	,	PUNCT
cblr-1794	288	5	supra	supra	PROPN
cblr-1794	288	6	note	note	PROPN
cblr-1794	288	7	14	14	NUM
cblr-1794	288	8	,	,	PUNCT
cblr-1794	288	9	at	at	ADP
cblr-1794	288	10	14	14	NUM
cblr-1794	288	11	.	.	PUNCT
cblr-1794	288	12	98	98	NUM
cblr-1794	288	13	see	see	VERB
cblr-1794	288	14	generally	generally	ADV
cblr-1794	288	15	henry	henry	PROPN
cblr-1794	288	16	g.	g.	PROPN
cblr-1794	288	17	grabowski	grabowski	PROPN
cblr-1794	288	18	,	,	PUNCT
cblr-1794	288	19	david	david	PROPN
cblr-1794	288	20	b.	b.	PROPN
cblr-1794	288	21	ridley	ridley	PROPN
cblr-1794	288	22	&	&	CCONJ
cblr-1794	288	23	kevin	kevin	PROPN
cblr-1794	288	24	a.	a.	PROPN
cblr-1794	288	25	schulman	schulman	PROPN
cblr-1794	288	26	,	,	PUNCT
cblr-1794	288	27	entry	entry	NOUN
cblr-1794	288	28	and	and	CCONJ
cblr-1794	288	29	competition	competition	NOUN
cblr-1794	288	30	in	in	ADP
cblr-1794	288	31	generic	generic	ADJ
cblr-1794	288	32	biologics	biologic	NOUN
cblr-1794	288	33	,	,	PUNCT
cblr-1794	288	34	28	28	NUM
cblr-1794	288	35	managerial	managerial	ADJ
cblr-1794	288	36	&	&	CCONJ
cblr-1794	288	37	decision	decision	PROPN
cblr-1794	288	38	econ	econ	PROPN
cblr-1794	288	39	.	.	PUNCT
cblr-1794	289	1	439	439	NUM
cblr-1794	289	2	,	,	PUNCT
cblr-1794	289	3	447	447	NUM
cblr-1794	289	4	(	(	PUNCT
cblr-1794	289	5	2007	2007	NUM
cblr-1794	289	6	)	)	PUNCT
cblr-1794	289	7	(	(	PUNCT
cblr-1794	289	8	arguing	argue	VERB
cblr-1794	289	9	that	that	SCONJ
cblr-1794	289	10	because	because	SCONJ
cblr-1794	289	11	of	of	ADP
cblr-1794	289	12	high	high	ADJ
cblr-1794	289	13	fixed	fix	VERB
cblr-1794	289	14	costs	cost	NOUN
cblr-1794	289	15	for	for	ADP
cblr-1794	289	16	biologic	biologic	NOUN
cblr-1794	289	17	manufacturing	manufacturing	NOUN
cblr-1794	289	18	facilities	facility	NOUN
cblr-1794	289	19	,	,	PUNCT
cblr-1794	289	20	for	for	ADP
cblr-1794	289	21	the	the	DET
cblr-1794	289	22	foreseeable	foreseeable	ADJ
cblr-1794	289	23	future	future	NOUN
cblr-1794	289	24	,	,	PUNCT
cblr-1794	289	25	the	the	DET
cblr-1794	289	26	number	number	NOUN
cblr-1794	289	27	of	of	ADP
cblr-1794	289	28	biosimilar	biosimilar	ADJ
cblr-1794	289	29	entrants	entrant	NOUN
cblr-1794	289	30	is	be	AUX
cblr-1794	289	31	likely	likely	ADJ
cblr-1794	289	32	to	to	PART
cblr-1794	289	33	be	be	AUX
cblr-1794	289	34	smaller	small	ADJ
cblr-1794	289	35	than	than	ADP
cblr-1794	289	36	that	that	PRON
cblr-1794	289	37	predicted	predict	VERB
cblr-1794	289	38	for	for	ADP
cblr-1794	289	39	generic	generic	ADJ
cblr-1794	289	40	pharmaceutical	pharmaceutical	ADJ
cblr-1794	289	41	markets	market	NOUN
cblr-1794	289	42	)	)	PUNCT
cblr-1794	289	43	.	.	PUNCT
cblr-1794	290	1	99	99	NUM
cblr-1794	290	2	see	see	VERB
cblr-1794	290	3	generally	generally	ADV
cblr-1794	290	4	grabowski	grabowski	PROPN
cblr-1794	290	5	et	et	PROPN
cblr-1794	290	6	al	al	PROPN
cblr-1794	290	7	.	.	PROPN
cblr-1794	290	8	,	,	PUNCT
cblr-1794	290	9	supra	supra	PROPN
cblr-1794	290	10	note	note	PROPN
cblr-1794	290	11	85	85	NUM
cblr-1794	290	12	,	,	PUNCT
cblr-1794	290	13	at	at	ADP
cblr-1794	290	14	518	518	NUM
cblr-1794	290	15	(	(	PUNCT
cblr-1794	290	16	explaining	explain	VERB
cblr-1794	290	17	that	that	SCONJ
cblr-1794	290	18	one	one	NUM
cblr-1794	290	19	proposal	proposal	NOUN
cblr-1794	290	20	for	for	ADP
cblr-1794	290	21	dealing	deal	VERB
cblr-1794	290	22	with	with	ADP
cblr-1794	290	23	the	the	DET
cblr-1794	290	24	phenomenon	phenomenon	NOUN
cblr-1794	290	25	of	of	ADP
cblr-1794	290	26	drift	drift	NOUN
cblr-1794	290	27	is	be	AUX
cblr-1794	290	28	establishing	establish	VERB
cblr-1794	290	29	a	a	DET
cblr-1794	290	30	post	post	ADJ
cblr-1794	290	31	-	-	ADJ
cblr-1794	290	32	marketing	marketing	ADJ
cblr-1794	290	33	system	system	NOUN
cblr-1794	290	34	to	to	PART
cblr-1794	290	35	monitor	monitor	VERB
cblr-1794	290	36	interchangeability	interchangeability	NOUN
cblr-1794	290	37	)	)	PUNCT
cblr-1794	290	38	.	.	PUNCT
cblr-1794	291	1	no	no	INTJ
cblr-1794	291	2	.	.	PUNCT
cblr-1794	292	1	1:209	1:209	NUM
cblr-1794	292	2	]	]	X
cblr-1794	292	3	bpcia	bpcia	NOUN
cblr-1794	292	4	:	:	PUNCT
cblr-1794	292	5	destined	destine	VERB
cblr-1794	292	6	for	for	ADP
cblr-1794	292	7	failure	failure	NOUN
cblr-1794	292	8	?	?	PUNCT
cblr-1794	293	1	225	225	NUM
cblr-1794	293	2	approval	approval	NOUN
cblr-1794	293	3	.	.	PUNCT
cblr-1794	294	1	"100	"100	NOUN
cblr-1794	294	2	to	to	PART
cblr-1794	294	3	protect	protect	VERB
cblr-1794	294	4	against	against	ADP
cblr-1794	294	5	complications	complication	NOUN
cblr-1794	294	6	from	from	ADP
cblr-1794	294	7	drift	drift	NOUN
cblr-1794	294	8	,	,	PUNCT
cblr-1794	294	9	the	the	DET
cblr-1794	294	10	fda	fda	PROPN
cblr-1794	294	11	could	could	AUX
cblr-1794	294	12	impose	impose	VERB
cblr-1794	294	13	strong	strong	ADJ
cblr-1794	294	14	pharmacovigilence	pharmacovigilence	NOUN
cblr-1794	294	15	and	and	CCONJ
cblr-1794	294	16	reporting	reporting	NOUN
cblr-1794	294	17	standards	standard	NOUN
cblr-1794	294	18	on	on	ADP
cblr-1794	294	19	the	the	DET
cblr-1794	294	20	biosimilar	biosimilar	NOUN
cblr-1794	294	21	manufacturer.o	manufacturer.o	ADP
cblr-1794	294	22	there	there	PRON
cblr-1794	294	23	is	be	VERB
cblr-1794	294	24	no	no	DET
cblr-1794	294	25	comparable	comparable	ADJ
cblr-1794	294	26	cost	cost	NOUN
cblr-1794	294	27	for	for	ADP
cblr-1794	294	28	generic	generic	ADJ
cblr-1794	294	29	manufacturers	manufacturer	NOUN
cblr-1794	294	30	,	,	PUNCT
cblr-1794	294	31	as	as	SCONJ
cblr-1794	294	32	drift	drift	NOUN
cblr-1794	294	33	does	do	AUX
cblr-1794	294	34	not	not	PART
cblr-1794	294	35	occur	occur	VERB
cblr-1794	294	36	in	in	ADP
cblr-1794	294	37	traditional	traditional	ADJ
cblr-1794	294	38	pharmaceutical	pharmaceutical	ADJ
cblr-1794	294	39	drugs	drug	NOUN
cblr-1794	294	40	.	.	PUNCT
cblr-1794	295	1	in	in	ADP
cblr-1794	295	2	light	light	NOUN
cblr-1794	295	3	of	of	ADP
cblr-1794	295	4	these	these	DET
cblr-1794	295	5	seemingly	seemingly	ADV
cblr-1794	295	6	staggering	staggering	ADJ
cblr-1794	295	7	entry	entry	NOUN
cblr-1794	295	8	costs	cost	NOUN
cblr-1794	295	9	,	,	PUNCT
cblr-1794	295	10	the	the	DET
cblr-1794	295	11	ftc	ftc	PROPN
cblr-1794	295	12	estimates	estimate	VERB
cblr-1794	295	13	that	that	SCONJ
cblr-1794	295	14	biosimilars	biosimilar	NOUN
cblr-1794	295	15	will	will	AUX
cblr-1794	295	16	only	only	ADV
cblr-1794	295	17	develop	develop	VERB
cblr-1794	295	18	for	for	ADP
cblr-1794	295	19	markets	market	NOUN
cblr-1794	295	20	with	with	ADP
cblr-1794	295	21	sales	sale	NOUN
cblr-1794	295	22	in	in	ADP
cblr-1794	295	23	excess	excess	NOUN
cblr-1794	295	24	of	of	ADP
cblr-1794	295	25	$	$	SYM
cblr-1794	295	26	250	250	NUM
cblr-1794	295	27	million	million	NUM
cblr-1794	295	28	per	per	ADP
cblr-1794	295	29	year	year	NOUN
cblr-1794	295	30	.	.	PUNCT
cblr-1794	296	1	102	102	NUM
cblr-1794	296	2	only	only	ADV
cblr-1794	296	3	large	large	ADJ
cblr-1794	296	4	companies	company	NOUN
cblr-1794	296	5	with	with	ADP
cblr-1794	296	6	substantial	substantial	ADJ
cblr-1794	296	7	resources	resource	NOUN
cblr-1794	296	8	are	be	AUX
cblr-1794	296	9	likely	likely	ADJ
cblr-1794	296	10	to	to	PART
cblr-1794	296	11	be	be	AUX
cblr-1794	296	12	able	able	ADJ
cblr-1794	296	13	to	to	PART
cblr-1794	296	14	produce	produce	VERB
cblr-1794	296	15	a	a	DET
cblr-1794	296	16	biosimilar.103	biosimilar.103	NOUN
cblr-1794	296	17	further	far	ADV
cblr-1794	296	18	,	,	PUNCT
cblr-1794	296	19	even	even	ADV
cblr-1794	296	20	when	when	SCONJ
cblr-1794	296	21	biosimilars	biosimilar	NOUN
cblr-1794	296	22	do	do	AUX
cblr-1794	296	23	enter	enter	VERB
cblr-1794	296	24	the	the	DET
cblr-1794	296	25	market	market	NOUN
cblr-1794	296	26	,	,	PUNCT
cblr-1794	296	27	high	high	ADJ
cblr-1794	296	28	costs	cost	NOUN
cblr-1794	296	29	will	will	AUX
cblr-1794	296	30	result	result	VERB
cblr-1794	296	31	in	in	ADP
cblr-1794	296	32	fewer	few	ADJ
cblr-1794	296	33	entrants	entrant	NOUN
cblr-1794	296	34	than	than	SCONJ
cblr-1794	296	35	would	would	AUX
cblr-1794	296	36	be	be	AUX
cblr-1794	296	37	expected	expect	VERB
cblr-1794	296	38	for	for	ADP
cblr-1794	296	39	the	the	DET
cblr-1794	296	40	generic	generic	ADJ
cblr-1794	296	41	pharmaceutical	pharmaceutical	NOUN
cblr-1794	296	42	market	market	NOUN
cblr-1794	296	43	.	.	PUNCT
cblr-1794	297	1	104	104	NUM
cblr-1794	297	2	one	one	NUM
cblr-1794	297	3	study	study	NOUN
cblr-1794	297	4	estimates	estimate	VERB
cblr-1794	297	5	that	that	SCONJ
cblr-1794	297	6	for	for	ADP
cblr-1794	297	7	a	a	DET
cblr-1794	297	8	$	$	SYM
cblr-1794	297	9	500	500	NUM
cblr-1794	297	10	million	million	NUM
cblr-1794	297	11	market	market	NOUN
cblr-1794	297	12	,	,	PUNCT
cblr-1794	297	13	only	only	ADV
cblr-1794	297	14	two	two	NUM
cblr-1794	297	15	biosimilars	biosimilar	NOUN
cblr-1794	297	16	would	would	AUX
cblr-1794	297	17	enter	enter	VERB
cblr-1794	297	18	,	,	PUNCT
cblr-1794	297	19	as	as	SCONJ
cblr-1794	297	20	compared	compare	VERB
cblr-1794	297	21	to	to	ADP
cblr-1794	297	22	nine	nine	NUM
cblr-1794	297	23	generic	generic	ADJ
cblr-1794	297	24	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	297	25	.	.	PUNCT
cblr-1794	298	1	105	105	NUM
cblr-1794	298	2	with	with	ADP
cblr-1794	298	3	fewer	few	ADJ
cblr-1794	298	4	biosimilar	biosimilar	PROPN
cblr-1794	298	5	competitors	competitor	NOUN
cblr-1794	298	6	,	,	PUNCT
cblr-1794	298	7	biosimilars	biosimilar	NOUN
cblr-1794	298	8	will	will	AUX
cblr-1794	298	9	likely	likely	ADV
cblr-1794	298	10	be	be	AUX
cblr-1794	298	11	relatively	relatively	ADV
cblr-1794	298	12	close	close	ADJ
cblr-1794	298	13	in	in	ADP
cblr-1794	298	14	price	price	NOUN
cblr-1794	298	15	to	to	PART
cblr-1794	298	16	branded	brand	VERB
cblr-1794	298	17	biologics.1	biologics.1	PROPN
cblr-1794	298	18	06	06	NUM
cblr-1794	298	19	b.	b.	PROPN
cblr-1794	298	20	interchangeability	interchangeability	NOUN
cblr-1794	298	21	vs.	vs.	ADP
cblr-1794	298	22	bioequivalence	bioequivalence	NOUN
cblr-1794	298	23	in	in	ADP
cblr-1794	298	24	order	order	NOUN
cblr-1794	298	25	to	to	PART
cblr-1794	298	26	achieve	achieve	VERB
cblr-1794	298	27	an	an	DET
cblr-1794	298	28	interchangeability	interchangeability	NOUN
cblr-1794	298	29	rating	rating	NOUN
cblr-1794	298	30	,	,	PUNCT
cblr-1794	298	31	a	a	DET
cblr-1794	298	32	biosimilar	biosimilar	ADJ
cblr-1794	298	33	sponsor	sponsor	NOUN
cblr-1794	298	34	must	must	AUX
cblr-1794	298	35	show	show	VERB
cblr-1794	298	36	that	that	SCONJ
cblr-1794	298	37	safety	safety	NOUN
cblr-1794	298	38	and	and	CCONJ
cblr-1794	298	39	efficacy	efficacy	NOUN
cblr-1794	298	40	risks	risk	NOUN
cblr-1794	298	41	do	do	AUX
cblr-1794	298	42	not	not	PART
cblr-1794	298	43	increase	increase	VERB
cblr-1794	298	44	when	when	SCONJ
cblr-1794	298	45	switching	switch	VERB
cblr-1794	298	46	between	between	ADP
cblr-1794	298	47	the	the	DET
cblr-1794	298	48	reference	reference	NOUN
cblr-1794	298	49	100	100	NUM
cblr-1794	298	50	grabowski	grabowski	PROPN
cblr-1794	298	51	et	et	PROPN
cblr-1794	298	52	al	al	PROPN
cblr-1794	298	53	.	.	PROPN
cblr-1794	298	54	,	,	PUNCT
cblr-1794	298	55	supra	supra	PROPN
cblr-1794	298	56	note	note	PROPN
cblr-1794	298	57	85	85	NUM
cblr-1794	298	58	,	,	PUNCT
cblr-1794	298	59	at	at	ADP
cblr-1794	298	60	518	518	NUM
cblr-1794	298	61	(	(	PUNCT
cblr-1794	298	62	citing	cite	VERB
cblr-1794	298	63	approval	approval	NOUN
cblr-1794	298	64	pathway	pathway	NOUN
cblr-1794	298	65	for	for	ADP
cblr-1794	298	66	biosimilar	biosimilar	NOUN
cblr-1794	298	67	and	and	CCONJ
cblr-1794	298	68	interchangeable	interchangeable	ADJ
cblr-1794	298	69	biological	biological	ADJ
cblr-1794	298	70	products	product	NOUN
cblr-1794	298	71	;	;	PUNCT
cblr-1794	298	72	public	public	ADJ
cblr-1794	298	73	hearing	hearing	NOUN
cblr-1794	298	74	;	;	PUNCT
cblr-1794	298	75	request	request	NOUN
cblr-1794	298	76	for	for	ADP
cblr-1794	298	77	comments	comment	NOUN
cblr-1794	298	78	,	,	PUNCT
cblr-1794	298	79	75	75	NUM
cblr-1794	298	80	fed	feed	VERB
cblr-1794	298	81	.	.	PUNCT
cblr-1794	299	1	reg	reg	PROPN
cblr-1794	299	2	.	.	PROPN
cblr-1794	300	1	61,497	61,497	NUM
cblr-1794	300	2	,	,	PUNCT
cblr-1794	300	3	61,499	61,499	NUM
cblr-1794	300	4	(	(	PUNCT
cblr-1794	300	5	fda	fda	PROPN
cblr-1794	300	6	,	,	PUNCT
cblr-1794	300	7	dep't	dep't	PROPN
cblr-1794	300	8	health	health	PROPN
cblr-1794	300	9	&	&	CCONJ
cblr-1794	300	10	human	human	PROPN
cblr-1794	300	11	servs	servs	PROPN
cblr-1794	300	12	.	.	PUNCT
cblr-1794	301	1	oct	oct	PROPN
cblr-1794	301	2	.	.	PROPN
cblr-1794	301	3	5	5	NUM
cblr-1794	301	4	,	,	PUNCT
cblr-1794	301	5	2010	2010	NUM
cblr-1794	301	6	)	)	PUNCT
cblr-1794	301	7	)	)	PUNCT
cblr-1794	301	8	.	.	PUNCT
cblr-1794	302	1	101	101	NUM
cblr-1794	303	1	i	i	PRON
cblr-1794	303	2	d.	d.	PROPN
cblr-1794	303	3	102	102	NUM
cblr-1794	303	4	ftc	ftc	PROPN
cblr-1794	303	5	report	report	PROPN
cblr-1794	303	6	,	,	PUNCT
cblr-1794	303	7	supra	supra	PROPN
cblr-1794	303	8	note	note	PROPN
cblr-1794	303	9	14	14	NUM
cblr-1794	303	10	,	,	PUNCT
cblr-1794	303	11	at	at	ADP
cblr-1794	303	12	15	15	NUM
cblr-1794	303	13	(	(	PUNCT
cblr-1794	303	14	citing	cite	VERB
cblr-1794	303	15	janet	janet	PROPN
cblr-1794	303	16	woodcock	woodcock	PROPN
cblr-1794	303	17	et	et	PROPN
cblr-1794	303	18	al	al	PROPN
cblr-1794	303	19	.	.	PROPN
cblr-1794	303	20	,	,	PUNCT
cblr-1794	303	21	supra	supra	PROPN
cblr-1794	303	22	note	note	VERB
cblr-1794	303	23	38	38	NUM
cblr-1794	303	24	,	,	PUNCT
cblr-1794	303	25	at	at	ADP
cblr-1794	303	26	446	446	NUM
cblr-1794	303	27	)	)	PUNCT
cblr-1794	303	28	.	.	PUNCT
cblr-1794	304	1	103	103	NUM
cblr-1794	305	1	i	i	PRON
cblr-1794	305	2	d.	d.	PROPN
cblr-1794	305	3	(	(	PUNCT
cblr-1794	305	4	listing	list	VERB
cblr-1794	305	5	the	the	DET
cblr-1794	305	6	companies	company	NOUN
cblr-1794	305	7	that	that	PRON
cblr-1794	305	8	are	be	AUX
cblr-1794	305	9	likely	likely	ADJ
cblr-1794	305	10	to	to	PART
cblr-1794	305	11	enter	enter	VERB
cblr-1794	305	12	the	the	DET
cblr-1794	305	13	biosimilars	biosimilar	NOUN
cblr-1794	305	14	market	market	NOUN
cblr-1794	305	15	:	:	PUNCT
cblr-1794	305	16	abbott	abbott	PROPN
cblr-1794	305	17	,	,	PUNCT
cblr-1794	305	18	astrazeneca	astrazeneca	PROPN
cblr-1794	305	19	,	,	PUNCT
cblr-1794	305	20	biogen	biogen	PROPN
cblr-1794	305	21	/	/	SYM
cblr-1794	305	22	idec	idec	PROPN
cblr-1794	305	23	,	,	PUNCT
cblr-1794	305	24	eli	eli	PROPN
cblr-1794	305	25	lilly	lilly	PROPN
cblr-1794	305	26	,	,	PUNCT
cblr-1794	305	27	johnson	johnson	PROPN
cblr-1794	305	28	&	&	CCONJ
cblr-1794	305	29	johnson	johnson	PROPN
cblr-1794	305	30	,	,	PUNCT
cblr-1794	305	31	pfizer	pfizer	PROPN
cblr-1794	305	32	,	,	PUNCT
cblr-1794	305	33	roche	roche	PROPN
cblr-1794	305	34	,	,	PUNCT
cblr-1794	305	35	novo	novo	NOUN
cblr-1794	305	36	nordisk	nordisk	NOUN
cblr-1794	305	37	and	and	CCONJ
cblr-1794	305	38	sanofi	sanofi	NOUN
cblr-1794	305	39	-	-	PUNCT
cblr-1794	305	40	aventis	aventis	PROPN
cblr-1794	305	41	)	)	PUNCT
cblr-1794	305	42	.	.	PUNCT
cblr-1794	306	1	104	104	NUM
cblr-1794	307	1	grabowski	grabowski	PROPN
cblr-1794	307	2	et	et	PROPN
cblr-1794	307	3	al	al	PROPN
cblr-1794	307	4	.	.	PROPN
cblr-1794	307	5	,	,	PUNCT
cblr-1794	307	6	supra	supra	PROPN
cblr-1794	307	7	note	note	NOUN
cblr-1794	307	8	98	98	NUM
cblr-1794	307	9	,	,	PUNCT
cblr-1794	307	10	at	at	ADP
cblr-1794	307	11	440	440	NUM
cblr-1794	307	12	.	.	PUNCT
cblr-1794	308	1	105	105	NUM
cblr-1794	309	1	i	i	PRON
cblr-1794	309	2	d.	d.	VERB
cblr-1794	309	3	this	this	DET
cblr-1794	309	4	study	study	NOUN
cblr-1794	309	5	,	,	PUNCT
cblr-1794	309	6	conducted	conduct	VERB
cblr-1794	309	7	before	before	SCONJ
cblr-1794	309	8	the	the	DET
cblr-1794	309	9	bpcia	bpcia	NOUN
cblr-1794	309	10	was	be	AUX
cblr-1794	309	11	passed	pass	VERB
cblr-1794	309	12	,	,	PUNCT
cblr-1794	309	13	is	be	AUX
cblr-1794	309	14	based	base	VERB
cblr-1794	309	15	on	on	ADP
cblr-1794	309	16	the	the	DET
cblr-1794	309	17	assumption	assumption	NOUN
cblr-1794	309	18	that	that	SCONJ
cblr-1794	309	19	fixed	fix	VERB
cblr-1794	309	20	costs	cost	NOUN
cblr-1794	309	21	of	of	ADP
cblr-1794	309	22	developing	develop	VERB
cblr-1794	309	23	a	a	DET
cblr-1794	309	24	biosimilar	biosimilar	NOUN
cblr-1794	309	25	will	will	AUX
cblr-1794	309	26	be	be	AUX
cblr-1794	309	27	150	150	NUM
cblr-1794	309	28	%	%	NOUN
cblr-1794	309	29	greater	great	ADJ
cblr-1794	309	30	than	than	ADP
cblr-1794	309	31	fixed	fix	VERB
cblr-1794	309	32	costs	cost	NOUN
cblr-1794	309	33	of	of	ADP
cblr-1794	309	34	developing	develop	VERB
cblr-1794	309	35	a	a	DET
cblr-1794	309	36	generic	generic	ADJ
cblr-1794	309	37	pharmaceutical	pharmaceutical	NOUN
cblr-1794	309	38	.	.	PUNCT
cblr-1794	310	1	based	base	VERB
cblr-1794	310	2	on	on	ADP
cblr-1794	310	3	analyses	analysis	NOUN
cblr-1794	310	4	of	of	ADP
cblr-1794	310	5	the	the	DET
cblr-1794	310	6	bpcia	bpcia	NOUN
cblr-1794	310	7	,	,	PUNCT
cblr-1794	310	8	this	this	DET
cblr-1794	310	9	estimate	estimate	NOUN
cblr-1794	310	10	seems	seem	VERB
cblr-1794	310	11	quite	quite	ADV
cblr-1794	310	12	conservative	conservative	ADJ
cblr-1794	310	13	.	.	PUNCT
cblr-1794	311	1	thus	thus	ADV
cblr-1794	311	2	,	,	PUNCT
cblr-1794	311	3	even	even	ADV
cblr-1794	311	4	fewer	few	ADJ
cblr-1794	311	5	biosimilars	biosimilar	NOUN
cblr-1794	311	6	may	may	AUX
cblr-1794	311	7	enter	enter	VERB
cblr-1794	311	8	the	the	DET
cblr-1794	311	9	market	market	NOUN
cblr-1794	311	10	than	than	SCONJ
cblr-1794	311	11	predicted	predict	VERB
cblr-1794	311	12	by	by	ADP
cblr-1794	311	13	this	this	DET
cblr-1794	311	14	study	study	NOUN
cblr-1794	311	15	.	.	PUNCT
cblr-1794	312	1	106	106	NUM
cblr-1794	313	1	i	i	PRON
cblr-1794	313	2	d.	d.	PROPN
cblr-1794	313	3	226	226	NUM
cblr-1794	313	4	col	col	PROPN
cblr-1794	313	5	umia	umia	PROPN
cblr-1794	313	6	b	b	PROPN
cblr-1794	313	7	usiness	usiness	PROPN
cblr-1794	313	8	la	la	PROPN
cblr-1794	313	9	w	w	PROPN
cblr-1794	313	10	re	re	PROPN
cblr-1794	313	11	vie	vie	PROPN
cblr-1794	313	12	w	w	PROPN
cblr-1794	314	1	[	[	X
cblr-1794	314	2	vol	vol	NOUN
cblr-1794	314	3	.	.	PUNCT
cblr-1794	314	4	2013	2013	NUM
cblr-1794	314	5	product	product	NOUN
cblr-1794	314	6	and	and	CCONJ
cblr-1794	314	7	the	the	DET
cblr-1794	314	8	biosimilar.o	biosimilar.o	PROPN
cblr-1794	314	9	'	'	PUNCT
cblr-1794	314	10	the	the	DET
cblr-1794	314	11	fda	fda	PROPN
cblr-1794	314	12	has	have	AUX
cblr-1794	314	13	not	not	PART
cblr-1794	314	14	explained	explain	VERB
cblr-1794	314	15	the	the	DET
cblr-1794	314	16	process	process	NOUN
cblr-1794	314	17	it	it	PRON
cblr-1794	314	18	will	will	AUX
cblr-1794	314	19	use	use	VERB
cblr-1794	314	20	to	to	PART
cblr-1794	314	21	determine	determine	VERB
cblr-1794	314	22	whether	whether	SCONJ
cblr-1794	314	23	a	a	DET
cblr-1794	314	24	biosimilar	biosimilar	NOUN
cblr-1794	314	25	receives	receive	VERB
cblr-1794	314	26	an	an	DET
cblr-1794	314	27	interchangeability	interchangeability	NOUN
cblr-1794	314	28	rating.1	rating.1	NOUN
cblr-1794	314	29	0	0	NUM
cblr-1794	314	30	8	8	NUM
cblr-1794	314	31	however	however	ADV
cblr-1794	314	32	,	,	PUNCT
cblr-1794	314	33	experts	expert	NOUN
cblr-1794	314	34	anticipate	anticipate	VERB
cblr-1794	314	35	that	that	SCONJ
cblr-1794	314	36	achieving	achieve	VERB
cblr-1794	314	37	an	an	DET
cblr-1794	314	38	interchangeability	interchangeability	NOUN
cblr-1794	314	39	rating	rating	NOUN
cblr-1794	314	40	will	will	AUX
cblr-1794	314	41	be	be	AUX
cblr-1794	314	42	quite	quite	ADV
cblr-1794	314	43	difficult	difficult	ADJ
cblr-1794	314	44	.	.	PUNCT
cblr-1794	315	1	the	the	DET
cblr-1794	315	2	fda	fda	PROPN
cblr-1794	315	3	may	may	AUX
cblr-1794	315	4	initially	initially	ADV
cblr-1794	315	5	limit	limit	VERB
cblr-1794	315	6	interchangeability	interchangeability	NOUN
cblr-1794	315	7	ratings	rating	NOUN
cblr-1794	315	8	to	to	ADP
cblr-1794	315	9	biologics	biologic	NOUN
cblr-1794	315	10	(	(	PUNCT
cblr-1794	315	11	such	such	ADJ
cblr-1794	315	12	as	as	ADP
cblr-1794	315	13	hgh	hgh	PROPN
cblr-1794	315	14	,	,	PUNCT
cblr-1794	315	15	discussed	discuss	VERB
cblr-1794	315	16	above	above	ADV
cblr-1794	315	17	)	)	PUNCT
cblr-1794	315	18	,	,	PUNCT
cblr-1794	315	19	"	"	PUNCT
cblr-1794	315	20	where	where	SCONJ
cblr-1794	315	21	molecules	molecule	NOUN
cblr-1794	315	22	meet	meet	VERB
cblr-1794	315	23	certain	certain	ADJ
cblr-1794	315	24	tests	test	NOUN
cblr-1794	315	25	for	for	ADP
cblr-1794	315	26	establishing	establish	VERB
cblr-1794	315	27	'	'	PUNCT
cblr-1794	315	28	sameness	sameness	NOUN
cblr-1794	315	29	'	'	PUNCT
cblr-1794	315	30	through	through	ADP
cblr-1794	315	31	differentiated	differentiated	ADJ
cblr-1794	315	32	characterization	characterization	NOUN
cblr-1794	315	33	or	or	CCONJ
cblr-1794	315	34	other	other	ADJ
cblr-1794	315	35	technology	technology	NOUN
cblr-1794	315	36	.	.	PUNCT
cblr-1794	316	1	"o0	"o0	PROPN
cblr-1794	316	2	the	the	DET
cblr-1794	316	3	fda	fda	PROPN
cblr-1794	316	4	may	may	AUX
cblr-1794	316	5	also	also	ADV
cblr-1794	316	6	require	require	VERB
cblr-1794	316	7	"	"	PUNCT
cblr-1794	316	8	crossover	crossover	ADP
cblr-1794	316	9	trial	trial	NOUN
cblr-1794	316	10	designs	design	NOUN
cblr-1794	316	11	in	in	ADP
cblr-1794	316	12	which	which	PRON
cblr-1794	316	13	patients	patient	NOUN
cblr-1794	316	14	in	in	ADP
cblr-1794	316	15	clinical	clinical	ADJ
cblr-1794	316	16	trials	trial	NOUN
cblr-1794	316	17	switch	switch	VERB
cblr-1794	316	18	between	between	ADP
cblr-1794	316	19	the	the	DET
cblr-1794	316	20	products	product	NOUN
cblr-1794	316	21	over	over	ADP
cblr-1794	316	22	time	time	NOUN
cblr-1794	316	23	.	.	PUNCT
cblr-1794	317	1	"1	"1	NOUN
cblr-1794	317	2	o	o	INTJ
cblr-1794	317	3	however	however	ADV
cblr-1794	317	4	,	,	PUNCT
cblr-1794	317	5	patients	patient	NOUN
cblr-1794	317	6	are	be	AUX
cblr-1794	317	7	often	often	ADV
cblr-1794	317	8	leery	leery	ADJ
cblr-1794	317	9	of	of	ADP
cblr-1794	317	10	participating	participate	VERB
cblr-1794	317	11	in	in	ADP
cblr-1794	317	12	crossover	crossover	NOUN
cblr-1794	317	13	trials	trial	NOUN
cblr-1794	317	14	,	,	PUNCT
cblr-1794	317	15	and	and	CCONJ
cblr-1794	317	16	crossover	crossover	VERB
cblr-1794	317	17	trials	trial	NOUN
cblr-1794	317	18	are	be	AUX
cblr-1794	317	19	often	often	ADV
cblr-1794	317	20	even	even	ADV
cblr-1794	317	21	more	more	ADV
cblr-1794	317	22	expensive	expensive	ADJ
cblr-1794	317	23	than	than	ADP
cblr-1794	317	24	more	more	ADV
cblr-1794	317	25	typical	typical	ADJ
cblr-1794	317	26	trials	trial	NOUN
cblr-1794	317	27	.	.	PUNCT
cblr-1794	318	1	"1	"1	NOUN
cblr-1794	318	2	further	far	ADV
cblr-1794	318	3	,	,	PUNCT
cblr-1794	318	4	the	the	DET
cblr-1794	318	5	trade	trade	NOUN
cblr-1794	318	6	association	association	NOUN
cblr-1794	318	7	for	for	ADP
cblr-1794	318	8	biotechnology	biotechnology	NOUN
cblr-1794	318	9	companies	company	NOUN
cblr-1794	318	10	,	,	PUNCT
cblr-1794	318	11	the	the	DET
cblr-1794	318	12	biotechnology	biotechnology	NOUN
cblr-1794	318	13	industry	industry	NOUN
cblr-1794	318	14	organization	organization	NOUN
cblr-1794	318	15	,	,	PUNCT
cblr-1794	318	16	has	have	AUX
cblr-1794	318	17	argued	argue	VERB
cblr-1794	318	18	that	that	SCONJ
cblr-1794	318	19	an	an	DET
cblr-1794	318	20	interchangeability	interchangeability	NOUN
cblr-1794	318	21	rating	rating	NOUN
cblr-1794	318	22	should	should	AUX
cblr-1794	318	23	not	not	PART
cblr-1794	318	24	be	be	AUX
cblr-1794	318	25	granted	grant	VERB
cblr-1794	318	26	upon	upon	SCONJ
cblr-1794	318	27	first	first	ADJ
cblr-1794	318	28	marketing	marketing	NOUN
cblr-1794	318	29	approval	approval	NOUN
cblr-1794	318	30	,	,	PUNCT
cblr-1794	318	31	"	"	PUNCT
cblr-1794	318	32	absent	absent	ADJ
cblr-1794	318	33	compelling	compelling	ADJ
cblr-1794	318	34	data	datum	NOUN
cblr-1794	318	35	.	.	PUNCT
cblr-1794	319	1	"	"	PUNCT
cblr-1794	319	2	"	"	PUNCT
cblr-1794	319	3	2	2	NUM
cblr-1794	319	4	many	many	ADJ
cblr-1794	319	5	biosimilars	biosimilar	NOUN
cblr-1794	319	6	are	be	AUX
cblr-1794	319	7	therefore	therefore	ADV
cblr-1794	319	8	unlikely	unlikely	ADJ
cblr-1794	319	9	to	to	PART
cblr-1794	319	10	have	have	VERB
cblr-1794	319	11	an	an	DET
cblr-1794	319	12	interchangeability	interchangeability	NOUN
cblr-1794	319	13	rating	rating	NOUN
cblr-1794	319	14	.	.	PUNCT
cblr-1794	320	1	the	the	DET
cblr-1794	320	2	lack	lack	NOUN
cblr-1794	320	3	of	of	ADP
cblr-1794	320	4	interchangeability	interchangeability	NOUN
cblr-1794	320	5	is	be	AUX
cblr-1794	320	6	"	"	PUNCT
cblr-1794	320	7	likely	likely	ADJ
cblr-1794	320	8	to	to	PART
cblr-1794	320	9	dampen	dampen	VERB
cblr-1794	320	10	how	how	SCONJ
cblr-1794	320	11	quickly	quickly	ADV
cblr-1794	320	12	a	a	DET
cblr-1794	320	13	[	[	X
cblr-1794	320	14	biosimilar	biosimilar	NOUN
cblr-1794	320	15	]	]	X
cblr-1794	320	16	manufacturer	manufacturer	NOUN
cblr-1794	320	17	acquires	acquire	VERB
cblr-1794	320	18	market	market	NOUN
cblr-1794	320	19	share	share	NOUN
cblr-1794	320	20	compared	compare	VERB
cblr-1794	320	21	to	to	ADP
cblr-1794	320	22	generic	generic	ADJ
cblr-1794	320	23	drug	drug	NOUN
cblr-1794	320	24	entry	entry	NOUN
cblr-1794	320	25	.	.	PUNCT
cblr-1794	321	1	"	"	PUNCT
cblr-1794	321	2	"	"	PUNCT
cblr-1794	321	3	3	3	NUM
cblr-1794	321	4	when	when	SCONJ
cblr-1794	321	5	a	a	DET
cblr-1794	321	6	generic	generic	ADJ
cblr-1794	321	7	is	be	AUX
cblr-1794	321	8	deemed	deem	VERB
cblr-1794	321	9	bioequivalent	bioequivalent	NOUN
cblr-1794	321	10	to	to	ADP
cblr-1794	321	11	a	a	DET
cblr-1794	321	12	reference	reference	NOUN
cblr-1794	321	13	product	product	NOUN
cblr-1794	321	14	,	,	PUNCT
cblr-1794	321	15	pharmacies	pharmacy	NOUN
cblr-1794	321	16	can	can	AUX
cblr-1794	321	17	automatically	automatically	ADV
cblr-1794	321	18	substitute	substitute	VERB
cblr-1794	321	19	the	the	DET
cblr-1794	321	20	generic	generic	ADJ
cblr-1794	321	21	product	product	NOUN
cblr-1794	321	22	without	without	ADP
cblr-1794	321	23	physician	physician	NOUN
cblr-1794	321	24	approval	approval	NOUN
cblr-1794	321	25	.	.	PUNCT
cblr-1794	321	26	"	"	PUNCT
cblr-1794	322	1	4	4	NUM
cblr-1794	322	2	this	this	PRON
cblr-1794	322	3	drives	drive	VERB
cblr-1794	322	4	rapid	rapid	ADJ
cblr-1794	322	5	market	market	NOUN
cblr-1794	322	6	share	share	NOUN
cblr-1794	322	7	loss	loss	NOUN
cblr-1794	322	8	by	by	ADP
cblr-1794	322	9	the	the	DET
cblr-1794	322	10	reference	reference	NOUN
cblr-1794	322	11	product	product	NOUN
cblr-1794	322	12	as	as	ADV
cblr-1794	322	13	soon	soon	ADV
cblr-1794	322	14	as	as	SCONJ
cblr-1794	322	15	the	the	DET
cblr-1794	322	16	first	first	ADJ
cblr-1794	322	17	generic	generic	ADJ
cblr-1794	322	18	enters	enter	VERB
cblr-1794	322	19	107	107	NUM
cblr-1794	322	20	see	see	VERB
cblr-1794	322	21	supra	supra	PROPN
cblr-1794	322	22	notes	note	VERB
cblr-1794	322	23	68	68	NUM
cblr-1794	322	24	-	-	SYM
cblr-1794	322	25	70	70	NUM
cblr-1794	322	26	and	and	CCONJ
cblr-1794	322	27	accompanying	accompany	VERB
cblr-1794	322	28	text	text	NOUN
cblr-1794	322	29	.	.	PUNCT
cblr-1794	323	1	108	108	NUM
cblr-1794	323	2	see	see	VERB
cblr-1794	323	3	generally	generally	ADV
cblr-1794	323	4	paradise	paradise	NOUN
cblr-1794	323	5	,	,	PUNCT
cblr-1794	323	6	supra	supra	PROPN
cblr-1794	323	7	note	note	NOUN
cblr-1794	323	8	90	90	NUM
cblr-1794	323	9	,	,	PUNCT
cblr-1794	323	10	at	at	ADP
cblr-1794	323	11	291	291	NUM
cblr-1794	323	12	(	(	PUNCT
cblr-1794	323	13	stating	state	VERB
cblr-1794	323	14	that	that	SCONJ
cblr-1794	323	15	the	the	DET
cblr-1794	323	16	industry	industry	NOUN
cblr-1794	323	17	is	be	AUX
cblr-1794	323	18	"	"	PUNCT
cblr-1794	323	19	eagerly	eagerly	ADV
cblr-1794	323	20	awaiting	await	VERB
cblr-1794	323	21	"	"	PUNCT
cblr-1794	323	22	news	news	NOUN
cblr-1794	323	23	regarding	regard	VERB
cblr-1794	323	24	how	how	SCONJ
cblr-1794	323	25	the	the	DET
cblr-1794	323	26	fda	fda	PROPN
cblr-1794	323	27	will	will	AUX
cblr-1794	323	28	interpret	interpret	VERB
cblr-1794	323	29	the	the	DET
cblr-1794	323	30	interchangeability	interchangeability	NOUN
cblr-1794	323	31	provisions	provision	NOUN
cblr-1794	323	32	of	of	ADP
cblr-1794	323	33	the	the	DET
cblr-1794	323	34	bpcia	bpcia	NOUN
cblr-1794	323	35	)	)	PUNCT
cblr-1794	323	36	.	.	PUNCT
cblr-1794	324	1	109	109	NUM
cblr-1794	324	2	grabowski	grabowski	PROPN
cblr-1794	324	3	et	et	PROPN
cblr-1794	324	4	al	al	PROPN
cblr-1794	324	5	.	.	PROPN
cblr-1794	324	6	,	,	PUNCT
cblr-1794	324	7	supra	supra	PROPN
cblr-1794	324	8	note	note	PROPN
cblr-1794	324	9	85	85	NUM
cblr-1794	324	10	,	,	PUNCT
cblr-1794	324	11	at	at	ADP
cblr-1794	324	12	519	519	NUM
cblr-1794	324	13	.	.	PUNCT
cblr-1794	325	1	110	110	NUM
cblr-1794	325	2	i	i	PRON
cblr-1794	325	3	d.	d.	VERB
cblr-1794	325	4	at	at	ADP
cblr-1794	325	5	524	524	NUM
cblr-1794	325	6	.	.	SYM
cblr-1794	325	7	111	111	NUM
cblr-1794	326	1	i	i	PROPN
cblr-1794	326	2	d.	d.	NOUN
cblr-1794	326	3	112	112	NUM
cblr-1794	326	4	letter	letter	NOUN
cblr-1794	326	5	from	from	ADP
cblr-1794	326	6	the	the	DET
cblr-1794	326	7	biotech	biotech	NOUN
cblr-1794	326	8	.	.	PUNCT
cblr-1794	327	1	indus	indus	PROPN
cblr-1794	327	2	.	.	PUNCT
cblr-1794	328	1	org	org	PROPN
cblr-1794	328	2	.	.	PUNCT
cblr-1794	329	1	to	to	ADP
cblr-1794	329	2	the	the	DET
cblr-1794	329	3	fda	fda	PROPN
cblr-1794	329	4	(	(	PUNCT
cblr-1794	329	5	dec	dec	PROPN
cblr-1794	329	6	.	.	PROPN
cblr-1794	329	7	23	23	NUM
cblr-1794	329	8	,	,	PUNCT
cblr-1794	329	9	2010	2010	NUM
cblr-1794	329	10	)	)	PUNCT
cblr-1794	329	11	,	,	PUNCT
cblr-1794	329	12	available	available	ADJ
cblr-1794	329	13	at	at	ADP
cblr-1794	329	14	http://www.bio.org/advocacy/letters/bio-comments-food-anddrug-administration-approval-pathway-biosimilar-and-interchan	http://www.bio.org/advocacy/letters/bio-comments-food-anddrug-administration-approval-pathway-biosimilar-and-interchan	PROPN
cblr-1794	329	15	.	.	PUNCT
cblr-1794	330	1	113	113	NUM
cblr-1794	330	2	ftc	ftc	PROPN
cblr-1794	330	3	report	report	NOUN
cblr-1794	330	4	,	,	PUNCT
cblr-1794	330	5	supra	supra	PROPN
cblr-1794	330	6	note	note	PROPN
cblr-1794	330	7	14	14	NUM
cblr-1794	330	8	,	,	PUNCT
cblr-1794	330	9	at	at	ADP
cblr-1794	330	10	16	16	NUM
cblr-1794	330	11	.	.	PUNCT
cblr-1794	330	12	114	114	NUM
cblr-1794	330	13	grabowski	grabowski	PROPN
cblr-1794	330	14	et	et	PROPN
cblr-1794	330	15	al	al	PROPN
cblr-1794	330	16	.	.	PROPN
cblr-1794	330	17	,	,	PUNCT
cblr-1794	330	18	supra	supra	PROPN
cblr-1794	330	19	note	note	PROPN
cblr-1794	330	20	85	85	NUM
cblr-1794	330	21	,	,	PUNCT
cblr-1794	330	22	at	at	ADP
cblr-1794	330	23	524	524	NUM
cblr-1794	330	24	.	.	PUNCT
cblr-1794	331	1	bpcia	bpcia	NOUN
cblr-1794	331	2	:	:	PUNCT
cblr-1794	331	3	destined	destine	VERB
cblr-1794	331	4	for	for	ADP
cblr-1794	331	5	failure	failure	NOUN
cblr-1794	331	6	?	?	PUNCT
cblr-1794	332	1	227no	227no	PROPN
cblr-1794	332	2	.	.	PUNCT
cblr-1794	333	1	1:209	1:209	NUM
cblr-1794	333	2	]	]	X
cblr-1794	333	3	the	the	DET
cblr-1794	333	4	market.115	market.115	PROPN
cblr-1794	333	5	products	product	NOUN
cblr-1794	333	6	deemed	deem	VERB
cblr-1794	333	7	bioequivalent	bioequivalent	NOUN
cblr-1794	333	8	"	"	PUNCT
cblr-1794	333	9	achieve	achieve	VERB
cblr-1794	333	10	upwards	upwards	ADV
cblr-1794	333	11	of	of	ADP
cblr-1794	333	12	a	a	DET
cblr-1794	333	13	90	90	NUM
cblr-1794	333	14	-	-	PUNCT
cblr-1794	333	15	95	95	NUM
cblr-1794	333	16	%	%	NOUN
cblr-1794	333	17	substitution	substitution	NOUN
cblr-1794	333	18	rate	rate	NOUN
cblr-1794	333	19	in	in	ADP
cblr-1794	333	20	as	as	ADV
cblr-1794	333	21	little	little	ADJ
cblr-1794	333	22	as	as	ADP
cblr-1794	333	23	one	one	NUM
cblr-1794	333	24	month	month	NOUN
cblr-1794	333	25	following	follow	VERB
cblr-1794	333	26	introduction	introduction	NOUN
cblr-1794	333	27	.	.	PUNCT
cblr-1794	334	1	"	"	PUNCT
cblr-1794	334	2	"	"	PUNCT
cblr-1794	334	3	'	'	PUNCT
cblr-1794	334	4	then	then	ADV
cblr-1794	334	5	,	,	PUNCT
cblr-1794	334	6	as	as	SCONJ
cblr-1794	334	7	subsequent	subsequent	ADJ
cblr-1794	334	8	generics	generic	NOUN
cblr-1794	334	9	are	be	AUX
cblr-1794	334	10	licensed	license	VERB
cblr-1794	334	11	,	,	PUNCT
cblr-1794	334	12	the	the	DET
cblr-1794	334	13	generics	generic	NOUN
cblr-1794	334	14	compete	compete	VERB
cblr-1794	334	15	for	for	ADP
cblr-1794	334	16	market	market	NOUN
cblr-1794	334	17	share	share	NOUN
cblr-1794	334	18	among	among	ADP
cblr-1794	334	19	themselves	themselves	PRON
cblr-1794	334	20	,	,	PUNCT
cblr-1794	334	21	quickly	quickly	ADV
cblr-1794	334	22	decreasing	decrease	VERB
cblr-1794	334	23	the	the	DET
cblr-1794	334	24	price	price	NOUN
cblr-1794	334	25	of	of	ADP
cblr-1794	334	26	obtaining	obtain	VERB
cblr-1794	334	27	the	the	DET
cblr-1794	334	28	drug.117	drug.117	NOUN
cblr-1794	334	29	however	however	ADV
cblr-1794	334	30	,	,	PUNCT
cblr-1794	334	31	the	the	DET
cblr-1794	334	32	lack	lack	NOUN
cblr-1794	334	33	of	of	ADP
cblr-1794	334	34	an	an	DET
cblr-1794	334	35	interchangeability	interchangeability	NOUN
cblr-1794	334	36	rating	rating	NOUN
cblr-1794	334	37	will	will	AUX
cblr-1794	334	38	prevent	prevent	VERB
cblr-1794	334	39	biosimilars	biosimilar	NOUN
cblr-1794	334	40	from	from	ADP
cblr-1794	334	41	being	be	AUX
cblr-1794	334	42	automatically	automatically	ADV
cblr-1794	334	43	substituted	substitute	VERB
cblr-1794	334	44	by	by	ADP
cblr-1794	334	45	pharmacists	pharmacist	NOUN
cblr-1794	334	46	without	without	ADP
cblr-1794	334	47	physician	physician	NOUN
cblr-1794	334	48	approval	approval	NOUN
cblr-1794	334	49	.	.	PUNCT
cblr-1794	335	1	"	"	PUNCT
cblr-1794	335	2	'	'	PUNCT
cblr-1794	335	3	physicians	physician	NOUN
cblr-1794	335	4	often	often	ADV
cblr-1794	335	5	exhibit	exhibit	VERB
cblr-1794	335	6	high	high	ADJ
cblr-1794	335	7	levels	level	NOUN
cblr-1794	335	8	of	of	ADP
cblr-1794	335	9	brand	brand	NOUN
cblr-1794	335	10	loyalty;119	loyalty;119	PROPN
cblr-1794	335	11	therefore	therefore	ADV
cblr-1794	335	12	,	,	PUNCT
cblr-1794	335	13	it	it	PRON
cblr-1794	335	14	will	will	AUX
cblr-1794	335	15	take	take	VERB
cblr-1794	335	16	longer	long	ADV
cblr-1794	335	17	for	for	ADP
cblr-1794	335	18	biosimilars	biosimilar	NOUN
cblr-1794	335	19	to	to	ADP
cblr-1794	335	20	"	"	PUNCT
cblr-1794	335	21	significant	significant	ADJ
cblr-1794	335	22	market	market	NOUN
cblr-1794	335	23	share	share	NOUN
cblr-1794	335	24	.	.	PUNCT
cblr-1794	336	1	"120	"120	PROPN
cblr-1794	336	2	brand	brand	PROPN
cblr-1794	336	3	manufacturers	manufacturer	NOUN
cblr-1794	336	4	will	will	AUX
cblr-1794	336	5	have	have	VERB
cblr-1794	336	6	less	less	ADJ
cblr-1794	336	7	incentive	incentive	NOUN
cblr-1794	336	8	to	to	PART
cblr-1794	336	9	compete	compete	VERB
cblr-1794	336	10	based	base	VERB
cblr-1794	336	11	on	on	ADP
cblr-1794	336	12	price	price	NOUN
cblr-1794	336	13	,	,	PUNCT
cblr-1794	336	14	and	and	CCONJ
cblr-1794	336	15	instead	instead	ADV
cblr-1794	336	16	will	will	AUX
cblr-1794	336	17	likely	likely	ADV
cblr-1794	336	18	"	"	PUNCT
cblr-1794	336	19	try	try	VERB
cblr-1794	336	20	to	to	PART
cblr-1794	336	21	out	out	ADJ
cblr-1794	336	22	-	-	PUNCT
cblr-1794	336	23	market	market	NOUN
cblr-1794	336	24	the	the	DET
cblr-1794	336	25	biosimilar	biosimilar	NOUN
cblr-1794	336	26	.	.	PUNCT
cblr-1794	337	1	"121	"121	PROPN
cblr-1794	337	2	the	the	DET
cblr-1794	337	3	introduction	introduction	NOUN
cblr-1794	337	4	of	of	ADP
cblr-1794	337	5	a	a	DET
cblr-1794	337	6	non	non	ADJ
cblr-1794	337	7	-	-	ADJ
cblr-1794	337	8	interchangeable	interchangeable	ADJ
cblr-1794	337	9	biosimilar	biosimilar	NOUN
cblr-1794	337	10	is	be	AUX
cblr-1794	337	11	thus	thus	ADV
cblr-1794	337	12	unlikely	unlikely	ADJ
cblr-1794	337	13	to	to	PART
cblr-1794	337	14	decrease	decrease	VERB
cblr-1794	337	15	prices	price	NOUN
cblr-1794	337	16	as	as	ADV
cblr-1794	337	17	significantly	significantly	ADV
cblr-1794	337	18	as	as	ADP
cblr-1794	337	19	the	the	DET
cblr-1794	337	20	introduction	introduction	NOUN
cblr-1794	337	21	of	of	ADP
cblr-1794	337	22	a	a	DET
cblr-1794	337	23	bioequivalent	bioequivalent	NOUN
cblr-1794	337	24	generic	generic	ADJ
cblr-1794	337	25	.	.	PUNCT
cblr-1794	338	1	further	far	ADV
cblr-1794	338	2	,	,	PUNCT
cblr-1794	338	3	biosimilars	biosimilar	VERB
cblr-1794	338	4	that	that	PRON
cblr-1794	338	5	are	be	AUX
cblr-1794	338	6	not	not	PART
cblr-1794	338	7	rated	rate	VERB
cblr-1794	338	8	as	as	ADP
cblr-1794	338	9	interchangeable	interchangeable	ADJ
cblr-1794	338	10	may	may	AUX
cblr-1794	338	11	be	be	AUX
cblr-1794	338	12	viewed	view	VERB
cblr-1794	338	13	skeptically	skeptically	ADV
cblr-1794	338	14	by	by	ADP
cblr-1794	338	15	both	both	DET
cblr-1794	338	16	physicians	physician	NOUN
cblr-1794	338	17	and	and	CCONJ
cblr-1794	338	18	115	115	NUM
cblr-1794	338	19	grabowski	grabowski	PROPN
cblr-1794	338	20	et	et	PROPN
cblr-1794	338	21	al	al	PROPN
cblr-1794	338	22	.	.	PROPN
cblr-1794	338	23	,	,	PUNCT
cblr-1794	338	24	supra	supra	PROPN
cblr-1794	338	25	note	note	PROPN
cblr-1794	338	26	85	85	NUM
cblr-1794	338	27	,	,	PUNCT
cblr-1794	338	28	at	at	ADP
cblr-1794	338	29	524	524	NUM
cblr-1794	338	30	.	.	PUNCT
cblr-1794	338	31	116	116	NUM
cblr-1794	338	32	letter	letter	NOUN
cblr-1794	338	33	from	from	ADP
cblr-1794	338	34	the	the	DET
cblr-1794	338	35	coalition	coalition	NOUN
cblr-1794	338	36	for	for	ADP
cblr-1794	338	37	a	a	DET
cblr-1794	338	38	competitive	competitive	ADJ
cblr-1794	338	39	pharmaceutical	pharmaceutical	ADJ
cblr-1794	338	40	mkt	mkt	PROPN
cblr-1794	338	41	.	.	PUNCT
cblr-1794	339	1	(	(	PUNCT
cblr-1794	339	2	"	"	PUNCT
cblr-1794	339	3	ccpm	ccpm	PROPN
cblr-1794	339	4	"	"	PUNCT
cblr-1794	339	5	)	)	PUNCT
cblr-1794	339	6	to	to	ADP
cblr-1794	339	7	the	the	DET
cblr-1794	339	8	ftc	ftc	PROPN
cblr-1794	339	9	(	(	PUNCT
cblr-1794	339	10	sept	sept	PROPN
cblr-1794	339	11	.	.	PROPN
cblr-1794	339	12	30	30	NUM
cblr-1794	339	13	,	,	PUNCT
cblr-1794	339	14	2008	2008	NUM
cblr-1794	339	15	)	)	PUNCT
cblr-1794	339	16	,	,	PUNCT
cblr-1794	339	17	available	available	ADJ
cblr-1794	339	18	at	at	ADP
cblr-1794	339	19	http://www.ftc.gov/os/	http://www.ftc.gov/os/	PROPN
cblr-1794	339	20	comments	comment	NOUN
cblr-1794	339	21	/	/	SYM
cblr-1794	339	22	healthcarecompissues/537778	healthcarecompissues/537778	NOUN
cblr-1794	339	23	-	-	PUNCT
cblr-1794	339	24	00012.pdf	00012.pdf	NOUN
cblr-1794	339	25	.	.	PUNCT
cblr-1794	340	1	117	117	NUM
cblr-1794	340	2	ftc	ftc	PROPN
cblr-1794	340	3	report	report	NOUN
cblr-1794	340	4	,	,	PUNCT
cblr-1794	340	5	supra	supra	PROPN
cblr-1794	340	6	note	note	PROPN
cblr-1794	340	7	14	14	NUM
cblr-1794	340	8	,	,	PUNCT
cblr-1794	340	9	at	at	ADP
cblr-1794	340	10	16	16	NUM
cblr-1794	340	11	.	.	PUNCT
cblr-1794	340	12	118	118	NUM
cblr-1794	341	1	i	i	NOUN
cblr-1794	341	2	d.	d.	PROPN
cblr-1794	341	3	119	119	NUM
cblr-1794	342	1	grabowski	grabowski	PROPN
cblr-1794	342	2	et	et	PROPN
cblr-1794	342	3	al	al	PROPN
cblr-1794	342	4	.	.	PROPN
cblr-1794	342	5	,	,	PUNCT
cblr-1794	342	6	supra	supra	PROPN
cblr-1794	342	7	note	note	PROPN
cblr-1794	342	8	85	85	NUM
cblr-1794	342	9	,	,	PUNCT
cblr-1794	342	10	at	at	ADP
cblr-1794	342	11	527	527	NUM
cblr-1794	342	12	(	(	PUNCT
cblr-1794	342	13	explaining	explain	VERB
cblr-1794	342	14	that	that	SCONJ
cblr-1794	342	15	rates	rate	NOUN
cblr-1794	342	16	of	of	ADP
cblr-1794	342	17	biosimilar	biosimilar	ADJ
cblr-1794	342	18	acceptance	acceptance	NOUN
cblr-1794	342	19	may	may	AUX
cblr-1794	342	20	vary	vary	VERB
cblr-1794	342	21	according	accord	VERB
cblr-1794	342	22	to	to	ADP
cblr-1794	342	23	whether	whether	SCONJ
cblr-1794	342	24	the	the	DET
cblr-1794	342	25	physician	physician	NOUN
cblr-1794	342	26	's	's	PART
cblr-1794	342	27	specialty	specialty	NOUN
cblr-1794	342	28	exhibits	exhibit	VERB
cblr-1794	342	29	high	high	ADJ
cblr-1794	342	30	levels	level	NOUN
cblr-1794	342	31	of	of	ADP
cblr-1794	342	32	brand	brand	NOUN
cblr-1794	342	33	loyalty	loyalty	NOUN
cblr-1794	342	34	)	)	PUNCT
cblr-1794	342	35	.	.	PUNCT
cblr-1794	343	1	120	120	NUM
cblr-1794	343	2	letter	letter	NOUN
cblr-1794	343	3	from	from	ADP
cblr-1794	343	4	the	the	DET
cblr-1794	343	5	ccpm	ccpm	NOUN
cblr-1794	343	6	to	to	ADP
cblr-1794	343	7	the	the	DET
cblr-1794	343	8	ftc	ftc	PROPN
cblr-1794	343	9	,	,	PUNCT
cblr-1794	343	10	supra	supra	PROPN
cblr-1794	343	11	note	note	PROPN
cblr-1794	343	12	116	116	NUM
cblr-1794	343	13	,	,	PUNCT
cblr-1794	343	14	at	at	ADP
cblr-1794	343	15	3	3	NUM
cblr-1794	343	16	.	.	NUM
cblr-1794	343	17	121	121	NUM
cblr-1794	344	1	i	i	PRON
cblr-1794	344	2	d.	d.	PROPN
cblr-1794	344	3	see	see	VERB
cblr-1794	344	4	also	also	ADV
cblr-1794	344	5	letter	letter	VERB
cblr-1794	344	6	from	from	ADP
cblr-1794	344	7	kelsey	kelsey	PROPN
cblr-1794	344	8	i.	i.	PROPN
cblr-1794	344	9	nix	nix	PROPN
cblr-1794	344	10	,	,	PUNCT
cblr-1794	344	11	partner	partner	NOUN
cblr-1794	344	12	,	,	PUNCT
cblr-1794	344	13	willkie	willkie	PROPN
cblr-1794	344	14	farr	farr	PROPN
cblr-1794	344	15	&	&	CCONJ
cblr-1794	344	16	gallagher	gallagher	PROPN
cblr-1794	344	17	llp	llp	PROPN
cblr-1794	344	18	,	,	PUNCT
cblr-1794	344	19	to	to	ADP
cblr-1794	344	20	the	the	DET
cblr-1794	344	21	ftc	ftc	PROPN
cblr-1794	344	22	5	5	NUM
cblr-1794	344	23	(	(	PUNCT
cblr-1794	344	24	dec	dec	PROPN
cblr-1794	344	25	.	.	PROPN
cblr-1794	344	26	22	22	NUM
cblr-1794	344	27	,	,	PUNCT
cblr-1794	344	28	2008	2008	NUM
cblr-1794	344	29	)	)	PUNCT
cblr-1794	344	30	,	,	PUNCT
cblr-1794	344	31	available	available	ADJ
cblr-1794	344	32	at	at	ADP
cblr-1794	344	33	http://	http://	PROPN
cblr-1794	344	34	www.ftc.gov/os/comments/healthcarecompissues/537778-00036.pdf	www.ftc.gov/os/comments/healthcarecompissues/537778-00036.pdf	PROPN
cblr-1794	344	35	(	(	PUNCT
cblr-1794	344	36	"	"	PUNCT
cblr-1794	344	37	without	without	ADP
cblr-1794	344	38	an	an	DET
cblr-1794	344	39	'	'	PUNCT
cblr-1794	344	40	interchangeable	interchangeable	ADJ
cblr-1794	344	41	'	'	PUNCT
cblr-1794	344	42	designation	designation	NOUN
cblr-1794	344	43	,	,	PUNCT
cblr-1794	344	44	biosimilar	biosimilar	ADJ
cblr-1794	344	45	companies	company	NOUN
cblr-1794	344	46	would	would	AUX
cblr-1794	344	47	be	be	AUX
cblr-1794	344	48	compelled	compel	VERB
cblr-1794	344	49	to	to	PART
cblr-1794	344	50	invest	invest	VERB
cblr-1794	344	51	significant	significant	ADJ
cblr-1794	344	52	sums	sum	NOUN
cblr-1794	344	53	to	to	ADP
cblr-1794	344	54	market	market	NOUN
cblr-1794	344	55	and	and	CCONJ
cblr-1794	344	56	promote	promote	VERB
cblr-1794	344	57	biosimilars	biosimilar	NOUN
cblr-1794	344	58	,	,	PUNCT
cblr-1794	344	59	thus	thus	ADV
cblr-1794	344	60	driving	drive	VERB
cblr-1794	344	61	up	up	ADP
cblr-1794	344	62	the	the	DET
cblr-1794	344	63	cost	cost	NOUN
cblr-1794	344	64	to	to	ADP
cblr-1794	344	65	the	the	DET
cblr-1794	344	66	consumer	consumer	NOUN
cblr-1794	344	67	.	.	PUNCT
cblr-1794	345	1	reference	reference	NOUN
cblr-1794	345	2	companies	company	NOUN
cblr-1794	345	3	also	also	ADV
cblr-1794	345	4	would	would	AUX
cblr-1794	345	5	have	have	VERB
cblr-1794	345	6	less	less	ADJ
cblr-1794	345	7	incentive	incentive	NOUN
cblr-1794	345	8	to	to	PART
cblr-1794	345	9	compete	compete	VERB
cblr-1794	345	10	on	on	ADP
cblr-1794	345	11	price	price	NOUN
cblr-1794	345	12	.	.	PUNCT
cblr-1794	346	1	reference	reference	NOUN
cblr-1794	346	2	drug	drug	NOUN
cblr-1794	346	3	companies	company	NOUN
cblr-1794	346	4	would	would	AUX
cblr-1794	346	5	more	more	ADV
cblr-1794	346	6	likely	likely	ADV
cblr-1794	346	7	try	try	VERB
cblr-1794	346	8	to	to	PART
cblr-1794	346	9	out	out	NOUN
cblr-1794	346	10	-	-	PUNCT
cblr-1794	346	11	market	market	NOUN
cblr-1794	346	12	the	the	DET
cblr-1794	346	13	biosimilar	biosimilar	PROPN
cblr-1794	346	14	companies	company	NOUN
cblr-1794	346	15	,	,	PUNCT
cblr-1794	346	16	further	far	ADV
cblr-1794	346	17	driving	drive	VERB
cblr-1794	346	18	up	up	ADP
cblr-1794	346	19	the	the	DET
cblr-1794	346	20	costs	cost	NOUN
cblr-1794	346	21	of	of	ADP
cblr-1794	346	22	both	both	CCONJ
cblr-1794	346	23	the	the	DET
cblr-1794	346	24	reference	reference	NOUN
cblr-1794	346	25	drug	drug	NOUN
cblr-1794	346	26	and	and	CCONJ
cblr-1794	346	27	market	market	NOUN
cblr-1794	346	28	entry	entry	NOUN
cblr-1794	346	29	by	by	ADP
cblr-1794	346	30	the	the	DET
cblr-1794	346	31	biosimilar	biosimilar	NOUN
cblr-1794	346	32	.	.	PUNCT
cblr-1794	346	33	"	"	PUNCT
cblr-1794	346	34	)	)	PUNCT
cblr-1794	346	35	.	.	PUNCT
cblr-1794	347	1	[	[	X
cblr-1794	347	2	vol	vol	NOUN
cblr-1794	347	3	.	.	PUNCT
cblr-1794	348	1	2013228	2013228	NUM
cblr-1794	348	2	col	col	PROPN
cblr-1794	348	3	umia	umia	PROPN
cblr-1794	348	4	b	b	PROPN
cblr-1794	348	5	usiness	usiness	PROPN
cblr-1794	348	6	la	la	PROPN
cblr-1794	348	7	w	w	PROPN
cblr-1794	348	8	re	re	PROPN
cblr-1794	348	9	vie	vie	PROPN
cblr-1794	348	10	w	w	PROPN
cblr-1794	348	11	patients.1	patients.1	PROPN
cblr-1794	348	12	22	22	NUM
cblr-1794	348	13	physicians	physician	NOUN
cblr-1794	348	14	and	and	CCONJ
cblr-1794	348	15	patients	patient	NOUN
cblr-1794	348	16	are	be	AUX
cblr-1794	348	17	both	both	ADV
cblr-1794	348	18	quite	quite	ADV
cblr-1794	348	19	familiar	familiar	ADJ
cblr-1794	348	20	with	with	ADP
cblr-1794	348	21	generic	generic	ADJ
cblr-1794	348	22	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	348	23	,	,	PUNCT
cblr-1794	348	24	but	but	CCONJ
cblr-1794	348	25	may	may	AUX
cblr-1794	348	26	be	be	AUX
cblr-1794	348	27	more	more	ADV
cblr-1794	348	28	reluctant	reluctant	ADJ
cblr-1794	348	29	to	to	PART
cblr-1794	348	30	substitute	substitute	VERB
cblr-1794	348	31	a	a	DET
cblr-1794	348	32	biosimilar	biosimilar	NOUN
cblr-1794	348	33	until	until	SCONJ
cblr-1794	348	34	"	"	PUNCT
cblr-1794	348	35	sufficient	sufficient	ADJ
cblr-1794	348	36	experience	experience	NOUN
cblr-1794	348	37	has	have	AUX
cblr-1794	348	38	accumulated	accumulate	VERB
cblr-1794	348	39	in	in	ADP
cblr-1794	348	40	clinical	clinical	ADJ
cblr-1794	348	41	practice	practice	NOUN
cblr-1794	348	42	settings	setting	NOUN
cblr-1794	348	43	,	,	PUNCT
cblr-1794	348	44	as	as	SCONJ
cblr-1794	348	45	opposed	oppose	VERB
cblr-1794	348	46	to	to	ADP
cblr-1794	348	47	clinical	clinical	ADJ
cblr-1794	348	48	trials	trial	NOUN
cblr-1794	348	49	.	.	PUNCT
cblr-1794	348	50	"123	"123	PROPN
cblr-1794	349	1	this	this	DET
cblr-1794	349	2	reluctance	reluctance	NOUN
cblr-1794	349	3	may	may	AUX
cblr-1794	349	4	be	be	AUX
cblr-1794	349	5	even	even	ADV
cblr-1794	349	6	greater	great	ADJ
cblr-1794	349	7	if	if	SCONJ
cblr-1794	349	8	the	the	DET
cblr-1794	349	9	biosimilar	biosimilar	NOUN
cblr-1794	349	10	and	and	CCONJ
cblr-1794	349	11	reference	reference	NOUN
cblr-1794	349	12	product	product	NOUN
cblr-1794	349	13	do	do	AUX
cblr-1794	349	14	not	not	PART
cblr-1794	349	15	share	share	VERB
cblr-1794	349	16	the	the	DET
cblr-1794	349	17	same	same	ADJ
cblr-1794	349	18	name	name	NOUN
cblr-1794	349	19	.	.	PUNCT
cblr-1794	350	1	124	124	NUM
cblr-1794	351	1	the	the	DET
cblr-1794	351	2	fda	fda	PROPN
cblr-1794	351	3	typically	typically	ADV
cblr-1794	351	4	permits	permit	VERB
cblr-1794	351	5	a	a	DET
cblr-1794	351	6	generic	generic	ADJ
cblr-1794	351	7	pharmaceutical	pharmaceutical	NOUN
cblr-1794	351	8	to	to	PART
cblr-1794	351	9	use	use	VERB
cblr-1794	351	10	the	the	DET
cblr-1794	351	11	same	same	ADJ
cblr-1794	351	12	name	name	NOUN
cblr-1794	351	13	as	as	ADP
cblr-1794	351	14	the	the	DET
cblr-1794	351	15	reference	reference	NOUN
cblr-1794	351	16	branded	brand	VERB
cblr-1794	351	17	drug	drug	NOUN
cblr-1794	351	18	because	because	SCONJ
cblr-1794	351	19	both	both	DET
cblr-1794	351	20	products	product	NOUN
cblr-1794	351	21	possess	possess	VERB
cblr-1794	351	22	the	the	DET
cblr-1794	351	23	same	same	ADJ
cblr-1794	351	24	active	active	ADJ
cblr-1794	351	25	ingredient	ingredient	NOUN
cblr-1794	351	26	.	.	PUNCT
cblr-1794	352	1	125	125	NUM
cblr-1794	352	2	however	however	ADV
cblr-1794	352	3	,	,	PUNCT
cblr-1794	352	4	many	many	ADJ
cblr-1794	352	5	experts	expert	NOUN
cblr-1794	352	6	believe	believe	VERB
cblr-1794	352	7	that	that	SCONJ
cblr-1794	352	8	biosimilars	biosimilar	NOUN
cblr-1794	352	9	should	should	AUX
cblr-1794	352	10	not	not	PART
cblr-1794	352	11	be	be	AUX
cblr-1794	352	12	allowed	allow	VERB
cblr-1794	352	13	to	to	PART
cblr-1794	352	14	share	share	VERB
cblr-1794	352	15	the	the	DET
cblr-1794	352	16	same	same	ADJ
cblr-1794	352	17	name	name	NOUN
cblr-1794	352	18	as	as	ADP
cblr-1794	352	19	the	the	DET
cblr-1794	352	20	reference	reference	NOUN
cblr-1794	352	21	product	product	NOUN
cblr-1794	352	22	.	.	PUNCT
cblr-1794	353	1	12	12	NUM
cblr-1794	353	2	6	6	NUM
cblr-1794	353	3	the	the	DET
cblr-1794	353	4	fda	fda	PROPN
cblr-1794	353	5	has	have	AUX
cblr-1794	353	6	not	not	PART
cblr-1794	353	7	specified	specify	VERB
cblr-1794	353	8	the	the	DET
cblr-1794	353	9	manner	manner	NOUN
cblr-1794	353	10	in	in	ADP
cblr-1794	353	11	which	which	PRON
cblr-1794	353	12	names	name	NOUN
cblr-1794	353	13	will	will	AUX
cblr-1794	353	14	be	be	AUX
cblr-1794	353	15	assigned	assign	VERB
cblr-1794	353	16	to	to	ADP
cblr-1794	353	17	biosimilars	biosimilar	NOUN
cblr-1794	353	18	approved	approve	VERB
cblr-1794	353	19	under	under	ADP
cblr-1794	353	20	the	the	DET
cblr-1794	353	21	bpcia,1	bpcia,1	NOUN
cblr-1794	353	22	27	27	NUM
cblr-1794	353	23	although	although	SCONJ
cblr-1794	353	24	many	many	ADJ
cblr-1794	353	25	interest	interest	NOUN
cblr-1794	353	26	groups	group	NOUN
cblr-1794	353	27	have	have	AUX
cblr-1794	353	28	lobbied	lobby	VERB
cblr-1794	353	29	for	for	ADP
cblr-1794	353	30	unique	unique	ADJ
cblr-1794	353	31	names	name	NOUN
cblr-1794	353	32	for	for	ADP
cblr-1794	353	33	biologic	biologic	NOUN
cblr-1794	353	34	and	and	CCONJ
cblr-1794	353	35	biosimilar	biosimilar	VERB
cblr-1794	353	36	therapeutics.128	therapeutics.128	NOUN
cblr-1794	353	37	especially	especially	ADV
cblr-1794	353	38	if	if	SCONJ
cblr-1794	353	39	names	name	NOUN
cblr-1794	353	40	are	be	AUX
cblr-1794	353	41	different	different	ADJ
cblr-1794	353	42	,	,	PUNCT
cblr-1794	353	43	"	"	PUNCT
cblr-1794	353	44	physicians	physician	NOUN
cblr-1794	353	45	and	and	CCONJ
cblr-1794	353	46	their	their	PRON
cblr-1794	353	47	patients	patient	NOUN
cblr-1794	353	48	who	who	PRON
cblr-1794	353	49	have	have	AUX
cblr-1794	353	50	safely	safely	ADV
cblr-1794	353	51	been	be	AUX
cblr-1794	353	52	taking	take	VERB
cblr-1794	353	53	a	a	DET
cblr-1794	353	54	pioneer	pioneer	NOUN
cblr-1794	353	55	biologic	biologic	NOUN
cblr-1794	353	56	drug	drug	NOUN
cblr-1794	353	57	may	may	AUX
cblr-1794	353	58	be	be	AUX
cblr-1794	353	59	reluctant	reluctant	ADJ
cblr-1794	353	60	to	to	PART
cblr-1794	353	61	switch	switch	VERB
cblr-1794	353	62	to	to	ADP
cblr-1794	353	63	a	a	DET
cblr-1794	353	64	[	[	X
cblr-1794	353	65	biosimilar	biosimilar	NOUN
cblr-1794	353	66	]	]	X
cblr-1794	353	67	because	because	SCONJ
cblr-1794	353	68	of	of	ADP
cblr-1794	353	69	the	the	DET
cblr-1794	353	70	risk	risk	NOUN
cblr-1794	353	71	that	that	SCONJ
cblr-1794	353	72	the	the	DET
cblr-1794	353	73	patient	patient	NOUN
cblr-1794	353	74	will	will	AUX
cblr-1794	353	75	react	react	VERB
cblr-1794	353	76	differently	differently	ADV
cblr-1794	353	77	to	to	ADP
cblr-1794	353	78	the	the	DET
cblr-1794	353	79	new	new	ADJ
cblr-1794	353	80	drug	drug	NOUN
cblr-1794	353	81	.	.	PUNCT
cblr-1794	354	1	"12	"12	PROPN
cblr-1794	354	2	9	9	NUM
cblr-1794	354	3	thus	thus	ADV
cblr-1794	354	4	,	,	PUNCT
cblr-1794	354	5	biosimilar	biosimilar	ADJ
cblr-1794	354	6	substitution	substitution	NOUN
cblr-1794	354	7	will	will	AUX
cblr-1794	354	8	likely	likely	ADV
cblr-1794	354	9	be	be	AUX
cblr-1794	354	10	concentrated	concentrate	VERB
cblr-1794	354	11	among	among	ADP
cblr-1794	354	12	new	new	ADJ
cblr-1794	354	13	patients,3	patients,3	NOUN
cblr-1794	354	14	o	o	NOUN
cblr-1794	354	15	or	or	CCONJ
cblr-1794	354	16	those	those	DET
cblr-1794	354	17	122	122	NUM
cblr-1794	354	18	see	see	VERB
cblr-1794	354	19	generally	generally	ADV
cblr-1794	354	20	grabowski	grabowski	PROPN
cblr-1794	354	21	et	et	PROPN
cblr-1794	354	22	al	al	PROPN
cblr-1794	354	23	.	.	PROPN
cblr-1794	354	24	,	,	PUNCT
cblr-1794	354	25	supra	supra	PROPN
cblr-1794	354	26	note	note	PROPN
cblr-1794	354	27	85	85	NUM
cblr-1794	354	28	,	,	PUNCT
cblr-1794	354	29	at	at	ADP
cblr-1794	354	30	527	527	NUM
cblr-1794	354	31	-	-	SYM
cblr-1794	354	32	28	28	NUM
cblr-1794	354	33	(	(	PUNCT
cblr-1794	354	34	arguing	argue	VERB
cblr-1794	354	35	that	that	PRON
cblr-1794	354	36	physician	physician	NOUN
cblr-1794	354	37	acceptance	acceptance	NOUN
cblr-1794	354	38	of	of	ADP
cblr-1794	354	39	biosimilars	biosimilar	NOUN
cblr-1794	354	40	is	be	AUX
cblr-1794	354	41	expected	expect	VERB
cblr-1794	354	42	to	to	PART
cblr-1794	354	43	be	be	AUX
cblr-1794	354	44	lower	low	ADJ
cblr-1794	354	45	when	when	SCONJ
cblr-1794	354	46	the	the	DET
cblr-1794	354	47	biosimilar	biosimilar	NOUN
cblr-1794	354	48	lacks	lack	VERB
cblr-1794	354	49	an	an	DET
cblr-1794	354	50	interchangeability	interchangeability	NOUN
cblr-1794	354	51	rating	rating	NOUN
cblr-1794	354	52	)	)	PUNCT
cblr-1794	354	53	.	.	PUNCT
cblr-1794	355	1	123	123	NUM
cblr-1794	356	1	i	i	PRON
cblr-1794	356	2	d.	d.	VERB
cblr-1794	356	3	at	at	ADP
cblr-1794	356	4	528	528	NUM
cblr-1794	356	5	.	.	PUNCT
cblr-1794	356	6	124	124	NUM
cblr-1794	356	7	ftc	ftc	PROPN
cblr-1794	356	8	report	report	NOUN
cblr-1794	356	9	,	,	PUNCT
cblr-1794	356	10	supra	supra	PROPN
cblr-1794	356	11	note	note	PROPN
cblr-1794	356	12	14	14	NUM
cblr-1794	356	13	,	,	PUNCT
cblr-1794	356	14	at	at	ADP
cblr-1794	356	15	16	16	NUM
cblr-1794	356	16	.	.	PUNCT
cblr-1794	357	1	125	125	NUM
cblr-1794	357	2	i	i	PRON
cblr-1794	357	3	d.	d.	PROPN
cblr-1794	357	4	at	at	ADP
cblr-1794	357	5	16	16	NUM
cblr-1794	357	6	n.55	n.55	NOUN
cblr-1794	357	7	.	.	PROPN
cblr-1794	357	8	126	126	NUM
cblr-1794	357	9	see	see	VERB
cblr-1794	357	10	generally	generally	ADV
cblr-1794	357	11	world	world	NOUN
cblr-1794	357	12	health	health	NOUN
cblr-1794	357	13	org	org	NOUN
cblr-1794	357	14	.	.	PUNCT
cblr-1794	358	1	[	[	X
cblr-1794	358	2	"	"	PUNCT
cblr-1794	358	3	who	who	PRON
cblr-1794	358	4	"	"	PUNCT
cblr-1794	358	5	]	]	X
cblr-1794	358	6	,	,	PUNCT
cblr-1794	358	7	who	who	PRON
cblr-1794	358	8	informal	informal	ADJ
cblr-1794	358	9	consultation	consultation	NOUN
cblr-1794	358	10	on	on	ADP
cblr-1794	358	11	international	international	ADJ
cblr-1794	358	12	nonproprietary	nonproprietary	ADJ
cblr-1794	358	13	names	name	NOUN
cblr-1794	358	14	(	(	PUNCT
cblr-1794	358	15	inn	inn	PROPN
cblr-1794	358	16	)	)	PUNCT
cblr-1794	358	17	policy	policy	NOUN
cblr-1794	358	18	for	for	ADP
cblr-1794	358	19	biosimilar	biosimilar	ADJ
cblr-1794	358	20	products	product	NOUN
cblr-1794	358	21	,	,	PUNCT
cblr-1794	358	22	inn	inn	PROPN
cblr-1794	358	23	working	work	VERB
cblr-1794	358	24	doc	doc	PROPN
cblr-1794	358	25	.	.	PROPN
cblr-1794	358	26	07.211	07.211	NUM
cblr-1794	358	27	(	(	PUNCT
cblr-1794	358	28	sept	sept	PROPN
cblr-1794	358	29	.	.	PROPN
cblr-1794	358	30	4	4	NUM
cblr-1794	358	31	-	-	SYM
cblr-1794	358	32	5	5	NUM
cblr-1794	358	33	,	,	PUNCT
cblr-1794	358	34	2006	2006	NUM
cblr-1794	358	35	)	)	PUNCT
cblr-1794	358	36	,	,	PUNCT
cblr-1794	358	37	available	available	ADJ
cblr-1794	358	38	at	at	ADP
cblr-1794	358	39	www.who.int/medicines/services/inn/biosimilarsinnreport	www.who.int/medicines/services/inn/biosimilarsinnreport	PROPN
cblr-1794	358	40	.pdf	.pdf	PROPN
cblr-1794	358	41	.	.	PUNCT
cblr-1794	359	1	(	(	PUNCT
cblr-1794	359	2	discussing	discuss	VERB
cblr-1794	359	3	the	the	DET
cblr-1794	359	4	challenges	challenge	NOUN
cblr-1794	359	5	associated	associate	VERB
cblr-1794	359	6	with	with	ADP
cblr-1794	359	7	naming	name	VERB
cblr-1794	359	8	biosimilar	biosimilar	NOUN
cblr-1794	359	9	products	product	NOUN
cblr-1794	359	10	and	and	CCONJ
cblr-1794	359	11	questioning	question	VERB
cblr-1794	359	12	whether	whether	SCONJ
cblr-1794	359	13	a	a	DET
cblr-1794	359	14	biosimilar	biosimilar	NOUN
cblr-1794	359	15	should	should	AUX
cblr-1794	359	16	be	be	AUX
cblr-1794	359	17	assigned	assign	VERB
cblr-1794	359	18	the	the	DET
cblr-1794	359	19	same	same	ADJ
cblr-1794	359	20	name	name	NOUN
cblr-1794	359	21	as	as	ADP
cblr-1794	359	22	the	the	DET
cblr-1794	359	23	reference	reference	NOUN
cblr-1794	359	24	product	product	NOUN
cblr-1794	359	25	)	)	PUNCT
cblr-1794	359	26	.	.	PUNCT
cblr-1794	360	1	127	127	NUM
cblr-1794	360	2	ftc	ftc	PROPN
cblr-1794	360	3	report	report	PROPN
cblr-1794	360	4	,	,	PUNCT
cblr-1794	360	5	supra	supra	PROPN
cblr-1794	360	6	note	note	PROPN
cblr-1794	360	7	14	14	NUM
cblr-1794	360	8	,	,	PUNCT
cblr-1794	360	9	at	at	ADP
cblr-1794	360	10	16	16	NUM
cblr-1794	360	11	n.55	n.55	NOUN
cblr-1794	360	12	.	.	PROPN
cblr-1794	360	13	128	128	NUM
cblr-1794	360	14	richard	richard	NOUN
cblr-1794	360	15	dolinar	dolinar	NOUN
cblr-1794	360	16	,	,	PUNCT
cblr-1794	360	17	it	it	PRON
cblr-1794	360	18	's	be	AUX
cblr-1794	360	19	all	all	PRON
cblr-1794	360	20	about	about	ADP
cblr-1794	360	21	the	the	DET
cblr-1794	360	22	name	name	NOUN
cblr-1794	360	23	:	:	PUNCT
cblr-1794	360	24	what	what	PRON
cblr-1794	360	25	is	be	AUX
cblr-1794	360	26	the	the	DET
cblr-1794	360	27	imperative	imperative	NOUN
cblr-1794	360	28	of	of	ADP
cblr-1794	360	29	adopting	adopt	VERB
cblr-1794	360	30	unique	unique	ADJ
cblr-1794	360	31	names	name	NOUN
cblr-1794	360	32	for	for	ADP
cblr-1794	360	33	biologic	biologic	NOUN
cblr-1794	360	34	and	and	CCONJ
cblr-1794	360	35	biosimilar	biosimilar	ADJ
cblr-1794	360	36	therapeutics	therapeutic	NOUN
cblr-1794	360	37	?	?	PUNCT
cblr-1794	360	38	,	,	PUNCT
cblr-1794	360	39	fdli	fdli	PROPN
cblr-1794	360	40	's	's	PART
cblr-1794	360	41	food	food	NOUN
cblr-1794	360	42	and	and	CCONJ
cblr-1794	360	43	drug	drug	NOUN
cblr-1794	360	44	pol'y	pol'y	NOUN
cblr-1794	360	45	f.	f.	PROPN
cblr-1794	360	46	,	,	PUNCT
cblr-1794	360	47	nov	nov	PROPN
cblr-1794	360	48	.	.	PROPN
cblr-1794	360	49	28	28	NUM
cblr-1794	360	50	,	,	PUNCT
cblr-1794	360	51	2012	2012	NUM
cblr-1794	360	52	,	,	PUNCT
cblr-1794	360	53	at	at	ADP
cblr-1794	360	54	1	1	NUM
cblr-1794	360	55	,	,	PUNCT
cblr-1794	360	56	available	available	ADJ
cblr-1794	360	57	at	at	ADP
cblr-1794	360	58	http:/	http:/	PROPN
cblr-1794	360	59	safebiologics.org/pdf/fdli-asbm-its-all-about-the-name.pdf	safebiologics.org/pdf/fdli-asbm-its-all-about-the-name.pdf	PROPN
cblr-1794	360	60	.	.	PUNCT
cblr-1794	361	1	129	129	NUM
cblr-1794	361	2	ftc	ftc	PROPN
cblr-1794	361	3	report	report	NOUN
cblr-1794	361	4	,	,	PUNCT
cblr-1794	361	5	supra	supra	PROPN
cblr-1794	361	6	note	note	PROPN
cblr-1794	361	7	14	14	NUM
cblr-1794	361	8	,	,	PUNCT
cblr-1794	361	9	at	at	ADP
cblr-1794	361	10	16	16	NUM
cblr-1794	361	11	-	-	SYM
cblr-1794	361	12	17	17	NUM
cblr-1794	361	13	.	.	PUNCT
cblr-1794	362	1	130	130	NUM
cblr-1794	363	1	grabowski	grabowski	PROPN
cblr-1794	363	2	et	et	PROPN
cblr-1794	363	3	al	al	PROPN
cblr-1794	363	4	.	.	PROPN
cblr-1794	363	5	,	,	PUNCT
cblr-1794	363	6	supra	supra	PROPN
cblr-1794	363	7	note	note	PROPN
cblr-1794	363	8	85	85	NUM
cblr-1794	363	9	,	,	PUNCT
cblr-1794	363	10	at	at	ADP
cblr-1794	363	11	527	527	NUM
cblr-1794	363	12	.	.	PUNCT
cblr-1794	364	1	bpcia	bpcia	NOUN
cblr-1794	364	2	:	:	PUNCT
cblr-1794	364	3	destined	destine	VERB
cblr-1794	364	4	for	for	ADP
cblr-1794	364	5	failure	failure	NOUN
cblr-1794	364	6	?	?	PUNCT
cblr-1794	365	1	229	229	NUM
cblr-1794	366	1	no	no	DET
cblr-1794	366	2	i:209	i:209	NOUN
cblr-1794	366	3	]	]	PUNCT
cblr-1794	366	4	whose	whose	DET
cblr-1794	366	5	symptoms	symptom	NOUN
cblr-1794	366	6	have	have	AUX
cblr-1794	366	7	not	not	PART
cblr-1794	366	8	improved	improve	VERB
cblr-1794	366	9	using	use	VERB
cblr-1794	366	10	the	the	DET
cblr-1794	366	11	reference	reference	NOUN
cblr-1794	366	12	biologic.131	biologic.131	VERB
cblr-1794	366	13	the	the	DET
cblr-1794	366	14	hgh	hgh	PROPN
cblr-1794	366	15	market	market	NOUN
cblr-1794	366	16	provides	provide	VERB
cblr-1794	366	17	an	an	DET
cblr-1794	366	18	example	example	NOUN
cblr-1794	366	19	of	of	ADP
cblr-1794	366	20	the	the	DET
cblr-1794	366	21	lack	lack	NOUN
cblr-1794	366	22	of	of	ADP
cblr-1794	366	23	market	market	NOUN
cblr-1794	366	24	share	share	NOUN
cblr-1794	366	25	commanded	command	VERB
cblr-1794	366	26	by	by	ADP
cblr-1794	366	27	biosimilars	biosimilar	NOUN
cblr-1794	366	28	.	.	PUNCT
cblr-1794	367	1	when	when	SCONJ
cblr-1794	367	2	omnitrope	omnitrope	NOUN
cblr-1794	367	3	entered	enter	VERB
cblr-1794	367	4	the	the	DET
cblr-1794	367	5	hgh	hgh	PROPN
cblr-1794	367	6	market	market	NOUN
cblr-1794	367	7	in	in	ADP
cblr-1794	367	8	2006	2006	NUM
cblr-1794	367	9	,	,	PUNCT
cblr-1794	367	10	it	it	PRON
cblr-1794	367	11	struggled	struggle	VERB
cblr-1794	367	12	to	to	PART
cblr-1794	367	13	gain	gain	VERB
cblr-1794	367	14	any	any	DET
cblr-1794	367	15	market	market	NOUN
cblr-1794	367	16	share	share	NOUN
cblr-1794	367	17	despite	despite	SCONJ
cblr-1794	367	18	a	a	DET
cblr-1794	367	19	thirty	thirty	NUM
cblr-1794	367	20	percent	percent	NOUN
cblr-1794	367	21	price	price	NOUN
cblr-1794	367	22	discount	discount	NOUN
cblr-1794	367	23	.	.	PUNCT
cblr-1794	368	1	13	13	NUM
cblr-1794	368	2	2	2	NUM
cblr-1794	368	3	in	in	ADP
cblr-1794	368	4	2008	2008	NUM
cblr-1794	368	5	,	,	PUNCT
cblr-1794	368	6	omnitrope	omnitrope	NOUN
cblr-1794	368	7	provided	provide	VERB
cblr-1794	368	8	a	a	DET
cblr-1794	368	9	forty	forty	NUM
cblr-1794	368	10	percent	percent	NOUN
cblr-1794	368	11	discount	discount	NOUN
cblr-1794	368	12	,	,	PUNCT
cblr-1794	368	13	but	but	CCONJ
cblr-1794	368	14	still	still	ADV
cblr-1794	368	15	only	only	ADV
cblr-1794	368	16	received	receive	VERB
cblr-1794	368	17	a	a	DET
cblr-1794	368	18	two	two	NUM
cblr-1794	368	19	percent	percent	NOUN
cblr-1794	368	20	market	market	NOUN
cblr-1794	368	21	share.133	share.133	NOUN
cblr-1794	368	22	omnitrope	omnitrope	NOUN
cblr-1794	368	23	's	's	PART
cblr-1794	368	24	experience	experience	NOUN
cblr-1794	368	25	might	might	AUX
cblr-1794	368	26	not	not	PART
cblr-1794	368	27	be	be	AUX
cblr-1794	368	28	typical	typical	ADJ
cblr-1794	368	29	of	of	ADP
cblr-1794	368	30	the	the	DET
cblr-1794	368	31	larger	large	ADJ
cblr-1794	368	32	biosimilars	biosimilar	NOUN
cblr-1794	368	33	market	market	NOUN
cblr-1794	368	34	,	,	PUNCT
cblr-1794	368	35	since	since	SCONJ
cblr-1794	368	36	an	an	DET
cblr-1794	368	37	important	important	ADJ
cblr-1794	368	38	factor	factor	NOUN
cblr-1794	368	39	in	in	ADP
cblr-1794	368	40	the	the	DET
cblr-1794	368	41	success	success	NOUN
cblr-1794	368	42	of	of	ADP
cblr-1794	368	43	an	an	DET
cblr-1794	368	44	hgh	hgh	NOUN
cblr-1794	368	45	product	product	NOUN
cblr-1794	368	46	is	be	AUX
cblr-1794	368	47	its	its	PRON
cblr-1794	368	48	delivery	delivery	NOUN
cblr-1794	368	49	system	system	NOUN
cblr-1794	368	50	.	.	PUNCT
cblr-1794	369	1	134	134	NUM
cblr-1794	370	1	the	the	DET
cblr-1794	370	2	established	establish	VERB
cblr-1794	370	3	brands	brand	NOUN
cblr-1794	370	4	have	have	AUX
cblr-1794	370	5	"	"	PUNCT
cblr-1794	370	6	invested	invest	VERB
cblr-1794	370	7	in	in	ADP
cblr-1794	370	8	more	more	ADV
cblr-1794	370	9	sophisticated	sophisticated	ADJ
cblr-1794	370	10	penor	penor	PROPN
cblr-1794	370	11	needle	needle	NOUN
cblr-1794	370	12	-	-	PUNCT
cblr-1794	370	13	free	free	ADJ
cblr-1794	370	14	delivery	delivery	NOUN
cblr-1794	370	15	systems	system	NOUN
cblr-1794	370	16	compared	compare	VERB
cblr-1794	370	17	to	to	ADP
cblr-1794	370	18	the	the	DET
cblr-1794	370	19	delivery	delivery	NOUN
cblr-1794	370	20	systems	system	NOUN
cblr-1794	370	21	used	use	VERB
cblr-1794	370	22	by	by	ADP
cblr-1794	370	23	recent	recent	ADJ
cblr-1794	370	24	lower	lower	ADV
cblr-1794	370	25	-	-	PUNCT
cblr-1794	370	26	priced	price	VERB
cblr-1794	370	27	entrants	entrant	NOUN
cblr-1794	370	28	.	.	PUNCT
cblr-1794	371	1	"135	"135	PROPN
cblr-1794	371	2	however	however	ADV
cblr-1794	371	3	,	,	PUNCT
cblr-1794	371	4	omnitrope	omnitrope	PROPN
cblr-1794	371	5	's	's	PART
cblr-1794	371	6	experience	experience	NOUN
cblr-1794	371	7	is	be	AUX
cblr-1794	371	8	still	still	ADV
cblr-1794	371	9	instructive	instructive	ADJ
cblr-1794	371	10	;	;	PUNCT
cblr-1794	371	11	it	it	PRON
cblr-1794	371	12	shows	show	VERB
cblr-1794	371	13	that	that	SCONJ
cblr-1794	371	14	a	a	DET
cblr-1794	371	15	significantly	significantly	ADV
cblr-1794	371	16	lower	low	ADJ
cblr-1794	371	17	price	price	NOUN
cblr-1794	371	18	will	will	AUX
cblr-1794	371	19	not	not	PART
cblr-1794	371	20	always	always	ADV
cblr-1794	371	21	lead	lead	VERB
cblr-1794	371	22	to	to	ADP
cblr-1794	371	23	a	a	DET
cblr-1794	371	24	high	high	ADJ
cblr-1794	371	25	market	market	NOUN
cblr-1794	371	26	share	share	NOUN
cblr-1794	371	27	.	.	PUNCT
cblr-1794	372	1	overall	overall	ADV
cblr-1794	372	2	,	,	PUNCT
cblr-1794	372	3	the	the	DET
cblr-1794	372	4	ftc	ftc	PROPN
cblr-1794	372	5	estimates	estimate	VERB
cblr-1794	372	6	that	that	SCONJ
cblr-1794	372	7	the	the	DET
cblr-1794	372	8	market	market	NOUN
cblr-1794	372	9	share	share	NOUN
cblr-1794	372	10	for	for	ADP
cblr-1794	372	11	biosimilars	biosimilar	NOUN
cblr-1794	372	12	will	will	AUX
cblr-1794	372	13	range	range	VERB
cblr-1794	372	14	from	from	ADP
cblr-1794	372	15	ten	ten	NUM
cblr-1794	372	16	to	to	PART
cblr-1794	372	17	thirty	thirty	NUM
cblr-1794	372	18	percent	percent	NOUN
cblr-1794	372	19	.	.	PUNCT
cblr-1794	373	1	136	136	NUM
cblr-1794	373	2	this	this	DET
cblr-1794	373	3	small	small	ADJ
cblr-1794	373	4	market	market	NOUN
cblr-1794	373	5	share	share	NOUN
cblr-1794	373	6	does	do	AUX
cblr-1794	373	7	not	not	PART
cblr-1794	373	8	pose	pose	VERB
cblr-1794	373	9	a	a	DET
cblr-1794	373	10	significant	significant	ADJ
cblr-1794	373	11	threat	threat	NOUN
cblr-1794	373	12	to	to	PART
cblr-1794	373	13	reference	reference	VERB
cblr-1794	373	14	drug	drug	NOUN
cblr-1794	373	15	manufacturers	manufacturer	NOUN
cblr-1794	373	16	,	,	PUNCT
cblr-1794	373	17	providing	provide	VERB
cblr-1794	373	18	them	they	PRON
cblr-1794	373	19	with	with	ADP
cblr-1794	373	20	little	little	ADJ
cblr-1794	373	21	incentive	incentive	NOUN
cblr-1794	373	22	to	to	PART
cblr-1794	373	23	compete	compete	VERB
cblr-1794	373	24	based	base	VERB
cblr-1794	373	25	on	on	ADP
cblr-1794	373	26	price	price	NOUN
cblr-1794	373	27	.	.	PUNCT
cblr-1794	374	1	c.	c.	PROPN
cblr-1794	374	2	exclusivity	exclusivity	PROPN
cblr-1794	374	3	periods	period	VERB
cblr-1794	374	4	the	the	DET
cblr-1794	374	5	bpcia	bpcia	NOUN
cblr-1794	374	6	creates	create	VERB
cblr-1794	374	7	two	two	NUM
cblr-1794	374	8	periods	period	NOUN
cblr-1794	374	9	of	of	ADP
cblr-1794	374	10	exclusivity	exclusivity	NOUN
cblr-1794	374	11	:	:	PUNCT
cblr-1794	374	12	one	one	NUM
cblr-1794	374	13	for	for	ADP
cblr-1794	374	14	the	the	DET
cblr-1794	374	15	reference	reference	NOUN
cblr-1794	374	16	biologic	biologic	NOUN
cblr-1794	374	17	,	,	PUNCT
cblr-1794	374	18	and	and	CCONJ
cblr-1794	374	19	one	one	NUM
cblr-1794	374	20	for	for	ADP
cblr-1794	374	21	the	the	DET
cblr-1794	374	22	first	first	ADJ
cblr-1794	374	23	interchangeable	interchangeable	ADJ
cblr-1794	374	24	biosimilar	biosimilar	NOUN
cblr-1794	374	25	to	to	PART
cblr-1794	374	26	be	be	AUX
cblr-1794	374	27	licensed.137	licensed.137	NOUN
cblr-1794	374	28	the	the	DET
cblr-1794	374	29	reference	reference	NOUN
cblr-1794	374	30	biologic	biologic	NOUN
cblr-1794	374	31	gets	get	VERB
cblr-1794	374	32	131	131	NUM
cblr-1794	374	33	ftc	ftc	PROPN
cblr-1794	374	34	report	report	NOUN
cblr-1794	374	35	,	,	PUNCT
cblr-1794	374	36	supra	supra	PROPN
cblr-1794	374	37	note	note	PROPN
cblr-1794	374	38	14	14	NUM
cblr-1794	374	39	,	,	PUNCT
cblr-1794	374	40	at	at	ADP
cblr-1794	374	41	17	17	NUM
cblr-1794	374	42	.	.	PUNCT
cblr-1794	375	1	132	132	NUM
cblr-1794	375	2	grabowski	grabowski	PROPN
cblr-1794	375	3	et	et	PROPN
cblr-1794	375	4	al	al	PROPN
cblr-1794	375	5	.	.	PROPN
cblr-1794	375	6	,	,	PUNCT
cblr-1794	375	7	supra	supra	PROPN
cblr-1794	375	8	note	note	PROPN
cblr-1794	375	9	85	85	NUM
cblr-1794	375	10	,	,	PUNCT
cblr-1794	375	11	at	at	ADP
cblr-1794	375	12	538	538	NUM
cblr-1794	375	13	.	.	PUNCT
cblr-1794	376	1	133	133	NUM
cblr-1794	377	1	i	i	PROPN
cblr-1794	377	2	d.	d.	PROPN
cblr-1794	377	3	134	134	NUM
cblr-1794	378	1	i	i	PROPN
cblr-1794	378	2	d.	d.	PROPN
cblr-1794	378	3	135	135	NUM
cblr-1794	379	1	i	i	PROPN
cblr-1794	379	2	d.	d.	PROPN
cblr-1794	379	3	136	136	NUM
cblr-1794	379	4	ftc	ftc	PROPN
cblr-1794	379	5	report	report	NOUN
cblr-1794	379	6	,	,	PUNCT
cblr-1794	379	7	supra	supra	PROPN
cblr-1794	379	8	note	note	PROPN
cblr-1794	379	9	14	14	NUM
cblr-1794	379	10	,	,	PUNCT
cblr-1794	379	11	at	at	ADP
cblr-1794	379	12	19	19	NUM
cblr-1794	379	13	.	.	PUNCT
cblr-1794	380	1	see	see	VERB
cblr-1794	380	2	also	also	ADV
cblr-1794	380	3	henry	henry	PROPN
cblr-1794	380	4	g.	g.	PROPN
cblr-1794	380	5	grabowski	grabowski	PROPN
cblr-1794	380	6	et	et	PROPN
cblr-1794	380	7	al	al	PROPN
cblr-1794	380	8	.	.	PROPN
cblr-1794	380	9	,	,	PUNCT
cblr-1794	380	10	the	the	DET
cblr-1794	380	11	effect	effect	NOUN
cblr-1794	380	12	on	on	ADP
cblr-1794	380	13	federal	federal	ADJ
cblr-1794	380	14	spending	spending	NOUN
cblr-1794	380	15	of	of	ADP
cblr-1794	380	16	legislation	legislation	NOUN
cblr-1794	380	17	creating	create	VERB
cblr-1794	380	18	a	a	DET
cblr-1794	380	19	regulatory	regulatory	ADJ
cblr-1794	380	20	framework	framework	NOUN
cblr-1794	380	21	for	for	ADP
cblr-1794	380	22	follow	follow	VERB
cblr-1794	380	23	-	-	PUNCT
cblr-1794	380	24	on	on	ADP
cblr-1794	380	25	biologics	biologic	NOUN
cblr-1794	380	26	:	:	PUNCT
cblr-1794	380	27	key	key	ADJ
cblr-1794	380	28	issues	issue	NOUN
cblr-1794	380	29	and	and	CCONJ
cblr-1794	380	30	assumptions	assumption	NOUN
cblr-1794	380	31	48	48	NUM
cblr-1794	380	32	(	(	PUNCT
cblr-1794	380	33	aug	aug	PROPN
cblr-1794	380	34	.	.	PROPN
cblr-1794	380	35	2007	2007	NUM
cblr-1794	380	36	)	)	PUNCT
cblr-1794	380	37	(	(	PUNCT
cblr-1794	380	38	unpublished	unpublished	ADJ
cblr-1794	380	39	white	white	ADJ
cblr-1794	380	40	paper	paper	NOUN
cblr-1794	380	41	)	)	PUNCT
cblr-1794	380	42	,	,	PUNCT
cblr-1794	381	1	http://www.bio.org/sites/default/files/	http://www.bio.org/sites/default/files/	PROPN
cblr-1794	381	2	federal	federal	ADJ
cblr-1794	381	3	spendingof	spendingof	PROPN
cblr-1794	381	4	followonbkg200709.pdf	followonbkg200709.pdf	PROPN
cblr-1794	381	5	(	(	PUNCT
cblr-1794	381	6	estimating	estimate	VERB
cblr-1794	381	7	that	that	SCONJ
cblr-1794	381	8	market	market	NOUN
cblr-1794	381	9	share	share	NOUN
cblr-1794	381	10	for	for	ADP
cblr-1794	381	11	biosimilars	biosimilar	NOUN
cblr-1794	381	12	will	will	AUX
cblr-1794	381	13	be	be	AUX
cblr-1794	381	14	between	between	ADP
cblr-1794	381	15	ten	ten	NUM
cblr-1794	381	16	and	and	CCONJ
cblr-1794	381	17	forty	forty	NUM
cblr-1794	381	18	-	-	PUNCT
cblr-1794	381	19	five	five	NUM
cblr-1794	381	20	percent	percent	NOUN
cblr-1794	381	21	)	)	PUNCT
cblr-1794	381	22	.	.	PUNCT
cblr-1794	382	1	137	137	NUM
cblr-1794	382	2	public	public	ADJ
cblr-1794	382	3	health	health	NOUN
cblr-1794	382	4	service	service	NOUN
cblr-1794	382	5	act	act	NOUN
cblr-1794	382	6	§	§	PROPN
cblr-1794	382	7	351	351	NUM
cblr-1794	382	8	,	,	PUNCT
cblr-1794	382	9	42	42	NUM
cblr-1794	382	10	u.s.c.a	u.s.c.a	PROPN
cblr-1794	382	11	.	.	PUNCT
cblr-1794	383	1	§	§	PROPN
cblr-1794	383	2	262(k)(6	262(k)(6	PROPN
cblr-1794	383	3	-	-	SYM
cblr-1794	383	4	7	7	NUM
cblr-1794	383	5	)	)	PUNCT
cblr-1794	383	6	(	(	PUNCT
cblr-1794	383	7	west	west	NOUN
cblr-1794	383	8	2012	2012	NUM
cblr-1794	383	9	)	)	PUNCT
cblr-1794	383	10	.	.	PUNCT
cblr-1794	384	1	230	230	NUM
cblr-1794	384	2	col	col	PROPN
cblr-1794	384	3	umbia	umbia	PROPN
cblr-1794	384	4	b	b	PROPN
cblr-1794	384	5	usiness	usiness	PROPN
cblr-1794	384	6	la	la	PROPN
cblr-1794	384	7	w	w	PROPN
cblr-1794	384	8	re	re	PROPN
cblr-1794	384	9	vie	vie	PROPN
cblr-1794	384	10	w	w	PROPN
cblr-1794	385	1	[	[	X
cblr-1794	385	2	vol	vol	NOUN
cblr-1794	385	3	.	.	PUNCT
cblr-1794	385	4	2013	2013	NUM
cblr-1794	385	5	bpcia	bpcia	NOUN
cblr-1794	385	6	:	:	PUNCT
cblr-1794	385	7	destined	destine	VERB
cblr-1794	385	8	for	for	ADP
cblr-1794	385	9	failure	failure	NOUN
cblr-1794	385	10	?	?	PUNCT
cblr-1794	386	1	twelve	twelve	NUM
cblr-1794	386	2	years	year	NOUN
cblr-1794	386	3	of	of	ADP
cblr-1794	386	4	exclusivity	exclusivity	NOUN
cblr-1794	386	5	under	under	ADP
cblr-1794	386	6	the	the	DET
cblr-1794	386	7	statute	statute	NOUN
cblr-1794	386	8	,	,	PUNCT
cblr-1794	386	9	while	while	SCONJ
cblr-1794	386	10	the	the	DET
cblr-1794	386	11	first	first	ADJ
cblr-1794	386	12	biosimilar	biosimilar	NOUN
cblr-1794	386	13	gets	get	VERB
cblr-1794	386	14	between	between	ADP
cblr-1794	386	15	twelve	twelve	NUM
cblr-1794	386	16	and	and	CCONJ
cblr-1794	386	17	forty	forty	NUM
cblr-1794	386	18	-	-	PUNCT
cblr-1794	386	19	two	two	NUM
cblr-1794	386	20	months	month	NOUN
cblr-1794	386	21	of	of	ADP
cblr-1794	386	22	exclusivity.1	exclusivity.1	ADP
cblr-1794	386	23	38	38	NUM
cblr-1794	386	24	both	both	DET
cblr-1794	386	25	exclusivity	exclusivity	NOUN
cblr-1794	386	26	periods	period	NOUN
cblr-1794	386	27	undermine	undermine	VERB
cblr-1794	386	28	the	the	DET
cblr-1794	386	29	bpcia	bpcia	NOUN
cblr-1794	386	30	's	's	PART
cblr-1794	386	31	ability	ability	NOUN
cblr-1794	386	32	to	to	PART
cblr-1794	386	33	create	create	VERB
cblr-1794	386	34	drug	drug	NOUN
cblr-1794	386	35	price	price	NOUN
cblr-1794	386	36	reduction	reduction	NOUN
cblr-1794	386	37	.	.	PUNCT
cblr-1794	387	1	1	1	X
cblr-1794	387	2	.	.	X
cblr-1794	387	3	exclusivity	exclusivity	NOUN
cblr-1794	387	4	period	period	NOUN
cblr-1794	387	5	for	for	ADP
cblr-1794	387	6	reference	reference	NOUN
cblr-1794	387	7	biologics	biologic	NOUN
cblr-1794	387	8	the	the	DET
cblr-1794	387	9	hatch	hatch	PROPN
cblr-1794	387	10	-	-	PUNCT
cblr-1794	387	11	waxman	waxman	PROPN
cblr-1794	387	12	act	act	NOUN
cblr-1794	387	13	does	do	AUX
cblr-1794	387	14	not	not	PART
cblr-1794	387	15	provide	provide	VERB
cblr-1794	387	16	an	an	DET
cblr-1794	387	17	exclusivity	exclusivity	NOUN
cblr-1794	387	18	period	period	NOUN
cblr-1794	387	19	for	for	ADP
cblr-1794	387	20	each	each	DET
cblr-1794	387	21	branded	brand	VERB
cblr-1794	387	22	pharmaceutical	pharmaceutical	NOUN
cblr-1794	387	23	.	.	PUNCT
cblr-1794	388	1	instead	instead	ADV
cblr-1794	388	2	,	,	PUNCT
cblr-1794	388	3	hatchwaxman	hatchwaxman	NOUN
cblr-1794	388	4	provides	provide	VERB
cblr-1794	388	5	for	for	ADP
cblr-1794	388	6	exclusivity	exclusivity	NOUN
cblr-1794	388	7	only	only	ADV
cblr-1794	388	8	"	"	PUNCT
cblr-1794	388	9	when	when	SCONJ
cblr-1794	388	10	market	market	NOUN
cblr-1794	388	11	-	-	PUNCT
cblr-1794	388	12	based	base	VERB
cblr-1794	388	13	pricing	pricing	NOUN
cblr-1794	388	14	has	have	AUX
cblr-1794	388	15	not	not	PART
cblr-1794	388	16	provided	provide	VERB
cblr-1794	388	17	sufficient	sufficient	ADJ
cblr-1794	388	18	incentive	incentive	NOUN
cblr-1794	388	19	"	"	PUNCT
cblr-1794	388	20	to	to	PART
cblr-1794	388	21	spur	spur	VERB
cblr-1794	388	22	further	further	ADJ
cblr-1794	388	23	innovation	innovation	NOUN
cblr-1794	388	24	.	.	PUNCT
cblr-1794	389	1	139	139	NUM
cblr-1794	389	2	this	this	PRON
cblr-1794	389	3	may	may	AUX
cblr-1794	389	4	occur	occur	VERB
cblr-1794	389	5	when	when	SCONJ
cblr-1794	389	6	the	the	DET
cblr-1794	389	7	molecule	molecule	NOUN
cblr-1794	389	8	is	be	AUX
cblr-1794	389	9	already	already	ADV
cblr-1794	389	10	in	in	ADP
cblr-1794	389	11	the	the	DET
cblr-1794	389	12	public	public	ADJ
cblr-1794	389	13	domain	domain	NOUN
cblr-1794	389	14	and	and	CCONJ
cblr-1794	389	15	therefore	therefore	ADV
cblr-1794	389	16	not	not	PART
cblr-1794	389	17	patentable	patentable	ADJ
cblr-1794	389	18	,	,	PUNCT
cblr-1794	389	19	or	or	CCONJ
cblr-1794	389	20	when	when	SCONJ
cblr-1794	389	21	the	the	DET
cblr-1794	389	22	target	target	NOUN
cblr-1794	389	23	patient	patient	ADJ
cblr-1794	389	24	population	population	NOUN
cblr-1794	389	25	is	be	AUX
cblr-1794	389	26	too	too	ADV
cblr-1794	389	27	small	small	ADJ
cblr-1794	389	28	to	to	PART
cblr-1794	389	29	make	make	VERB
cblr-1794	389	30	research	research	NOUN
cblr-1794	389	31	and	and	CCONJ
cblr-1794	389	32	development	development	NOUN
cblr-1794	389	33	of	of	ADP
cblr-1794	389	34	a	a	DET
cblr-1794	389	35	drug	drug	NOUN
cblr-1794	389	36	commercially	commercially	ADV
cblr-1794	389	37	viable.14	viable.14	NOUN
cblr-1794	389	38	0	0	NUM
cblr-1794	390	1	the	the	DET
cblr-1794	390	2	bpcia	bpcia	NOUN
cblr-1794	390	3	departs	depart	VERB
cblr-1794	390	4	from	from	ADP
cblr-1794	390	5	the	the	DET
cblr-1794	390	6	hatch	hatch	NOUN
cblr-1794	390	7	-	-	PUNCT
cblr-1794	390	8	waxman	waxman	PROPN
cblr-1794	390	9	model	model	NOUN
cblr-1794	390	10	,	,	PUNCT
cblr-1794	390	11	choosing	choose	VERB
cblr-1794	390	12	to	to	PART
cblr-1794	390	13	provide	provide	VERB
cblr-1794	390	14	a	a	DET
cblr-1794	390	15	twelve	twelve	NUM
cblr-1794	390	16	-	-	PUNCT
cblr-1794	390	17	year	year	NOUN
cblr-1794	390	18	exclusivity	exclusivity	NOUN
cblr-1794	390	19	period	period	NOUN
cblr-1794	390	20	to	to	ADP
cblr-1794	390	21	each	each	DET
cblr-1794	390	22	reference	reference	NOUN
cblr-1794	390	23	product.1	product.1	VERB
cblr-1794	390	24	4	4	NUM
cblr-1794	390	25	1	1	NUM
cblr-1794	390	26	such	such	DET
cblr-1794	390	27	a	a	DET
cblr-1794	390	28	lengthy	lengthy	ADJ
cblr-1794	390	29	exclusivity	exclusivity	NOUN
cblr-1794	390	30	period	period	NOUN
cblr-1794	390	31	will	will	AUX
cblr-1794	390	32	ensure	ensure	VERB
cblr-1794	390	33	that	that	SCONJ
cblr-1794	390	34	biologic	biologic	NOUN
cblr-1794	390	35	prices	price	NOUN
cblr-1794	390	36	remain	remain	VERB
cblr-1794	390	37	higher	high	ADJ
cblr-1794	390	38	for	for	ADP
cblr-1794	390	39	longer	long	ADV
cblr-1794	390	40	,	,	PUNCT
cblr-1794	390	41	and	and	CCONJ
cblr-1794	390	42	is	be	AUX
cblr-1794	390	43	unnecessary	unnecessary	ADJ
cblr-1794	390	44	to	to	PART
cblr-1794	390	45	spur	spur	VERB
cblr-1794	390	46	innovation	innovation	NOUN
cblr-1794	390	47	.	.	PUNCT
cblr-1794	391	1	innovative	innovative	ADJ
cblr-1794	391	2	biologics	biologic	NOUN
cblr-1794	391	3	manufacturers	manufacturer	NOUN
cblr-1794	391	4	can	can	AUX
cblr-1794	391	5	rely	rely	VERB
cblr-1794	391	6	on	on	ADP
cblr-1794	391	7	the	the	DET
cblr-1794	391	8	patent	patent	NOUN
cblr-1794	391	9	system	system	NOUN
cblr-1794	391	10	to	to	PART
cblr-1794	391	11	safeguard	safeguard	VERB
cblr-1794	391	12	innovation	innovation	NOUN
cblr-1794	391	13	and	and	CCONJ
cblr-1794	391	14	prevent	prevent	VERB
cblr-1794	391	15	rival	rival	ADJ
cblr-1794	391	16	manufacturers	manufacturer	NOUN
cblr-1794	391	17	from	from	ADP
cblr-1794	391	18	free	free	ADJ
cblr-1794	391	19	-	-	PUNCT
cblr-1794	391	20	riding	riding	NOUN
cblr-1794	391	21	on	on	ADP
cblr-1794	391	22	discoveries	discovery	NOUN
cblr-1794	391	23	.	.	PUNCT
cblr-1794	392	1	1	1	NUM
cblr-1794	392	2	42	42	NUM
cblr-1794	392	3	patent	patent	NOUN
cblr-1794	392	4	law	law	NOUN
cblr-1794	392	5	exists	exist	VERB
cblr-1794	392	6	in	in	ADP
cblr-1794	392	7	order	order	NOUN
cblr-1794	392	8	to	to	PART
cblr-1794	392	9	incentivize	incentivize	VERB
cblr-1794	392	10	innovation	innovation	NOUN
cblr-1794	392	11	.	.	PUNCT
cblr-1794	393	1	1	1	NUM
cblr-1794	393	2	4	4	NUM
cblr-1794	393	3	3	3	NUM
cblr-1794	393	4	thus	thus	ADV
cblr-1794	393	5	,	,	PUNCT
cblr-1794	393	6	biosimilar	biosimilar	ADJ
cblr-1794	393	7	manufacturers	manufacturer	NOUN
cblr-1794	393	8	will	will	AUX
cblr-1794	393	9	not	not	PART
cblr-1794	393	10	be	be	AUX
cblr-1794	393	11	permitted	permit	VERB
cblr-1794	393	12	to	to	PART
cblr-1794	393	13	infringe	infringe	VERB
cblr-1794	393	14	patents	patent	NOUN
cblr-1794	393	15	when	when	SCONJ
cblr-1794	393	16	attempting	attempt	VERB
cblr-1794	393	17	to	to	PART
cblr-1794	393	18	develop	develop	VERB
cblr-1794	393	19	a	a	DET
cblr-1794	393	20	biosimilar	biosimilar	NOUN
cblr-1794	393	21	.	.	PUNCT
cblr-1794	394	1	14	14	NUM
cblr-1794	394	2	4	4	NUM
cblr-1794	394	3	moreover	moreover	ADV
cblr-1794	394	4	,	,	PUNCT
cblr-1794	394	5	138	138	NUM
cblr-1794	394	6	public	public	ADJ
cblr-1794	394	7	health	health	NOUN
cblr-1794	394	8	service	service	PROPN
cblr-1794	394	9	act	act	NOUN
cblr-1794	394	10	§	§	PROPN
cblr-1794	394	11	351	351	NUM
cblr-1794	394	12	,	,	PUNCT
cblr-1794	394	13	42	42	NUM
cblr-1794	394	14	u.s.c.a	u.s.c.a	PROPN
cblr-1794	394	15	.	.	PUNCT
cblr-1794	395	1	§	§	PROPN
cblr-1794	395	2	262(k)(6)-(7	262(k)(6)-(7	NUM
cblr-1794	395	3	)	)	PUNCT
cblr-1794	395	4	(	(	PUNCT
cblr-1794	395	5	west	west	NOUN
cblr-1794	395	6	2012	2012	NUM
cblr-1794	395	7	)	)	PUNCT
cblr-1794	395	8	.	.	PUNCT
cblr-1794	396	1	139	139	NUM
cblr-1794	396	2	ftc	ftc	PROPN
cblr-1794	396	3	report	report	NOUN
cblr-1794	396	4	,	,	PUNCT
cblr-1794	396	5	supra	supra	PROPN
cblr-1794	396	6	note	note	PROPN
cblr-1794	396	7	14	14	NUM
cblr-1794	396	8	,	,	PUNCT
cblr-1794	396	9	at	at	ADP
cblr-1794	396	10	27	27	NUM
cblr-1794	396	11	.	.	PUNCT
cblr-1794	397	1	140	140	NUM
cblr-1794	398	1	i	i	NOUN
cblr-1794	398	2	d.	d.	PROPN
cblr-1794	398	3	141	141	NUM
cblr-1794	398	4	public	public	ADJ
cblr-1794	398	5	health	health	NOUN
cblr-1794	398	6	service	service	NOUN
cblr-1794	398	7	act	act	NOUN
cblr-1794	398	8	§	§	PROPN
cblr-1794	398	9	351	351	NUM
cblr-1794	398	10	,	,	PUNCT
cblr-1794	398	11	42	42	NUM
cblr-1794	398	12	u.s.c.a	u.s.c.a	PROPN
cblr-1794	398	13	.	.	PUNCT
cblr-1794	399	1	§	§	PROPN
cblr-1794	399	2	262(k)(7	262(k)(7	PROPN
cblr-1794	399	3	)	)	PUNCT
cblr-1794	399	4	(	(	PUNCT
cblr-1794	399	5	west	west	NOUN
cblr-1794	399	6	2012	2012	NUM
cblr-1794	399	7	)	)	PUNCT
cblr-1794	399	8	.	.	PUNCT
cblr-1794	400	1	142	142	NUM
cblr-1794	400	2	ftc	ftc	PROPN
cblr-1794	400	3	report	report	NOUN
cblr-1794	400	4	,	,	PUNCT
cblr-1794	400	5	supra	supra	PROPN
cblr-1794	400	6	note	note	PROPN
cblr-1794	400	7	14	14	NUM
cblr-1794	400	8	,	,	PUNCT
cblr-1794	400	9	at	at	ADP
cblr-1794	400	10	26	26	NUM
cblr-1794	400	11	.	.	PUNCT
cblr-1794	401	1	143	143	PRON
cblr-1794	401	2	see	see	NOUN
cblr-1794	401	3	,	,	PUNCT
cblr-1794	401	4	e.g.	e.g.	ADV
cblr-1794	401	5	,	,	PUNCT
cblr-1794	401	6	bonito	bonito	ADJ
cblr-1794	401	7	boats	boat	NOUN
cblr-1794	401	8	,	,	PUNCT
cblr-1794	401	9	inc	inc	PROPN
cblr-1794	401	10	.	.	PROPN
cblr-1794	402	1	v.	v.	ADP
cblr-1794	402	2	thunder	thunder	NOUN
cblr-1794	402	3	craft	craft	NOUN
cblr-1794	402	4	boats	boat	NOUN
cblr-1794	402	5	,	,	PUNCT
cblr-1794	402	6	inc	inc	PROPN
cblr-1794	402	7	.	.	PROPN
cblr-1794	402	8	,	,	PUNCT
cblr-1794	402	9	489	489	NUM
cblr-1794	402	10	u.s	u.s	PROPN
cblr-1794	402	11	.	.	PROPN
cblr-1794	402	12	141	141	NUM
cblr-1794	402	13	,	,	PUNCT
cblr-1794	402	14	146	146	NUM
cblr-1794	402	15	(	(	PUNCT
cblr-1794	402	16	1989	1989	NUM
cblr-1794	402	17	)	)	PUNCT
cblr-1794	402	18	(	(	PUNCT
cblr-1794	402	19	"	"	PUNCT
cblr-1794	402	20	[	[	X
cblr-1794	402	21	t]he	t]he	ADV
cblr-1794	402	22	federal	federal	ADJ
cblr-1794	402	23	patent	patent	NOUN
cblr-1794	402	24	laws	law	NOUN
cblr-1794	402	25	have	have	AUX
cblr-1794	402	26	embodied	embody	VERB
cblr-1794	402	27	a	a	DET
cblr-1794	402	28	careful	careful	ADJ
cblr-1794	402	29	balance	balance	NOUN
cblr-1794	402	30	between	between	ADP
cblr-1794	402	31	the	the	DET
cblr-1794	402	32	need	need	NOUN
cblr-1794	402	33	to	to	PART
cblr-1794	402	34	promote	promote	VERB
cblr-1794	402	35	innovation	innovation	NOUN
cblr-1794	402	36	and	and	CCONJ
cblr-1794	402	37	the	the	DET
cblr-1794	402	38	recognition	recognition	NOUN
cblr-1794	402	39	that	that	SCONJ
cblr-1794	402	40	imitation	imitation	NOUN
cblr-1794	402	41	and	and	CCONJ
cblr-1794	402	42	refinement	refinement	NOUN
cblr-1794	402	43	through	through	ADP
cblr-1794	402	44	imitation	imitation	NOUN
cblr-1794	402	45	are	be	AUX
cblr-1794	402	46	both	both	ADV
cblr-1794	402	47	necessary	necessary	ADJ
cblr-1794	402	48	to	to	PART
cblr-1794	402	49	invention	invention	VERB
cblr-1794	402	50	itself	itself	PRON
cblr-1794	402	51	and	and	CCONJ
cblr-1794	402	52	the	the	DET
cblr-1794	402	53	very	very	ADJ
cblr-1794	402	54	lifeblood	lifeblood	NOUN
cblr-1794	402	55	of	of	ADP
cblr-1794	402	56	a	a	DET
cblr-1794	402	57	competitive	competitive	ADJ
cblr-1794	402	58	economy	economy	NOUN
cblr-1794	402	59	.	.	PUNCT
cblr-1794	402	60	"	"	PUNCT
cblr-1794	402	61	)	)	PUNCT
cblr-1794	402	62	.	.	PUNCT
cblr-1794	403	1	144	144	NUM
cblr-1794	403	2	see	see	VERB
cblr-1794	403	3	generally	generally	ADV
cblr-1794	403	4	ftc	ftc	PROPN
cblr-1794	403	5	report	report	PROPN
cblr-1794	403	6	,	,	PUNCT
cblr-1794	403	7	supra	supra	PROPN
cblr-1794	403	8	note	note	PROPN
cblr-1794	403	9	14	14	NUM
cblr-1794	403	10	,	,	PUNCT
cblr-1794	403	11	at	at	ADP
cblr-1794	403	12	26	26	NUM
cblr-1794	403	13	(	(	PUNCT
cblr-1794	403	14	"	"	PUNCT
cblr-1794	403	15	nothing	nothing	PRON
cblr-1794	403	16	about	about	ADP
cblr-1794	403	17	the	the	DET
cblr-1794	403	18	introduction	introduction	NOUN
cblr-1794	403	19	of	of	ADP
cblr-1794	403	20	[	[	X
cblr-1794	403	21	biosimilar	biosimilar	X
cblr-1794	403	22	]	]	PUNCT
cblr-1794	403	23	drug	drug	NOUN
cblr-1794	403	24	products	product	NOUN
cblr-1794	403	25	changes	change	VERB
cblr-1794	403	26	the	the	DET
cblr-1794	403	27	relationship	relationship	NOUN
cblr-1794	403	28	of	of	ADP
cblr-1794	403	29	no	no	PRON
cblr-1794	403	30	.	.	PUNCT
cblr-1794	404	1	i1:209	i1:209	NOUN
cblr-1794	404	2	]	]	PUNCT
cblr-1794	405	1	231	231	NUM
cblr-1794	405	2	innovative	innovative	ADJ
cblr-1794	405	3	biologics	biologic	NOUN
cblr-1794	405	4	are	be	AUX
cblr-1794	405	5	covered	cover	VERB
cblr-1794	405	6	by	by	ADP
cblr-1794	405	7	higher	high	ADJ
cblr-1794	405	8	numbers	number	NOUN
cblr-1794	405	9	of	of	ADP
cblr-1794	405	10	patents	patent	NOUN
cblr-1794	405	11	than	than	ADP
cblr-1794	405	12	innovative	innovative	ADJ
cblr-1794	405	13	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	405	14	.	.	PUNCT
cblr-1794	406	1	145	145	NUM
cblr-1794	406	2	in	in	ADP
cblr-1794	406	3	fact	fact	NOUN
cblr-1794	406	4	,	,	PUNCT
cblr-1794	406	5	there	there	PRON
cblr-1794	406	6	is	be	VERB
cblr-1794	406	7	evidence	evidence	NOUN
cblr-1794	406	8	to	to	PART
cblr-1794	406	9	suggest	suggest	VERB
cblr-1794	406	10	that	that	SCONJ
cblr-1794	406	11	competitors	competitor	NOUN
cblr-1794	406	12	will	will	AUX
cblr-1794	406	13	have	have	VERB
cblr-1794	406	14	a	a	DET
cblr-1794	406	15	more	more	ADV
cblr-1794	406	16	difficult	difficult	ADJ
cblr-1794	406	17	time	time	NOUN
cblr-1794	406	18	designing	design	VERB
cblr-1794	406	19	around	around	ADP
cblr-1794	406	20	patents	patent	NOUN
cblr-1794	406	21	covering	cover	VERB
cblr-1794	406	22	biologics	biologic	NOUN
cblr-1794	406	23	.	.	PUNCT
cblr-1794	407	1	biologics	biologic	NOUN
cblr-1794	407	2	and	and	CCONJ
cblr-1794	407	3	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	407	4	are	be	AUX
cblr-1794	407	5	covered	cover	VERB
cblr-1794	407	6	by	by	ADP
cblr-1794	407	7	the	the	DET
cblr-1794	407	8	same	same	ADJ
cblr-1794	407	9	types	type	NOUN
cblr-1794	407	10	of	of	ADP
cblr-1794	407	11	patents	patent	NOUN
cblr-1794	407	12	with	with	ADP
cblr-1794	407	13	one	one	NUM
cblr-1794	407	14	exception	exception	NOUN
cblr-1794	407	15	:	:	PUNCT
cblr-1794	407	16	process	process	NOUN
cblr-1794	407	17	patents	patent	NOUN
cblr-1794	407	18	and	and	CCONJ
cblr-1794	407	19	technology	technology	NOUN
cblr-1794	407	20	platform	platform	NOUN
cblr-1794	407	21	patents	patent	NOUN
cblr-1794	407	22	are	be	AUX
cblr-1794	407	23	more	more	ADV
cblr-1794	407	24	significant	significant	ADJ
cblr-1794	407	25	for	for	ADP
cblr-1794	407	26	biologics	biologic	NOUN
cblr-1794	407	27	.	.	PUNCT
cblr-1794	408	1	146	146	NUM
cblr-1794	408	2	process	process	NOUN
cblr-1794	408	3	patents	patent	NOUN
cblr-1794	408	4	are	be	AUX
cblr-1794	408	5	important	important	ADJ
cblr-1794	408	6	because	because	SCONJ
cblr-1794	408	7	"	"	PUNCT
cblr-1794	408	8	the	the	DET
cblr-1794	408	9	'	'	PUNCT
cblr-1794	408	10	processes	process	NOUN
cblr-1794	408	11	by	by	ADP
cblr-1794	408	12	which	which	PRON
cblr-1794	408	13	biologics	biologic	NOUN
cblr-1794	408	14	are	be	AUX
cblr-1794	408	15	made	make	VERB
cblr-1794	408	16	are	be	AUX
cblr-1794	408	17	highly	highly	ADV
cblr-1794	408	18	specific	specific	ADJ
cblr-1794	408	19	,	,	PUNCT
cblr-1794	408	20	complex	complex	ADJ
cblr-1794	408	21	,	,	PUNCT
cblr-1794	408	22	and	and	CCONJ
cblr-1794	408	23	determine	determine	VERB
cblr-1794	408	24	many	many	ADJ
cblr-1794	408	25	of	of	ADP
cblr-1794	408	26	the	the	DET
cblr-1794	408	27	biologic	biologic	NOUN
cblr-1794	408	28	's	's	PART
cblr-1794	408	29	functional	functional	ADJ
cblr-1794	408	30	and	and	CCONJ
cblr-1794	408	31	structural	structural	ADJ
cblr-1794	408	32	characteristics	characteristic	NOUN
cblr-1794	408	33	.	.	PUNCT
cblr-1794	408	34	.	.	PUNCT
cblr-1794	408	35	.	.	PUNCT
cblr-1794	409	1	[	[	X
cblr-1794	409	2	that	that	PRON
cblr-1794	409	3	]	]	PUNCT
cblr-1794	409	4	can	can	AUX
cblr-1794	409	5	often	often	ADV
cblr-1794	409	6	be	be	AUX
cblr-1794	409	7	expected	expect	VERB
cblr-1794	409	8	to	to	PART
cblr-1794	409	9	affect	affect	VERB
cblr-1794	409	10	the	the	DET
cblr-1794	409	11	product	product	NOUN
cblr-1794	409	12	's	's	PART
cblr-1794	409	13	safety	safety	NOUN
cblr-1794	409	14	,	,	PUNCT
cblr-1794	409	15	purity	purity	NOUN
cblr-1794	409	16	,	,	PUNCT
cblr-1794	409	17	and	and	CCONJ
cblr-1794	409	18	efficacy	efficacy	NOUN
cblr-1794	409	19	profile	profile	NOUN
cblr-1794	409	20	,	,	PUNCT
cblr-1794	409	21	and	and	CCONJ
cblr-1794	409	22	thus	thus	ADV
cblr-1794	409	23	are	be	AUX
cblr-1794	409	24	integral	integral	ADJ
cblr-1794	409	25	to	to	ADP
cblr-1794	409	26	the	the	DET
cblr-1794	409	27	approval	approval	NOUN
cblr-1794	409	28	of	of	ADP
cblr-1794	409	29	the	the	DET
cblr-1794	409	30	product	product	NOUN
cblr-1794	409	31	itself	itself	PRON
cblr-1794	409	32	.	.	PUNCT
cblr-1794	410	1	"	"	PUNCT
cblr-1794	410	2	'	'	PUNCT
cblr-1794	410	3	147	147	NUM
cblr-1794	410	4	process	process	NOUN
cblr-1794	410	5	patents	patent	NOUN
cblr-1794	410	6	likely	likely	ADV
cblr-1794	410	7	provide	provide	VERB
cblr-1794	410	8	additional	additional	ADJ
cblr-1794	410	9	protection	protection	NOUN
cblr-1794	410	10	against	against	ADP
cblr-1794	410	11	infringing	infringe	VERB
cblr-1794	410	12	patents	patent	NOUN
cblr-1794	410	13	,	,	PUNCT
cblr-1794	410	14	which	which	PRON
cblr-1794	410	15	will	will	AUX
cblr-1794	410	16	make	make	VERB
cblr-1794	410	17	it	it	PRON
cblr-1794	410	18	more	more	ADV
cblr-1794	410	19	difficult	difficult	ADJ
cblr-1794	410	20	for	for	SCONJ
cblr-1794	410	21	biosimilar	biosimilar	ADJ
cblr-1794	410	22	manufacturers	manufacturer	NOUN
cblr-1794	410	23	to	to	PART
cblr-1794	410	24	design	design	VERB
cblr-1794	410	25	around	around	ADP
cblr-1794	410	26	patents	patent	NOUN
cblr-1794	410	27	.	.	PUNCT
cblr-1794	411	1	148	148	NUM
cblr-1794	411	2	pioneer	pioneer	NOUN
cblr-1794	411	3	biologic	biologic	NOUN
cblr-1794	411	4	manufacturers	manufacturer	NOUN
cblr-1794	411	5	argue	argue	VERB
cblr-1794	411	6	that	that	SCONJ
cblr-1794	411	7	a	a	DET
cblr-1794	411	8	biologic	biologic	NOUN
cblr-1794	411	9	firm	firm	NOUN
cblr-1794	411	10	can	can	AUX
cblr-1794	411	11	never	never	ADV
cblr-1794	411	12	be	be	AUX
cblr-1794	411	13	certain	certain	ADJ
cblr-1794	411	14	whether	whether	SCONJ
cblr-1794	411	15	its	its	PRON
cblr-1794	411	16	patent	patent	NOUN
cblr-1794	411	17	estate	estate	NOUN
cblr-1794	411	18	will	will	AUX
cblr-1794	411	19	cover	cover	VERB
cblr-1794	411	20	the	the	DET
cblr-1794	411	21	exact	exact	ADJ
cblr-1794	411	22	molecule	molecule	NOUN
cblr-1794	411	23	that	that	SCONJ
cblr-1794	411	24	the	the	DET
cblr-1794	411	25	biosimilar	biosimilar	ADJ
cblr-1794	411	26	manufacturer	manufacturer	NOUN
cblr-1794	411	27	produces	produce	VERB
cblr-1794	411	28	.	.	PUNCT
cblr-1794	411	29	149	149	NUM
cblr-1794	411	30	since	since	SCONJ
cblr-1794	411	31	generic	generic	ADJ
cblr-1794	411	32	drugs	drug	NOUN
cblr-1794	411	33	are	be	AUX
cblr-1794	411	34	made	make	VERB
cblr-1794	411	35	from	from	ADP
cblr-1794	411	36	the	the	DET
cblr-1794	411	37	exact	exact	ADJ
cblr-1794	411	38	same	same	ADJ
cblr-1794	411	39	molecule	molecule	NOUN
cblr-1794	411	40	as	as	ADP
cblr-1794	411	41	the	the	DET
cblr-1794	411	42	pioneer	pioneer	NOUN
cblr-1794	411	43	pharmaceutical	pharmaceutical	NOUN
cblr-1794	411	44	,	,	PUNCT
cblr-1794	411	45	the	the	DET
cblr-1794	411	46	pioneer	pioneer	NOUN
cblr-1794	411	47	pharmaceutical	pharmaceutical	NOUN
cblr-1794	411	48	manufacturer	manufacturer	NOUN
cblr-1794	411	49	can	can	AUX
cblr-1794	411	50	rest	rest	VERB
cblr-1794	411	51	assured	assure	VERB
cblr-1794	411	52	that	that	SCONJ
cblr-1794	411	53	its	its	PRON
cblr-1794	411	54	patents	patent	NOUN
cblr-1794	411	55	,	,	PUNCT
cblr-1794	411	56	while	while	SCONJ
cblr-1794	411	57	in	in	ADP
cblr-1794	411	58	force	force	NOUN
cblr-1794	411	59	,	,	PUNCT
cblr-1794	411	60	will	will	AUX
cblr-1794	411	61	prevent	prevent	VERB
cblr-1794	411	62	a	a	DET
cblr-1794	411	63	generic	generic	ADJ
cblr-1794	411	64	manufacturer	manufacturer	NOUN
cblr-1794	411	65	from	from	ADP
cblr-1794	411	66	bringing	bring	VERB
cblr-1794	411	67	a	a	DET
cblr-1794	411	68	generic	generic	NOUN
cblr-1794	411	69	to	to	ADP
cblr-1794	411	70	market	market	NOUN
cblr-1794	411	71	.	.	PUNCT
cblr-1794	412	1	however	however	ADV
cblr-1794	412	2	,	,	PUNCT
cblr-1794	412	3	pioneer	pioneer	NOUN
cblr-1794	412	4	biologic	biologic	NOUN
cblr-1794	412	5	manufacturers	manufacturer	NOUN
cblr-1794	412	6	worry	worry	VERB
cblr-1794	412	7	that	that	SCONJ
cblr-1794	412	8	the	the	DET
cblr-1794	412	9	"	"	PUNCT
cblr-1794	412	10	uncertain	uncertain	ADJ
cblr-1794	412	11	'	'	PUNCT
cblr-1794	412	12	similarity	similarity	NOUN
cblr-1794	412	13	'	'	PUNCT
cblr-1794	412	14	standard	standard	NOUN
cblr-1794	412	15	for	for	ADP
cblr-1794	412	16	approval	approval	NOUN
cblr-1794	412	17	of	of	ADP
cblr-1794	412	18	[	[	X
cblr-1794	412	19	biosimilars	biosimilar	NOUN
cblr-1794	412	20	]	]	PUNCT
cblr-1794	412	21	creates	create	VERB
cblr-1794	412	22	a	a	DET
cblr-1794	412	23	greater	great	ADJ
cblr-1794	412	24	potential	potential	NOUN
cblr-1794	412	25	for	for	SCONJ
cblr-1794	412	26	the	the	DET
cblr-1794	412	27	biologic	biologic	NOUN
cblr-1794	412	28	patents	patent	NOUN
cblr-1794	412	29	to	to	PART
cblr-1794	412	30	be	be	AUX
cblr-1794	412	31	designed	design	VERB
cblr-1794	412	32	around	around	ADP
cblr-1794	412	33	.	.	PUNCT
cblr-1794	413	1	"5	"5	NOUN
cblr-1794	414	1	o	o	NOUN
cblr-1794	414	2	the	the	DET
cblr-1794	414	3	pioneer	pioneer	PROPN
cblr-1794	414	4	biologic	biologic	NOUN
cblr-1794	414	5	drug	drug	NOUN
cblr-1794	414	6	products	product	NOUN
cblr-1794	414	7	to	to	ADP
cblr-1794	414	8	the	the	DET
cblr-1794	414	9	patents	patent	NOUN
cblr-1794	414	10	protecting	protect	VERB
cblr-1794	414	11	them	they	PRON
cblr-1794	414	12	.	.	PUNCT
cblr-1794	415	1	as	as	ADP
cblr-1794	415	2	a	a	DET
cblr-1794	415	3	result	result	NOUN
cblr-1794	415	4	,	,	PUNCT
cblr-1794	415	5	patent	patent	NOUN
cblr-1794	415	6	protection	protection	NOUN
cblr-1794	415	7	should	should	AUX
cblr-1794	415	8	continue	continue	VERB
cblr-1794	415	9	to	to	PART
cblr-1794	415	10	incentivize	incentivize	VERB
cblr-1794	415	11	biotechnology	biotechnology	NOUN
cblr-1794	415	12	innovation	innovation	NOUN
cblr-1794	415	13	.	.	PUNCT
cblr-1794	416	1	"	"	PUNCT
cblr-1794	416	2	)	)	PUNCT
cblr-1794	416	3	.	.	PUNCT
cblr-1794	417	1	145	145	NUM
cblr-1794	417	2	ftc	ftc	PROPN
cblr-1794	417	3	report	report	NOUN
cblr-1794	417	4	,	,	PUNCT
cblr-1794	417	5	supra	supra	PROPN
cblr-1794	417	6	note	note	PROPN
cblr-1794	417	7	14	14	NUM
cblr-1794	417	8	,	,	PUNCT
cblr-1794	417	9	at	at	ADP
cblr-1794	417	10	26	26	NUM
cblr-1794	417	11	146	146	NUM
cblr-1794	417	12	i	i	PRON
cblr-1794	417	13	d.	d.	PROPN
cblr-1794	417	14	at	at	ADP
cblr-1794	417	15	31	31	NUM
cblr-1794	417	16	.	.	PUNCT
cblr-1794	418	1	147	147	NUM
cblr-1794	419	1	i	i	PROPN
cblr-1794	419	2	d.	d.	PROPN
cblr-1794	419	3	(	(	PUNCT
cblr-1794	419	4	alteration	alteration	NOUN
cblr-1794	419	5	in	in	ADP
cblr-1794	419	6	original	original	ADJ
cblr-1794	419	7	)	)	PUNCT
cblr-1794	419	8	(	(	PUNCT
cblr-1794	419	9	quoting	quote	VERB
cblr-1794	419	10	letter	letter	NOUN
cblr-1794	419	11	from	from	ADP
cblr-1794	419	12	the	the	DET
cblr-1794	419	13	biotech	biotech	NOUN
cblr-1794	419	14	.	.	PUNCT
cblr-1794	420	1	indus	indus	PROPN
cblr-1794	420	2	.	.	PUNCT
cblr-1794	421	1	org	org	PROPN
cblr-1794	421	2	.	.	PUNCT
cblr-1794	422	1	to	to	ADP
cblr-1794	422	2	the	the	DET
cblr-1794	422	3	fda	fda	PROPN
cblr-1794	422	4	12	12	NUM
cblr-1794	422	5	(	(	PUNCT
cblr-1794	422	6	dec	dec	PROPN
cblr-1794	422	7	.	.	PROPN
cblr-1794	422	8	23	23	NUM
cblr-1794	422	9	,	,	PUNCT
cblr-1794	422	10	2010	2010	NUM
cblr-1794	422	11	)	)	PUNCT
cblr-1794	422	12	,	,	PUNCT
cblr-1794	422	13	available	available	ADJ
cblr-1794	422	14	at	at	ADP
cblr-1794	422	15	http://www.bio.org/	http://www.bio.org/	PROPN
cblr-1794	422	16	advocacy	advocacy	NOUN
cblr-1794	422	17	/	/	SYM
cblr-1794	422	18	letters	letter	NOUN
cblr-1794	422	19	/	/	SYM
cblr-1794	422	20	bio	bio	NOUN
cblr-1794	422	21	-	-	PUNCT
cblr-1794	422	22	comments	comment	NOUN
cblr-1794	422	23	-	-	PUNCT
cblr-1794	422	24	food	food	NOUN
cblr-1794	422	25	-	-	PUNCT
cblr-1794	422	26	and	and	CCONJ
cblr-1794	422	27	-	-	PUNCT
cblr-1794	422	28	drug	drug	NOUN
cblr-1794	422	29	-	-	PUNCT
cblr-1794	422	30	administration	administration	NOUN
cblr-1794	422	31	-	-	PUNCT
cblr-1794	422	32	approvalpathway	approvalpathway	NOUN
cblr-1794	422	33	-	-	PUNCT
cblr-1794	422	34	biosimilar	biosimilar	ADJ
cblr-1794	422	35	-	-	PUNCT
cblr-1794	422	36	and	and	CCONJ
cblr-1794	422	37	-	-	PUNCT
cblr-1794	422	38	interchan	interchan	ADJ
cblr-1794	422	39	)	)	PUNCT
cblr-1794	422	40	.	.	PUNCT
cblr-1794	423	1	148	148	NUM
cblr-1794	423	2	see	see	VERB
cblr-1794	423	3	letter	letter	NOUN
cblr-1794	423	4	from	from	ADP
cblr-1794	423	5	kelsey	kelsey	PROPN
cblr-1794	423	6	i.	i.	PROPN
cblr-1794	423	7	nix	nix	PROPN
cblr-1794	423	8	to	to	ADP
cblr-1794	423	9	the	the	DET
cblr-1794	423	10	ftc	ftc	PROPN
cblr-1794	423	11	,	,	PUNCT
cblr-1794	423	12	supra	supra	PROPN
cblr-1794	423	13	note	note	PROPN
cblr-1794	423	14	121	121	NUM
cblr-1794	423	15	,	,	PUNCT
cblr-1794	423	16	at	at	ADP
cblr-1794	423	17	3	3	NUM
cblr-1794	423	18	.	.	NOUN
cblr-1794	423	19	149	149	NUM
cblr-1794	423	20	see	see	VERB
cblr-1794	423	21	letter	letter	NOUN
cblr-1794	423	22	from	from	ADP
cblr-1794	423	23	the	the	DET
cblr-1794	423	24	biotech	biotech	NOUN
cblr-1794	423	25	.	.	PUNCT
cblr-1794	424	1	indus	indus	PROPN
cblr-1794	424	2	.	.	PUNCT
cblr-1794	425	1	org	org	PROPN
cblr-1794	425	2	.	.	PUNCT
cblr-1794	426	1	supra	supra	PROPN
cblr-1794	426	2	note	note	PROPN
cblr-1794	426	3	147	147	NUM
cblr-1794	426	4	,	,	PUNCT
cblr-1794	426	5	at	at	ADP
cblr-1794	426	6	5	5	NUM
cblr-1794	426	7	-	-	SYM
cblr-1794	426	8	6	6	NUM
cblr-1794	426	9	.	.	NUM
cblr-1794	426	10	150	150	NUM
cblr-1794	426	11	ftc	ftc	PROPN
cblr-1794	426	12	report	report	NOUN
cblr-1794	426	13	,	,	PUNCT
cblr-1794	426	14	supra	supra	PROPN
cblr-1794	426	15	note	note	PROPN
cblr-1794	426	16	14	14	NUM
cblr-1794	426	17	,	,	PUNCT
cblr-1794	426	18	at	at	ADP
cblr-1794	426	19	33	33	NUM
cblr-1794	426	20	.	.	PUNCT
cblr-1794	427	1	232	232	NUM
cblr-1794	428	1	columia	columia	NOUN
cblr-1794	428	2	businessla	businessla	PROPN
cblr-1794	428	3	wreview	wreview	VERB
cblr-1794	428	4	[	[	X
cblr-1794	428	5	vol	vol	NOUN
cblr-1794	428	6	.	.	PUNCT
cblr-1794	429	1	2013	2013	NUM
cblr-1794	429	2	bpcia	bpcia	NOUN
cblr-1794	429	3	:	:	PUNCT
cblr-1794	429	4	destined	destine	VERB
cblr-1794	429	5	for	for	ADP
cblr-1794	429	6	failure	failure	NOUN
cblr-1794	429	7	?	?	PUNCT
cblr-1794	430	1	however	however	ADV
cblr-1794	430	2	,	,	PUNCT
cblr-1794	430	3	this	this	DET
cblr-1794	430	4	fear	fear	NOUN
cblr-1794	430	5	appears	appear	VERB
cblr-1794	430	6	largely	largely	ADV
cblr-1794	430	7	unfounded	unfounded	ADJ
cblr-1794	430	8	.	.	PUNCT
cblr-1794	431	1	the	the	DET
cblr-1794	431	2	ftc	ftc	PROPN
cblr-1794	431	3	argues	argue	VERB
cblr-1794	431	4	that	that	SCONJ
cblr-1794	431	5	there	there	PRON
cblr-1794	431	6	is	be	VERB
cblr-1794	431	7	no	no	DET
cblr-1794	431	8	reason	reason	NOUN
cblr-1794	431	9	to	to	PART
cblr-1794	431	10	believe	believe	VERB
cblr-1794	431	11	that	that	SCONJ
cblr-1794	431	12	patents	patent	NOUN
cblr-1794	431	13	for	for	ADP
cblr-1794	431	14	innovative	innovative	ADJ
cblr-1794	431	15	biologics	biologic	NOUN
cblr-1794	431	16	have	have	AUX
cblr-1794	431	17	been	be	AUX
cblr-1794	431	18	designed	design	VERB
cblr-1794	431	19	around	around	ADP
cblr-1794	431	20	more	more	ADV
cblr-1794	431	21	frequently	frequently	ADV
cblr-1794	431	22	than	than	ADP
cblr-1794	431	23	patents	patent	NOUN
cblr-1794	431	24	for	for	ADP
cblr-1794	431	25	innovative	innovative	ADJ
cblr-1794	431	26	pharmaceuticals	pharmaceutical	NOUN
cblr-1794	431	27	.	.	PUNCT
cblr-1794	432	1	"	"	PUNCT
cblr-1794	432	2	'	'	PUNCT
cblr-1794	432	3	further	far	ADV
cblr-1794	432	4	,	,	PUNCT
cblr-1794	432	5	the	the	DET
cblr-1794	432	6	patent	patent	NOUN
cblr-1794	432	7	and	and	CCONJ
cblr-1794	432	8	trademark	trademark	NOUN
cblr-1794	432	9	office	office	NOUN
cblr-1794	432	10	's	's	PART
cblr-1794	432	11	written	write	VERB
cblr-1794	432	12	guidelines	guideline	NOUN
cblr-1794	432	13	acknowledge	acknowledge	VERB
cblr-1794	432	14	the	the	DET
cblr-1794	432	15	"	"	PUNCT
cblr-1794	432	16	percent	percent	NOUN
cblr-1794	432	17	identity	identity	NOUN
cblr-1794	432	18	"	"	PUNCT
cblr-1794	432	19	doctrine	doctrine	NOUN
cblr-1794	432	20	,	,	PUNCT
cblr-1794	432	21	allowing	allow	VERB
cblr-1794	432	22	pioneer	pioneer	NOUN
cblr-1794	432	23	biologics	biologic	NOUN
cblr-1794	432	24	manufacturers	manufacturer	NOUN
cblr-1794	432	25	to	to	PART
cblr-1794	432	26	claim	claim	VERB
cblr-1794	432	27	their	their	PRON
cblr-1794	432	28	patent	patent	NOUN
cblr-1794	432	29	has	have	AUX
cblr-1794	432	30	been	be	AUX
cblr-1794	432	31	infringed	infringe	VERB
cblr-1794	432	32	if	if	SCONJ
cblr-1794	432	33	another	another	DET
cblr-1794	432	34	molecule	molecule	NOUN
cblr-1794	432	35	shares	share	NOUN
cblr-1794	432	36	at	at	ADV
cblr-1794	432	37	least	least	ADV
cblr-1794	432	38	seventy	seventy	NUM
cblr-1794	432	39	percent	percent	NOUN
cblr-1794	432	40	identity	identity	NOUN
cblr-1794	432	41	with	with	ADP
cblr-1794	432	42	the	the	DET
cblr-1794	432	43	patented	patent	VERB
cblr-1794	432	44	amino	amino	NOUN
cblr-1794	432	45	acid	acid	NOUN
cblr-1794	432	46	sequence	sequence	NOUN
cblr-1794	432	47	.	.	PUNCT
cblr-1794	433	1	152	152	NUM
cblr-1794	433	2	thus	thus	ADV
cblr-1794	433	3	,	,	PUNCT
cblr-1794	433	4	a	a	DET
cblr-1794	433	5	molecule	molecule	NOUN
cblr-1794	433	6	could	could	AUX
cblr-1794	433	7	differ	differ	VERB
cblr-1794	433	8	by	by	ADP
cblr-1794	433	9	thirty	thirty	NUM
cblr-1794	433	10	percent	percent	NOUN
cblr-1794	433	11	from	from	ADP
cblr-1794	433	12	the	the	DET
cblr-1794	433	13	pioneer	pioneer	NOUN
cblr-1794	433	14	biologic	biologic	NOUN
cblr-1794	433	15	and	and	CCONJ
cblr-1794	433	16	still	still	ADV
cblr-1794	433	17	be	be	AUX
cblr-1794	433	18	covered	cover	VERB
cblr-1794	433	19	by	by	ADP
cblr-1794	433	20	the	the	DET
cblr-1794	433	21	pioneer	pioneer	PROPN
cblr-1794	433	22	biologic	biologic	NOUN
cblr-1794	433	23	's	's	PART
cblr-1794	433	24	patent	patent	NOUN
cblr-1794	433	25	estate	estate	NOUN
cblr-1794	433	26	.	.	PUNCT
cblr-1794	434	1	it	it	PRON
cblr-1794	434	2	will	will	AUX
cblr-1794	434	3	likely	likely	ADV
cblr-1794	434	4	be	be	AUX
cblr-1794	434	5	difficult	difficult	ADJ
cblr-1794	434	6	for	for	SCONJ
cblr-1794	434	7	a	a	DET
cblr-1794	434	8	product	product	NOUN
cblr-1794	434	9	to	to	PART
cblr-1794	434	10	differ	differ	VERB
cblr-1794	434	11	by	by	ADP
cblr-1794	434	12	thirty	thirty	NUM
cblr-1794	434	13	percent	percent	NOUN
cblr-1794	434	14	and	and	CCONJ
cblr-1794	434	15	still	still	ADV
cblr-1794	434	16	be	be	AUX
cblr-1794	434	17	found	find	VERB
cblr-1794	434	18	biosimilar	biosimilar	ADJ
cblr-1794	434	19	,	,	PUNCT
cblr-1794	434	20	no	no	ADV
cblr-1794	434	21	matter	matter	ADV
cblr-1794	434	22	how	how	SCONJ
cblr-1794	434	23	the	the	DET
cblr-1794	434	24	fda	fda	PROPN
cblr-1794	434	25	interprets	interpret	VERB
cblr-1794	434	26	the	the	DET
cblr-1794	434	27	biosimilarity	biosimilarity	NOUN
cblr-1794	434	28	language	language	NOUN
cblr-1794	434	29	in	in	ADP
cblr-1794	434	30	the	the	DET
cblr-1794	434	31	bpcia	bpcia	NOUN
cblr-1794	434	32	.	.	PUNCT
cblr-1794	435	1	under	under	ADP
cblr-1794	435	2	the	the	DET
cblr-1794	435	3	rare	rare	ADJ
cblr-1794	435	4	circumstance	circumstance	NOUN
cblr-1794	435	5	that	that	SCONJ
cblr-1794	435	6	a	a	DET
cblr-1794	435	7	patent	patent	NOUN
cblr-1794	435	8	estate	estate	NOUN
cblr-1794	435	9	could	could	AUX
cblr-1794	435	10	be	be	AUX
cblr-1794	435	11	designed	design	VERB
cblr-1794	435	12	around	around	ADV
cblr-1794	435	13	,	,	PUNCT
cblr-1794	435	14	a	a	DET
cblr-1794	435	15	twelve	twelve	NUM
cblr-1794	435	16	-	-	PUNCT
cblr-1794	435	17	year	year	NOUN
cblr-1794	435	18	exclusivity	exclusivity	NOUN
cblr-1794	435	19	period	period	NOUN
cblr-1794	435	20	is	be	AUX
cblr-1794	435	21	unnecessarily	unnecessarily	ADV
cblr-1794	435	22	long	long	ADJ
cblr-1794	435	23	.	.	PUNCT
cblr-1794	436	1	the	the	DET
cblr-1794	436	2	twelve	twelve	NUM
cblr-1794	436	3	-	-	PUNCT
cblr-1794	436	4	year	year	NOUN
cblr-1794	436	5	exclusivity	exclusivity	NOUN
cblr-1794	436	6	period	period	NOUN
cblr-1794	436	7	is	be	AUX
cblr-1794	436	8	based	base	VERB
cblr-1794	436	9	on	on	ADP
cblr-1794	436	10	a	a	DET
cblr-1794	436	11	study	study	NOUN
cblr-1794	436	12	,	,	PUNCT
cblr-1794	436	13	published	publish	VERB
cblr-1794	436	14	in	in	ADP
cblr-1794	436	15	nature	nature	NOUN
cblr-1794	436	16	reviews	review	VERB
cblr-1794	436	17	drug	drug	NOUN
cblr-1794	436	18	discovery	discovery	NOUN
cblr-1794	436	19	,	,	PUNCT
cblr-1794	436	20	which	which	PRON
cblr-1794	436	21	found	find	VERB
cblr-1794	436	22	that	that	SCONJ
cblr-1794	436	23	biologics	biologic	NOUN
cblr-1794	436	24	manufacturers	manufacturer	NOUN
cblr-1794	436	25	break	break	VERB
cblr-1794	436	26	even	even	ADV
cblr-1794	436	27	between	between	ADP
cblr-1794	436	28	12.9	12.9	NUM
cblr-1794	436	29	and	and	CCONJ
cblr-1794	436	30	16.2	16.2	NUM
cblr-1794	436	31	years	year	NOUN
cblr-1794	436	32	after	after	SCONJ
cblr-1794	436	33	launch.153	launch.153	NOUN
cblr-1794	436	34	however	however	ADV
cblr-1794	436	35	,	,	PUNCT
cblr-1794	436	36	the	the	DET
cblr-1794	436	37	ftc	ftc	PROPN
cblr-1794	436	38	has	have	AUX
cblr-1794	436	39	contested	contest	VERB
cblr-1794	436	40	the	the	DET
cblr-1794	436	41	results	result	NOUN
cblr-1794	436	42	of	of	ADP
cblr-1794	436	43	that	that	DET
cblr-1794	436	44	study	study	NOUN
cblr-1794	436	45	,	,	PUNCT
cblr-1794	436	46	finding	find	VERB
cblr-1794	436	47	that	that	SCONJ
cblr-1794	436	48	even	even	ADV
cblr-1794	436	49	the	the	DET
cblr-1794	436	50	methodology	methodology	NOUN
cblr-1794	436	51	used	use	VERB
cblr-1794	436	52	by	by	ADP
cblr-1794	436	53	the	the	DET
cblr-1794	436	54	study	study	NOUN
cblr-1794	436	55	supports	support	VERB
cblr-1794	436	56	the	the	DET
cblr-1794	436	57	finding	finding	NOUN
cblr-1794	436	58	that	that	SCONJ
cblr-1794	436	59	pioneer	pioneer	NOUN
cblr-1794	436	60	biologics	biologic	NOUN
cblr-1794	436	61	manufacturers	manufacturer	NOUN
cblr-1794	436	62	break	break	VERB
cblr-1794	436	63	even	even	ADV
cblr-1794	436	64	just	just	ADV
cblr-1794	436	65	seven	seven	NUM
cblr-1794	436	66	years	year	NOUN
cblr-1794	436	67	after	after	ADP
cblr-1794	436	68	launch	launch	NOUN
cblr-1794	436	69	.	.	PUNCT
cblr-1794	437	1	154	154	NUM
cblr-1794	437	2	other	other	ADJ
cblr-1794	437	3	independent	independent	ADJ
cblr-1794	437	4	researchers	researcher	NOUN
cblr-1794	437	5	have	have	AUX
cblr-1794	437	6	sided	side	VERB
cblr-1794	437	7	with	with	ADP
cblr-1794	437	8	the	the	DET
cblr-1794	437	9	ftc	ftc	PROPN
cblr-1794	437	10	,	,	PUNCT
cblr-1794	437	11	arguing	argue	VERB
cblr-1794	437	12	that	that	SCONJ
cblr-1794	437	13	a	a	DET
cblr-1794	437	14	seven	seven	NUM
cblr-1794	437	15	-	-	PUNCT
cblr-1794	437	16	year	year	NOUN
cblr-1794	437	17	exclusivity	exclusivity	NOUN
cblr-1794	437	18	period	period	NOUN
cblr-1794	437	19	is	be	AUX
cblr-1794	437	20	sufficient	sufficient	ADJ
cblr-1794	437	21	to	to	PART
cblr-1794	437	22	promote	promote	VERB
cblr-1794	437	23	innovation	innovation	NOUN
cblr-1794	437	24	.	.	PUNCT
cblr-1794	438	1	'5	'5	PROPN
cblr-1794	438	2	5	5	NUM
cblr-1794	438	3	151	151	NUM
cblr-1794	438	4	ftc	ftc	PROPN
cblr-1794	438	5	report	report	NOUN
cblr-1794	438	6	,	,	PUNCT
cblr-1794	438	7	supra	supra	PROPN
cblr-1794	438	8	note	note	PROPN
cblr-1794	438	9	14	14	NUM
cblr-1794	438	10	,	,	PUNCT
cblr-1794	438	11	at	at	ADP
cblr-1794	438	12	26	26	NUM
cblr-1794	438	13	.	.	PUNCT
cblr-1794	439	1	152	152	NUM
cblr-1794	439	2	see	see	VERB
cblr-1794	439	3	patent	patent	NOUN
cblr-1794	439	4	&	&	CCONJ
cblr-1794	439	5	trademark	trademark	PROPN
cblr-1794	439	6	office	office	NOUN
cblr-1794	439	7	,	,	PUNCT
cblr-1794	439	8	written	write	VERB
cblr-1794	439	9	description	description	NOUN
cblr-1794	439	10	training	training	NOUN
cblr-1794	439	11	iviaterials	iviaterial	NOUN
cblr-1794	439	12	(	(	PUNCT
cblr-1794	439	13	rev	rev	PROPN
cblr-1794	439	14	.	.	PROPN
cblr-1794	439	15	1	1	NUM
cblr-1794	439	16	2008	2008	NUM
cblr-1794	439	17	)	)	PUNCT
cblr-1794	439	18	,	,	PUNCT
cblr-1794	439	19	available	available	ADJ
cblr-1794	439	20	at	at	ADP
cblr-1794	439	21	http://www.uspto.gov/web/menul	http://www.uspto.gov/web/menul	PROPN
cblr-1794	439	22	written.pdf	written.pdf	PROPN
cblr-1794	439	23	.	.	PROPN
cblr-1794	440	1	153	153	NUM
cblr-1794	440	2	henry	henry	PROPN
cblr-1794	440	3	g.	g.	PROPN
cblr-1794	440	4	grabowski	grabowski	PROPN
cblr-1794	440	5	,	,	PUNCT
cblr-1794	440	6	follow	follow	VERB
cblr-1794	440	7	-	-	PUNCT
cblr-1794	440	8	on	on	ADP
cblr-1794	440	9	biologics	biologic	NOUN
cblr-1794	440	10	:	:	PUNCT
cblr-1794	440	11	data	datum	NOUN
cblr-1794	440	12	exclusivity	exclusivity	NOUN
cblr-1794	440	13	and	and	CCONJ
cblr-1794	440	14	the	the	DET
cblr-1794	440	15	balance	balance	NOUN
cblr-1794	440	16	between	between	ADP
cblr-1794	440	17	innovation	innovation	NOUN
cblr-1794	440	18	and	and	CCONJ
cblr-1794	440	19	competition	competition	NOUN
cblr-1794	440	20	,	,	PUNCT
cblr-1794	440	21	7	7	NUM
cblr-1794	440	22	nature	nature	NOUN
cblr-1794	440	23	revs	revs	VERB
cblr-1794	440	24	.	.	PUNCT
cblr-1794	441	1	drug	drug	NOUN
cblr-1794	441	2	discovery	discovery	PROPN
cblr-1794	441	3	479	479	NUM
cblr-1794	441	4	,	,	PUNCT
cblr-1794	441	5	486	486	NUM
cblr-1794	441	6	(	(	PUNCT
cblr-1794	441	7	2008	2008	NUM
cblr-1794	441	8	)	)	PUNCT
cblr-1794	441	9	.	.	PUNCT
cblr-1794	442	1	154	154	NUM
cblr-1794	442	2	ftc	ftc	PROPN
cblr-1794	442	3	report	report	NOUN
cblr-1794	442	4	,	,	PUNCT
cblr-1794	442	5	supra	supra	PROPN
cblr-1794	442	6	note	note	PROPN
cblr-1794	442	7	14	14	NUM
cblr-1794	442	8	,	,	PUNCT
cblr-1794	442	9	at	at	ADP
cblr-1794	442	10	app	app	PROPN
cblr-1794	442	11	.	.	PUNCT
cblr-1794	443	1	a	a	PRON
cblr-1794	443	2	(	(	PUNCT
cblr-1794	443	3	finding	find	VERB
cblr-1794	443	4	that	that	PRON
cblr-1794	443	5	with	with	ADP
cblr-1794	443	6	an	an	DET
cblr-1794	443	7	exclusivity	exclusivity	NOUN
cblr-1794	443	8	period	period	NOUN
cblr-1794	443	9	of	of	ADP
cblr-1794	443	10	seven	seven	NUM
cblr-1794	443	11	years	year	NOUN
cblr-1794	443	12	,	,	PUNCT
cblr-1794	443	13	there	there	PRON
cblr-1794	443	14	is	be	VERB
cblr-1794	443	15	only	only	ADV
cblr-1794	443	16	one	one	NUM
cblr-1794	443	17	set	set	NOUN
cblr-1794	443	18	of	of	ADP
cblr-1794	443	19	assumptions	assumption	NOUN
cblr-1794	443	20	(	(	PUNCT
cblr-1794	443	21	of	of	ADP
cblr-1794	443	22	those	those	PRON
cblr-1794	443	23	most	most	ADV
cblr-1794	443	24	commonly	commonly	ADV
cblr-1794	443	25	used	use	VERB
cblr-1794	443	26	)	)	PUNCT
cblr-1794	443	27	that	that	PRON
cblr-1794	443	28	does	do	AUX
cblr-1794	443	29	not	not	PART
cblr-1794	443	30	result	result	VERB
cblr-1794	443	31	in	in	ADP
cblr-1794	443	32	the	the	DET
cblr-1794	443	33	branded	brand	VERB
cblr-1794	443	34	manufacturer	manufacturer	NOUN
cblr-1794	443	35	breaking	break	VERB
cblr-1794	443	36	even	even	ADV
cblr-1794	443	37	)	)	PUNCT
cblr-1794	443	38	.	.	PUNCT
cblr-1794	444	1	155	155	NUM
cblr-1794	444	2	alex	alex	PROPN
cblr-1794	444	3	brill	brill	PROPN
cblr-1794	444	4	,	,	PUNCT
cblr-1794	444	5	a	a	DET
cblr-1794	444	6	research	research	NOUN
cblr-1794	444	7	fellow	fellow	NOUN
cblr-1794	444	8	at	at	ADP
cblr-1794	444	9	the	the	DET
cblr-1794	444	10	american	american	PROPN
cblr-1794	444	11	enterprise	enterprise	PROPN
cblr-1794	444	12	institute	institute	PROPN
cblr-1794	444	13	,	,	PUNCT
cblr-1794	444	14	supports	support	VERB
cblr-1794	444	15	a	a	DET
cblr-1794	444	16	seven	seven	NUM
cblr-1794	444	17	-	-	PUNCT
cblr-1794	444	18	year	year	NOUN
cblr-1794	444	19	exclusivity	exclusivity	NOUN
cblr-1794	444	20	period	period	NOUN
cblr-1794	444	21	.	.	PUNCT
cblr-1794	445	1	he	he	PRON
cblr-1794	445	2	argues	argue	VERB
cblr-1794	445	3	that	that	SCONJ
cblr-1794	445	4	"	"	PUNCT
cblr-1794	445	5	seven	seven	NUM
cblr-1794	445	6	years	year	NOUN
cblr-1794	445	7	is	be	AUX
cblr-1794	445	8	no	no	PRON
cblr-1794	445	9	.	.	PUNCT
cblr-1794	445	10	i:209	i:209	PROPN
cblr-1794	445	11	]	]	PUNCT
cblr-1794	445	12	233	233	NUM
cblr-1794	445	13	if	if	SCONJ
cblr-1794	445	14	the	the	DET
cblr-1794	445	15	majority	majority	NOUN
cblr-1794	445	16	of	of	ADP
cblr-1794	445	17	pioneer	pioneer	NOUN
cblr-1794	445	18	biologics	biologic	NOUN
cblr-1794	445	19	manufacturers	manufacturer	NOUN
cblr-1794	445	20	break	break	VERB
cblr-1794	445	21	even	even	ADV
cblr-1794	445	22	seven	seven	NUM
cblr-1794	445	23	years	year	NOUN
cblr-1794	445	24	after	after	ADP
cblr-1794	445	25	launch	launch	NOUN
cblr-1794	445	26	,	,	PUNCT
cblr-1794	445	27	a	a	DET
cblr-1794	445	28	twelve	twelve	NUM
cblr-1794	445	29	-	-	PUNCT
cblr-1794	445	30	year	year	NOUN
cblr-1794	445	31	exclusivity	exclusivity	NOUN
cblr-1794	445	32	period	period	NOUN
cblr-1794	445	33	provides	provide	VERB
cblr-1794	445	34	a	a	DET
cblr-1794	445	35	windfall	windfall	NOUN
cblr-1794	445	36	to	to	ADP
cblr-1794	445	37	these	these	DET
cblr-1794	445	38	firms	firm	NOUN
cblr-1794	445	39	.	.	PUNCT
cblr-1794	446	1	as	as	SCONJ
cblr-1794	446	2	discussed	discuss	VERB
cblr-1794	446	3	above	above	ADV
cblr-1794	446	4	,	,	PUNCT
cblr-1794	446	5	unlike	unlike	ADP
cblr-1794	446	6	in	in	ADP
cblr-1794	446	7	the	the	DET
cblr-1794	446	8	pharmaceutical	pharmaceutical	ADJ
cblr-1794	446	9	industry	industry	NOUN
cblr-1794	446	10	,	,	PUNCT
cblr-1794	446	11	neither	neither	CCONJ
cblr-1794	446	12	the	the	DET
cblr-1794	446	13	price	price	NOUN
cblr-1794	446	14	of	of	ADP
cblr-1794	446	15	the	the	DET
cblr-1794	446	16	drug	drug	NOUN
cblr-1794	446	17	nor	nor	CCONJ
cblr-1794	446	18	reference	reference	NOUN
cblr-1794	446	19	product	product	NOUN
cblr-1794	446	20	market	market	NOUN
cblr-1794	446	21	share	share	NOUN
cblr-1794	446	22	drop	drop	VERB
cblr-1794	446	23	substantially	substantially	ADV
cblr-1794	446	24	when	when	SCONJ
cblr-1794	446	25	biosimilars	biosimilar	NOUN
cblr-1794	446	26	begin	begin	VERB
cblr-1794	446	27	to	to	PART
cblr-1794	446	28	enter	enter	VERB
cblr-1794	446	29	the	the	DET
cblr-1794	446	30	market.15	market.15	NOUN
cblr-1794	446	31	6	6	NUM
cblr-1794	446	32	thus	thus	ADV
cblr-1794	446	33	,	,	PUNCT
cblr-1794	446	34	the	the	DET
cblr-1794	446	35	biologic	biologic	NOUN
cblr-1794	446	36	manufacturer	manufacturer	NOUN
cblr-1794	446	37	continues	continue	VERB
cblr-1794	446	38	to	to	PART
cblr-1794	446	39	make	make	VERB
cblr-1794	446	40	a	a	DET
cblr-1794	446	41	profit	profit	NOUN
cblr-1794	446	42	long	long	ADV
cblr-1794	446	43	after	after	SCONJ
cblr-1794	446	44	the	the	DET
cblr-1794	446	45	exclusivity	exclusivity	NOUN
cblr-1794	446	46	period	period	NOUN
cblr-1794	446	47	expires	expire	VERB
cblr-1794	446	48	.	.	PUNCT
cblr-1794	447	1	a	a	DET
cblr-1794	447	2	twelve	twelve	NUM
cblr-1794	447	3	-	-	PUNCT
cblr-1794	447	4	year	year	NOUN
cblr-1794	447	5	exclusivity	exclusivity	NOUN
cblr-1794	447	6	period	period	NOUN
cblr-1794	447	7	is	be	AUX
cblr-1794	447	8	therefore	therefore	ADV
cblr-1794	447	9	unnecessary	unnecessary	ADJ
cblr-1794	447	10	to	to	PART
cblr-1794	447	11	incentivize	incentivize	VERB
cblr-1794	447	12	biologics	biologic	NOUN
cblr-1794	447	13	manufacturers	manufacturer	NOUN
cblr-1794	447	14	to	to	PART
cblr-1794	447	15	create	create	VERB
cblr-1794	447	16	new	new	ADJ
cblr-1794	447	17	drugs	drug	NOUN
cblr-1794	447	18	.	.	PUNCT
cblr-1794	448	1	further	far	ADV
cblr-1794	448	2	,	,	PUNCT
cblr-1794	448	3	such	such	DET
cblr-1794	448	4	a	a	DET
cblr-1794	448	5	long	long	ADJ
cblr-1794	448	6	exclusivity	exclusivity	NOUN
cblr-1794	448	7	period	period	NOUN
cblr-1794	448	8	detracts	detract	VERB
cblr-1794	448	9	from	from	ADP
cblr-1794	448	10	the	the	DET
cblr-1794	448	11	cost	cost	NOUN
cblr-1794	448	12	savings	saving	NOUN
cblr-1794	448	13	that	that	SCONJ
cblr-1794	448	14	the	the	DET
cblr-1794	448	15	bpcia	bpcia	NOUN
cblr-1794	448	16	is	be	AUX
cblr-1794	448	17	trying	try	VERB
cblr-1794	448	18	to	to	PART
cblr-1794	448	19	create	create	VERB
cblr-1794	448	20	.	.	PUNCT
cblr-1794	449	1	2	2	X
cblr-1794	449	2	.	.	X
cblr-1794	449	3	exclusivity	exclusivity	NOUN
cblr-1794	449	4	period	period	NOUN
cblr-1794	449	5	for	for	ADP
cblr-1794	449	6	the	the	DET
cblr-1794	449	7	first	first	ADJ
cblr-1794	449	8	interchangeable	interchangeable	ADJ
cblr-1794	449	9	biosimilar	biosimilar	NOUN
cblr-1794	449	10	the	the	DET
cblr-1794	449	11	hatch	hatch	NOUN
cblr-1794	449	12	-	-	PUNCT
cblr-1794	449	13	waxman	waxman	PROPN
cblr-1794	449	14	act	act	NOUN
cblr-1794	449	15	provides	provide	VERB
cblr-1794	449	16	a	a	DET
cblr-1794	449	17	180	180	NUM
cblr-1794	449	18	-	-	PUNCT
cblr-1794	449	19	day	day	NOUN
cblr-1794	449	20	marketing	marketing	NOUN
cblr-1794	449	21	exclusivity	exclusivity	NOUN
cblr-1794	449	22	period	period	NOUN
cblr-1794	449	23	to	to	ADP
cblr-1794	449	24	the	the	DET
cblr-1794	449	25	first	first	ADJ
cblr-1794	449	26	generic	generic	ADJ
cblr-1794	449	27	drug	drug	NOUN
cblr-1794	449	28	applicant	applicant	NOUN
cblr-1794	449	29	that	that	PRON
cblr-1794	449	30	challenges	challenge	VERB
cblr-1794	449	31	the	the	DET
cblr-1794	449	32	patents	patent	NOUN
cblr-1794	449	33	relating	relate	VERB
cblr-1794	449	34	to	to	ADP
cblr-1794	449	35	the	the	DET
cblr-1794	449	36	branded	brand	VERB
cblr-1794	449	37	drug	drug	NOUN
cblr-1794	449	38	.	.	PUNCT
cblr-1794	450	1	'57	'57	NUM
cblr-1794	450	2	the	the	DET
cblr-1794	450	3	d.c	d.c	PROPN
cblr-1794	450	4	.	.	PROPN
cblr-1794	450	5	circuit	circuit	PROPN
cblr-1794	450	6	explains	explain	VERB
cblr-1794	450	7	that	that	SCONJ
cblr-1794	450	8	the	the	DET
cblr-1794	450	9	180	180	NUM
cblr-1794	450	10	-	-	PUNCT
cblr-1794	450	11	day	day	NOUN
cblr-1794	450	12	exclusivity	exclusivity	NOUN
cblr-1794	450	13	period	period	NOUN
cblr-1794	450	14	rewards	reward	VERB
cblr-1794	450	15	the	the	DET
cblr-1794	450	16	first	first	ADJ
cblr-1794	450	17	generic	generic	ADJ
cblr-1794	450	18	applicant	applicant	NOUN
cblr-1794	450	19	for	for	ADP
cblr-1794	450	20	the	the	DET
cblr-1794	450	21	expense	expense	NOUN
cblr-1794	450	22	and	and	CCONJ
cblr-1794	450	23	effort	effort	NOUN
cblr-1794	450	24	involved	involve	VERB
cblr-1794	450	25	in	in	ADP
cblr-1794	450	26	challenging	challenge	VERB
cblr-1794	450	27	the	the	DET
cblr-1794	450	28	branded	brand	VERB
cblr-1794	450	29	drug	drug	NOUN
cblr-1794	450	30	's	's	PART
cblr-1794	450	31	patents.s58	patents.s58	NOUN
cblr-1794	450	32	the	the	DET
cblr-1794	450	33	first	first	ADJ
cblr-1794	450	34	generic	generic	ADJ
cblr-1794	450	35	sponsor	sponsor	NOUN
cblr-1794	450	36	can	can	AUX
cblr-1794	450	37	sell	sell	VERB
cblr-1794	450	38	its	its	PRON
cblr-1794	450	39	product	product	NOUN
cblr-1794	450	40	at	at	ADP
cblr-1794	450	41	seventy	seventy	NUM
cblr-1794	450	42	-	-	PUNCT
cblr-1794	450	43	five	five	NUM
cblr-1794	450	44	percent	percent	NOUN
cblr-1794	450	45	of	of	ADP
cblr-1794	450	46	the	the	DET
cblr-1794	450	47	price	price	NOUN
cblr-1794	450	48	of	of	ADP
cblr-1794	450	49	the	the	DET
cblr-1794	450	50	reference	reference	NOUN
cblr-1794	450	51	pharmaceutical	pharmaceutical	NOUN
cblr-1794	450	52	.	.	PUNCT
cblr-1794	451	1	1	1	NUM
cblr-1794	451	2	59	59	NUM
cblr-1794	451	3	however	however	ADV
cblr-1794	451	4	,	,	PUNCT
cblr-1794	451	5	once	once	SCONJ
cblr-1794	451	6	the	the	DET
cblr-1794	451	7	first	first	ADJ
cblr-1794	451	8	generic	generic	ADJ
cblr-1794	451	9	sponsor	sponsor	NOUN
cblr-1794	451	10	makes	make	VERB
cblr-1794	451	11	a	a	DET
cblr-1794	451	12	successful	successful	ADJ
cblr-1794	451	13	challenge	challenge	NOUN
cblr-1794	451	14	,	,	PUNCT
cblr-1794	451	15	subsequent	subsequent	ADJ
cblr-1794	451	16	generic	generic	ADJ
cblr-1794	451	17	sponsors	sponsor	NOUN
cblr-1794	451	18	do	do	AUX
cblr-1794	451	19	not	not	PART
cblr-1794	451	20	have	have	VERB
cblr-1794	451	21	to	to	PART
cblr-1794	451	22	relitigate	relitigate	VERB
cblr-1794	451	23	the	the	DET
cblr-1794	451	24	patents	patent	NOUN
cblr-1794	451	25	and	and	CCONJ
cblr-1794	451	26	can	can	AUX
cblr-1794	451	27	quickly	quickly	ADV
cblr-1794	451	28	enter	enter	VERB
cblr-1794	451	29	the	the	DET
cblr-1794	451	30	market	market	NOUN
cblr-1794	451	31	.	.	PUNCT
cblr-1794	452	1	16	16	NUM
cblr-1794	452	2	0	0	NUM
cblr-1794	452	3	sufficient	sufficient	ADJ
cblr-1794	452	4	to	to	PART
cblr-1794	452	5	ensure	ensure	VERB
cblr-1794	452	6	that	that	SCONJ
cblr-1794	452	7	innovator	innovator	NOUN
cblr-1794	452	8	drug	drug	NOUN
cblr-1794	452	9	companies	company	NOUN
cblr-1794	452	10	continue	continue	VERB
cblr-1794	452	11	to	to	PART
cblr-1794	452	12	earn	earn	VERB
cblr-1794	452	13	the	the	DET
cblr-1794	452	14	necessary	necessary	ADJ
cblr-1794	452	15	economic	economic	ADJ
cblr-1794	452	16	rents	rent	NOUN
cblr-1794	452	17	,	,	PUNCT
cblr-1794	452	18	but	but	CCONJ
cblr-1794	452	19	that	that	SCONJ
cblr-1794	452	20	a	a	DET
cblr-1794	452	21	long	long	ADJ
cblr-1794	452	22	period	period	NOUN
cblr-1794	452	23	would	would	AUX
cblr-1794	452	24	lead	lead	VERB
cblr-1794	452	25	to	to	ADP
cblr-1794	452	26	unreasonably	unreasonably	ADV
cblr-1794	452	27	large	large	ADJ
cblr-1794	452	28	rent[s	rent[	NOUN
cblr-1794	452	29	]	]	PUNCT
cblr-1794	452	30	.	.	PUNCT
cblr-1794	452	31	.	.	PUNCT
cblr-1794	452	32	.	.	PUNCT
cblr-1794	453	1	and	and	CCONJ
cblr-1794	453	2	provide	provide	VERB
cblr-1794	453	3	no	no	DET
cblr-1794	453	4	additional	additional	ADJ
cblr-1794	453	5	benefit	benefit	NOUN
cblr-1794	453	6	to	to	ADP
cblr-1794	453	7	consumers	consumer	NOUN
cblr-1794	453	8	.	.	PUNCT
cblr-1794	453	9	"	"	PUNCT
cblr-1794	454	1	carver	carver	NOUN
cblr-1794	454	2	et	et	PROPN
cblr-1794	454	3	al	al	PROPN
cblr-1794	454	4	.	.	PROPN
cblr-1794	454	5	,	,	PUNCT
cblr-1794	454	6	supra	supra	PROPN
cblr-1794	454	7	note	note	PROPN
cblr-1794	454	8	20	20	NUM
cblr-1794	454	9	,	,	PUNCT
cblr-1794	454	10	at	at	ADP
cblr-1794	454	11	797	797	NUM
cblr-1794	454	12	(	(	PUNCT
cblr-1794	454	13	alteration	alteration	NOUN
cblr-1794	454	14	in	in	ADP
cblr-1794	454	15	original	original	ADJ
cblr-1794	454	16	)	)	PUNCT
cblr-1794	454	17	(	(	PUNCT
cblr-1794	454	18	internal	internal	ADJ
cblr-1794	454	19	quotation	quotation	NOUN
cblr-1794	454	20	marks	mark	NOUN
cblr-1794	454	21	omitted	omit	VERB
cblr-1794	454	22	)	)	PUNCT
cblr-1794	454	23	.	.	PUNCT
cblr-1794	455	1	156	156	NUM
cblr-1794	455	2	see	see	VERB
cblr-1794	455	3	supra	supra	PROPN
cblr-1794	455	4	part	part	PROPN
cblr-1794	455	5	iii.a	iii.a	PROPN
cblr-1794	455	6	-	-	PROPN
cblr-1794	455	7	b.	b.	PROPN
cblr-1794	455	8	157	157	NUM
cblr-1794	455	9	ftc	ftc	PROPN
cblr-1794	455	10	report	report	NOUN
cblr-1794	455	11	,	,	PUNCT
cblr-1794	455	12	supra	supra	PROPN
cblr-1794	455	13	note	note	PROPN
cblr-1794	455	14	14	14	NUM
cblr-1794	455	15	,	,	PUNCT
cblr-1794	455	16	at	at	ADP
cblr-1794	455	17	65	65	NUM
cblr-1794	455	18	.	.	PUNCT
cblr-1794	456	1	158	158	NUM
cblr-1794	456	2	mova	mova	PROPN
cblr-1794	456	3	pharmaceutical	pharmaceutical	PROPN
cblr-1794	456	4	corp	corp	PROPN
cblr-1794	456	5	.	.	PROPN
cblr-1794	456	6	v.	v.	PROPN
cblr-1794	456	7	shalala	shalala	PROPN
cblr-1794	456	8	,	,	PUNCT
cblr-1794	456	9	140	140	NUM
cblr-1794	456	10	f.3d	f.3d	NUM
cblr-1794	456	11	1060	1060	NUM
cblr-1794	456	12	,	,	PUNCT
cblr-1794	456	13	1074	1074	NUM
cblr-1794	456	14	(	(	PUNCT
cblr-1794	456	15	d.c	d.c	PROPN
cblr-1794	456	16	.	.	PROPN
cblr-1794	456	17	cir	cir	PROPN
cblr-1794	456	18	.	.	PUNCT
cblr-1794	456	19	1998	1998	NUM
cblr-1794	456	20	)	)	PUNCT
cblr-1794	456	21	.	.	PUNCT
cblr-1794	457	1	159	159	NUM
cblr-1794	457	2	see	see	VERB
cblr-1794	457	3	generally	generally	ADV
cblr-1794	457	4	ftc	ftc	PROPN
cblr-1794	457	5	report	report	PROPN
cblr-1794	457	6	,	,	PUNCT
cblr-1794	457	7	supra	supra	PROPN
cblr-1794	457	8	note	note	PROPN
cblr-1794	457	9	14	14	NUM
cblr-1794	457	10	,	,	PUNCT
cblr-1794	457	11	at	at	ADP
cblr-1794	457	12	12	12	NUM
cblr-1794	457	13	(	(	PUNCT
cblr-1794	457	14	noting	note	VERB
cblr-1794	457	15	that	that	SCONJ
cblr-1794	457	16	the	the	DET
cblr-1794	457	17	first	first	ADJ
cblr-1794	457	18	generic	generic	ADJ
cblr-1794	457	19	entrant	entrant	NOUN
cblr-1794	457	20	generally	generally	ADV
cblr-1794	457	21	offers	offer	VERB
cblr-1794	457	22	a	a	DET
cblr-1794	457	23	price	price	NOUN
cblr-1794	457	24	that	that	PRON
cblr-1794	457	25	is	be	AUX
cblr-1794	457	26	twenty	twenty	NUM
cblr-1794	457	27	-	-	PUNCT
cblr-1794	457	28	five	five	NUM
cblr-1794	457	29	percent	percent	NOUN
cblr-1794	457	30	lower	low	ADJ
cblr-1794	457	31	than	than	ADP
cblr-1794	457	32	the	the	DET
cblr-1794	457	33	reference	reference	NOUN
cblr-1794	457	34	drug	drug	NOUN
cblr-1794	457	35	price	price	NOUN
cblr-1794	457	36	)	)	PUNCT
cblr-1794	457	37	.	.	PUNCT
cblr-1794	458	1	160	160	NUM
cblr-1794	459	1	i	i	PRON
cblr-1794	459	2	d.	d.	PROPN
cblr-1794	459	3	at	at	ADP
cblr-1794	459	4	65	65	NUM
cblr-1794	459	5	.	.	PUNCT
cblr-1794	460	1	coluama	coluama	PROPN
cblr-1794	461	1	b	b	PRON
cblr-1794	461	2	usiness	usiness	NOUN
cblr-1794	461	3	la	la	PROPN
cblr-1794	461	4	w	w	PROPN
cblr-1794	461	5	re	re	PROPN
cblr-1794	461	6	vie	vie	PROPN
cblr-1794	461	7	w	w	PROPN
cblr-1794	462	1	[	[	X
cblr-1794	462	2	vol	vol	NOUN
cblr-1794	462	3	.	.	PUNCT
cblr-1794	462	4	2013234	2013234	NUM
cblr-1794	462	5	once	once	SCONJ
cblr-1794	462	6	multiple	multiple	ADJ
cblr-1794	462	7	generics	generic	NOUN
cblr-1794	462	8	have	have	AUX
cblr-1794	462	9	entered	enter	VERB
cblr-1794	462	10	the	the	DET
cblr-1794	462	11	market	market	NOUN
cblr-1794	462	12	,	,	PUNCT
cblr-1794	462	13	the	the	DET
cblr-1794	462	14	price	price	NOUN
cblr-1794	462	15	will	will	AUX
cblr-1794	462	16	decrease	decrease	VERB
cblr-1794	462	17	to	to	ADP
cblr-1794	462	18	around	around	ADV
cblr-1794	462	19	twenty	twenty	NUM
cblr-1794	462	20	percent	percent	NOUN
cblr-1794	462	21	of	of	ADP
cblr-1794	462	22	the	the	DET
cblr-1794	462	23	original	original	ADJ
cblr-1794	462	24	price.161	price.161	NOUN
cblr-1794	462	25	the	the	DET
cblr-1794	462	26	180	180	NUM
cblr-1794	462	27	-	-	PUNCT
cblr-1794	462	28	day	day	NOUN
cblr-1794	462	29	exclusivity	exclusivity	NOUN
cblr-1794	462	30	period	period	NOUN
cblr-1794	462	31	allows	allow	VERB
cblr-1794	462	32	"	"	PUNCT
cblr-1794	462	33	the	the	DET
cblr-1794	462	34	first	first	ADJ
cblr-1794	462	35	generic	generic	ADJ
cblr-1794	462	36	entrant	entrant	NOUN
cblr-1794	462	37	to	to	PART
cblr-1794	462	38	recoup	recoup	VERB
cblr-1794	462	39	its	its	PRON
cblr-1794	462	40	patent	patent	NOUN
cblr-1794	462	41	litigation	litigation	NOUN
cblr-1794	462	42	costs	cost	NOUN
cblr-1794	462	43	before	before	ADP
cblr-1794	462	44	the	the	DET
cblr-1794	462	45	substantial	substantial	ADJ
cblr-1794	462	46	price	price	NOUN
cblr-1794	462	47	drop	drop	NOUN
cblr-1794	462	48	caused	cause	VERB
cblr-1794	462	49	by	by	ADP
cblr-1794	462	50	multiple	multiple	ADJ
cblr-1794	462	51	generic	generic	ADJ
cblr-1794	462	52	entrants	entrant	NOUN
cblr-1794	462	53	[	[	X
cblr-1794	462	54	occurs]."162	occurs]."162	NOUN
cblr-1794	462	55	the	the	DET
cblr-1794	462	56	bpcia	bpcia	NOUN
cblr-1794	462	57	provides	provide	VERB
cblr-1794	462	58	that	that	SCONJ
cblr-1794	462	59	the	the	DET
cblr-1794	462	60	fda	fda	PROPN
cblr-1794	462	61	may	may	AUX
cblr-1794	462	62	not	not	PART
cblr-1794	462	63	designate	designate	VERB
cblr-1794	462	64	a	a	DET
cblr-1794	462	65	second	second	ADJ
cblr-1794	462	66	product	product	NOUN
cblr-1794	462	67	as	as	ADP
cblr-1794	462	68	biosimilar	biosimilar	NOUN
cblr-1794	462	69	until	until	ADP
cblr-1794	462	70	the	the	DET
cblr-1794	462	71	earlier	early	ADJ
cblr-1794	462	72	of	of	ADP
cblr-1794	462	73	(	(	PUNCT
cblr-1794	462	74	1	1	NUM
cblr-1794	462	75	)	)	PUNCT
cblr-1794	462	76	one	one	NUM
cblr-1794	462	77	year	year	NOUN
cblr-1794	462	78	after	after	ADP
cblr-1794	462	79	commercial	commercial	ADJ
cblr-1794	462	80	marketing	marketing	NOUN
cblr-1794	462	81	of	of	ADP
cblr-1794	462	82	the	the	DET
cblr-1794	462	83	first	first	ADJ
cblr-1794	462	84	interchangeable	interchangeable	ADJ
cblr-1794	462	85	biosimilar	biosimilar	NOUN
cblr-1794	462	86	;	;	PUNCT
cblr-1794	462	87	(	(	PUNCT
cblr-1794	462	88	2	2	NUM
cblr-1794	462	89	)	)	PUNCT
cblr-1794	462	90	eighteen	eighteen	NUM
cblr-1794	462	91	months	month	NOUN
cblr-1794	462	92	after	after	ADP
cblr-1794	462	93	a	a	DET
cblr-1794	462	94	final	final	ADJ
cblr-1794	462	95	court	court	NOUN
cblr-1794	462	96	decision	decision	NOUN
cblr-1794	462	97	or	or	CCONJ
cblr-1794	462	98	dismissal	dismissal	NOUN
cblr-1794	462	99	on	on	ADP
cblr-1794	462	100	all	all	DET
cblr-1794	462	101	patents	patent	NOUN
cblr-1794	462	102	in	in	ADP
cblr-1794	462	103	suit	suit	NOUN
cblr-1794	462	104	brought	bring	VERB
cblr-1794	462	105	against	against	ADP
cblr-1794	462	106	the	the	DET
cblr-1794	462	107	first	first	ADJ
cblr-1794	462	108	approved	approve	VERB
cblr-1794	462	109	interchangeable	interchangeable	ADJ
cblr-1794	462	110	biosimilar	biosimilar	NOUN
cblr-1794	462	111	;	;	PUNCT
cblr-1794	462	112	(	(	PUNCT
cblr-1794	462	113	3	3	X
cblr-1794	462	114	)	)	PUNCT
cblr-1794	462	115	forty	forty	NUM
cblr-1794	462	116	-	-	PUNCT
cblr-1794	462	117	two	two	NUM
cblr-1794	462	118	months	month	NOUN
cblr-1794	462	119	after	after	ADP
cblr-1794	462	120	approval	approval	NOUN
cblr-1794	462	121	of	of	ADP
cblr-1794	462	122	the	the	DET
cblr-1794	462	123	first	first	ADJ
cblr-1794	462	124	interchangeable	interchangeable	ADJ
cblr-1794	462	125	biosimilar	biosimilar	NOUN
cblr-1794	462	126	if	if	SCONJ
cblr-1794	462	127	litigation	litigation	NOUN
cblr-1794	462	128	is	be	AUX
cblr-1794	462	129	still	still	ADV
cblr-1794	462	130	ongoing	ongoing	ADJ
cblr-1794	462	131	;	;	PUNCT
cblr-1794	462	132	or	or	CCONJ
cblr-1794	462	133	(	(	PUNCT
cblr-1794	462	134	4	4	NUM
cblr-1794	462	135	)	)	PUNCT
cblr-1794	462	136	eighteen	eighteen	NUM
cblr-1794	462	137	months	month	NOUN
cblr-1794	462	138	after	after	ADP
cblr-1794	462	139	approval	approval	NOUN
cblr-1794	462	140	of	of	ADP
cblr-1794	462	141	the	the	DET
cblr-1794	462	142	first	first	ADJ
cblr-1794	462	143	interchangeable	interchangeable	ADJ
cblr-1794	462	144	biosimilar	biosimilar	NOUN
cblr-1794	462	145	if	if	SCONJ
cblr-1794	462	146	the	the	DET
cblr-1794	462	147	sponsor	sponsor	NOUN
cblr-1794	462	148	has	have	AUX
cblr-1794	462	149	not	not	PART
cblr-1794	462	150	been	be	AUX
cblr-1794	462	151	sued	sue	VERB
cblr-1794	462	152	.	.	PUNCT
cblr-1794	463	1	16	16	NUM
cblr-1794	463	2	3	3	NUM
cblr-1794	463	3	the	the	DET
cblr-1794	463	4	exclusivity	exclusivity	NOUN
cblr-1794	463	5	period	period	NOUN
cblr-1794	463	6	thus	thus	ADV
cblr-1794	463	7	ranges	range	VERB
cblr-1794	463	8	from	from	ADP
cblr-1794	463	9	one	one	NUM
cblr-1794	463	10	year	year	NOUN
cblr-1794	463	11	to	to	ADP
cblr-1794	463	12	forty	forty	NUM
cblr-1794	463	13	-	-	PUNCT
cblr-1794	463	14	two	two	NUM
cblr-1794	463	15	months	month	NOUN
cblr-1794	463	16	.	.	PUNCT
cblr-1794	464	1	an	an	DET
cblr-1794	464	2	exclusivity	exclusivity	NOUN
cblr-1794	464	3	period	period	NOUN
cblr-1794	464	4	for	for	ADP
cblr-1794	464	5	the	the	DET
cblr-1794	464	6	first	first	ADJ
cblr-1794	464	7	interchangeable	interchangeable	ADJ
cblr-1794	464	8	biosimilar	biosimilar	NOUN
cblr-1794	464	9	is	be	AUX
cblr-1794	464	10	unnecessary	unnecessary	ADJ
cblr-1794	464	11	.	.	PUNCT
cblr-1794	465	1	the	the	DET
cblr-1794	465	2	entrance	entrance	NOUN
cblr-1794	465	3	of	of	ADP
cblr-1794	465	4	the	the	DET
cblr-1794	465	5	first	first	ADJ
cblr-1794	465	6	interchangeable	interchangeable	ADJ
cblr-1794	465	7	biosimilar	biosimilar	NOUN
cblr-1794	465	8	will	will	AUX
cblr-1794	465	9	not	not	PART
cblr-1794	465	10	lead	lead	VERB
cblr-1794	465	11	to	to	ADP
cblr-1794	465	12	a	a	DET
cblr-1794	465	13	flood	flood	NOUN
cblr-1794	465	14	of	of	ADP
cblr-1794	465	15	subsequent	subsequent	ADJ
cblr-1794	465	16	interchangeable	interchangeable	ADJ
cblr-1794	465	17	biosimilars	biosimilar	NOUN
cblr-1794	465	18	on	on	ADP
cblr-1794	465	19	the	the	DET
cblr-1794	465	20	market	market	NOUN
cblr-1794	465	21	because	because	SCONJ
cblr-1794	465	22	demonstrating	demonstrate	VERB
cblr-1794	465	23	interchangeability	interchangeability	NOUN
cblr-1794	465	24	will	will	AUX
cblr-1794	465	25	almost	almost	ADV
cblr-1794	465	26	certainly	certainly	ADV
cblr-1794	465	27	require	require	VERB
cblr-1794	465	28	clinical	clinical	ADJ
cblr-1794	465	29	trials.1	trials.1	NOUN
cblr-1794	465	30	64	64	NUM
cblr-1794	465	31	unlike	unlike	ADP
cblr-1794	465	32	sponsors	sponsor	NOUN
cblr-1794	465	33	of	of	ADP
cblr-1794	465	34	subsequent	subsequent	ADJ
cblr-1794	465	35	generics	generic	NOUN
cblr-1794	465	36	,	,	PUNCT
cblr-1794	465	37	sponsors	sponsor	NOUN
cblr-1794	465	38	of	of	ADP
cblr-1794	465	39	subsequent	subsequent	ADJ
cblr-1794	465	40	interchangeable	interchangeable	ADJ
cblr-1794	465	41	biologics	biologic	NOUN
cblr-1794	465	42	will	will	AUX
cblr-1794	465	43	be	be	AUX
cblr-1794	465	44	unable	unable	ADJ
cblr-1794	465	45	to	to	PART
cblr-1794	465	46	simply	simply	ADV
cblr-1794	465	47	begin	begin	VERB
cblr-1794	465	48	production	production	NOUN
cblr-1794	465	49	as	as	ADV
cblr-1794	465	50	soon	soon	ADV
cblr-1794	465	51	as	as	SCONJ
cblr-1794	465	52	patent	patent	NOUN
cblr-1794	465	53	challenges	challenge	NOUN
cblr-1794	465	54	are	be	AUX
cblr-1794	465	55	cleared	clear	VERB
cblr-1794	465	56	.	.	PUNCT
cblr-1794	466	1	thus	thus	ADV
cblr-1794	466	2	,	,	PUNCT
cblr-1794	466	3	the	the	DET
cblr-1794	466	4	price	price	NOUN
cblr-1794	466	5	for	for	ADP
cblr-1794	466	6	the	the	DET
cblr-1794	466	7	biologic	biologic	NOUN
cblr-1794	466	8	will	will	AUX
cblr-1794	466	9	not	not	PART
cblr-1794	466	10	drop	drop	VERB
cblr-1794	466	11	as	as	ADV
cblr-1794	466	12	substantially	substantially	ADV
cblr-1794	466	13	as	as	SCONJ
cblr-1794	466	14	when	when	SCONJ
cblr-1794	466	15	the	the	DET
cblr-1794	466	16	first	first	ADJ
cblr-1794	466	17	generic	generic	ADJ
cblr-1794	466	18	enters	enter	VERB
cblr-1794	466	19	the	the	DET
cblr-1794	466	20	market	market	NOUN
cblr-1794	466	21	;	;	PUNCT
cblr-1794	466	22	the	the	DET
cblr-1794	466	23	sponsor	sponsor	NOUN
cblr-1794	466	24	of	of	ADP
cblr-1794	466	25	the	the	DET
cblr-1794	466	26	first	first	ADJ
cblr-1794	466	27	interchangeable	interchangeable	ADJ
cblr-1794	466	28	biosimilar	biosimilar	NOUN
cblr-1794	466	29	will	will	AUX
cblr-1794	466	30	not	not	PART
cblr-1794	466	31	need	need	VERB
cblr-1794	466	32	the	the	DET
cblr-1794	466	33	period	period	NOUN
cblr-1794	466	34	of	of	ADP
cblr-1794	466	35	higher	high	ADJ
cblr-1794	466	36	pricing	pricing	NOUN
cblr-1794	466	37	to	to	PART
cblr-1794	466	38	recoup	recoup	VERB
cblr-1794	466	39	its	its	PRON
cblr-1794	466	40	investment	investment	NOUN
cblr-1794	466	41	.	.	PUNCT
cblr-1794	467	1	indeed	indeed	ADV
cblr-1794	467	2	,	,	PUNCT
cblr-1794	467	3	in	in	ADP
cblr-1794	467	4	comments	comment	NOUN
cblr-1794	467	5	to	to	ADP
cblr-1794	467	6	the	the	DET
cblr-1794	467	7	fda	fda	PROPN
cblr-1794	467	8	,	,	PUNCT
cblr-1794	467	9	a	a	DET
cblr-1794	467	10	potential	potential	ADJ
cblr-1794	467	11	biosimilar	biosimilar	ADJ
cblr-1794	467	12	sponsor	sponsor	NOUN
cblr-1794	467	13	argued	argue	VERB
cblr-1794	467	14	that	that	SCONJ
cblr-1794	467	15	companies	company	NOUN
cblr-1794	467	16	"	"	PUNCT
cblr-1794	467	17	will	will	AUX
cblr-1794	467	18	not	not	PART
cblr-1794	467	19	likely	likely	ADV
cblr-1794	467	20	rely	rely	VERB
cblr-1794	467	21	on	on	ADP
cblr-1794	467	22	winning	win	VERB
cblr-1794	467	23	exclusivity	exclusivity	NOUN
cblr-1794	467	24	to	to	PART
cblr-1794	467	25	invest	invest	VERB
cblr-1794	467	26	in	in	ADP
cblr-1794	467	27	the	the	DET
cblr-1794	467	28	161	161	NUM
cblr-1794	467	29	see	see	NOUN
cblr-1794	467	30	generally	generally	ADV
cblr-1794	467	31	ftc	ftc	PROPN
cblr-1794	467	32	report	report	PROPN
cblr-1794	467	33	,	,	PUNCT
cblr-1794	467	34	supra	supra	PROPN
cblr-1794	467	35	note	note	PROPN
cblr-1794	467	36	14	14	NUM
cblr-1794	467	37	,	,	PUNCT
cblr-1794	467	38	at	at	ADP
cblr-1794	467	39	12	12	NUM
cblr-1794	467	40	(	(	PUNCT
cblr-1794	467	41	noting	note	VERB
cblr-1794	467	42	that	that	SCONJ
cblr-1794	467	43	the	the	DET
cblr-1794	467	44	price	price	NOUN
cblr-1794	467	45	discount	discount	NOUN
cblr-1794	467	46	increases	increase	VERB
cblr-1794	467	47	to	to	ADP
cblr-1794	467	48	eighty	eighty	NUM
cblr-1794	467	49	percent	percent	NOUN
cblr-1794	467	50	once	once	SCONJ
cblr-1794	467	51	multiple	multiple	ADJ
cblr-1794	467	52	generics	generic	NOUN
cblr-1794	467	53	have	have	AUX
cblr-1794	467	54	entered	enter	VERB
cblr-1794	467	55	the	the	DET
cblr-1794	467	56	market	market	NOUN
cblr-1794	467	57	)	)	PUNCT
cblr-1794	467	58	.	.	PUNCT
cblr-1794	468	1	162	162	NUM
cblr-1794	469	1	i	i	PRON
cblr-1794	469	2	d.	d.	PROPN
cblr-1794	469	3	163	163	NUM
cblr-1794	469	4	42	42	NUM
cblr-1794	469	5	u.s.c.a	u.s.c.a	PROPN
cblr-1794	469	6	.	.	PUNCT
cblr-1794	469	7	§	§	PROPN
cblr-1794	469	8	262(k)(6)(a)-(c	262(k)(6)(a)-(c	NUM
cblr-1794	469	9	)	)	PUNCT
cblr-1794	469	10	(	(	PUNCT
cblr-1794	469	11	west	west	NOUN
cblr-1794	469	12	2012	2012	NUM
cblr-1794	469	13	)	)	PUNCT
cblr-1794	469	14	.	.	PUNCT
cblr-1794	470	1	164	164	NUM
cblr-1794	470	2	see	see	VERB
cblr-1794	470	3	supra	supra	PROPN
cblr-1794	470	4	notes	note	VERB
cblr-1794	470	5	107	107	NUM
cblr-1794	470	6	-	-	SYM
cblr-1794	470	7	11	11	NUM
cblr-1794	470	8	and	and	CCONJ
cblr-1794	470	9	accompanying	accompany	VERB
cblr-1794	470	10	text	text	NOUN
cblr-1794	470	11	.	.	PUNCT
cblr-1794	471	1	no	no	INTJ
cblr-1794	471	2	.	.	PUNCT
cblr-1794	472	1	1:209	1:209	NUM
cblr-1794	472	2	]	]	X
cblr-1794	472	3	bpcia	bpcia	NOUN
cblr-1794	472	4	:	:	PUNCT
cblr-1794	472	5	destined	destine	VERB
cblr-1794	472	6	for	for	ADP
cblr-1794	472	7	failure	failure	NOUN
cblr-1794	472	8	?	?	PUNCT
cblr-1794	473	1	235	235	NUM
cblr-1794	473	2	products	product	NOUN
cblr-1794	473	3	because	because	SCONJ
cblr-1794	473	4	the	the	DET
cblr-1794	473	5	development	development	NOUN
cblr-1794	473	6	time	time	NOUN
cblr-1794	473	7	and	and	CCONJ
cblr-1794	473	8	investment	investment	NOUN
cblr-1794	473	9	for	for	ADP
cblr-1794	473	10	[	[	X
cblr-1794	473	11	biosimilars	biosimilar	NOUN
cblr-1794	473	12	]	]	PUNCT
cblr-1794	473	13	is	be	AUX
cblr-1794	473	14	so	so	ADV
cblr-1794	473	15	great	great	ADJ
cblr-1794	473	16	.	.	PUNCT
cblr-1794	474	1	"1	"1	NOUN
cblr-1794	474	2	65	65	NUM
cblr-1794	474	3	not	not	PART
cblr-1794	474	4	only	only	ADV
cblr-1794	474	5	is	be	AUX
cblr-1794	474	6	this	this	DET
cblr-1794	474	7	exclusivity	exclusivity	NOUN
cblr-1794	474	8	period	period	NOUN
cblr-1794	474	9	unnecessary	unnecessary	ADJ
cblr-1794	474	10	to	to	PART
cblr-1794	474	11	spur	spur	VERB
cblr-1794	474	12	the	the	DET
cblr-1794	474	13	first	first	ADJ
cblr-1794	474	14	interchangeable	interchangeable	ADJ
cblr-1794	474	15	biosimilar	biosimilar	NOUN
cblr-1794	474	16	to	to	ADP
cblr-1794	474	17	market	market	NOUN
cblr-1794	474	18	,	,	PUNCT
cblr-1794	474	19	it	it	PRON
cblr-1794	474	20	is	be	AUX
cblr-1794	474	21	also	also	ADV
cblr-1794	474	22	antithetical	antithetical	ADJ
cblr-1794	474	23	to	to	ADP
cblr-1794	474	24	the	the	DET
cblr-1794	474	25	bpcia	bpcia	NOUN
cblr-1794	474	26	's	's	PART
cblr-1794	474	27	goal	goal	NOUN
cblr-1794	474	28	of	of	ADP
cblr-1794	474	29	reducing	reduce	VERB
cblr-1794	474	30	biologic	biologic	NOUN
cblr-1794	474	31	prices	price	NOUN
cblr-1794	474	32	.	.	PUNCT
cblr-1794	475	1	even	even	ADV
cblr-1794	475	2	the	the	DET
cblr-1794	475	3	shortest	short	ADJ
cblr-1794	475	4	exclusivity	exclusivity	NOUN
cblr-1794	475	5	period	period	NOUN
cblr-1794	475	6	of	of	ADP
cblr-1794	475	7	one	one	NUM
cblr-1794	475	8	year	year	NOUN
cblr-1794	475	9	is	be	AUX
cblr-1794	475	10	significantly	significantly	ADV
cblr-1794	475	11	longer	long	ADJ
cblr-1794	475	12	than	than	ADP
cblr-1794	475	13	the	the	DET
cblr-1794	475	14	180	180	NUM
cblr-1794	475	15	-	-	PUNCT
cblr-1794	475	16	day	day	NOUN
cblr-1794	475	17	exclusivity	exclusivity	NOUN
cblr-1794	475	18	period	period	NOUN
cblr-1794	475	19	under	under	ADP
cblr-1794	475	20	hatch	hatch	NOUN
cblr-1794	475	21	-	-	PUNCT
cblr-1794	475	22	waxman	waxman	NOUN
cblr-1794	475	23	.	.	PUNCT
cblr-1794	476	1	the	the	DET
cblr-1794	476	2	exclusivity	exclusivity	NOUN
cblr-1794	476	3	period	period	NOUN
cblr-1794	476	4	"	"	PUNCT
cblr-1794	476	5	blocks	block	VERB
cblr-1794	476	6	entry	entry	NOUN
cblr-1794	476	7	of	of	ADP
cblr-1794	476	8	a	a	DET
cblr-1794	476	9	subsequent	subsequent	ADJ
cblr-1794	476	10	interchangeable	interchangeable	ADJ
cblr-1794	476	11	product	product	NOUN
cblr-1794	476	12	for	for	ADP
cblr-1794	476	13	a	a	DET
cblr-1794	476	14	period	period	NOUN
cblr-1794	476	15	of	of	ADP
cblr-1794	476	16	time	time	NOUN
cblr-1794	476	17	and	and	CCONJ
cblr-1794	476	18	thereby	thereby	ADV
cblr-1794	476	19	denies	deny	VERB
cblr-1794	476	20	consumers	consumer	NOUN
cblr-1794	476	21	price	price	NOUN
cblr-1794	476	22	competition	competition	NOUN
cblr-1794	476	23	.	.	PUNCT
cblr-1794	476	24	"	"	PUNCT
cblr-1794	477	1	1	1	NUM
cblr-1794	477	2	6	6	NUM
cblr-1794	477	3	6	6	NUM
cblr-1794	477	4	iv	iv	NOUN
cblr-1794	477	5	.	.	PUNCT
cblr-1794	477	6	recommendations	recommendation	NOUN
cblr-1794	477	7	and	and	CCONJ
cblr-1794	477	8	conclusion	conclusion	NOUN
cblr-1794	477	9	the	the	DET
cblr-1794	477	10	bpcia	bpcia	NOUN
cblr-1794	477	11	represents	represent	VERB
cblr-1794	477	12	an	an	DET
cblr-1794	477	13	important	important	ADJ
cblr-1794	477	14	first	first	ADJ
cblr-1794	477	15	step	step	NOUN
cblr-1794	477	16	toward	toward	ADP
cblr-1794	477	17	reducing	reduce	VERB
cblr-1794	477	18	biologics	biologic	NOUN
cblr-1794	477	19	prices	price	NOUN
cblr-1794	477	20	.	.	PUNCT
cblr-1794	478	1	however	however	ADV
cblr-1794	478	2	,	,	PUNCT
cblr-1794	478	3	for	for	ADP
cblr-1794	478	4	the	the	DET
cblr-1794	478	5	reasons	reason	NOUN
cblr-1794	478	6	discussed	discuss	VERB
cblr-1794	478	7	above	above	ADV
cblr-1794	478	8	,	,	PUNCT
cblr-1794	478	9	the	the	DET
cblr-1794	478	10	bpcia	bpcia	NOUN
cblr-1794	478	11	is	be	AUX
cblr-1794	478	12	unlikely	unlikely	ADJ
cblr-1794	478	13	to	to	PART
cblr-1794	478	14	be	be	AUX
cblr-1794	478	15	as	as	ADV
cblr-1794	478	16	successful	successful	ADJ
cblr-1794	478	17	at	at	ADP
cblr-1794	478	18	controlling	control	VERB
cblr-1794	478	19	costs	cost	NOUN
cblr-1794	478	20	as	as	ADP
cblr-1794	478	21	the	the	DET
cblr-1794	478	22	hatch	hatch	PROPN
cblr-1794	478	23	-	-	PUNCT
cblr-1794	478	24	waxman	waxman	PROPN
cblr-1794	478	25	act	act	PROPN
cblr-1794	478	26	.	.	PUNCT
cblr-1794	479	1	congress	congress	PROPN
cblr-1794	479	2	and	and	CCONJ
cblr-1794	479	3	the	the	DET
cblr-1794	479	4	fda	fda	PROPN
cblr-1794	479	5	must	must	AUX
cblr-1794	479	6	take	take	VERB
cblr-1794	479	7	further	further	ADJ
cblr-1794	479	8	steps	step	NOUN
cblr-1794	479	9	to	to	PART
cblr-1794	479	10	help	help	VERB
cblr-1794	479	11	incentivize	incentivize	VERB
cblr-1794	479	12	a	a	DET
cblr-1794	479	13	vibrant	vibrant	ADJ
cblr-1794	479	14	and	and	CCONJ
cblr-1794	479	15	successful	successful	ADJ
cblr-1794	479	16	biosimilars	biosimilar	NOUN
cblr-1794	479	17	market	market	NOUN
cblr-1794	479	18	.	.	PUNCT
cblr-1794	480	1	first	first	ADV
cblr-1794	480	2	,	,	PUNCT
cblr-1794	480	3	congress	congress	PROPN
cblr-1794	480	4	should	should	AUX
cblr-1794	480	5	create	create	VERB
cblr-1794	480	6	tax	tax	NOUN
cblr-1794	480	7	credits	credit	NOUN
cblr-1794	480	8	to	to	PART
cblr-1794	480	9	incentivize	incentivize	VERB
cblr-1794	480	10	the	the	DET
cblr-1794	480	11	manufacture	manufacture	NOUN
cblr-1794	480	12	of	of	ADP
cblr-1794	480	13	biosimilars	biosimilar	NOUN
cblr-1794	480	14	.	.	PUNCT
cblr-1794	481	1	such	such	ADJ
cblr-1794	481	2	credits	credit	NOUN
cblr-1794	481	3	,	,	PUNCT
cblr-1794	481	4	including	include	VERB
cblr-1794	481	5	bonus	bonus	NOUN
cblr-1794	481	6	depreciation	depreciation	NOUN
cblr-1794	481	7	,	,	PUNCT
cblr-1794	481	8	already	already	ADV
cblr-1794	481	9	exist	exist	VERB
cblr-1794	481	10	to	to	PART
cblr-1794	481	11	incentivize	incentivize	VERB
cblr-1794	481	12	businesses	business	NOUN
cblr-1794	481	13	to	to	PART
cblr-1794	481	14	invest	invest	VERB
cblr-1794	481	15	in	in	ADP
cblr-1794	481	16	tangible	tangible	ADJ
cblr-1794	481	17	property	property	NOUN
cblr-1794	481	18	.	.	PUNCT
cblr-1794	482	1	bonus	bonus	NOUN
cblr-1794	482	2	depreciation	depreciation	NOUN
cblr-1794	482	3	allows	allow	VERB
cblr-1794	482	4	companies	company	NOUN
cblr-1794	482	5	to	to	PART
cblr-1794	482	6	write	write	VERB
cblr-1794	482	7	off	off	ADP
cblr-1794	482	8	a	a	DET
cblr-1794	482	9	percentage	percentage	NOUN
cblr-1794	482	10	of	of	ADP
cblr-1794	482	11	their	their	PRON
cblr-1794	482	12	investment	investment	NOUN
cblr-1794	482	13	in	in	ADP
cblr-1794	482	14	qualified	qualified	ADJ
cblr-1794	482	15	property	property	NOUN
cblr-1794	482	16	,	,	PUNCT
cblr-1794	482	17	such	such	ADJ
cblr-1794	482	18	as	as	ADP
cblr-1794	482	19	tractors	tractor	NOUN
cblr-1794	482	20	and	and	CCONJ
cblr-1794	482	21	computers.16	computers.16	PROPN
cblr-1794	482	22	'	'	PART
cblr-1794	482	23	a	a	DET
cblr-1794	482	24	165	165	NUM
cblr-1794	482	25	ftc	ftc	PROPN
cblr-1794	482	26	report	report	NOUN
cblr-1794	482	27	,	,	PUNCT
cblr-1794	482	28	supra	supra	PROPN
cblr-1794	482	29	note	note	PROPN
cblr-1794	482	30	14	14	NUM
cblr-1794	482	31	,	,	PUNCT
cblr-1794	482	32	at	at	ADP
cblr-1794	482	33	68	68	NUM
cblr-1794	482	34	.	.	PUNCT
cblr-1794	483	1	166	166	NUM
cblr-1794	483	2	i	i	PRON
cblr-1794	483	3	d.	d.	PROPN
cblr-1794	483	4	at	at	ADP
cblr-1794	483	5	71	71	NUM
cblr-1794	483	6	.	.	PUNCT
cblr-1794	483	7	167	167	NUM
cblr-1794	483	8	see	see	NOUN
cblr-1794	483	9	,	,	PUNCT
cblr-1794	483	10	e.g.	e.g.	ADV
cblr-1794	483	11	,	,	PUNCT
cblr-1794	483	12	quick	quick	ADJ
cblr-1794	483	13	facts	fact	NOUN
cblr-1794	483	14	:	:	PUNCT
cblr-1794	483	15	bonus	bonus	NOUN
cblr-1794	483	16	depreciation	depreciation	NOUN
cblr-1794	483	17	and	and	CCONJ
cblr-1794	483	18	100	100	NUM
cblr-1794	483	19	percent	percent	NOUN
cblr-1794	483	20	expensing	expense	VERB
cblr-1794	483	21	,	,	PUNCT
cblr-1794	483	22	tax	tax	NOUN
cblr-1794	483	23	pol'y	pol'y	NOUN
cblr-1794	483	24	ctr	ctr	PROPN
cblr-1794	483	25	.	.	PROPN
cblr-1794	483	26	,	,	PUNCT
cblr-1794	483	27	available	available	ADJ
cblr-1794	483	28	at	at	ADP
cblr-1794	483	29	http://www.taxpolicycenter.org	http://www.taxpolicycenter.org	PROPN
cblr-1794	483	30	/taxtopics	/taxtopics	SYM
cblr-1794	483	31	/	/	SYM
cblr-1794	483	32	bonus	bonus	NOUN
cblr-1794	483	33	-	-	PUNCT
cblr-1794	483	34	depreciation	depreciation	NOUN
cblr-1794	483	35	-	-	PUNCT
cblr-1794	483	36	and-100	and-100	NOUN
cblr-1794	483	37	-	-	PUNCT
cblr-1794	483	38	percent	percent	NOUN
cblr-1794	483	39	-	-	PUNCT
cblr-1794	483	40	expensing.cfm#2	expensing.cfm#2	PROPN
cblr-1794	483	41	(	(	PUNCT
cblr-1794	483	42	last	last	ADJ
cblr-1794	483	43	visited	visit	VERB
cblr-1794	483	44	mar	mar	PROPN
cblr-1794	483	45	.	.	PROPN
cblr-1794	483	46	22	22	NUM
cblr-1794	483	47	,	,	PUNCT
cblr-1794	483	48	2013	2013	NUM
cblr-1794	483	49	)	)	PUNCT
cblr-1794	483	50	;	;	PUNCT
cblr-1794	483	51	the	the	DET
cblr-1794	483	52	tax	tax	NOUN
cblr-1794	483	53	policy	policy	NOUN
cblr-1794	483	54	center	center	NOUN
cblr-1794	483	55	explains	explain	VERB
cblr-1794	483	56	bonus	bonus	NOUN
cblr-1794	483	57	depreciation	depreciation	NOUN
cblr-1794	483	58	as	as	SCONJ
cblr-1794	483	59	follows	follow	VERB
cblr-1794	483	60	:	:	PUNCT
cblr-1794	483	61	to	to	PART
cblr-1794	483	62	determine	determine	VERB
cblr-1794	483	63	taxable	taxable	ADJ
cblr-1794	483	64	income	income	NOUN
cblr-1794	483	65	,	,	PUNCT
cblr-1794	483	66	businesses	business	NOUN
cblr-1794	483	67	subtract	subtract	VERB
cblr-1794	483	68	expenses	expense	NOUN
cblr-1794	483	69	from	from	ADP
cblr-1794	483	70	their	their	PRON
cblr-1794	483	71	receipts	receipt	NOUN
cblr-1794	483	72	.	.	PUNCT
cblr-1794	484	1	some	some	DET
cblr-1794	484	2	business	business	NOUN
cblr-1794	484	3	expenses	expense	NOUN
cblr-1794	484	4	are	be	AUX
cblr-1794	484	5	for	for	ADP
cblr-1794	484	6	items	item	NOUN
cblr-1794	484	7	that	that	PRON
cblr-1794	484	8	are	be	AUX
cblr-1794	484	9	entirely	entirely	ADV
cblr-1794	484	10	used	use	VERB
cblr-1794	484	11	up	up	ADP
cblr-1794	484	12	during	during	ADP
cblr-1794	484	13	the	the	DET
cblr-1794	484	14	year	year	NOUN
cblr-1794	484	15	(	(	PUNCT
cblr-1794	484	16	e.g.	e.g.	ADV
cblr-1794	484	17	,	,	PUNCT
cblr-1794	484	18	materials	material	NOUN
cblr-1794	484	19	and	and	CCONJ
cblr-1794	484	20	labor	labor	NOUN
cblr-1794	484	21	)	)	PUNCT
cblr-1794	484	22	,	,	PUNCT
cblr-1794	484	23	but	but	CCONJ
cblr-1794	484	24	other	other	ADJ
cblr-1794	484	25	expenses	expense	NOUN
cblr-1794	484	26	are	be	AUX
cblr-1794	484	27	for	for	ADP
cblr-1794	484	28	durable	durable	ADJ
cblr-1794	484	29	goods	good	NOUN
cblr-1794	484	30	that	that	PRON
cblr-1794	484	31	last	last	VERB
cblr-1794	484	32	for	for	ADP
cblr-1794	484	33	many	many	ADJ
cblr-1794	484	34	years	year	NOUN
cblr-1794	484	35	.	.	PUNCT
cblr-1794	485	1	the	the	DET
cblr-1794	485	2	expense	expense	NOUN
cblr-1794	485	3	for	for	ADP
cblr-1794	485	4	investment	investment	NOUN
cblr-1794	485	5	in	in	ADP
cblr-1794	485	6	capital	capital	NOUN
cblr-1794	485	7	equipment	equipment	NOUN
cblr-1794	485	8	(	(	PUNCT
cblr-1794	485	9	e.g.	e.g.	ADV
cblr-1794	485	10	,	,	PUNCT
cblr-1794	485	11	tractors	tractor	NOUN
cblr-1794	485	12	,	,	PUNCT
cblr-1794	485	13	computers	computer	NOUN
cblr-1794	485	14	,	,	PUNCT
cblr-1794	485	15	and	and	CCONJ
cblr-1794	485	16	wind	wind	NOUN
cblr-1794	485	17	turbines	turbine	NOUN
cblr-1794	485	18	)	)	PUNCT
cblr-1794	485	19	occurs	occur	VERB
cblr-1794	485	20	over	over	ADP
cblr-1794	485	21	many	many	ADJ
cblr-1794	485	22	years	year	NOUN
cblr-1794	485	23	as	as	SCONJ
cblr-1794	485	24	the	the	DET
cblr-1794	485	25	value	value	NOUN
cblr-1794	485	26	of	of	ADP
cblr-1794	485	27	that	that	DET
cblr-1794	485	28	investment	investment	NOUN
cblr-1794	485	29	is	be	AUX
cblr-1794	485	30	used	use	VERB
cblr-1794	485	31	up	up	ADP
cblr-1794	485	32	or	or	CCONJ
cblr-1794	485	33	depreciated	depreciate	VERB
cblr-1794	485	34	.	.	PUNCT
cblr-1794	486	1	under	under	ADP
cblr-1794	486	2	current	current	ADJ
cblr-1794	486	3	law	law	NOUN
cblr-1794	486	4	,	,	PUNCT
cblr-1794	486	5	[	[	X
cblr-1794	486	6	vol	vol	NOUN
cblr-1794	486	7	.	.	PUNCT
cblr-1794	486	8	2013236	2013236	NUM
cblr-1794	486	9	col	col	PROPN
cblr-1794	486	10	umbia	umbia	PROPN
cblr-1794	486	11	b	b	PROPN
cblr-1794	486	12	usiness	usiness	PROPN
cblr-1794	486	13	la	la	PROPN
cblr-1794	486	14	w	w	PROPN
cblr-1794	486	15	re	re	PROPN
cblr-1794	486	16	vie	vie	PROPN
cblr-1794	486	17	w	w	PROPN
cblr-1794	486	18	bpcia	bpcia	PROPN
cblr-1794	486	19	:	:	PUNCT
cblr-1794	486	20	destined	destine	VERB
cblr-1794	486	21	for	for	ADP
cblr-1794	486	22	failure	failure	NOUN
cblr-1794	486	23	?	?	PUNCT
cblr-1794	487	1	biosimilar	biosimilar	ADJ
cblr-1794	487	2	manufacturer	manufacturer	NOUN
cblr-1794	487	3	could	could	AUX
cblr-1794	487	4	use	use	VERB
cblr-1794	487	5	bonus	bonus	NOUN
cblr-1794	487	6	depreciation	depreciation	NOUN
cblr-1794	487	7	as	as	ADP
cblr-1794	487	8	a	a	DET
cblr-1794	487	9	tax	tax	NOUN
cblr-1794	487	10	credit	credit	NOUN
cblr-1794	487	11	for	for	ADP
cblr-1794	487	12	the	the	DET
cblr-1794	487	13	purchase	purchase	NOUN
cblr-1794	487	14	of	of	ADP
cblr-1794	487	15	equipment	equipment	NOUN
cblr-1794	487	16	,	,	PUNCT
cblr-1794	487	17	such	such	ADJ
cblr-1794	487	18	as	as	ADP
cblr-1794	487	19	a	a	DET
cblr-1794	487	20	centrifuge	centrifuge	NOUN
cblr-1794	487	21	,	,	PUNCT
cblr-1794	487	22	to	to	PART
cblr-1794	487	23	be	be	AUX
cblr-1794	487	24	used	use	VERB
cblr-1794	487	25	in	in	ADP
cblr-1794	487	26	a	a	DET
cblr-1794	487	27	manufacturing	manufacturing	NOUN
cblr-1794	487	28	facility	facility	NOUN
cblr-1794	487	29	.	.	PUNCT
cblr-1794	488	1	however	however	ADV
cblr-1794	488	2	,	,	PUNCT
cblr-1794	488	3	manufacturing	manufacturing	NOUN
cblr-1794	488	4	facilities	facility	NOUN
cblr-1794	488	5	for	for	ADP
cblr-1794	488	6	biosimilars	biosimilar	NOUN
cblr-1794	488	7	will	will	AUX
cblr-1794	488	8	likely	likely	ADV
cblr-1794	488	9	cost	cost	VERB
cblr-1794	488	10	between	between	ADP
cblr-1794	488	11	$	$	SYM
cblr-1794	488	12	250	250	NUM
cblr-1794	488	13	million	million	NUM
cblr-1794	488	14	and	and	CCONJ
cblr-1794	488	15	$	$	SYM
cblr-1794	488	16	1	1	NUM
cblr-1794	488	17	billion	billion	NUM
cblr-1794	488	18	to	to	PART
cblr-1794	488	19	create	create	VERB
cblr-1794	488	20	.	.	PUNCT
cblr-1794	489	1	6	6	NUM
cblr-1794	489	2	8	8	NUM
cblr-1794	489	3	bonus	bonus	NOUN
cblr-1794	489	4	depreciation	depreciation	NOUN
cblr-1794	489	5	for	for	ADP
cblr-1794	489	6	equipment	equipment	NOUN
cblr-1794	489	7	alone	alone	ADV
cblr-1794	489	8	will	will	AUX
cblr-1794	489	9	likely	likely	ADV
cblr-1794	489	10	not	not	PART
cblr-1794	489	11	incentivize	incentivize	VERB
cblr-1794	489	12	companies	company	NOUN
cblr-1794	489	13	to	to	PART
cblr-1794	489	14	build	build	VERB
cblr-1794	489	15	such	such	DET
cblr-1794	489	16	a	a	DET
cblr-1794	489	17	factory	factory	NOUN
cblr-1794	489	18	.	.	PUNCT
cblr-1794	490	1	instead	instead	ADV
cblr-1794	490	2	,	,	PUNCT
cblr-1794	490	3	congress	congress	PROPN
cblr-1794	490	4	should	should	AUX
cblr-1794	490	5	create	create	VERB
cblr-1794	490	6	a	a	DET
cblr-1794	490	7	new	new	ADJ
cblr-1794	490	8	tax	tax	NOUN
cblr-1794	490	9	credit	credit	NOUN
cblr-1794	490	10	,	,	PUNCT
cblr-1794	490	11	similar	similar	ADJ
cblr-1794	490	12	to	to	ADP
cblr-1794	490	13	bonus	bonus	NOUN
cblr-1794	490	14	depreciation	depreciation	NOUN
cblr-1794	490	15	,	,	PUNCT
cblr-1794	490	16	which	which	PRON
cblr-1794	490	17	would	would	AUX
cblr-1794	490	18	allow	allow	VERB
cblr-1794	490	19	biosimilar	biosimilar	NOUN
cblr-1794	490	20	manufacturers	manufacturer	NOUN
cblr-1794	490	21	to	to	PART
cblr-1794	490	22	deduct	deduct	VERB
cblr-1794	490	23	from	from	ADP
cblr-1794	490	24	their	their	PRON
cblr-1794	490	25	income	income	NOUN
cblr-1794	490	26	some	some	DET
cblr-1794	490	27	percentage	percentage	NOUN
cblr-1794	490	28	of	of	ADP
cblr-1794	490	29	an	an	DET
cblr-1794	490	30	fdaapproved	fdaapprove	VERB
cblr-1794	490	31	biosimilars	biosimilar	NOUN
cblr-1794	490	32	manufacturing	manufacturing	NOUN
cblr-1794	490	33	facility	facility	NOUN
cblr-1794	490	34	.	.	PUNCT
cblr-1794	491	1	the	the	DET
cblr-1794	491	2	bpcia	bpcia	NOUN
cblr-1794	491	3	will	will	AUX
cblr-1794	491	4	function	function	VERB
cblr-1794	491	5	at	at	ADP
cblr-1794	491	6	its	its	PRON
cblr-1794	491	7	best	good	ADJ
cblr-1794	491	8	as	as	SCONJ
cblr-1794	491	9	more	more	ADJ
cblr-1794	491	10	biosimilars	biosimilar	NOUN
cblr-1794	491	11	enter	enter	VERB
cblr-1794	491	12	the	the	DET
cblr-1794	491	13	market	market	NOUN
cblr-1794	491	14	,	,	PUNCT
cblr-1794	491	15	increasing	increase	VERB
cblr-1794	491	16	competition	competition	NOUN
cblr-1794	491	17	and	and	CCONJ
cblr-1794	491	18	forcing	force	VERB
cblr-1794	491	19	all	all	DET
cblr-1794	491	20	firms	firm	NOUN
cblr-1794	491	21	to	to	PART
cblr-1794	491	22	price	price	VERB
cblr-1794	491	23	their	their	PRON
cblr-1794	491	24	products	product	NOUN
cblr-1794	491	25	competitively	competitively	ADV
cblr-1794	491	26	to	to	PART
cblr-1794	491	27	fight	fight	VERB
cblr-1794	491	28	for	for	ADP
cblr-1794	491	29	market	market	NOUN
cblr-1794	491	30	share	share	NOUN
cblr-1794	491	31	.	.	PUNCT
cblr-1794	492	1	without	without	ADP
cblr-1794	492	2	incentives	incentive	NOUN
cblr-1794	492	3	to	to	PART
cblr-1794	492	4	build	build	VERB
cblr-1794	492	5	manufacturing	manufacturing	NOUN
cblr-1794	492	6	facilities	facility	NOUN
cblr-1794	492	7	,	,	PUNCT
cblr-1794	492	8	biosimilars	biosimilar	NOUN
cblr-1794	492	9	will	will	AUX
cblr-1794	492	10	not	not	PART
cblr-1794	492	11	be	be	AUX
cblr-1794	492	12	economically	economically	ADV
cblr-1794	492	13	feasible	feasible	ADJ
cblr-1794	492	14	in	in	ADP
cblr-1794	492	15	many	many	ADJ
cblr-1794	492	16	markets	market	NOUN
cblr-1794	492	17	.	.	PUNCT
cblr-1794	493	1	by	by	ADP
cblr-1794	493	2	creating	create	VERB
cblr-1794	493	3	a	a	DET
cblr-1794	493	4	tax	tax	NOUN
cblr-1794	493	5	incentive	incentive	NOUN
cblr-1794	493	6	similar	similar	ADJ
cblr-1794	493	7	to	to	ADP
cblr-1794	493	8	bonus	bonus	NOUN
cblr-1794	493	9	depreciation	depreciation	NOUN
cblr-1794	493	10	,	,	PUNCT
cblr-1794	493	11	congress	congress	PROPN
cblr-1794	493	12	could	could	AUX
cblr-1794	493	13	help	help	VERB
cblr-1794	493	14	ensure	ensure	VERB
cblr-1794	493	15	that	that	SCONJ
cblr-1794	493	16	the	the	DET
cblr-1794	493	17	bpcia	bpcia	NOUN
cblr-1794	493	18	is	be	AUX
cblr-1794	493	19	successful	successful	ADJ
cblr-1794	493	20	in	in	ADP
cblr-1794	493	21	creating	create	VERB
cblr-1794	493	22	savings	saving	NOUN
cblr-1794	493	23	for	for	ADP
cblr-1794	493	24	consumers	consumer	NOUN
cblr-1794	493	25	and	and	CCONJ
cblr-1794	493	26	insurers	insurer	NOUN
cblr-1794	493	27	.	.	PUNCT
cblr-1794	494	1	second	second	ADJ
cblr-1794	494	2	,	,	PUNCT
cblr-1794	494	3	the	the	DET
cblr-1794	494	4	fda	fda	PROPN
cblr-1794	494	5	should	should	AUX
cblr-1794	494	6	create	create	VERB
cblr-1794	494	7	as	as	ADV
cblr-1794	494	8	much	much	ADJ
cblr-1794	494	9	predictability	predictability	NOUN
cblr-1794	494	10	as	as	ADP
cblr-1794	494	11	possible	possible	ADJ
cblr-1794	494	12	in	in	ADP
cblr-1794	494	13	the	the	DET
cblr-1794	494	14	licensing	licensing	NOUN
cblr-1794	494	15	of	of	ADP
cblr-1794	494	16	biosimilars	biosimilar	NOUN
cblr-1794	494	17	.	.	PUNCT
cblr-1794	495	1	the	the	DET
cblr-1794	495	2	fda	fda	PROPN
cblr-1794	495	3	has	have	AUX
cblr-1794	495	4	already	already	ADV
cblr-1794	495	5	begun	begin	VERB
cblr-1794	495	6	this	this	DET
cblr-1794	495	7	process	process	NOUN
cblr-1794	495	8	.	.	PUNCT
cblr-1794	496	1	in	in	ADP
cblr-1794	496	2	february	february	PROPN
cblr-1794	496	3	2012	2012	NUM
cblr-1794	496	4	,	,	PUNCT
cblr-1794	496	5	the	the	DET
cblr-1794	496	6	fda	fda	PROPN
cblr-1794	496	7	released	release	VERB
cblr-1794	496	8	draft	draft	NOUN
cblr-1794	496	9	guidance	guidance	NOUN
cblr-1794	496	10	providing	provide	VERB
cblr-1794	496	11	a	a	DET
cblr-1794	496	12	high	high	ADJ
cblr-1794	496	13	-	-	PUNCT
cblr-1794	496	14	level	level	NOUN
cblr-1794	496	15	overview	overview	NOUN
cblr-1794	496	16	of	of	ADP
cblr-1794	496	17	the	the	DET
cblr-1794	496	18	process	process	NOUN
cblr-1794	496	19	through	through	ADP
cblr-1794	496	20	which	which	PRON
cblr-1794	496	21	the	the	DET
cblr-1794	496	22	agency	agency	NOUN
cblr-1794	496	23	will	will	AUX
cblr-1794	496	24	determine	determine	VERB
cblr-1794	496	25	biosimilarity	biosimilarity	NOUN
cblr-1794	496	26	.	.	PUNCT
cblr-1794	497	1	"	"	PUNCT
cblr-1794	497	2	'	'	PUNCT
cblr-1794	497	3	businesses	business	NOUN
cblr-1794	497	4	calculate	calculate	VERB
cblr-1794	497	5	taxable	taxable	ADJ
cblr-1794	497	6	income	income	NOUN
cblr-1794	497	7	by	by	ADP
cblr-1794	497	8	deducting	deduct	VERB
cblr-1794	497	9	capital	capital	NOUN
cblr-1794	497	10	costs	cost	NOUN
cblr-1794	497	11	over	over	ADP
cblr-1794	497	12	time	time	NOUN
cblr-1794	497	13	according	accord	VERB
cblr-1794	497	14	to	to	ADP
cblr-1794	497	15	fixed	fix	VERB
cblr-1794	497	16	depreciation	depreciation	NOUN
cblr-1794	497	17	schedules	schedule	NOUN
cblr-1794	497	18	.	.	PUNCT
cblr-1794	498	1	bonus	bonus	NOUN
cblr-1794	498	2	depreciation	depreciation	NOUN
cblr-1794	498	3	allows	allow	VERB
cblr-1794	498	4	for	for	ADP
cblr-1794	498	5	an	an	DET
cblr-1794	498	6	additional	additional	ADJ
cblr-1794	498	7	deduction	deduction	NOUN
cblr-1794	498	8	when	when	SCONJ
cblr-1794	498	9	the	the	DET
cblr-1794	498	10	asset	asset	NOUN
cblr-1794	498	11	is	be	AUX
cblr-1794	498	12	first	first	ADV
cblr-1794	498	13	purchased	purchase	VERB
cblr-1794	498	14	.	.	PUNCT
cblr-1794	499	1	for	for	ADP
cblr-1794	499	2	example	example	NOUN
cblr-1794	499	3	,	,	PUNCT
cblr-1794	499	4	a	a	DET
cblr-1794	499	5	50	50	NUM
cblr-1794	499	6	percent	percent	NOUN
cblr-1794	499	7	bonus	bonus	NOUN
cblr-1794	499	8	depreciation	depreciation	NOUN
cblr-1794	499	9	allowance	allowance	NOUN
cblr-1794	499	10	would	would	AUX
cblr-1794	499	11	mean	mean	VERB
cblr-1794	499	12	that	that	SCONJ
cblr-1794	499	13	businesses	business	NOUN
cblr-1794	499	14	could	could	AUX
cblr-1794	499	15	immediately	immediately	ADV
cblr-1794	499	16	deduct	deduct	VERB
cblr-1794	499	17	50	50	NUM
cblr-1794	499	18	cents	cent	NOUN
cblr-1794	499	19	of	of	ADP
cblr-1794	499	20	every	every	DET
cblr-1794	499	21	dollar	dollar	NOUN
cblr-1794	499	22	spent	spend	VERB
cblr-1794	499	23	on	on	ADP
cblr-1794	499	24	qualifying	qualify	VERB
cblr-1794	499	25	investment	investment	NOUN
cblr-1794	499	26	purchases	purchase	NOUN
cblr-1794	499	27	.	.	PUNCT
cblr-1794	500	1	the	the	DET
cblr-1794	500	2	remaining	remain	VERB
cblr-1794	500	3	50	50	NUM
cblr-1794	500	4	cents	cent	NOUN
cblr-1794	500	5	would	would	AUX
cblr-1794	500	6	be	be	AUX
cblr-1794	500	7	deducted	deduct	VERB
cblr-1794	500	8	according	accord	VERB
cblr-1794	500	9	to	to	ADP
cblr-1794	500	10	regular	regular	ADJ
cblr-1794	500	11	depreciation	depreciation	NOUN
cblr-1794	500	12	schedules	schedule	NOUN
cblr-1794	500	13	.	.	PUNCT
cblr-1794	501	1	i	i	PRON
cblr-1794	501	2	d.	d.	PROPN
cblr-1794	501	3	168	168	NUM
cblr-1794	501	4	see	see	VERB
cblr-1794	501	5	supra	supra	PROPN
cblr-1794	501	6	notes	note	VERB
cblr-1794	501	7	92	92	NUM
cblr-1794	501	8	-	-	SYM
cblr-1794	501	9	94	94	NUM
cblr-1794	501	10	and	and	CCONJ
cblr-1794	501	11	accompanying	accompany	VERB
cblr-1794	501	12	text	text	NOUN
cblr-1794	501	13	.	.	PUNCT
cblr-1794	502	1	169	169	NUM
cblr-1794	502	2	see	see	VERB
cblr-1794	502	3	ctr	ctr	PROPN
cblr-1794	502	4	.	.	PUNCT
cblr-1794	503	1	for	for	ADP
cblr-1794	503	2	drug	drug	NOUN
cblr-1794	503	3	evaluation	evaluation	NOUN
cblr-1794	503	4	and	and	CCONJ
cblr-1794	503	5	research	research	NOUN
cblr-1794	503	6	,	,	PUNCT
cblr-1794	503	7	fda	fda	PROPN
cblr-1794	503	8	,	,	PUNCT
cblr-1794	503	9	guidance	guidance	NOUN
cblr-1794	503	10	for	for	ADP
cblr-1794	503	11	industry	industry	NOUN
cblr-1794	503	12	:	:	PUNCT
cblr-1794	503	13	scientific	scientific	ADJ
cblr-1794	503	14	considerations	consideration	NOUN
cblr-1794	503	15	in	in	ADP
cblr-1794	503	16	demonstrating	demonstrate	VERB
cblr-1794	503	17	biosimilarity	biosimilarity	NOUN
cblr-1794	503	18	to	to	ADP
cblr-1794	503	19	a	a	DET
cblr-1794	503	20	reference	reference	NOUN
cblr-1794	503	21	product	product	NOUN
cblr-1794	503	22	2	2	NUM
cblr-1794	503	23	(	(	PUNCT
cblr-1794	503	24	2012	2012	NUM
cblr-1794	503	25	)	)	PUNCT
cblr-1794	504	1	[	[	X
cblr-1794	504	2	hereinafter	hereinafter	NOUN
cblr-1794	504	3	biosimilarity	biosimilarity	NOUN
cblr-1794	504	4	guidance	guidance	NOUN
cblr-1794	504	5	]	]	X
cblr-1794	504	6	,	,	PUNCT
cblr-1794	504	7	available	available	ADJ
cblr-1794	504	8	at	at	ADP
cblr-1794	504	9	http://www.fda.gov/downloads/	http://www.fda.gov/downloads/	PROPN
cblr-1794	504	10	no	no	NOUN
cblr-1794	504	11	.	.	PUNCT
cblr-1794	505	1	i:209	i:209	PROPN
cblr-1794	505	2	]	]	PUNCT
cblr-1794	505	3	237	237	NUM
cblr-1794	505	4	the	the	DET
cblr-1794	505	5	draft	draft	NOUN
cblr-1794	505	6	guidance	guidance	NOUN
cblr-1794	505	7	reminds	remind	VERB
cblr-1794	505	8	sponsors	sponsor	NOUN
cblr-1794	505	9	that	that	SCONJ
cblr-1794	505	10	applications	application	NOUN
cblr-1794	505	11	must	must	AUX
cblr-1794	505	12	include	include	VERB
cblr-1794	505	13	"	"	PUNCT
cblr-1794	505	14	data	datum	NOUN
cblr-1794	505	15	derived	derive	VERB
cblr-1794	505	16	from	from	ADP
cblr-1794	505	17	analytical	analytical	ADJ
cblr-1794	505	18	studies	study	NOUN
cblr-1794	505	19	,	,	PUNCT
cblr-1794	505	20	animal	animal	NOUN
cblr-1794	505	21	studies	study	NOUN
cblr-1794	505	22	,	,	PUNCT
cblr-1794	505	23	or	or	CCONJ
cblr-1794	505	24	a	a	DET
cblr-1794	505	25	clinical	clinical	ADJ
cblr-1794	505	26	study	study	NOUN
cblr-1794	505	27	or	or	CCONJ
cblr-1794	505	28	studies	study	NOUN
cblr-1794	505	29	"	"	PUNCT
cblr-1794	505	30	unless	unless	SCONJ
cblr-1794	505	31	the	the	DET
cblr-1794	505	32	fda	fda	PROPN
cblr-1794	505	33	determines	determine	VERB
cblr-1794	505	34	one	one	NUM
cblr-1794	505	35	of	of	ADP
cblr-1794	505	36	these	these	DET
cblr-1794	505	37	elements	element	NOUN
cblr-1794	505	38	is	be	AUX
cblr-1794	505	39	unnecessary.17	unnecessary.17	PROPN
cblr-1794	505	40	0	0	PROPN
cblr-1794	506	1	the	the	DET
cblr-1794	506	2	fda	fda	PROPN
cblr-1794	506	3	specifies	specify	VERB
cblr-1794	506	4	that	that	SCONJ
cblr-1794	506	5	it	it	PRON
cblr-1794	506	6	will	will	AUX
cblr-1794	506	7	take	take	VERB
cblr-1794	506	8	a	a	DET
cblr-1794	506	9	"	"	PUNCT
cblr-1794	506	10	risk	risk	NOUN
cblr-1794	506	11	-	-	PUNCT
cblr-1794	506	12	based	base	VERB
cblr-1794	506	13	,	,	PUNCT
cblr-1794	506	14	totality	totality	NOUN
cblr-1794	506	15	-	-	PUNCT
cblr-1794	506	16	of	of	ADP
cblr-1794	506	17	-	-	PUNCT
cblr-1794	506	18	theevidence	theevidence	NOUN
cblr-1794	506	19	approach	approach	NOUN
cblr-1794	506	20	"	"	PUNCT
cblr-1794	506	21	in	in	ADP
cblr-1794	506	22	evaluating	evaluate	VERB
cblr-1794	506	23	biosimilarity	biosimilarity	NOUN
cblr-1794	506	24	.	.	PUNCT
cblr-1794	507	1	'	'	PUNCT
cblr-1794	507	2	17	17	NUM
cblr-1794	507	3	additionally	additionally	ADV
cblr-1794	507	4	,	,	PUNCT
cblr-1794	507	5	the	the	DET
cblr-1794	507	6	fda	fda	PROPN
cblr-1794	507	7	advises	advise	VERB
cblr-1794	507	8	sponsors	sponsor	NOUN
cblr-1794	507	9	to	to	PART
cblr-1794	507	10	take	take	VERB
cblr-1794	507	11	a	a	DET
cblr-1794	507	12	stepwise	stepwise	ADJ
cblr-1794	507	13	approach	approach	NOUN
cblr-1794	507	14	to	to	ADP
cblr-1794	507	15	showing	show	VERB
cblr-1794	507	16	biosimilarity.172	biosimilarity.172	NOUN
cblr-1794	507	17	this	this	DET
cblr-1794	507	18	approach	approach	NOUN
cblr-1794	507	19	should	should	AUX
cblr-1794	507	20	begin	begin	VERB
cblr-1794	507	21	with	with	ADP
cblr-1794	507	22	"	"	PUNCT
cblr-1794	507	23	extensive	extensive	ADJ
cblr-1794	507	24	structural	structural	ADJ
cblr-1794	507	25	and	and	CCONJ
cblr-1794	507	26	functional	functional	ADJ
cblr-1794	507	27	characterization	characterization	NOUN
cblr-1794	507	28	of	of	ADP
cblr-1794	507	29	both	both	CCONJ
cblr-1794	507	30	the	the	DET
cblr-1794	507	31	proposed	propose	VERB
cblr-1794	507	32	product	product	NOUN
cblr-1794	507	33	and	and	CCONJ
cblr-1794	507	34	the	the	DET
cblr-1794	507	35	reference	reference	NOUN
cblr-1794	507	36	product	product	NOUN
cblr-1794	507	37	.	.	PUNCT
cblr-1794	508	1	"	"	PUNCT
cblr-1794	508	2	'	'	PUNCT
cblr-1794	508	3	73	73	NUM
cblr-1794	508	4	next	next	ADV
cblr-1794	508	5	,	,	PUNCT
cblr-1794	508	6	the	the	DET
cblr-1794	508	7	sponsor	sponsor	NOUN
cblr-1794	508	8	should	should	AUX
cblr-1794	508	9	consider	consider	VERB
cblr-1794	508	10	the	the	DET
cblr-1794	508	11	role	role	NOUN
cblr-1794	508	12	of	of	ADP
cblr-1794	508	13	animal	animal	NOUN
cblr-1794	508	14	data	datum	NOUN
cblr-1794	508	15	in	in	ADP
cblr-1794	508	16	assessing	assess	VERB
cblr-1794	508	17	toxicity	toxicity	NOUN
cblr-1794	508	18	and	and	CCONJ
cblr-1794	508	19	providing	provide	VERB
cblr-1794	508	20	additional	additional	ADJ
cblr-1794	508	21	support	support	NOUN
cblr-1794	508	22	for	for	ADP
cblr-1794	508	23	biosimilarity.174	biosimilarity.174	ADJ
cblr-1794	508	24	the	the	DET
cblr-1794	508	25	sponsor	sponsor	NOUN
cblr-1794	508	26	should	should	AUX
cblr-1794	508	27	"	"	PUNCT
cblr-1794	508	28	conduct	conduct	VERB
cblr-1794	508	29	comparative	comparative	ADJ
cblr-1794	508	30	human	human	NOUN
cblr-1794	508	31	[	[	X
cblr-1794	508	32	pharmacokinetics	pharmacokinetic	NOUN
cblr-1794	508	33	]	]	PUNCT
cblr-1794	508	34	studies	study	NOUN
cblr-1794	508	35	,	,	PUNCT
cblr-1794	508	36	and	and	CCONJ
cblr-1794	508	37	[	[	X
cblr-1794	508	38	pharmacodynamic	pharmacodynamic	ADJ
cblr-1794	508	39	]	]	PUNCT
cblr-1794	508	40	studies	study	NOUN
cblr-1794	508	41	if	if	SCONJ
cblr-1794	508	42	there	there	PRON
cblr-1794	508	43	is	be	VERB
cblr-1794	508	44	a	a	DET
cblr-1794	508	45	clinically	clinically	ADV
cblr-1794	508	46	relevant	relevant	ADJ
cblr-1794	508	47	[	[	X
cblr-1794	508	48	pharmacodynamic	pharmacodynamic	ADJ
cblr-1794	508	49	]	]	PUNCT
cblr-1794	508	50	measure	measure	NOUN
cblr-1794	508	51	.	.	PUNCT
cblr-1794	509	1	"1	"1	NOUN
cblr-1794	509	2	7	7	NUM
cblr-1794	509	3	'	'	PUNCT
cblr-1794	509	4	finally	finally	ADV
cblr-1794	509	5	,	,	PUNCT
cblr-1794	509	6	sponsors	sponsor	NOUN
cblr-1794	509	7	should	should	AUX
cblr-1794	509	8	compare	compare	VERB
cblr-1794	509	9	the	the	DET
cblr-1794	509	10	clinical	clinical	ADJ
cblr-1794	509	11	immunogenicity	immunogenicity	NOUN
cblr-1794	509	12	of	of	ADP
cblr-1794	509	13	biosimilar	biosimilar	NOUN
cblr-1794	509	14	and	and	CCONJ
cblr-1794	509	15	the	the	DET
cblr-1794	509	16	reference	reference	NOUN
cblr-1794	509	17	product	product	NOUN
cblr-1794	509	18	.	.	PUNCT
cblr-1794	510	1	17	17	NUM
cblr-1794	510	2	1	1	NUM
cblr-1794	510	3	if	if	SCONJ
cblr-1794	510	4	there	there	PRON
cblr-1794	510	5	are	be	VERB
cblr-1794	510	6	residual	residual	ADJ
cblr-1794	510	7	uncertainties	uncertainty	NOUN
cblr-1794	510	8	,	,	PUNCT
cblr-1794	510	9	the	the	DET
cblr-1794	510	10	fda	fda	PROPN
cblr-1794	510	11	then	then	ADV
cblr-1794	510	12	specifies	specify	VERB
cblr-1794	510	13	that	that	SCONJ
cblr-1794	510	14	the	the	DET
cblr-1794	510	15	sponsor	sponsor	NOUN
cblr-1794	510	16	should	should	AUX
cblr-1794	510	17	consider	consider	VERB
cblr-1794	510	18	what	what	PRON
cblr-1794	510	19	other	other	ADJ
cblr-1794	510	20	types	type	NOUN
cblr-1794	510	21	of	of	ADP
cblr-1794	510	22	clinical	clinical	ADJ
cblr-1794	510	23	data	datum	NOUN
cblr-1794	510	24	"	"	PUNCT
cblr-1794	510	25	may	may	AUX
cblr-1794	510	26	be	be	AUX
cblr-1794	510	27	adequate	adequate	ADJ
cblr-1794	510	28	.	.	PUNCT
cblr-1794	511	1	"'7	"'7	NOUN
cblr-1794	511	2	7	7	NUM
cblr-1794	511	3	although	although	SCONJ
cblr-1794	511	4	this	this	DET
cblr-1794	511	5	guidance	guidance	NOUN
cblr-1794	511	6	is	be	AUX
cblr-1794	511	7	a	a	DET
cblr-1794	511	8	good	good	ADJ
cblr-1794	511	9	first	first	ADJ
cblr-1794	511	10	step	step	NOUN
cblr-1794	511	11	,	,	PUNCT
cblr-1794	511	12	sponsors	sponsor	NOUN
cblr-1794	511	13	would	would	AUX
cblr-1794	511	14	benefit	benefit	VERB
cblr-1794	511	15	from	from	ADP
cblr-1794	511	16	information	information	NOUN
cblr-1794	511	17	containing	contain	VERB
cblr-1794	511	18	a	a	DET
cblr-1794	511	19	greater	great	ADJ
cblr-1794	511	20	degree	degree	NOUN
cblr-1794	511	21	of	of	ADP
cblr-1794	511	22	specificity	specificity	NOUN
cblr-1794	511	23	.	.	PUNCT
cblr-1794	512	1	for	for	ADP
cblr-1794	512	2	each	each	PRON
cblr-1794	512	3	of	of	ADP
cblr-1794	512	4	the	the	DET
cblr-1794	512	5	most	most	ADV
cblr-1794	512	6	common	common	ADJ
cblr-1794	512	7	protein	protein	NOUN
cblr-1794	512	8	classes	class	NOUN
cblr-1794	512	9	,	,	PUNCT
cblr-1794	512	10	the	the	DET
cblr-1794	512	11	fda	fda	PROPN
cblr-1794	512	12	should	should	AUX
cblr-1794	512	13	release	release	VERB
cblr-1794	512	14	additional	additional	ADJ
cblr-1794	512	15	guidance	guidance	NOUN
cblr-1794	512	16	documents	document	NOUN
cblr-1794	512	17	specifying	specify	VERB
cblr-1794	512	18	exactly	exactly	ADV
cblr-1794	512	19	which	which	DET
cblr-1794	512	20	types	type	NOUN
cblr-1794	512	21	of	of	ADP
cblr-1794	512	22	data	datum	NOUN
cblr-1794	512	23	will	will	AUX
cblr-1794	512	24	be	be	AUX
cblr-1794	512	25	required	require	VERB
cblr-1794	512	26	to	to	PART
cblr-1794	512	27	prove	prove	VERB
cblr-1794	512	28	biosimilarity	biosimilarity	NOUN
cblr-1794	512	29	and/or	and/or	CCONJ
cblr-1794	512	30	interchangeability	interchangeability	NOUN
cblr-1794	512	31	for	for	ADP
cblr-1794	512	32	each	each	DET
cblr-1794	512	33	class	class	NOUN
cblr-1794	512	34	of	of	ADP
cblr-1794	512	35	drugs	drug	NOUN
cblr-1794	512	36	/	/	SYM
cblr-1794	512	37	guidancecomplianceregulatorylnformation	guidancecomplianceregulatorylnformation	NOUN
cblr-1794	512	38	/	/	SYM
cblr-1794	512	39	guidances	guidance	NOUN
cblr-1794	512	40	/	/	SYM
cblr-1794	512	41	ucm29112	ucm29112	ADJ
cblr-1794	512	42	8.pdf	8.pdf	NOUN
cblr-1794	512	43	.	.	PUNCT
cblr-1794	513	1	170	170	NUM
cblr-1794	513	2	see	see	VERB
cblr-1794	513	3	biosimilt'ry	biosimilt'ry	PROPN
cblr-1794	513	4	guidance	guidance	NOUN
cblr-1794	513	5	,	,	PUNCT
cblr-1794	513	6	supra	supra	PROPN
cblr-1794	513	7	note	note	NOUN
cblr-1794	513	8	169	169	NUM
cblr-1794	513	9	,	,	PUNCT
cblr-1794	513	10	at	at	ADP
cblr-1794	513	11	5	5	NUM
cblr-1794	513	12	.	.	NOUN
cblr-1794	513	13	171	171	NUM
cblr-1794	514	1	i	i	PRON
cblr-1794	514	2	d.	d.	PROPN
cblr-1794	514	3	at	at	ADP
cblr-1794	514	4	8	8	NUM
cblr-1794	514	5	.	.	X
cblr-1794	514	6	172	172	NUM
cblr-1794	515	1	i	i	PRON
cblr-1794	515	2	d.	d.	PROPN
cblr-1794	515	3	at	at	ADP
cblr-1794	515	4	5	5	NUM
cblr-1794	515	5	.	.	PUNCT
cblr-1794	515	6	173	173	NUM
cblr-1794	516	1	i	i	PRON
cblr-1794	516	2	d.	d.	PROPN
cblr-1794	516	3	at	at	ADP
cblr-1794	516	4	7	7	NUM
cblr-1794	516	5	.	.	NOUN
cblr-1794	516	6	174	174	NUM
cblr-1794	517	1	i	i	PRON
cblr-1794	517	2	d.	d.	PROPN
cblr-1794	517	3	175	175	NUM
cblr-1794	518	1	i	i	PRON
cblr-1794	518	2	d.	d.	PROPN
cblr-1794	518	3	176	176	NUM
cblr-1794	518	4	biosimlarity	biosimlarity	NOUN
cblr-1794	518	5	guidance	guidance	NOUN
cblr-1794	518	6	,	,	PUNCT
cblr-1794	518	7	supra	supra	PROPN
cblr-1794	518	8	note	note	NOUN
cblr-1794	518	9	169	169	NUM
cblr-1794	518	10	,	,	PUNCT
cblr-1794	518	11	at	at	ADP
cblr-1794	518	12	7	7	NUM
cblr-1794	518	13	.	.	NOUN
cblr-1794	518	14	177	177	NUM
cblr-1794	519	1	i	i	PRON
cblr-1794	519	2	d.	d.	PROPN
cblr-1794	519	3	at	at	ADP
cblr-1794	519	4	12	12	NUM
cblr-1794	519	5	(	(	PUNCT
cblr-1794	519	6	"	"	PUNCT
cblr-1794	519	7	the	the	DET
cblr-1794	519	8	scope	scope	NOUN
cblr-1794	519	9	and	and	CCONJ
cblr-1794	519	10	magnitude	magnitude	NOUN
cblr-1794	519	11	of	of	ADP
cblr-1794	519	12	clinical	clinical	ADJ
cblr-1794	519	13	studies	study	NOUN
cblr-1794	519	14	will	will	AUX
cblr-1794	519	15	depend	depend	VERB
cblr-1794	519	16	on	on	ADP
cblr-1794	519	17	the	the	DET
cblr-1794	519	18	extent	extent	NOUN
cblr-1794	519	19	of	of	ADP
cblr-1794	519	20	residual	residual	ADJ
cblr-1794	519	21	uncertainty	uncertainty	NOUN
cblr-1794	519	22	about	about	ADP
cblr-1794	519	23	the	the	DET
cblr-1794	519	24	biosimilarity	biosimilarity	NOUN
cblr-1794	519	25	of	of	ADP
cblr-1794	519	26	the	the	DET
cblr-1794	519	27	two	two	NUM
cblr-1794	519	28	products	product	NOUN
cblr-1794	519	29	after	after	ADP
cblr-1794	519	30	conducting	conduct	VERB
cblr-1794	519	31	structural	structural	ADJ
cblr-1794	519	32	and	and	CCONJ
cblr-1794	519	33	functional	functional	ADJ
cblr-1794	519	34	characterization	characterization	NOUN
cblr-1794	519	35	and	and	CCONJ
cblr-1794	519	36	possible	possible	ADJ
cblr-1794	519	37	animal	animal	NOUN
cblr-1794	519	38	studies	study	NOUN
cblr-1794	519	39	.	.	PUNCT
cblr-1794	519	40	"	"	PUNCT
cblr-1794	519	41	)	)	PUNCT
cblr-1794	519	42	.	.	PUNCT
cblr-1794	520	1	[	[	X
cblr-1794	520	2	vol	vol	NOUN
cblr-1794	520	3	.	.	PUNCT
cblr-1794	520	4	2013238	2013238	NUM
cblr-1794	520	5	col	col	PROPN
cblr-1794	520	6	umbia	umbia	PROPN
cblr-1794	520	7	b	b	PROPN
cblr-1794	520	8	usiness	usiness	PROPN
cblr-1794	520	9	la	la	PROPN
cblr-1794	520	10	w	w	PROPN
cblr-1794	520	11	re	re	X
cblr-1794	520	12	vie	vie	PROPN
cblr-1794	520	13	w	w	PROPN
cblr-1794	520	14	protein	protein	NOUN
cblr-1794	520	15	.	.	PUNCT
cblr-1794	521	1	in	in	ADP
cblr-1794	521	2	europe	europe	PROPN
cblr-1794	521	3	,	,	PUNCT
cblr-1794	521	4	the	the	DET
cblr-1794	521	5	european	european	PROPN
cblr-1794	521	6	medicines	medicine	NOUN
cblr-1794	521	7	agency	agency	NOUN
cblr-1794	521	8	(	(	PUNCT
cblr-1794	521	9	"	"	PUNCT
cblr-1794	521	10	ema	ema	X
cblr-1794	521	11	"	"	PUNCT
cblr-1794	521	12	)	)	PUNCT
cblr-1794	521	13	has	have	AUX
cblr-1794	521	14	released	release	VERB
cblr-1794	521	15	guidance	guidance	NOUN
cblr-1794	521	16	for	for	ADP
cblr-1794	521	17	six	six	NUM
cblr-1794	521	18	different	different	ADJ
cblr-1794	521	19	protein	protein	NOUN
cblr-1794	521	20	classes.17	classes.17	NOUN
cblr-1794	521	21	8	8	NUM
cblr-1794	521	22	ema	ema	NOUN
cblr-1794	521	23	guidance	guidance	NOUN
cblr-1794	521	24	helps	help	VERB
cblr-1794	521	25	biosimilar	biosimilar	ADJ
cblr-1794	521	26	manufacturers	manufacturer	NOUN
cblr-1794	521	27	estimate	estimate	VERB
cblr-1794	521	28	costs	cost	NOUN
cblr-1794	521	29	and	and	CCONJ
cblr-1794	521	30	obtain	obtain	VERB
cblr-1794	521	31	ema	ema	PROPN
cblr-1794	521	32	approval	approval	NOUN
cblr-1794	521	33	the	the	DET
cblr-1794	521	34	first	first	ADJ
cblr-1794	521	35	time	time	NOUN
cblr-1794	521	36	the	the	DET
cblr-1794	521	37	product	product	NOUN
cblr-1794	521	38	is	be	AUX
cblr-1794	521	39	reviewed	review	VERB
cblr-1794	521	40	.	.	PUNCT
cblr-1794	522	1	the	the	DET
cblr-1794	522	2	fda	fda	PROPN
cblr-1794	522	3	should	should	AUX
cblr-1794	522	4	follow	follow	VERB
cblr-1794	522	5	the	the	DET
cblr-1794	522	6	ema	ema	PROPN
cblr-1794	522	7	's	's	PART
cblr-1794	522	8	lead	lead	NOUN
cblr-1794	522	9	and	and	CCONJ
cblr-1794	522	10	issue	issue	VERB
cblr-1794	522	11	similar	similar	ADJ
cblr-1794	522	12	guidance	guidance	NOUN
cblr-1794	522	13	as	as	ADV
cblr-1794	522	14	quickly	quickly	ADV
cblr-1794	522	15	as	as	ADP
cblr-1794	522	16	feasible	feasible	ADJ
cblr-1794	522	17	.	.	PUNCT
cblr-1794	523	1	additionally	additionally	ADV
cblr-1794	523	2	,	,	PUNCT
cblr-1794	523	3	the	the	DET
cblr-1794	523	4	ema	ema	PROPN
cblr-1794	523	5	issues	issue	VERB
cblr-1794	523	6	a	a	DET
cblr-1794	523	7	detailed	detailed	ADJ
cblr-1794	523	8	scientific	scientific	ADJ
cblr-1794	523	9	document	document	NOUN
cblr-1794	523	10	shortly	shortly	ADV
cblr-1794	523	11	after	after	SCONJ
cblr-1794	523	12	a	a	DET
cblr-1794	523	13	biosimilar	biosimilar	ADJ
cblr-1794	523	14	application	application	NOUN
cblr-1794	523	15	is	be	AUX
cblr-1794	523	16	approved	approve	VERB
cblr-1794	523	17	,	,	PUNCT
cblr-1794	523	18	rejected	reject	VERB
cblr-1794	523	19	,	,	PUNCT
cblr-1794	523	20	or	or	CCONJ
cblr-1794	523	21	withdrawn	withdraw	VERB
cblr-1794	523	22	.	.	PUNCT
cblr-1794	524	1	179	179	NUM
cblr-1794	524	2	these	these	DET
cblr-1794	524	3	reports	report	NOUN
cblr-1794	524	4	have	have	AUX
cblr-1794	524	5	been	be	AUX
cblr-1794	524	6	"	"	PUNCT
cblr-1794	524	7	helpful	helpful	ADJ
cblr-1794	524	8	in	in	ADP
cblr-1794	524	9	elucidating	elucidate	VERB
cblr-1794	524	10	how	how	SCONJ
cblr-1794	524	11	the	the	DET
cblr-1794	524	12	guidelines	guideline	NOUN
cblr-1794	524	13	and	and	CCONJ
cblr-1794	524	14	standards	standard	NOUN
cblr-1794	524	15	have	have	AUX
cblr-1794	524	16	been	be	AUX
cblr-1794	524	17	applied	apply	VERB
cblr-1794	524	18	to	to	ADP
cblr-1794	524	19	regulatory	regulatory	ADJ
cblr-1794	524	20	decision	decision	NOUN
cblr-1794	524	21	-	-	PUNCT
cblr-1794	524	22	making	making	NOUN
cblr-1794	524	23	.	.	PUNCT
cblr-1794	524	24	"	"	PUNCT
cblr-1794	525	1	18	18	NUM
cblr-1794	525	2	0	0	NUM
cblr-1794	525	3	transparency	transparency	NOUN
cblr-1794	525	4	in	in	ADP
cblr-1794	525	5	the	the	DET
cblr-1794	525	6	approval	approval	NOUN
cblr-1794	525	7	process	process	NOUN
cblr-1794	525	8	will	will	AUX
cblr-1794	525	9	aid	aid	VERB
cblr-1794	525	10	biosimilar	biosimilar	NOUN
cblr-1794	525	11	manufacturers	manufacturer	NOUN
cblr-1794	525	12	in	in	ADP
cblr-1794	525	13	understanding	understand	VERB
cblr-1794	525	14	what	what	PRON
cblr-1794	525	15	is	be	AUX
cblr-1794	525	16	needed	need	VERB
cblr-1794	525	17	to	to	PART
cblr-1794	525	18	achieve	achieve	VERB
cblr-1794	525	19	biosimilarity	biosimilarity	NOUN
cblr-1794	525	20	and/or	and/or	CCONJ
cblr-1794	525	21	interchangeability	interchangeability	NOUN
cblr-1794	525	22	.	.	PUNCT
cblr-1794	526	1	this	this	DET
cblr-1794	526	2	understanding	understanding	NOUN
cblr-1794	526	3	will	will	AUX
cblr-1794	526	4	lead	lead	VERB
cblr-1794	526	5	to	to	ADP
cblr-1794	526	6	increased	increase	VERB
cblr-1794	526	7	consistency	consistency	NOUN
cblr-1794	526	8	and	and	CCONJ
cblr-1794	526	9	predictability	predictability	NOUN
cblr-1794	526	10	,	,	PUNCT
cblr-1794	526	11	which	which	PRON
cblr-1794	526	12	may	may	AUX
cblr-1794	526	13	help	help	VERB
cblr-1794	526	14	convince	convince	VERB
cblr-1794	526	15	manufacturers	manufacturer	NOUN
cblr-1794	526	16	to	to	PART
cblr-1794	526	17	take	take	VERB
cblr-1794	526	18	the	the	DET
cblr-1794	526	19	risk	risk	NOUN
cblr-1794	526	20	of	of	ADP
cblr-1794	526	21	developing	develop	VERB
cblr-1794	526	22	a	a	DET
cblr-1794	526	23	biosimilar	biosimilar	NOUN
cblr-1794	526	24	.	.	PUNCT
cblr-1794	527	1	therefore	therefore	ADV
cblr-1794	527	2	,	,	PUNCT
cblr-1794	527	3	the	the	DET
cblr-1794	527	4	fda	fda	PROPN
cblr-1794	527	5	should	should	AUX
cblr-1794	527	6	adopt	adopt	VERB
cblr-1794	527	7	the	the	DET
cblr-1794	527	8	ema	ema	PROPN
cblr-1794	527	9	's	's	PART
cblr-1794	527	10	practice	practice	NOUN
cblr-1794	527	11	of	of	ADP
cblr-1794	527	12	issuing	issue	VERB
cblr-1794	527	13	detailed	detailed	ADJ
cblr-1794	527	14	decision	decision	NOUN
cblr-1794	527	15	letters	letter	NOUN
cblr-1794	527	16	for	for	ADP
cblr-1794	527	17	each	each	DET
cblr-1794	527	18	biosimilar	biosimilar	PROPN
cblr-1794	527	19	application	application	NOUN
cblr-1794	527	20	.	.	PUNCT
cblr-1794	528	1	third	third	ADJ
cblr-1794	528	2	,	,	PUNCT
cblr-1794	528	3	congress	congress	PROPN
cblr-1794	528	4	should	should	AUX
cblr-1794	528	5	reduce	reduce	VERB
cblr-1794	528	6	the	the	DET
cblr-1794	528	7	exclusivity	exclusivity	NOUN
cblr-1794	528	8	period	period	NOUN
cblr-1794	528	9	for	for	ADP
cblr-1794	528	10	reference	reference	NOUN
cblr-1794	528	11	biologics	biologic	NOUN
cblr-1794	528	12	from	from	ADP
cblr-1794	528	13	twelve	twelve	NUM
cblr-1794	528	14	to	to	PART
cblr-1794	528	15	seven	seven	NUM
cblr-1794	528	16	years	year	NOUN
cblr-1794	528	17	.	.	PUNCT
cblr-1794	529	1	president	president	PROPN
cblr-1794	529	2	obama	obama	PROPN
cblr-1794	529	3	has	have	AUX
cblr-1794	529	4	taken	take	VERB
cblr-1794	529	5	a	a	DET
cblr-1794	529	6	step	step	NOUN
cblr-1794	529	7	in	in	ADP
cblr-1794	529	8	this	this	DET
cblr-1794	529	9	direction	direction	NOUN
cblr-1794	529	10	,	,	PUNCT
cblr-1794	529	11	by	by	ADP
cblr-1794	529	12	including	include	VERB
cblr-1794	529	13	a	a	DET
cblr-1794	529	14	recommendation	recommendation	NOUN
cblr-1794	529	15	for	for	ADP
cblr-1794	529	16	a	a	DET
cblr-1794	529	17	seven	seven	NUM
cblr-1794	529	18	-	-	PUNCT
cblr-1794	529	19	year	year	NOUN
cblr-1794	529	20	exclusivity	exclusivity	NOUN
cblr-1794	529	21	period	period	NOUN
cblr-1794	529	22	in	in	ADP
cblr-1794	529	23	his	his	PRON
cblr-1794	529	24	fiscal	fiscal	ADJ
cblr-1794	529	25	year	year	NOUN
cblr-1794	529	26	2012	2012	NUM
cblr-1794	529	27	budget.s18	budget.s18	NOUN
cblr-1794	529	28	the	the	DET
cblr-1794	529	29	budget	budget	NOUN
cblr-1794	529	30	states	state	NOUN
cblr-1794	529	31	:	:	PUNCT
cblr-1794	529	32	178	178	NUM
cblr-1794	529	33	see	see	VERB
cblr-1794	529	34	product	product	NOUN
cblr-1794	529	35	-	-	PUNCT
cblr-1794	529	36	specific	specific	ADJ
cblr-1794	529	37	biosimilar	biosimilar	NOUN
cblr-1794	529	38	guidelines	guideline	NOUN
cblr-1794	529	39	,	,	PUNCT
cblr-1794	530	1	eur	eur	PROPN
cblr-1794	530	2	.	.	PUNCT
cblr-1794	530	3	med	med	PROPN
cblr-1794	530	4	.	.	PROPN
cblr-1794	530	5	agency	agency	PROPN
cblr-1794	530	6	,	,	PUNCT
cblr-1794	530	7	http://www.ema.europa.eulema/index.jsp?curl=pages/regulation/general/ge	http://www.ema.europa.eulema/index.jsp?curl=pages/regulation/general/ge	PROPN
cblr-1794	530	8	neral	neral	PROPN
cblr-1794	530	9	content_000408.jsp&mid	content_000408.jsp&mid	PROPN
cblr-1794	530	10	=	=	PRON
cblr-1794	530	11	wc0b01aco58002958c&jsenabled	wc0b01aco58002958c&jsenable	VERB
cblr-1794	530	12	=	=	PROPN
cblr-1794	530	13	true#p	true#p	PROPN
cblr-1794	530	14	roductspecificbiosimilarguidelines	roductspecificbiosimilarguideline	NOUN
cblr-1794	530	15	(	(	PUNCT
cblr-1794	530	16	last	last	ADV
cblr-1794	530	17	visited	visit	VERB
cblr-1794	530	18	mar	mar	PROPN
cblr-1794	530	19	.	.	PROPN
cblr-1794	530	20	19	19	NUM
cblr-1794	530	21	,	,	PUNCT
cblr-1794	530	22	2013	2013	NUM
cblr-1794	530	23	)	)	PUNCT
cblr-1794	530	24	.	.	PUNCT
cblr-1794	531	1	productspecific	productspecific	PROPN
cblr-1794	531	2	guidelines	guideline	NOUN
cblr-1794	531	3	have	have	AUX
cblr-1794	531	4	been	be	AUX
cblr-1794	531	5	released	release	VERB
cblr-1794	531	6	for	for	ADP
cblr-1794	531	7	insulin	insulin	NOUN
cblr-1794	531	8	,	,	PUNCT
cblr-1794	531	9	somatropin	somatropin	NOUN
cblr-1794	531	10	,	,	PUNCT
cblr-1794	531	11	granulocytecolony	granulocytecolony	NOUN
cblr-1794	531	12	stimulating	stimulating	ADJ
cblr-1794	531	13	factor	factor	NOUN
cblr-1794	531	14	,	,	PUNCT
cblr-1794	531	15	alpha	alpha	NOUN
cblr-1794	531	16	interferon	interferon	ADJ
cblr-1794	531	17	,	,	PUNCT
cblr-1794	531	18	low	low	ADJ
cblr-1794	531	19	-	-	PUNCT
cblr-1794	531	20	weight	weight	NOUN
cblr-1794	531	21	molecular	molecular	ADJ
cblr-1794	531	22	heparins	heparin	NOUN
cblr-1794	531	23	,	,	PUNCT
cblr-1794	531	24	and	and	CCONJ
cblr-1794	531	25	erythropoietins	erythropoietin	NOUN
cblr-1794	531	26	.	.	PUNCT
cblr-1794	532	1	i	i	PRON
cblr-1794	532	2	d.	d.	VERB
cblr-1794	532	3	at	at	ADV
cblr-1794	532	4	least	least	ADV
cblr-1794	532	5	four	four	NUM
cblr-1794	532	6	more	more	ADJ
cblr-1794	532	7	product	product	NOUN
cblr-1794	532	8	-	-	PUNCT
cblr-1794	532	9	specific	specific	ADJ
cblr-1794	532	10	guidelines	guideline	NOUN
cblr-1794	532	11	are	be	AUX
cblr-1794	532	12	at	at	ADP
cblr-1794	532	13	the	the	DET
cblr-1794	532	14	concept	concept	NOUN
cblr-1794	532	15	or	or	CCONJ
cblr-1794	532	16	draft	draft	NOUN
cblr-1794	532	17	stage	stage	NOUN
cblr-1794	532	18	.	.	PUNCT
cblr-1794	533	1	i	i	PRON
cblr-1794	533	2	d.	d.	PROPN
cblr-1794	533	3	179	179	NUM
cblr-1794	533	4	barbara	barbara	PROPN
cblr-1794	533	5	mounho	mounho	PROPN
cblr-1794	533	6	et	et	PROPN
cblr-1794	533	7	al	al	PROPN
cblr-1794	533	8	.	.	PROPN
cblr-1794	533	9	,	,	PUNCT
cblr-1794	533	10	global	global	ADJ
cblr-1794	533	11	regulatory	regulatory	ADJ
cblr-1794	533	12	standards	standard	NOUN
cblr-1794	533	13	for	for	ADP
cblr-1794	533	14	the	the	DET
cblr-1794	533	15	approval	approval	NOUN
cblr-1794	533	16	of	of	ADP
cblr-1794	533	17	biosimilars	biosimilar	NOUN
cblr-1794	533	18	,	,	PUNCT
cblr-1794	533	19	65	65	NUM
cblr-1794	533	20	food	food	NOUN
cblr-1794	533	21	&	&	CCONJ
cblr-1794	533	22	drug	drug	PROPN
cblr-1794	533	23	l.j	l.j	PROPN
cblr-1794	533	24	.	.	PROPN
cblr-1794	533	25	819	819	NUM
cblr-1794	533	26	,	,	PUNCT
cblr-1794	533	27	823	823	NUM
cblr-1794	533	28	(	(	PUNCT
cblr-1794	533	29	2010	2010	NUM
cblr-1794	533	30	)	)	PUNCT
cblr-1794	533	31	.	.	PUNCT
cblr-1794	534	1	180	180	NUM
cblr-1794	534	2	i	i	PROPN
cblr-1794	534	3	d.	d.	PROPN
cblr-1794	534	4	181	181	NUM
cblr-1794	534	5	office	office	NOUN
cblr-1794	534	6	of	of	ADP
cblr-1794	534	7	mgmt	mgmt	PROPN
cblr-1794	534	8	.	.	PROPN
cblr-1794	534	9	&	&	CCONJ
cblr-1794	534	10	budget	budget	PROPN
cblr-1794	534	11	,	,	PUNCT
cblr-1794	534	12	exec	exec	NOUN
cblr-1794	534	13	.	.	PUNCT
cblr-1794	535	1	office	office	NOUN
cblr-1794	535	2	of	of	ADP
cblr-1794	535	3	the	the	DET
cblr-1794	535	4	president	president	NOUN
cblr-1794	535	5	,	,	PUNCT
cblr-1794	535	6	budget	budget	NOUN
cblr-1794	535	7	of	of	ADP
cblr-1794	535	8	the	the	DET
cblr-1794	535	9	u.s	u.s	PROPN
cblr-1794	535	10	.	.	PROPN
cblr-1794	535	11	government	government	NOUN
cblr-1794	535	12	,	,	PUNCT
cblr-1794	535	13	fiscal	fiscal	ADJ
cblr-1794	535	14	year	year	NOUN
cblr-1794	535	15	2012	2012	NUM
cblr-1794	535	16	terminations	termination	NOUN
cblr-1794	535	17	,	,	PUNCT
cblr-1794	535	18	reductions	reduction	NOUN
cblr-1794	535	19	,	,	PUNCT
cblr-1794	535	20	and	and	CCONJ
cblr-1794	535	21	savings	saving	NOUN
cblr-1794	535	22	119	119	NUM
cblr-1794	535	23	(	(	PUNCT
cblr-1794	535	24	2012	2012	NUM
cblr-1794	535	25	)	)	PUNCT
cblr-1794	536	1	[	[	X
cblr-1794	536	2	hereinafter	hereinafter	NOUN
cblr-1794	536	3	omb	omb	NOUN
cblr-1794	536	4	2012	2012	NUM
cblr-1794	536	5	report	report	NOUN
cblr-1794	536	6	]	]	PUNCT
cblr-1794	536	7	,	,	PUNCT
cblr-1794	536	8	available	available	ADJ
cblr-1794	536	9	at	at	ADP
cblr-1794	536	10	http://www.whitehouse.gov/sites/default/files/ombfbudget/	http://www.whitehouse.gov/sites/default/files/ombfbudget/	PROPN
cblr-1794	536	11	fy2012	fy2012	PROPN
cblr-1794	536	12	/	/	SYM
cblr-1794	536	13	assets	asset	NOUN
cblr-1794	536	14	/	/	SYM
cblr-1794	536	15	trs.pdf	trs.pdf	NUM
cblr-1794	536	16	.	.	PUNCT
cblr-1794	537	1	bpcia	bpcia	NOUN
cblr-1794	537	2	:	:	PUNCT
cblr-1794	537	3	destined	destine	VERB
cblr-1794	537	4	for	for	ADP
cblr-1794	537	5	fail	fail	VERB
cblr-1794	537	6	ure	ure	PROPN
cblr-1794	537	7	?	?	PUNCT
cblr-1794	537	8	239no	239no	PROPN
cblr-1794	537	9	.	.	PUNCT
cblr-1794	538	1	1:209]1	1:209]1	NUM
cblr-1794	538	2	12	12	NUM
cblr-1794	538	3	-	-	PUNCT
cblr-1794	538	4	year	year	NOUN
cblr-1794	538	5	exclusivity	exclusivity	NOUN
cblr-1794	538	6	is	be	AUX
cblr-1794	538	7	unnecessary	unnecessary	ADJ
cblr-1794	538	8	to	to	PART
cblr-1794	538	9	promote	promote	VERB
cblr-1794	538	10	innovation	innovation	NOUN
cblr-1794	538	11	by	by	ADP
cblr-1794	538	12	brand	brand	NOUN
cblr-1794	538	13	biologic	biologic	NOUN
cblr-1794	538	14	drug	drug	NOUN
cblr-1794	538	15	manufacturers	manufacturer	NOUN
cblr-1794	538	16	and	and	CCONJ
cblr-1794	538	17	can	can	AUX
cblr-1794	538	18	potentially	potentially	ADV
cblr-1794	538	19	harm	harm	VERB
cblr-1794	538	20	consumers	consumer	NOUN
cblr-1794	538	21	by	by	ADP
cblr-1794	538	22	directing	direct	VERB
cblr-1794	538	23	scarce	scarce	ADJ
cblr-1794	538	24	research	research	NOUN
cblr-1794	538	25	and	and	CCONJ
cblr-1794	538	26	development	development	NOUN
cblr-1794	538	27	funding	funding	NOUN
cblr-1794	538	28	toward	toward	ADP
cblr-1794	538	29	developing	develop	VERB
cblr-1794	538	30	low	low	ADJ
cblr-1794	538	31	-	-	PUNCT
cblr-1794	538	32	risk	risk	NOUN
cblr-1794	538	33	clinical	clinical	ADJ
cblr-1794	538	34	data	datum	NOUN
cblr-1794	538	35	for	for	ADP
cblr-1794	538	36	drug	drug	NOUN
cblr-1794	538	37	products	product	NOUN
cblr-1794	538	38	with	with	ADP
cblr-1794	538	39	proven	prove	VERB
cblr-1794	538	40	mechanisms	mechanism	NOUN
cblr-1794	538	41	of	of	ADP
cblr-1794	538	42	action	action	NOUN
cblr-1794	538	43	rather	rather	ADV
cblr-1794	538	44	than	than	ADP
cblr-1794	538	45	toward	toward	ADP
cblr-1794	538	46	new	new	ADJ
cblr-1794	538	47	products	product	NOUN
cblr-1794	538	48	to	to	PART
cblr-1794	538	49	address	address	VERB
cblr-1794	538	50	unmet	unmet	NOUN
cblr-1794	538	51	medical	medical	PROPN
cblr-1794	538	52	needs.182	needs.182	PROPN
cblr-1794	538	53	the	the	DET
cblr-1794	538	54	budget	budget	NOUN
cblr-1794	538	55	document	document	NOUN
cblr-1794	538	56	estimates	estimate	VERB
cblr-1794	538	57	that	that	SCONJ
cblr-1794	538	58	changing	change	VERB
cblr-1794	538	59	the	the	DET
cblr-1794	538	60	exclusivity	exclusivity	NOUN
cblr-1794	538	61	period	period	NOUN
cblr-1794	538	62	from	from	ADP
cblr-1794	538	63	twelve	twelve	NUM
cblr-1794	538	64	to	to	PART
cblr-1794	538	65	seven	seven	NUM
cblr-1794	538	66	years	year	NOUN
cblr-1794	538	67	would	would	AUX
cblr-1794	538	68	result	result	VERB
cblr-1794	538	69	in	in	ADP
cblr-1794	538	70	savings	saving	NOUN
cblr-1794	538	71	of	of	ADP
cblr-1794	538	72	$	$	SYM
cblr-1794	538	73	2.34	2.34	NUM
cblr-1794	538	74	billion	billion	NUM
cblr-1794	538	75	by	by	ADP
cblr-1794	538	76	2021.183	2021.183	NUM
cblr-1794	538	77	however	however	ADV
cblr-1794	538	78	,	,	PUNCT
cblr-1794	538	79	president	president	PROPN
cblr-1794	538	80	obama	obama	PROPN
cblr-1794	538	81	's	's	PART
cblr-1794	538	82	proposal	proposal	NOUN
cblr-1794	538	83	has	have	AUX
cblr-1794	538	84	already	already	ADV
cblr-1794	538	85	encountered	encounter	VERB
cblr-1794	538	86	significant	significant	ADJ
cblr-1794	538	87	resistance	resistance	NOUN
cblr-1794	538	88	from	from	ADP
cblr-1794	538	89	congress	congress	PROPN
cblr-1794	538	90	.	.	PUNCT
cblr-1794	539	1	fifty	fifty	NUM
cblr-1794	539	2	-	-	PUNCT
cblr-1794	539	3	one	one	NUM
cblr-1794	539	4	members	member	NOUN
cblr-1794	539	5	of	of	ADP
cblr-1794	539	6	the	the	DET
cblr-1794	539	7	house	house	NOUN
cblr-1794	539	8	,	,	PUNCT
cblr-1794	539	9	from	from	ADP
cblr-1794	539	10	both	both	DET
cblr-1794	539	11	sides	side	NOUN
cblr-1794	539	12	of	of	ADP
cblr-1794	539	13	the	the	DET
cblr-1794	539	14	aisle	aisle	NOUN
cblr-1794	539	15	,	,	PUNCT
cblr-1794	539	16	sent	send	VERB
cblr-1794	539	17	a	a	DET
cblr-1794	539	18	letter	letter	NOUN
cblr-1794	539	19	to	to	PART
cblr-1794	539	20	president	president	PROPN
cblr-1794	539	21	obama	obama	PROPN
cblr-1794	539	22	reminding	remind	VERB
cblr-1794	539	23	him	he	PRON
cblr-1794	539	24	that	that	SCONJ
cblr-1794	539	25	the	the	DET
cblr-1794	539	26	twelve	twelve	NUM
cblr-1794	539	27	-	-	PUNCT
cblr-1794	539	28	year	year	NOUN
cblr-1794	539	29	exclusivity	exclusivity	NOUN
cblr-1794	539	30	provision	provision	NOUN
cblr-1794	539	31	was	be	AUX
cblr-1794	539	32	passed	pass	VERB
cblr-1794	539	33	with	with	ADP
cblr-1794	539	34	significant	significant	ADJ
cblr-1794	539	35	bipartisan	bipartisan	ADJ
cblr-1794	539	36	support.18	support.18	NOUN
cblr-1794	539	37	4	4	NUM
cblr-1794	539	38	the	the	DET
cblr-1794	539	39	letter	letter	NOUN
cblr-1794	539	40	warned	warn	VERB
cblr-1794	539	41	that	that	SCONJ
cblr-1794	539	42	reducing	reduce	VERB
cblr-1794	539	43	the	the	DET
cblr-1794	539	44	exclusivity	exclusivity	NOUN
cblr-1794	539	45	period	period	NOUN
cblr-1794	539	46	would	would	AUX
cblr-1794	539	47	undermine	undermine	VERB
cblr-1794	539	48	the	the	DET
cblr-1794	539	49	bpcia	bpcia	NOUN
cblr-1794	539	50	's	's	PART
cblr-1794	539	51	attempt	attempt	NOUN
cblr-1794	539	52	to	to	PART
cblr-1794	539	53	protect	protect	VERB
cblr-1794	539	54	innovation	innovation	NOUN
cblr-1794	539	55	,	,	PUNCT
cblr-1794	539	56	causing	cause	VERB
cblr-1794	539	57	biotechnology	biotechnology	NOUN
cblr-1794	539	58	firms	firm	NOUN
cblr-1794	539	59	to	to	PART
cblr-1794	539	60	move	move	VERB
cblr-1794	539	61	their	their	PRON
cblr-1794	539	62	businesses	business	NOUN
cblr-1794	539	63	to	to	ADP
cblr-1794	539	64	more	more	ADV
cblr-1794	539	65	hospitable	hospitable	ADJ
cblr-1794	539	66	countries	country	NOUN
cblr-1794	539	67	such	such	ADJ
cblr-1794	539	68	as	as	ADP
cblr-1794	539	69	india	india	PROPN
cblr-1794	539	70	or	or	CCONJ
cblr-1794	539	71	china.185	china.185	NOUN
cblr-1794	539	72	however	however	ADV
cblr-1794	539	73	,	,	PUNCT
cblr-1794	539	74	a	a	DET
cblr-1794	539	75	twelve	twelve	NUM
cblr-1794	539	76	-	-	PUNCT
cblr-1794	539	77	year	year	NOUN
cblr-1794	539	78	exclusivity	exclusivity	NOUN
cblr-1794	539	79	period	period	NOUN
cblr-1794	539	80	is	be	AUX
cblr-1794	539	81	unnecessary	unnecessary	ADJ
cblr-1794	539	82	to	to	PART
cblr-1794	539	83	promote	promote	VERB
cblr-1794	539	84	innovation	innovation	NOUN
cblr-1794	539	85	.	.	PUNCT
cblr-1794	540	1	as	as	SCONJ
cblr-1794	540	2	noted	note	VERB
cblr-1794	540	3	above	above	ADV
cblr-1794	540	4	,	,	PUNCT
cblr-1794	540	5	the	the	DET
cblr-1794	540	6	patent	patent	NOUN
cblr-1794	540	7	system	system	NOUN
cblr-1794	540	8	provides	provide	VERB
cblr-1794	540	9	adequate	adequate	ADJ
cblr-1794	540	10	protection	protection	NOUN
cblr-1794	540	11	for	for	ADP
cblr-1794	540	12	innovative	innovative	ADJ
cblr-1794	540	13	biologics	biologic	NOUN
cblr-1794	540	14	manufacturers	manufacturer	NOUN
cblr-1794	540	15	.	.	PUNCT
cblr-1794	540	16	'	'	PUNCT
cblr-1794	541	1	additionally	additionally	ADV
cblr-1794	541	2	,	,	PUNCT
cblr-1794	541	3	most	most	ADJ
cblr-1794	541	4	biosimilars	biosimilar	NOUN
cblr-1794	541	5	will	will	AUX
cblr-1794	541	6	not	not	PART
cblr-1794	541	7	be	be	AUX
cblr-1794	541	8	automatically	automatically	ADV
cblr-1794	541	9	substituted	substitute	VERB
cblr-1794	541	10	for	for	ADP
cblr-1794	541	11	their	their	PRON
cblr-1794	541	12	reference	reference	NOUN
cblr-1794	541	13	products	product	NOUN
cblr-1794	541	14	.	.	PUNCT
cblr-1794	542	1	the	the	DET
cblr-1794	542	2	reference	reference	NOUN
cblr-1794	542	3	biologic	biologic	NOUN
cblr-1794	542	4	manufacturer	manufacturer	NOUN
cblr-1794	542	5	will	will	AUX
cblr-1794	542	6	therefore	therefore	ADV
cblr-1794	542	7	continue	continue	VERB
cblr-1794	542	8	to	to	PART
cblr-1794	542	9	reap	reap	VERB
cblr-1794	542	10	substantial	substantial	ADJ
cblr-1794	542	11	profits	profit	NOUN
cblr-1794	542	12	even	even	ADV
cblr-1794	542	13	after	after	ADP
cblr-1794	542	14	the	the	DET
cblr-1794	542	15	introduction	introduction	NOUN
cblr-1794	542	16	of	of	ADP
cblr-1794	542	17	one	one	NUM
cblr-1794	542	18	or	or	CCONJ
cblr-1794	542	19	more	more	ADJ
cblr-1794	542	20	biosimilars	biosimilar	NOUN
cblr-1794	542	21	.	.	PUNCT
cblr-1794	543	1	'87	'87	NUM
cblr-1794	543	2	182	182	NUM
cblr-1794	543	3	omb	omb	NOUN
cblr-1794	543	4	2012	2012	NUM
cblr-1794	543	5	report	report	NOUN
cblr-1794	543	6	,	,	PUNCT
cblr-1794	543	7	supra	supra	PROPN
cblr-1794	543	8	note	note	NOUN
cblr-1794	543	9	181	181	NUM
cblr-1794	543	10	.	.	NOUN
cblr-1794	544	1	183	183	NUM
cblr-1794	545	1	i	i	PROPN
cblr-1794	545	2	d.	d.	PROPN
cblr-1794	545	3	184	184	NUM
cblr-1794	545	4	letter	letter	NOUN
cblr-1794	545	5	from	from	ADP
cblr-1794	545	6	anna	anna	PROPN
cblr-1794	545	7	eshoo	eshoo	PROPN
cblr-1794	545	8	et	et	PROPN
cblr-1794	545	9	al	al	PROPN
cblr-1794	545	10	.	.	PROPN
cblr-1794	546	1	to	to	PART
cblr-1794	546	2	barack	barack	VERB
cblr-1794	546	3	obama	obama	PROPN
cblr-1794	546	4	,	,	PUNCT
cblr-1794	546	5	supra	supra	PROPN
cblr-1794	546	6	note	note	NOUN
cblr-1794	546	7	10	10	NUM
cblr-1794	546	8	,	,	PUNCT
cblr-1794	546	9	at	at	ADP
cblr-1794	546	10	1	1	NUM
cblr-1794	546	11	(	(	PUNCT
cblr-1794	546	12	"	"	PUNCT
cblr-1794	546	13	the	the	DET
cblr-1794	546	14	kennedy	kennedy	PROPN
cblr-1794	546	15	-	-	PUNCT
cblr-1794	546	16	eshoo	eshoo	ADJ
cblr-1794	546	17	legislation	legislation	NOUN
cblr-1794	546	18	to	to	PART
cblr-1794	546	19	create	create	VERB
cblr-1794	546	20	a	a	DET
cblr-1794	546	21	new	new	ADJ
cblr-1794	546	22	pathway	pathway	NOUN
cblr-1794	546	23	for	for	ADP
cblr-1794	546	24	biosimilars	biosimilar	NOUN
cblr-1794	546	25	at	at	ADP
cblr-1794	546	26	the	the	DET
cblr-1794	546	27	fda	fda	PROPN
cblr-1794	546	28	had	have	AUX
cblr-1794	546	29	overwhelming	overwhelming	ADJ
cblr-1794	546	30	bipartisan	bipartisan	ADJ
cblr-1794	546	31	and	and	CCONJ
cblr-1794	546	32	bicameral	bicameral	ADJ
cblr-1794	546	33	support	support	NOUN
cblr-1794	546	34	.	.	PUNCT
cblr-1794	547	1	the	the	DET
cblr-1794	547	2	bill	bill	NOUN
cblr-1794	547	3	had	have	VERB
cblr-1794	547	4	149	149	NUM
cblr-1794	547	5	cosponsors	cosponsor	NOUN
cblr-1794	547	6	[	[	X
cblr-1794	547	7	sic	sic	ADJ
cblr-1794	547	8	]	]	PUNCT
cblr-1794	547	9	in	in	ADP
cblr-1794	547	10	the	the	DET
cblr-1794	547	11	house	house	NOUN
cblr-1794	547	12	and	and	CCONJ
cblr-1794	547	13	passed	pass	VERB
cblr-1794	547	14	by	by	ADP
cblr-1794	547	15	a	a	DET
cblr-1794	547	16	vote	vote	NOUN
cblr-1794	547	17	of	of	ADP
cblr-1794	547	18	47	47	NUM
cblr-1794	547	19	-	-	SYM
cblr-1794	547	20	11	11	NUM
cblr-1794	547	21	in	in	ADP
cblr-1794	547	22	the	the	DET
cblr-1794	547	23	energy	energy	NOUN
cblr-1794	547	24	and	and	CCONJ
cblr-1794	547	25	commerce	commerce	PROPN
cblr-1794	547	26	committee	committee	NOUN
cblr-1794	547	27	.	.	PUNCT
cblr-1794	548	1	the	the	DET
cblr-1794	548	2	senate	senate	PROPN
cblr-1794	548	3	version	version	NOUN
cblr-1794	548	4	was	be	AUX
cblr-1794	548	5	introduced	introduce	VERB
cblr-1794	548	6	as	as	ADP
cblr-1794	548	7	an	an	DET
cblr-1794	548	8	amendment	amendment	NOUN
cblr-1794	548	9	in	in	ADP
cblr-1794	548	10	the	the	DET
cblr-1794	548	11	[	[	X
cblr-1794	548	12	health	health	NOUN
cblr-1794	548	13	,	,	PUNCT
cblr-1794	548	14	education	education	NOUN
cblr-1794	548	15	,	,	PUNCT
cblr-1794	548	16	labor	labor	NOUN
cblr-1794	548	17	&	&	CCONJ
cblr-1794	548	18	pensions	pensions	PROPN
cblr-1794	548	19	]	]	PUNCT
cblr-1794	548	20	help	help	VERB
cblr-1794	548	21	committee	committee	NOUN
cblr-1794	548	22	and	and	CCONJ
cblr-1794	548	23	passed	pass	VERB
cblr-1794	548	24	by	by	ADP
cblr-1794	548	25	a	a	DET
cblr-1794	548	26	vote	vote	NOUN
cblr-1794	548	27	of	of	ADP
cblr-1794	548	28	16	16	NUM
cblr-1794	548	29	-	-	SYM
cblr-1794	548	30	7	7	NUM
cblr-1794	548	31	.	.	PUNCT
cblr-1794	548	32	"	"	PUNCT
cblr-1794	548	33	)	)	PUNCT
cblr-1794	548	34	.	.	PUNCT
cblr-1794	549	1	185	185	NUM
cblr-1794	550	1	i	i	PRON
cblr-1794	550	2	d.	d.	VERB
cblr-1794	550	3	at	at	ADP
cblr-1794	550	4	2	2	NUM
cblr-1794	550	5	.	.	NUM
cblr-1794	550	6	186	186	NUM
cblr-1794	550	7	see	see	VERB
cblr-1794	550	8	supra	supra	PROPN
cblr-1794	550	9	notes	note	VERB
cblr-1794	550	10	142	142	NUM
cblr-1794	550	11	-	-	SYM
cblr-1794	550	12	52	52	NUM
cblr-1794	550	13	and	and	CCONJ
cblr-1794	550	14	accompanying	accompany	VERB
cblr-1794	550	15	text	text	NOUN
cblr-1794	550	16	.	.	PUNCT
cblr-1794	551	1	187	187	NUM
cblr-1794	551	2	see	see	VERB
cblr-1794	551	3	supra	supra	PROPN
cblr-1794	551	4	notes	note	VERB
cblr-1794	551	5	118	118	NUM
cblr-1794	551	6	-	-	SYM
cblr-1794	551	7	30	30	NUM
cblr-1794	551	8	and	and	CCONJ
cblr-1794	551	9	accompanying	accompany	VERB
cblr-1794	551	10	text	text	NOUN
cblr-1794	551	11	.	.	PUNCT
cblr-1794	552	1	240	240	NUM
cblr-1794	552	2	coluama	coluama	NOUN
cblr-1794	552	3	b	b	NUM
cblr-1794	552	4	usiness	usiness	NOUN
cblr-1794	552	5	la	la	PROPN
cblr-1794	552	6	w	w	PROPN
cblr-1794	552	7	re	re	PROPN
cblr-1794	552	8	vie	vie	PROPN
cblr-1794	552	9	w	w	PROPN
cblr-1794	553	1	[	[	X
cblr-1794	553	2	vol	vol	NOUN
cblr-1794	553	3	.	.	PUNCT
cblr-1794	553	4	2013	2013	NUM
cblr-1794	553	5	bpcia	bpcia	NOUN
cblr-1794	553	6	:	:	PUNCT
cblr-1794	553	7	destined	destine	VERB
cblr-1794	553	8	for	for	ADP
cblr-1794	553	9	failure	failure	NOUN
cblr-1794	553	10	?	?	PUNCT
cblr-1794	554	1	still	still	ADV
cblr-1794	554	2	,	,	PUNCT
cblr-1794	554	3	the	the	DET
cblr-1794	554	4	twelve	twelve	NUM
cblr-1794	554	5	-	-	PUNCT
cblr-1794	554	6	year	year	NOUN
cblr-1794	554	7	exclusivity	exclusivity	NOUN
cblr-1794	554	8	period	period	NOUN
cblr-1794	554	9	is	be	AUX
cblr-1794	554	10	law	law	NOUN
cblr-1794	554	11	,	,	PUNCT
cblr-1794	554	12	and	and	CCONJ
cblr-1794	554	13	president	president	PROPN
cblr-1794	554	14	obama	obama	PROPN
cblr-1794	554	15	can	can	AUX
cblr-1794	554	16	not	not	PART
cblr-1794	554	17	unilaterally	unilaterally	ADV
cblr-1794	554	18	change	change	VERB
cblr-1794	554	19	the	the	DET
cblr-1794	554	20	law	law	NOUN
cblr-1794	554	21	.	.	PUNCT
cblr-1794	555	1	for	for	ADP
cblr-1794	555	2	a	a	DET
cblr-1794	555	3	seven	seven	NUM
cblr-1794	555	4	-	-	PUNCT
cblr-1794	555	5	year	year	NOUN
cblr-1794	555	6	exclusivity	exclusivity	NOUN
cblr-1794	555	7	period	period	NOUN
cblr-1794	555	8	to	to	PART
cblr-1794	555	9	take	take	VERB
cblr-1794	555	10	effect	effect	NOUN
cblr-1794	555	11	,	,	PUNCT
cblr-1794	555	12	congress	congress	PROPN
cblr-1794	555	13	will	will	AUX
cblr-1794	555	14	have	have	VERB
cblr-1794	555	15	to	to	PART
cblr-1794	555	16	amend	amend	VERB
cblr-1794	555	17	the	the	DET
cblr-1794	555	18	bpcia	bpcia	NOUN
cblr-1794	555	19	and	and	CCONJ
cblr-1794	555	20	should	should	AUX
cblr-1794	555	21	do	do	VERB
cblr-1794	555	22	so	so	ADV
cblr-1794	555	23	as	as	ADV
cblr-1794	555	24	soon	soon	ADV
cblr-1794	555	25	as	as	ADP
cblr-1794	555	26	possible	possible	ADJ
cblr-1794	555	27	.	.	PUNCT
cblr-1794	556	1	however	however	ADV
cblr-1794	556	2	,	,	PUNCT
cblr-1794	556	3	debates	debate	NOUN
cblr-1794	556	4	over	over	ADP
cblr-1794	556	5	the	the	DET
cblr-1794	556	6	efficacy	efficacy	NOUN
cblr-1794	556	7	of	of	ADP
cblr-1794	556	8	the	the	DET
cblr-1794	556	9	bpcia	bpcia	NOUN
cblr-1794	556	10	as	as	SCONJ
cblr-1794	556	11	written	write	VERB
cblr-1794	556	12	should	should	AUX
cblr-1794	556	13	not	not	PART
cblr-1794	556	14	prevent	prevent	VERB
cblr-1794	556	15	implementation	implementation	NOUN
cblr-1794	556	16	of	of	ADP
cblr-1794	556	17	the	the	DET
cblr-1794	556	18	bpcia	bpcia	NOUN
cblr-1794	556	19	in	in	ADP
cblr-1794	556	20	its	its	PRON
cblr-1794	556	21	current	current	ADJ
cblr-1794	556	22	form	form	NOUN
cblr-1794	556	23	.	.	PUNCT
cblr-1794	557	1	the	the	DET
cblr-1794	557	2	astronomical	astronomical	ADJ
cblr-1794	557	3	prices	price	NOUN
cblr-1794	557	4	of	of	ADP
cblr-1794	557	5	biologics	biologic	NOUN
cblr-1794	557	6	warrant	warrant	VERB
cblr-1794	557	7	an	an	DET
cblr-1794	557	8	immediate	immediate	ADJ
cblr-1794	557	9	solution	solution	NOUN
cblr-1794	557	10	.	.	PUNCT
cblr-1794	558	1	until	until	SCONJ
cblr-1794	558	2	reform	reform	NOUN
cblr-1794	558	3	is	be	AUX
cblr-1794	558	4	implemented	implement	VERB
cblr-1794	558	5	,	,	PUNCT
cblr-1794	558	6	high	high	ADJ
cblr-1794	558	7	biologics	biologic	NOUN
cblr-1794	558	8	prices	price	NOUN
cblr-1794	558	9	will	will	AUX
cblr-1794	558	10	continue	continue	VERB
cblr-1794	558	11	to	to	PART
cblr-1794	558	12	weaken	weaken	VERB
cblr-1794	558	13	the	the	DET
cblr-1794	558	14	economy	economy	NOUN
cblr-1794	558	15	by	by	ADP
cblr-1794	558	16	consuming	consume	VERB
cblr-1794	558	17	more	more	ADJ
cblr-1794	558	18	and	and	CCONJ
cblr-1794	558	19	more	more	ADJ
cblr-1794	558	20	of	of	ADP
cblr-1794	558	21	the	the	DET
cblr-1794	558	22	budgets	budget	NOUN
cblr-1794	558	23	of	of	ADP
cblr-1794	558	24	consumers	consumer	NOUN
cblr-1794	558	25	and	and	CCONJ
cblr-1794	558	26	government	government	NOUN
cblr-1794	558	27	insurers	insurer	NOUN
cblr-1794	558	28	.	.	PUNCT
cblr-1794	559	1	and	and	CCONJ
cblr-1794	559	2	just	just	ADV
cblr-1794	559	3	as	as	ADP
cblr-1794	559	4	significantly	significantly	ADV
cblr-1794	559	5	,	,	PUNCT
cblr-1794	559	6	high	high	ADJ
cblr-1794	559	7	biologics	biologic	NOUN
cblr-1794	559	8	prices	price	NOUN
cblr-1794	559	9	result	result	VERB
cblr-1794	559	10	in	in	ADP
cblr-1794	559	11	a	a	DET
cblr-1794	559	12	social	social	ADJ
cblr-1794	559	13	cost	cost	NOUN
cblr-1794	559	14	that	that	PRON
cblr-1794	559	15	is	be	AUX
cblr-1794	559	16	borne	bear	VERB
cblr-1794	559	17	by	by	ADP
cblr-1794	559	18	vulnerable	vulnerable	ADJ
cblr-1794	559	19	patients	patient	NOUN
cblr-1794	559	20	.	.	PUNCT
cblr-1794	560	1	mrs	mrs	PROPN
cblr-1794	560	2	.	.	PROPN
cblr-1794	560	3	cramer	cramer	PROPN
cblr-1794	560	4	,	,	PUNCT
cblr-1794	560	5	the	the	DET
cblr-1794	560	6	arthritis	arthritis	NOUN
cblr-1794	560	7	patient	patient	NOUN
cblr-1794	560	8	taking	take	VERB
cblr-1794	560	9	enbrel	enbrel	NOUN
cblr-1794	560	10	,	,	PUNCT
cblr-1794	560	11	recounts	recount	VERB
cblr-1794	560	12	leaving	leave	VERB
cblr-1794	560	13	her	her	PRON
cblr-1794	560	14	doctor	doctor	NOUN
cblr-1794	560	15	's	's	PART
cblr-1794	560	16	office	office	NOUN
cblr-1794	560	17	in	in	ADP
cblr-1794	560	18	tears	tear	NOUN
cblr-1794	560	19	after	after	ADP
cblr-1794	560	20	meeting	meet	VERB
cblr-1794	560	21	other	other	ADJ
cblr-1794	560	22	patients	patient	NOUN
cblr-1794	560	23	in	in	ADP
cblr-1794	560	24	her	her	PRON
cblr-1794	560	25	situation	situation	NOUN
cblr-1794	560	26	who	who	PRON
cblr-1794	560	27	could	could	AUX
cblr-1794	560	28	not	not	PART
cblr-1794	560	29	afford	afford	VERB
cblr-1794	560	30	enbrel.as	enbrel.as	PRON
cblr-1794	560	31	the	the	DET
cblr-1794	560	32	bpcia	bpcia	NOUN
cblr-1794	560	33	is	be	AUX
cblr-1794	560	34	important	important	ADJ
cblr-1794	560	35	legislation	legislation	NOUN
cblr-1794	560	36	.	.	PUNCT
cblr-1794	561	1	with	with	ADP
cblr-1794	561	2	a	a	DET
cblr-1794	561	3	few	few	ADJ
cblr-1794	561	4	tweaks	tweak	NOUN
cblr-1794	561	5	,	,	PUNCT
cblr-1794	561	6	it	it	PRON
cblr-1794	561	7	has	have	VERB
cblr-1794	561	8	the	the	DET
cblr-1794	561	9	potential	potential	NOUN
cblr-1794	561	10	to	to	PART
cblr-1794	561	11	improve	improve	VERB
cblr-1794	561	12	the	the	DET
cblr-1794	561	13	economy	economy	NOUN
cblr-1794	561	14	and	and	CCONJ
cblr-1794	561	15	enhance	enhance	VERB
cblr-1794	561	16	patients	patient	NOUN
cblr-1794	561	17	'	'	PART
cblr-1794	561	18	lives	life	NOUN
cblr-1794	561	19	.	.	PUNCT
cblr-1794	562	1	congress	congress	PROPN
cblr-1794	562	2	and	and	CCONJ
cblr-1794	562	3	the	the	DET
cblr-1794	562	4	fda	fda	PROPN
cblr-1794	562	5	must	must	AUX
cblr-1794	562	6	act	act	VERB
cblr-1794	562	7	to	to	PART
cblr-1794	562	8	make	make	VERB
cblr-1794	562	9	the	the	DET
cblr-1794	562	10	bpcia	bpcia	NOUN
cblr-1794	562	11	as	as	ADV
cblr-1794	562	12	strong	strong	ADJ
cblr-1794	562	13	as	as	ADP
cblr-1794	562	14	possible	possible	ADJ
cblr-1794	562	15	so	so	SCONJ
cblr-1794	562	16	that	that	SCONJ
cblr-1794	562	17	these	these	DET
cblr-1794	562	18	important	important	ADJ
cblr-1794	562	19	goals	goal	NOUN
cblr-1794	562	20	can	can	AUX
cblr-1794	562	21	be	be	AUX
cblr-1794	562	22	achieved	achieve	VERB
cblr-1794	562	23	.	.	PUNCT
cblr-1794	563	1	188	188	NUM
cblr-1794	563	2	barrett	barrett	PROPN
cblr-1794	563	3	,	,	PUNCT
cblr-1794	563	4	supra	supra	PROPN
cblr-1794	563	5	note	note	NOUN
cblr-1794	563	6	1	1	NUM
cblr-1794	563	7	.	.	PUNCT
cblr-1794	564	1	no	no	INTJ
cblr-1794	564	2	.	.	PUNCT
cblr-1794	565	1	1:209	1:209	NUM
cblr-1794	565	2	]	]	X
cblr-1794	565	3	241	241	NUM